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Previous research indicates that many people with MS (pwMS) experience pain. Studies 
show that pain is associated with several potentially unhelpful psychosocial factors or 
processes, which may impact on pwMS’ functioning and quality of life. 
 
This thesis presents a series of studies outlining the development of a theoretical model 
of Multiple Sclerosis (MS) pain and a preliminary intervention to support pain 
management for pwMS. 
 
Study 1: A systematic review of the literature proposed a cognitive behavioural model 
of MS pain showing that several psychosocial factors are associated with pain and 
related disability. A literature review of predominant theoretical models in chronic pain, 
their key constructs, empirical evidence, and treatment approaches, were shown to have 
comparable efficacy, and may potentially be relevant to pwMS. 
 
Study 2: Following the literature reviews, a qualitative interview study exploring pwMS 
experiences of pain (n = 25) provided insights into pain-related beliefs, emotional 
reactions, disparate pain management attitudes and behaviours. 
 
Study 3: A large quantitative cross-sectional questionnaire study of pwMS (n = 608) 
explored additional psychological factors, focusing on theory and gaps identified within 
the literature reviews. Cognitive and contextual behavioural variables explained 
substantial variance in pain and related functioning. 
 
Study 4: The literature reviews, interviews and survey refined the MS pain model. This 
informed the development of a telephone supported hybrid cognitive and contextual 
behavioural self-management intervention aiming to alleviate the negative impact of 
pain in MS. 
 
Study 5: A case series (n = 7) explored the potential efficacy of the self-management 
intervention for pwMS with different types of MS pain, showing mixed findings in pain 




This project has improved our understanding of MS pain, providing a potential tool that 
requires further evaluation, which may help pwMS better manage pain more effectively 
in the future.  
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Chapter 1 : Providing a Context: Understanding Multiple Sclerosis 
(MS), its Psychosocial Impact and Current Evidence for 
Psychological Interventions. 
 
1.1 Chapter overview 
 
This first chapter will introduce the principal characteristics of Multiple Sclerosis (MS), 
outlining its pathophysiology, symptoms, phenotypes or courses, epidemiology, 
aetiology, diagnosis and current treatments. This will be followed by a brief account of 
the impact of MS, and a short review of psychological interventions developed 
specifically to manage psychosocial consequences and symptoms, including depression, 
adjustment and fatigue. An introduction to painful symptoms associated with MS, their 
negative impact, and a preliminary biopsychosocial model and psychological treatments 
will also be outlined. Finally, the chapter will conclude with a context and rationale for 




1.2 Understanding Multiple Sclerosis 
 




Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and 
neurodegenerative disease of the central nervous system (CNS) (Kingwell et al., 2013). 
MS is presumed to have an autoimmune pathogenesis (Sellner et al., 2011) in which the 
immune system becomes overactive, resulting in stripping and thinning of myelin 
sheaths that coat nerve fibres responsible for efficient transmission of nerve impulses. 
While MS has for a long time been regarded a demyelinating disease (Murray, 2006), 
recent evidence indicates a more complex interplay between several processes, 
including widespread inflammation (Confavreux, Vukusic, Moreau, & Adeleine, 2000), 
demyelination and re-myelination, glial cell loss and scarring, and neuronal and axonal 
degeneration (Compston & Coles, 2008). Whilst the order and relation of these 
processes remains unclear, over time they typically lead to an accumulation of lesions or 
sclerotic plaques in the nerves, resulting in irreversible disease progression and 




Since the CNS is primarily affected in MS, several areas in the body can potentially be 
affected. Whilst evidence suggests disease processes are present long before the first 
symptom (Murray, 2006), clinical manifestations show the involvement of sensory, 
visual, motor and autonomic systems (Compston & Coles, 2008). Specifically, classic 
neurological symptoms (or ‘signs’) include muscle weakness or spasms, blurred or 
double vision, and loss, or unpleasant distortions, of sensation (Samkoff & Goodman, 
2011; Vollmer, Preiningerova, & Waxman, 2002). Fatigue, depression, and bladder 
dysfunction are the most commonly reported MS symptoms (Induruwa, Constantinescu, 
& Gran, 2012; Krupp, 2006; Minden et al., 2006), whilst others include pain, 
paraesthesia (tingling), hypoesthesia (numbness), cognitive impairment, balance 
disruption, and difficulties with speech and swallowing. However, a hallmark of MS is 
the considerable variability of neurological symptoms observed between individuals 
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(Vollmer et al., 2002), which can be acute or chronic in nature. Whilst correlations 
between cranial magnetic resonance imaging (MRI) and brain pathology are consistent, 
severity of relapses, changes in neurological status and symptoms, including fatigue and 
depression, are not associated with disease activity (Murray, 2006). Furthermore, there 
is now compelling evidence to suggest environmental factors, such as heat (Krupp, 
Alvarez, LaRocca, & Scheinberg, 1988) and certain types of stress are associated with 
worsening symptoms (Mitsonis, Potagas, Zervas, & Sfagos, 2009), even in the absence 




It is unclear whether MS represents one or several distinct diseases, since it can follow 
very different patterns of progression and variable rates of disability accumulation over 
several decades (Compston & Coles, 2008; Goldenberg, 2012). While several 
mechanisms have been proposed to explain the different pathogenesis of courses 
(Kremenchutzky, Rice, Baskerville, Wingerchuk, & Ebers, 2006; Lassmann, van 
Horssen, & Mahad, 2012), three major clinical phenotypes have been defined (Lublin & 
Reingold, 1996). Phenotypes include relapsing-remitting MS (RRMS), secondary 
progressive MS (SPMS) and primary progressive MS (PPMS). 
 
Around 85% of pwMS present with RRMS (Murray, 2006), which is described as an 
acute worsening of neurological functioning, followed by a variable degree of recovery, 
with a stable course between attacks (Lublin & Reingold, 1996). Some researchers have 
suggested the process of re-myelination may contribute to periods of partial or complete 
recovery for individuals with RRMS (Compston & Coles, 2008). However, over time 
around 65% of people with MS (pwMS) with RRMS enter the SPMS phase, 
characterised by uninterrupted progression with or without occasional relapses, minor 
remissions and plateaus (Lublin & Reingold, 1996). Whilst progressive disease 
typically begins around 40 years of age (Confavreux & Vukusic, 2006), 10% to 20% of 
pwMS may experience progressive illness from disease onset (Compston & Coles, 
2008; Lassmann et al., 2012). Fifteen percent of pwMS present initially with PPMS 
(Murray, 2006), reflecting a gradual and almost continuously worsening baseline with 
minor fluctuations usually without relapses (Lublin & Reingold, 1996). Primary and 
secondary MS have been regarded as essentially similar (Compston & Coles, 2008; 




There are two further MS categories that elude consensus in terms of an established 
clinical definition. A small number of pwMS are thought to experience “relapsing-
progressive” MS (RPMS), characterised by a combination of relapse and progression 
(Bamer, Cetin, Amtmann, Bowen, & Johnson, 2007; Lublin & Reingold, 1996). In 
addition, around 15% of pwMS experience “benign MS”, described as a 10 to 15 year 
period of minor symptoms or disability after a diagnosis, presumed to be a mild form of 
RRMS (Pittock et al., 2004). 
 
The age of MS onset typically ranges from 20 to 45 years. Although MS often presents 
in middle age (Goldenberg, 2012), more recent evidence suggests around 3% to 10% of 
pwMS experience illness onset before 18 years of age (Mikaeloff, 2012). At 15 years 
post-diagnosis 80% of pwMS experience functional limitations, around 50% to 60% 
need assistance with ambulation, 70% are limited or unable to perform activities of 
daily living, and 75% are unemployed (Hauser & Oksenberg, 2006). Predictors of future 
disability in all MS subtypes include age of disease onset, sex (i.e. female), and extent 
of recovery after the first episode (Voskuhl & Gold, 2012). However, recent evidence 
shows that actual rates of disability accrual in pwMS with progressive disease vary 
considerably, where some experience long periods of clinical stability in absence of 
clinical worsening (Pandey et al., 2014). Despite the female preponderance in MS, men 
appear to have a poorer prognosis than women (Voskuhl & Gold, 2012). Whilst MS is 
not considered immediately fatal 50 to 60% of pwMS die from increased risk of 
infections, usually related to bladder, chest and skin complications at the more advanced 
stages of disease progression (Compston & Coles, 2008; Sadovnick, Eisen, Ebers, & 
Paty, 1991). The median time to death is around 30 years from disease onset, which 
equates to a reduction in life expectancy of 5 to10 years (Brønnum‐Hansen, Koch‐














MS is the most common cause of neurological disability in young adults, and is 
estimated to affect around 2.1 million people worldwide, with approximately 175,000 
newly diagnosed cases each year (WHO, 2008). According to more recent estimates 
126,669 people were living with MS in the UK in 2010, and around 6000 new cases 
were diagnosed (Mackenzie, Morant, Bloomfield, MacDonald, & O'Riordan, 2014). 
Northern Europe is regarded a “high frequency zone” for MS (≥30/100,000), 
comprising over half of the  population of people diagnosed across the globe (Kurtzke, 
2000).  
 
Epidemiological studies spanning the past six decades show incidence and prevalence 
estimates are higher in women compared to men (ratios ranging from 2:1 to 3:1, 
according to region), and recent meta-analyses indicate that the overall incidence of MS 
has increased over time, which is attributed to the increasing incidence among women 
(Duquette et al., 1992; Kingwell et al., 2013; Koch-Henriksen & Sørensen, 2010). 
Researchers propose several reasons why estimates have increased in the last few 
decades. Some argue the increase represents changes in heightened awareness and 
earlier detection, improved diagnostic techniques and longer survival (Compston & 
Coles, 2008; Koch-Henriksen & Sørensen, 2010; Ramagopalan & Sadovnick, 2011). 
Others suggest variation in study methods and quality, and a lack of diagnostic 
standardisation across geographic areas, may inflate current estimates (Kingwell et al., 
2013; Poser & Brinar, 2007). However, it has been argued that increases in incidence 
cannot be attributed to advances in neuroimaging or changes in diagnostic criteria alone 
(Visser, Wilde, Wilson, Yong, & Counsell, 2012). 
 
1.2.2.2 Aetiology: Genes and environmental factors 
 
The causes or potential triggers of MS are not yet fully understood. However, it is 
widely accepted that a complex multifactorial interplay of genetic and environmental 
factors contribute to disease development (Almohmeed, Avenell, Aucott, & Vickers, 
2013; Handel et al., 2011; Ramagopalan, Dobson, Meier, & Giovannoni, 2010; Vollmer 
20 
 
et al., 2002). Whilst there is evidence for a genetic risk component in MS (Compston & 
Coles, 2008), a large proportion of the disease heritability is still unaccounted for 
(Gourraud, Harbo, Hauser, & Baranzini, 2012). This may reflect limitations with 
genetic analyses, which often assume MS is one disease, when in fact there is evidence 
for genetic heterogeneity (Compston & Coles, 2008). Familial recurrence is around 
20%, where first-degree relatives are most at risk (3%), and monozygotic (or identical) 
twins have five times the risk of developing the disease compared to dizygotic twins 
(25% vs. 5%). Consistent with the uneven geographic distribution of MS, prevalence 
rates vary substantially among different racial and ethnic groups, with the highest rates 
existing in Northern European Caucasians, and lowest in people of African or Asian 
origin (Vollmer et al., 2002). 
 
A number of environmental risk factors have also been shown to determine 
susceptibility to MS and its disease course (Ebers, 2008; Koch, Metz, Agrawal, & 
Yong, 2013). The latitudinal gradient hypothesis suggests the global distribution of MS 
increases with greater distance north or south of the equator (Compston & Coles, 2008; 
Ramagopalan & Sadovnick, 2011), varying considerably between regions and 
populations, even when accounting for genetic factors (Simpson, Blizzard, Otahal, Van 
der Mei, & Taylor, 2011; Vollmer et al., 2002). The latitudinal gradient hypothesis and 
association between disease onset and migration from low- to high-risk regions before 
adolescence (Compston & Coles, 2008; O’Gorman, Lucas, & Taylor, 2012) has led 
researchers to examine evidence for the hygiene hypothesis (Leibowitz et al., 1966). 
The hygiene hypothesis assumes that a lack of exposure to childhood infections may 
predispose susceptible individuals to autoimmune and allergic diseases in later life 
(Fleming & Fabry, 2007). Therefore, Epstein–Barr virus (EBV), herpes simplex virus 
types 1, 2 and 6, measles, mumps and rubella have all been implicated as potential 
triggers of MS (Kakalacheva, Münz, & Lünemann, 2011; Vollmer et al., 2002). 
However, empirical support for the importance of viruses remains largely inconsistent. 
Whilst EBV in particular has received a lot of research attention more recently, studies 
examining the association between EBV and MS also show divergent results, and those 
examining causal relationships have several methodological limitations (Almohmeed et 
al., 2013; Ascherio & Munger, 2007; Kakalacheva et al., 2011; Koch et al., 2013). In 
addition, there is conflicting evidence for the association between MS and other 




More recently, inconclusive findings related to virus detection and infective agents have 
resulted in research examining environmental factors that vary with latitude. One of the 
most researched factors to date is ultraviolet radiation (UVR) or vitamin D (Simpson et 
al., 2011). Low exposure to sunlight, mediated through vitamin D insufficiency, appears 
to be associated with MS (Ho, Alappat, & Awad, 2012; O’Gorman et al., 2012; 
Ramagopalan & Sadovnick, 2011), and is regarded as a critical factor for the increasing 
incidence and prevalence of female cases (Sellner et al., 2011). Another potentially 
important environmental factor is cigarette smoking, which according to a recent meta-
analysis, is associated with MS susceptibility in earlier life, although the effect on 
disease progression is less clear (Handel et al., 2011). 
 




There is no single diagnostic test for MS (Goldenberg, 2012). Poser’s diagnostic criteria 
emerged during the 1980s, requiring individuals to have at least two relapses or 
exacerbations typical of MS (time dissemination criterion), and evidence of disease 
involvement of white matter in more than one site in the CNS (space dissemination 
criterion) (Poser et al., 1983). McDonald’s criteria later incorporated MRI findings to 
identify multiple areas of involvement, whilst examining patterns of change over time to 
detect new enhancing lesions (Fangerau et al., 2004; McDonald et al., 2001). A third 
criterion is chronic inflammation of the CNS, determined by analysis of cerebrospinal 
fluid with lumbar puncture procedures (inflammatory criterion) (Goldenberg, 2012). 
McDonald’s criteria has improved diagnostic specificity and sensitivity (Murray, 2006; 
Pollmann & Feneberg, 2008), where the presence of one or more of these criteria allows 




Currently there is no cure for MS (Goldenberg, 2012; Ramagopalan & Sadovnick, 
2011). However, advances in diagnostic techniques have enabled earlier decisions about 
pharmacological treatment options (Murray, 2006). Early treatments for pwMS included 
symptomatic therapies, supplemented by rehabilitation, exercise and diet (Vollmer et 
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al., 2002). The development of immunomodulatory or disease modifying drugs (DMDs) 
emerged in the 1990s (Compston & Coles, 2008), having a significant impact on 
altering the natural history of MS (Samkoff & Goodman, 2011). Early generalised 
immunosuppression DMDs included chemotherapies and corticosteroids. Whilst these 
have only demonstrated modest benefits in terms of slowing disease progression 
(Vollmer et al., 2002), they are often used to treat acute exacerbations to shorten the 
duration of MS attacks (Goldenberg, 2012).  
 
A newer group of DMDs include beta interferon, an injectable therapy, which alters a 
class of immune system functions, irrespective of antigenic target, without causing 
generalised immunosuppression (Vollmer et al., 2002). A recent review indicates these 
drugs reduce relapses by one third and MRI-associated disease activity by 50% to 80% 
(Goldenberg, 2012), with effects persisting beyond two years of treatment (Duquette et 
al., 1995). Another treatment is an oral agent called glatiramer acetate, which alters 
immune response to a specific antigenic target (Vollmer et al., 2002). Three reviews 
suggest that large RCTs show newer DMDs reduce the severity and frequency of new 
demyelinating episodes (Compston & Coles, 2008; Lassmann et al., 2012; Murray, 
2006). However, DMDs are only partially effective for people with RRMS and those 
with SPMS who continue to have relapses, but have very little benefit for those with 
PPMS (Compston & Coles, 2008; Goldenberg, 2012; Goodin, Cohen, O’Connor, 
Kappos, & Stevens, 2008). In addition, DMDs can potentially have unpleasant side 
effects (Goldenberg, 2012; Goodin et al., 2007) and do not lessen irreversible axonal 
injury, which is thought to account for the symptomatic burden of MS (Samkoff & 
Goodman, 2011). Therefore, treatment of MS-related symptoms aim to improve quality 
of life (Compston & Coles, 2008) and are regarded as an essential cornerstone of 
comprehensive care for pwMS (Boissy & Cohen, 2007). Pharmacological treatments 
have been used to manage several symptoms, including  fatigue, bladder dysfunction, 
spasticity and mood, albeit with relative success (Compston & Coles, 2008). However, 
researchers suggest more difficult symptoms include pain and dysesthesia (abnormal 
sensation), motor problems, sexual dysfunction, weakness, tremor, ataxia (coordination 
and balance) and cognitive changes (Murray, 2006). 
 
According to current National Institute for Health and Care Excellence (NICE) 
guidance for MS (NICE, 2003, 2014), in addition to the role of neurologists and 
pharmacological treatments, pwMS may also receive comprehensive care that includes 
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access to physiotherapists, occupational therapists, speech and language therapists, 
psychologists, social workers, pharmacists and continence specialists. These 
professionals provide expertise in the management of chronic neurological illness, with 
specialist nurse practitioners playing a key role in coordinating services and 
management for pwMS.   
 
1.2.4 A Disease with high burden 
 
A diagnosis of MS has profound social and psychological consequences for the 
individual, having the potential to threaten independence, autonomy, dignity and future 
plans (Boeije, Duijnstee, Grypdonck, & Pool, 2002; Vleugels et al., 1998). The onset of 
physical limitations associated with MS often occurs at a time when individuals are 
developing careers, building families or forming romantic relationships (Robinson, 
1988). Evidence shows that symptoms and worsening disability may adversely affect 
several domains of functioning, placing limits on an individual’s ability to work and 
generate an income, and engage in family and a broader social life. PwMS can also 
experience symptoms as embarrassing and unpredictable, which can be transient or 
invisible, resulting in the presence and seriousness of illness being doubted by others 
(Robinson, 1988). Quality of life (QoL), and physical and psychological domains of 
health-related quality of life (HQoL), defined as the capacity to derive satisfaction from 
meaningful behaviour despite disease (Benedict et al., 2005), are commonly associated 
with higher levels of fatigue, depression, physical disability and unemployment in MS 
(Aronson, 1997; Lobentanz et al., 2004; Miller & Dishon, 2006; Piwko et al., 2007; Rao 
et al., 1991). However, there is also a growing awareness that psychological, social and 
psychiatric issues influence HQoL in MS independent of physical disability (Mitchell, 
Benito-León, González, & Rivera-Navarro, 2005). Researchers have suggested that 
some pwMS appear to adapt well to modest disabilities, whilst others cope well even 
when faced with severe setbacks (Cruveilhier, 1998; Devins, Seland, Klein, Edworthy, 
& Saary, 1993).  
 
MS also has a potentially negative impact on the wider social context. Although higher 
levels of social support are associated with greater QoL for pwMS (Schwartz & 
Frohner, 2005), poorer QoL in caregivers is associated with several factors, including 
being  a spouse, caregiving for a long duration, greater severity of MS symptoms and 
disease subtype of the care recipient (Aronson, 1997). MS also has high costs for 
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society. Worsening disability in MS is associated with high health and social care costs 
and significant productivity losses in the UK (Kobelt, Berg, Lindgren, Fredrikson, & 
Jönsson, 2006; McCrone, Heslin, Knapp, Bull, & Thompson, 2008), Europe (Kobelt et 
al., 2006), Canada (Piwko et al., 2007) and the US (Zwibel & Smrtka, 2011). The 
overall cost of MS in the UK alone was estimated to be £1.5 billion in 1999, with a 
mean annual cost of over £30,000 per individual (Kobelt et al., 2000). Therefore, the 
negative consequences of MS are far-reaching, presenting an important challenge for 
health and social care providers worldwide. 
 
1.2.5 Psychological consequences of MS and associated interventions  
 
The literature highlights a variety of negative psychological consequences associated 
with MS. One review suggests that psychosocial factors are more strongly associated 
with reduced quality of life than disease variables (Mitchell et al., 2005). Since the 
1980s psychological interventions have been developed to address some of these 
problems and have demonstrated promising efficacy. A brief summary of this research 
will be outlined in the following section, focusing on the specific contribution of 
cognitive behavioural treatments. 
 
1.2.5.1 Cognitive behavioural therapy for depression and adjustment in MS 
 
A common psychological consequence of MS is depression. Estimates of depression 
over the course of a person’s lifetime range from 25% to 50%, which is 2 to 5 times 
greater than the general population, depending on the assessments used and the country 
studied (Feinstein, Magalhaes, Richard, Audet, & Moore, 2014; Ghaffar & Feinstein, 
2007; Minden & Schiffer, 1990; Sadovnick et al., 1996; Siegert & Abernethy, 2005). 
Anxiety is not as well researched as depression in MS, but studies show that anxiety 
prevalence estimates range from 34% to 45% (Janssens et al., 2003; Korostil & 
Feinstein, 2007; Wood et al., 2012). Whilst recent longitudinal data suggests pwMS 
experience gradual reductions in anxiety over time (Wood et al., 2012), depression in 
MS is thought not to spontaneously remit (Mohr & Goodkin, 1999). Researchers have 
suggested that depression may be caused by a manifestation of cerebral inflammation, 
and a response to the uncertainties and restrictions imposed by the progressive and 
disabling nature of the condition (Compston & Coles, 2008). Depression has also been 
highlighted as a risk factor contributing to the 7.5 fold increase in suicide rates among 
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pwMS when compared to healthy controls (Sadovnick et al., 1991), with a cumulative 
lifetime risk of suicide from MS onset of 1.95% (Stenager et al., 1992) .    
 
Five systematic reviews, including two meta-analyses, have summarised evidence for 
psychological interventions for depression and adjustment in MS (Hind et al., 2014; 
Mohr & Goodkin, 1999; Simpson et al., 2014; Thomas, Thomas, Hillier, Galvin, & 
Baker, 2006). Collectively, these reviews have predominantly focused on the efficacy of 
cognitive behavioural therapy (CBT), showing promising support for improved 
outcomes in pwMS. Broadly speaking, CBT is founded on the premise that 
physiological, cognitive (thinking), emotional, and behavioural responses may influence 
one another in a reciprocal way within the context of the social environment, where 
change in any one of these responses may produce changes in others (Beck, 1991; 
Dennison & Moss-Morris, 2010). The first review by Mohr et al (Mohr & Goodkin, 
1999) included 5 studies showing that all treatments for depression in MS, including 
medication, stress management, insight-oriented therapy, and three studies evaluating 
CBT, were significantly more effective than no treatment, and comparable to 
antidepressant medication. A subsequent Cochrane review summarised rather limited 
trial evidence in this area, but concluded that CBT approaches may be beneficial in the 
treatment of depression and adjustment to MS (Thomas et al., 2006). The third review 
indicated that core components of CBT (i.e. goal setting and home work) were more 
beneficial in improving pwMS QoL compared to other non-pharmacological treatments 
(Malcomson, Dunwoody, & Lowe-Strong, 2007). A more recent meta-analysis of seven 
studies evaluating CBT for depression in MS showed a medium treatment effect size 
when compared to standard care and other alternative psychotherapeutic interventions 
(Hind et al., 2014). Overall, most of the reviewed studies have several methodological 
limitations, where many used small samples that were uncontrolled and non-
randomised. However, a more recent clinical audit supports these efficacy-based trials, 
showing that CBT for depression and anxiety in routine clinical practice may be 
effective for pwMS (Askey-Jones, David, Silber, Shaw, & Chalder, 2013). Whilst CBT 
has been adapted for pwMS in these studies, few were guided by an empirically 
supported conceptual model of anxiety or depression specific to MS.  
 
In contrast, there has been growing support for a theoretical model of adjustment that 
has guided treatment developments in MS. Adjustment has been variably defined in the 
context of chronic illness  as “the healthy rebalancing by patients to their new 
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circumstances” (de Ridder, Geenen, Kuijer, & van Middendorp, 2008, p.246) or as 
affecting a range of life domains, unfolding over time and varying considerably between 
individuals (Stanton, Revenson, & Tennen, 2007). A large systematic review 
(Dennison, Moss-Morris, & Chalder, 2009), summarising evidence from 72 empirical 
studies, shows that several potentially modifiable cognitive behavioural factors, 
including perceptions related to illness, perceived stress and certain emotion-focused 
coping strategies, are associated with poorer outcomes across a number of domains in 
MS. These findings informed the development a conceptual model of MS adjustment 
(Dennison et al., 2009). 
 
Briefly, the conceptual model of MS adjustment integrates elements within existing 
contextual and cognitive behavioural psychological models (Beck, 1976; Hayes, 1999). 
The model suggests that a person’s previous learning history, and individual 
personality, influence the development of beliefs about one’s self, the world or future 
(the cognitive triad). A person’s beliefs are hypothesised to influence their behaviours, 
which includes their values and goals. However, critical events, including those specific 
to MS, such as receiving a diagnosis or experiencing new symptoms, relapse or disease 
progression, may interfere with pwMS’ values, goals and behaviours. Consequently, a 
person’s emotional equilibrium may become disrupted, posing a threat to their overall 
wellbeing and quality of life. Although emotional distress from the disruption is 
considered to be an expected response to critical events, the model suggests that 
prolonged distress may indicate problems with adjustment. The model identifies a 
variety of empirically supported cognitive behavioural factors or processes involved in 
this disruption process, which may interact and maintain distress. These include MS-
specific illness representations or symptom perceptions, and related behavioural 
responses, such as excessive rest or avoidance of activities. The illness-specific nature 
of these cognitions and behaviours are distinct from more general beliefs (e.g. cognitive 
triad and threat perceptions) and behaviours typically addressed in the context of CBT 
for patients with anxiety and depression. 
 
In combination with qualitative findings (Dennison, Yardley, Devereux, & Moss-
Morris, 2010), a subsequent cross-sectional study of pwMS provided further support for 
the model of adjustment by showing that whilst disease factors, such as disease severity 
and MS subtype, accounted for around 25% of the variance in functional impairment, a 
further 20% was explained by cognitive and behavioural factors drawn from the model. 
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Specifically, behavioural responses to symptoms, including activity avoidance or 
excessive rest, and “all-or-nothing” behaviour, defined as over-exerting oneself when 
feeling well to meet perceived demands, resulting in periods where they need to rest and 
recover due to exhaustion, were identified as the strongest predictors of functional 
impairment. In addition, disease factors accounted for only 2.2% of the variance in 
distress, whilst cognitive and behavioural variables, including beliefs related to the self 
and how well pwMS understood their condition (coherence), accounted for a further 
37%, in which self-related beliefs were the strongest predictors of distress (Dennison, 
Moss-Morris, Silber, Galea, & Chalder, 2010). The empirically supported model 
mapped directly onto the development of a nurse-led CBT intervention tailored 
specifically for MS adjustment (Moss-Morris et al., 2013). Whilst the intervention did 
not show significant treatment effects in functional outcomes and quality of life within 
the CBT (n = 48) compared to a supportive listening control group (n = 46), it did 
significantly reduce levels of distress for up to 12 months. Findings showed that the 
effect size observed in distress reduced from a moderate to small treatment effect from 
end of treatment to 12 months follow-up, which might be explained by the active 
ingredients of the supportive listening control group sharing some overlap with core 
components of CBT. There was also potential for aggregation bias, since pwMS with 
longer disease duration and greater levels of disability at baseline experienced larger 
decreases in quality of life. Overall, results indicate that a nurse led CBT treatment 
based on an empirically supported model of MS adjustment is likely to be helpful for 
pwMS. 
    
To date, there has been a greater focus on using CBT for improving mental health and 
wellbeing in MS (Dennison & Moss-Morris, 2010), but less research has targeted the 
severity and impact of other MS symptoms traditionally viewed as ‘somatic’ in nature. 
However, a growing number of studies show that modifying psychological factors with 
CBT may improve management of other symptoms. A recent review including 22 
studies indicates that whilst a variety of psychological interventions, including CBT, 
appear to reduce levels of depression and distress in MS, they also improve symptoms 
of fatigue, pain and insomnia (Pagnini, Bosma, Phillips, & Langer, 2014). However, to 
date few of these studies aimed to specifically target these symptoms, and only one has 
been guided by an empirically supported conceptual model of MS fatigue (van Kessel et 




1.2.5.2 A conceptual model and cognitive behavioural treatment for MS fatigue 
 
Fatigue is one of the most prevalent and disabling MS symptoms (Krupp et al., 1988; 
Monks, 1989), having the potential to limit a person’s ability to carry out everyday 
activities, and result in unemployment and reduced quality of life  (Amato et al., 2001; 
Bol, Duits, Hupperts, Vlaeyen, & Verhey, 2009). Whilst current biomedical treatments 
for fatigue demonstrate modest efficacy (van Kessel et al., 2008), a larger body of MS 
empirical studies (Bol et al., 2009) and a conceptual model of MS fatigue (van Kessel & 
Moss-Morris, 2006) suggest that biological, emotional, cognitive and behavioural 
factors play a potentially important role in the maintenance of this multifactorial 
symptom. Whilst disease inflammation and demyelination are thought to trigger fatigue, 
cognitive behavioural factors such as anxiety, depression, helplessness, emotional 
representations (i.e. the extent to which the fatigue affects them emotionally), and 
beliefs surrounding fatigue, related to somatic or causal attributions, consequences, 
timeline (i.e. how long the person believes the fatigue will last), control and coherence 
(i.e. the extent the person believes that they understand their fatigue) are consistently 
associated with worse fatigue severity and related disability (Bol et al., 2009; Jopson & 
Moss-Morris, 2003; Knoop, van Kessel, & Moss-Morris, 2012)1. In addition, findings 
indicate that specific behavioural responses may also result in greater fatigue and 
disability. Specifically, pwMS may either engage in excessive rest or avoid activity 
(both forms of behavioural avoidance), or “all-or-nothing” behaviour (Skerrett & Moss-
Morris, 2006). The model suggests that these responses contribute to the maintenance of 










                                                 
1For more details on the theory that underpins these psychological variables see Leventhal’s Common 
Sense Model of Illness Perceptions outlined in chapter 2 section 2.3.2.3 (Leventhal, Brissette, & 
















Figure 1: An example of cognitive and behavioural factors involved in of MS Fatigue 
(van Kessel & Moss-Morris, 2006) 
 
There have also been a number of psychological interventions designed to address 
improved fatigue management in MS. One recent scoping review (Asano, Berg, 
Johnson, Turpin, & Finlayson, 2014) and two systematic reviews (Asano & Finlayson, 
2014; Khan, Amatya, & Galea, 2014) show that non-pharmacological interventions, 
including CBT, are more effective in reducing fatigue and its impact compared to 
current pharmacological treatments. However, only two of the reviewed studies 
evaluated CBT programmes specifically targeting factors in the MS fatigue model 
outlined above to improve fatigue management (Moss-Morris et al., 2012; van Kessel et 
al., 2008). Both studies also indicated that CBT was substantially more effective in 
these studies compared to other reviewed educational or psychological interventions.  
 
One of the studies was an RCT, which compared an eight-week manualised CBT 
programme tailored specifically for MS fatigue (n = 35) to relaxation training (n = 37). 
The study showed that both treatments were clinically effective in reducing fatigue to 
levels of a healthy comparison group, and these large significant effects were 
maintained at six months follow-up (van Kessel et al., 2008). Whilst there were no 
significant differences between the treatment groups on secondary outcomes, there were 
trends of improvement in fatigue-related impairment in both groups, and greater 
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one potential limitation is that these findings may reflect non-specific treatment factors, 
including pwMS’ expectations, along with support and therapist time and attention 
common to both approaches (van Kessel et al., 2008). However, a secondary data 
analysis provided additional support for the MS fatigue model, where avoidance 
behaviour and cognitive variables, including symptom focusing, believing symptoms 
were a sign of damage, and negative illness perceptions of fatigue, mediated treatment 
effects, showing that change in these factors predicted the greater improvement in the 
CBT compared to the relaxation group (Knoop et al., 2012).  
 
The second study was a smaller pilot RCT, which evaluated the feasibility, efficacy and 
cost-effectiveness of a web-based version of the same MS fatigue intervention. Findings 
showed that pwMS receiving online CBT (n = 23) showed significantly greater 
improvements in anxiety and depression, and quality-adjusted life years compared to 
standard care (n = 17) (Moss-Morris et al., 2012). Furthermore, another recent pilot 
RCT, which was not included in the reviews outlined, used the online elements of the 
self-management intervention only (van Kessel, Wouldes, & Moss-Morris, 2015). 
Findings demonstrated that pwMS who received online CBT with email support (n = 
19) had significantly greater reductions in fatigue severity and impact compared to those 
without email support (n = 20). Overall, these findings provide further evidence for the 
proposed cognitive behavioural model of MS fatigue (van Kessel & Moss-Morris, 
2006), and suggest that low and high intensity tailored CBT interventions  mapping 
directly onto the model of MS fatigue, may be clinically, and potentially cost-effective, 
treatments. However, larger pragmatic RCTs evaluating both clinical- and cost-
effectiveness are needed before firm conclusions can be drawn. Research on MS fatigue 
has parallels with research in chronic pain, which is conceptualised using 
biopsychosocial and cognitive behavioural models (these will be discussed in greater 
detail in chapter 2). However, there has been little work in this area focusing 









1.2.6 The problem of pain in MS 
 
1.2.6.1 Prevalence and aetiology  
 
A recent meta-analytic review suggests that pain affects around 63% of pwMS (Foley et 
al., 2013). However, many studies report variable prevalence estimates, which may in 
part be due to divergent definitions of pain, measurements used and patient populations 
studied (Alschuler, Jensen, & Ehde, 2012b; Michalski, Liebig, Thomae, Hinz, & Bergh, 
2011; O'Connor, Schwid, Herrmann, Markman, & Dworkin, 2008). MS associated pain 
is not a single symptom, but rather reflects a number of complex syndromes arising 
from multiple aetiologies (Osborne, Jensen, Ehde, Hanley, & Kraft, 2007). Whilst a 
review of neuroimaging studies has identified positive associations between the location 
of demyelinating lesions and specific neuropathic pain syndromes in MS, neuro-
radiological correlates of pain are generally small (Seixas et al., 2014). Therefore, the 
precise underlying biological mechanisms of painful syndromes in MS remains unclear, 
and causal distinctions related to chronicity used in the literature may not necessarily be 
accurate (Seixas et al., 2014). PwMS can experience acute or chronic pain (Indaco, 
Iachetta, Nappi, Socci, & et al., 1994), which is broadly classified as either neuropathic 
pain, resulting from nerve damage due to the underlying pathological process (Beard, 
Hunn, & Wight, 2003), musculoskeletal pain, related to degenerative muscle or joint 
dysfunction, usually secondary to spasticity, mobility, or gait and posture anomalies 
(Grasso et al., 2008). PwMS may also experience migraine headache (O'Connor et al., 
2008), which may be neuropathic in origin, or unrelated or secondary to disease 
processes (Moisset et al., 2013). Pain may also be caused by other MS symptoms and 
treatments (Pöllmann, Erasmus, Feneberg, Bergh, & Straube, 2002; Pollmann & 
Feneberg, 2008). Neuropathic pain includes central neuropathic (‘‘dysesthetic’’) 
extremity pain (described as burning sensations in the limbs), trigeminal neuralgia 
(facial pain), Lhermitte's sign (a sudden electric shock-like sensations in the neck, 
which spreads to the arms or legs, usually triggered by flexion in the neck, bending 
forward, coughing or sneezing), and painful tonic spasms, including paroxysms (MS 
Society UK, 2011). One review suggests the most common form of pain in MS is 
central dysesthetic extremity pain (O'Connor et al., 2008). However, pwMS usually 
experience one or more of these painful symptoms over the course of their disease 




Several demographic and disease factors appear to be associated with a greater 
likelihood of painful symptoms in MS. These include older age, longer disease duration, 
and greater disease severity, where people with progressive MS have a greater risk of 
developing pain compared to other MS subtypes (O'Connor et al., 2008). Whilst other 
studies suggest the presence of MS pain is not consistently associated with age or 
gender (Archibald et al., 1994; Beiske, Pedersen, Czujko, & Myhr, 2004; Ehde et al., 
2003; Stenager, Knudsen, & Jensen, 1991), women tend to report greater intensity or 
severity of pain (Hadjimichael, Kerns, Rizzo, Cutter, & Vollmer, 2007). Since there are 
no reliable biomarkers of pain in MS, pain severity has been operationalised in clinical 
and research settings using subjective self-report instruments. Whilst instruments can 
vary in the literature, pain severity is commonly measured using numerical rating scales 
(NRS), which can either range from 0 (no pain) to 10 (pain as bad as you can imagine) 
or 0 to 100, or visual analogue scales (VAS). Recent efforts to categorise pain 
experience using 0 to 10 point NRS suggest that MS pain can be classified as mild, 
moderate or severe (Alschuler et al., 2012b). One of the largest MS pain studies in the 
literature (n = 7579) indicates that greater pain severity is associated with lower 
educational level, increased age and disability, and an unstable disease course 
(Hadjimichael et al., 2007). 
 
1.2.6.1 The impact of MS pain 
 
MS pain is directly associated with reduced QoL and HQoL in MS (Mitchell et al., 
2005; O'Connor et al., 2008). Pain severity is also related to reduced physical 
functioning and role limitations (Brochet et al., 2009; Kalia & O'Connor, 2005; 
Newland, Naismith, & Ullione, 2009), and increased pain interference (Bruce & Arnett, 
2009; Glowacka, 2010; Hirsh, Turner, Ehde, & Haselkorn, 2009). Alschuler et al’s 
classification system for pain severity in MS was developed in conjunction with 
measures of pain interference (Alschuler et al., 2012b), reflecting another key outcome 
within chronic pain trials (Dworkin et al., 2010; Dworkin et al., 2008). Pain interference 
has been defined as the extent to which pain interferes with every-day life activities, 
including sleep, mood, mobility, relationships and recreational activities (Ehde, 
Osborne, Hanley, Jensen, & Kraft, 2006; Osborne, Raichle, Jensen, Ehde, & Kraft, 
2006). Pain-related interference is also typically measured using NRS ranging from 0 
(does not interfere) to 10 (completely interferes), across these different life domains.  
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There are mixed findings for the relationship between the presence of pain and 
unemployment status in MS (Julian, Vella, Vollmer, Hadjimichael, & Mohr, 2008; 
Miller & Dishon, 2006; Newland, Fearing, M., & Neath, 2012; Simmons, Tribe, & 
McDonald, 2010), but longitudinal evidence suggests pain does not appear to predict 
unemployment over time (Julian et al., 2008). However, several studies show that 
pwMS with greater pain severity tend to report higher levels of disability and make 
more health care visits than those without pain (Alschuler, Jensen, & Ehde, 2012a; 
Hadjimichael et al., 2007; Khan & Pallant, 2007; Sullivan, Edgley, Mikail, Dehoux, & 
et al., 1992). A recent cross-sectional study in the US indicates that 75% of pwMS 
report at least one visit to their healthcare provider for pain within a 6 month period, 
with an average of 9.7 visits per person (Ehde, Alschuler, et al., 2015), which indicates 
pain may be inadequately treated and is associated with high healthcare costs. 
 
The majority of existing MS studies show that pain is associated with impaired 
psychosocial functioning (Douglas, Wollin, & Windsor, 2008; Ehde et al., 2006; Grasso 
et al., 2008; Hirsh, Bockow, & Jensen, 2011; Hirsh et al., 2009; Khan & Pallant, 2007), 
and is related to increased rates of depression (Alschuler, Ehde, & Jensen, 2013; 
Brochet et al., 2009; Hadjimichael et al., 2007; Newland et al., 2009; White, White, & 
Russell, 2008) and anxiety (Bruce & Arnett, 2009; Kalia & O'Connor, 2005; Rog, 
Nurmikko, Friede, & Young, 2007; White et al., 2008). This is consistent with the 
finding that pwMS also view pain as one of the most distressing MS symptoms (Kalia 
& O'Connor, 2005).  
 
1.2.6.2 Current treatments 
 
Recent studies indicate the most common treatments for pain reported by pwMS are 
biomedical or biomechanical in nature, including pharmacological therapies, physical 
therapies, stimulation techniques and surgical interventions (Ehde, Alschuler, et al., 
2015; Jensen & Finnerup, 2007; Khan & Pallant, 2007). According to a recent US 
study, pwMS have access to a range of drug treatments for pain (Ehde, Alschuler, et al., 
2015). Anticonvulsants and tricyclic antidepressants are typically prescribed for 
neuropathic pain (Jensen & Finnerup, 2007; Kalso, Aldington, & Moore, 2013), whilst 
other drug classes include non-steroidal anti-inflammatory drugs (NSAIDS), 
acetaminophen, serotonin–norepinephrine reuptake inhibitors (SNRIS), opioids, 
cannabinoids, compound analgesics, local anesthetics, triptans, benzodiazepines, 
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benzoxazocine, benzcycloheptenes, and capsaicinoids. Whilst certain 
pharmacotherapies for pain have known mechanisms of action, researchers in the area 
concede that it can be difficult to determine the specific underlying causal mechanisms 
for each patient (Jensen & Finnerup, 2007). Four reviews show that pharmacological 
treatments for MS pain range in their effectiveness depending on the medication 
evaluated (Beard et al., 2003; De Santi & Annunziata, 2012; Jawahar, Oh, Yang, & 
Lapane, 2013; Siniscalchi, Gallelli, & De Sarro, 2007). However, few drug treatments 
have been examined within RCTs, and generally there is insufficient evidence to 
support their efficacy despite some being well-established in the clinical context. 
Another limitation cited in these reviews is the lack of consistency of pain severity and 
other outcome measures across studies (Beard et al., 2003).  
 
One recent cross-sectional study suggests that some pwMS report benefits from 
biomedical treatments, achieving around 30% to 60% of pain relief from a range of 
medications, including non-prescribed smoked marijuana (Ehde, Alschuler, et al., 2015; 
Khan & Pallant, 2007). However, other studies indicate MS pain is often described as 
pervasive and overwhelming (Douglas, Windsor, & Wollin, 2008), and the majority of 
individuals experience persistent pain that is poorly controlled (Kerns, 2000). Therefore, 
it is not surprising that pwMS can often feel dissatisfied with their doctor’s efforts to 
manage their pain (Hadjimichael et al., 2007). Consistent with these findings, one cross-
sectional study shows that 45% of pwMS rated pain medications as the most effective 
treatment, but 48% felt they were ineffective (Heckman-Stone & Stone, 2001). It is also 
evident that most drug treatments for MS pain appear to have unpleasant side effects, 
including tiredness, interrupted sleep, nausea, diarrhoea, seizures and physical 
dependence (Siniscalchi et al., 2007; Smith, 2007; Wade, Makela, House, Bateman, & 
Robson, 2006), and some pwMS may fear the use of analgesics and prefer to avoid 
them (Abe et al., 2008). 
 
There is also a range of physical treatments for MS pain, although to date few have been 
carefully evaluated in the context of RCTs. Physical treatments include strengthening 
exercises, physical therapy, massage, pressure, heat or ice, whirlpool, mobility or range 
of motion exercises, change in position, change of clothes, comfortable furniture, 
chiropractic care, acupuncture, electric vibration, and nerve blocks (Ehde, Alschuler, et 
al., 2015; Khan & Pallant, 2007). According to a recent review (Jawahar, Oh, Yang, & 
Lapane, 2014), one potentially useful physical treatment is transcutaneous electrical 
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nerve stimulation (TENS), which has shown clinically, but not statistically, significant 
reductions in pain severity in two studies (Al-Smadi et al., 2003; Warke, Al-Smadi, 
Baxter, Walsh, & Lowe-Strong, 2006). However, only one of these studies was an RCT, 
and TENS effects tend to be short-term and only suitable for pwMS with chronic low 
back pain. Overall, whilst 44% of pwMS report using physical therapies (Khan & 
Pallant, 2007), most report achieving anywhere between 38% to 67% of pain relief 
(Ehde, Alschuler, et al., 2015). The variability in these findings is consistent with a 
recent systematic review of 13 studies showing that some non-pharmacological 
treatments, may reduce non-spastic and non-trigeminal central neuropathic pain severity 
(Jawahar et al., 2014). However, these studies focused primarily on pain severity and 
not pain-related functioning, and support for educational and physical interventions was 
mostly inconclusive due to a lack of RCTs evaluating their efficacy. Therefore, whilst 
educational, drug and physical treatments appear to have some benefit, it may be that 
offering pwMS an additional approach, alongside these treatments, may reduce pain 
severity and improve self-management and pain-related functioning.  
 
1.2.6.3 Preliminary biopsychosocial model of MS pain and psychological 
intervention research 
 
Compared to the primary chronic pain literature (see chapter 2), the psychosocial 
aspects of MS pain have received far less research attention to date, although there are 
studies examining the role of psychosocial factors in MS pain (see systematic review 
Harrison, McCracken, et al., 2015 in chapter 3). However, the majority of these studies 
have investigated psychosocial variables in isolation, and were not guided by a 
conceptual model that explains how these factors may contribute to pain severity and 
related disability, and how they interact with the neurobiology underpinning pain. 
 
One biopsychosocial conceptualisation of MS pain has been proposed in the literature 
(Kerns, 2000; Kerns, Kassirer, & Otis, 2002). Based on the diathesis stress model, this 
conceptualisation proposes that MS pain is multidimensional. Specifically, it suggests 
that in addition to neurobiological factors (including genetics), a person’s predisposing 
characteristics or vulnerabilities, learning history or life circumstances, will also 
influence their cognitive, emotional and behavioural responses to the stress associated 
with the challenges of pain and MS. Kerns also highlights how a person’s social 
context, including interactions with others, and observations of their behaviour (i.e. 
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social learning theory), may also influence how well they adapt to pain. Importantly, the 
model emphasises that all dimensions have equal importance in contributing to pain 
experience and functioning, which together determine an individual’s adjustment. 
Kerns’ model is therefore consistent with the diathesis stress theory of chronic pain, 
which suggests that when pain affects an individual who is already under significant 
psychological strain, or whose coping resources are already over-stretched, this may 
result in greater functional limitations and lead to higher levels of emotional distress 
(Flor, 2007; Linton & Shaw, 2011). However, an important adaption of Kerns’ model 
was that is recognised neurobiological factors specific to MS that may contribute to pain 
experience (e.g. disease status, relapse and pain medications), and highlighted the 
dynamic nature of a person’s adjustment in response to changing symptoms and disease 
progression. A key strength of the model is that it clearly identifies the need to examine 
the role of neurobiological variables specific to MS pain, including disability status, 
mental status, MRI findings and medication use, in conjunction with psychosocial 
elements.  
 
Kerns’ diathesis stress model also has some limitations. First, the model is more global 
in nature and fails to provide the content specificity of chronic pain models outlined in 
chapter 2 (Hasenbring & Verbunt, 2010; McCracken & Morley, 2014; Turk, 
Meichenbaum, & Genest, 1983; Vlaeyen & Linton, 2000). Specifically, the model 
predominantly focuses on pwMS’ predisposing vulnerability factors, which in 
combination with disease or pain-related stress, determines their perceived ability to 
cope with pain and its consequences (i.e. appraisals of coping efficacy), ultimately 
influencing the way in which they respond to pain. However, the model does not outline 
the specific cognitive or behavioural responses described in existing chronic pain 
theories, such as viewing pain as chronic or as a sign of damage, which may lead to 
excessive rest or over-exertion avoidance behaviours. In addition, it does not explain 
how these psychosocial factors interact with each other or neurobiological aspects. 
Consequently, the model does not distinguish between those psychosocial factors or 
processes that may be more or less helpful in this context. Therefore, it reflects a more 
broad-brush model that provides limited understanding of pwMS’ specific cognitive and 
behavioural responses to pain, and therefore offers limited guidance on how to intervene 
with cognitive behavioural treatments. Another limitation relates to review findings 
showing that neuropathic pain is relatively common in MS (O'Connor et al., 2008). 
Whilst Kerns highlights the importance of neurobiological factors, the model does not 
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explicitly distinguish between neuropathic and non-neuropathic (musculoskeletal) pain 
subtypes, which may lead to different psychosocial responses. Overall Kerns’ adaption 
of the diathesis stress model is a useful way of understanding MS pain because it 
emphasises interactions between a broad range of biological and psychosocial elements 
(Dworkin & Banks, 1999). Therefore, the model has been helpful in highlighting that 
MS pain has mainly been considered from a biomedical perspective, and a shift towards 
a broader biopsychosocial model is now needed. 
 
Another model in the MS literature draws on the motivational model of pain self-
management initially proposed by Jensen, Nielson and Kerns  (see Figure 2) (Jensen, 
Nielson, & Kerns, 2003). In contrast to Kerns’ global conceptualisation, this model 
focuses more on the motivational dimension of pain, emphasising that a person’s pain 
experience will depend, to a large extent, on how they choose to cope with pain and its 
impact. Specifically, it suggests that a person’s readiness to change (or maintain) more 
adaptive self-management behaviours, and avoid maladaptive responses, is influenced 
by their beliefs about the importance of coping behaviours and their ability to 
successfully perform them (i.e. self-efficacy). In turn the person’s behavioural coping 
responses are assumed to influence their overall functioning. The model has recently 
been empirically tested in the context of MS (Kratz, Molton, Jensen, Ehde, & Nielson, 
2011). Consistent with other chronic pain populations (Molton, Jensen, Nielson, 
Cardenas, & Ehde, 2008), findings indicated that perceived importance and self-efficacy 
beliefs about coping were not directly related to pwMS’ engagement with self-reported 
exercise or task persistence self-management behaviours. However, the relationship 
between both perceived importance and self-efficacy, and self-management behaviours 
was mediated by the person’s readiness to engage in those behaviours. As with other 
chronic pain models outlined in chapter 2, a key strength of the motivational model of 
pain is that it provides greater content specificity in terms of motivational processes. 
These constructs can therefore be empirically tested and targeted in the context of 
psychological interventions. Another strength of this model is that psychological 
constructs investigated map directly onto clinical approaches in the broader field of 
psychology, such as motivational interviewing (Miller & Rollnick, 2002), which can be 
incorporated within CBT treatments.  
 
The motivational model of pain self-management also has several limitations. First, the 
model has a narrower motivational focus, since it only includes pwMS’ beliefs about the 
38 
 
importance of engaging in pain management behaviours, and their ability to perform 
them successfully. The emphasis on motivation therefore appears to be to the exclusion 
of other potentially important cognitive factors or processes and emotional responses 
outlined in chronic pain theories in chapter 2. In addition, the model fails to 
acknowledge the role of neurobiological variables outlined in Kerns’ conceptualisation 
(Kerns et al., 2002). Therefore, the model may not be broad enough to explain the role 
of other potentially important psychological factors or processes associated with MS 
pain reviewed in chapter 3. Second, it is less clear whether self-management behaviours 
in the model are necessarily maladaptive or adaptive. For example, recent theories in 
chronic pain would argue that adaptive behaviours in the motivational model, such as 
ignoring pain, or persisting with tasks, could actually reflect potentially unhelpful 
behaviours in some circumstances (Eccleston & Crombez, 2007; Hasenbring & 
Verbunt, 2010; McCracken & Morley, 2014). Conversely, asking others for assistance 
when experiencing pain may not always be a maladaptive response. Another related 
issue is that the primary chronic pain literature generally regards pain severity and pain 
interference as important outcomes in all chronic pain trials (Dworkin et al., 2008). 
However, the primary outcomes identified in the motivational model of pain self-
management is coping behaviour, which is variably defined as behaviours or cognitions 
that are hypothesised to reflect either adaptive or maladaptive coping responses (Jensen 
et al., 2003). Therefore, the motivational model of pain self-management fails to specify 
which outcomes are of key importance, and does not explain how psychosocial 
variables interact with pain severity and pain interference outcomes, or neurobiological 
factors specific to MS. A final point is that the model specifies directionality by 
suggesting that cognitive factors influence coping responses. However, Kratz et al 
(Kratz et al., 2011) do not clearly explain how these factors may interact in a reciprocal 























Figure 2: The motivational model of pain self-management (Kratz et al., 2011) 
 
A more recent study has also proposed a biopsychosocial model of MS pain by 
examining associations between pain severity, other MS symptoms, depression and 
social support (Day et al., 2015). Consistent with a similar MS study (Shahrbanian, 
Duquette, Ahmed, & Mayo, 2015), findings indicate that most of these variables were 
significantly correlated with pain severity. However, the path-analytic model outlined 
was not explicitly linked to any established psychological theory, and focused mostly on 
depression to the exclusion of other potentially modifiable cognitive behavioural 
variables identified in existing chronic pain theories.  
 
In summary, whilst a few theories of MS pain have been proposed they all have some 
limitations, and most fail to review models in light of existing empirical evidence. It 
might therefore be useful to learn from more established chronic pain research spanning 
over the past fifty years to understand if specific psychosocial constructs from chronic 
pain theories can explain pain in MS. This large body of research might be helpful for 
explaining pwMS’ experience of non-neuropathic (musculoskeletal) pain in particular. 
However, it may also be helpful to explore the relevance of primary chronic pain 













Readiness to change  
(or maintain) self-












Avoid asking for assistance 
Avoid guarding 
Avoid catastrophizing 
Avoid pain contingent rest 




1.3 Thesis rationale and overview 
 
The current thesis aims to develop a conceptual model to guide the design and 
evaluation of a treatment to support pain management for pwMS. The empirical studies 
conducted in this thesis aimed to improve our understanding of MS pain and provide a 
potential intervention to assist pwMS to better manage this symptom in the future.  
 
To enhance our conceptual understanding of MS pain, literature describing the 
predominant theoretical models, key constructs, empirical evidence, and treatment 
approaches and their efficacy, in the context of chronic pain is reviewed and critiqued in 
chapter 2. This is followed by a brief summary of how these approaches may be 
relevant to MS pain. In chapter 3, a systematic review of studies investigating 
potentially modifiable psychosocial factors and processes associated with pain severity 
and pain related interference in MS was conducted (published article, Psychosomatic 
Research)2. The review findings contributed to the development of a preliminary 
cognitive behavioural theoretical model of MS pain. The following two chapters used 
different methods to test and refine the theoretical model of MS pain developed from 
the review. Chapter 4 presents a qualitative interview study using thematic analysis 
exploring key themes in experiences of pain in MS (published article, Multiple Sclerosis 
Journal). Chapter 5 describes a large quantitative cross-sectional questionnaire study of 
pwMS exploring associations between cognitive, emotional and behavioural variables 
drawn from the model, and pain severity and pain interference (published article, 
European Journal of Neurology). Chapter 6 summarises the development of a self-
management intervention for MS pain, and how it links to the updated cognitive 
behavioural theoretical model. A recently submitted article summarising individual 
case-series using mix-methods to evaluate the potential efficacy of an eight-week self-
management intervention with telephone support aiming to reduce pain severity and 
pain-related interference in pwMS is then presented in chapter 7. An examination of key 
processes of change in this study enabled further refinement of the theoretical model. 
Finally chapter 8 includes a discussion of findings and limitations across the studies 
included in the thesis, providing directions for future research. 
 
                                                 
2All citations within published articles have been converted to APA 6th style and will be included in the 
final reference section of the thesis.  
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Chapter 2 : Theoretical and Methodological Approaches to 
Understanding and Treating Primary Chronic, Non-disease 
Related, Pain Conditions. 
 
2.1 Chapter overview 
 
In order to advance the development of a working theoretical model of MS pain, the 
following chapter will briefly summarise evidence for psychological approaches used to 
understand and treat individuals with primary, non-disease related, chronic pain 
conditions. First, a brief context surrounding current conceptualisations of chronic pain 
will be outlined, along with definitions used within this thesis. Second, a critical 
evaluation of empirical evidence for the most prominent theoretical models and 
frameworks attempting to understand and treat primary chronic pain conditions will be 
discussed. The chapter will then conclude with a brief summary of how these 
approaches may be relevant to MS pain. The evolution of research developing 
psychological theories in chronic pain is voluminous extending over half a century. 
Therefore, the author will selectively summarise this literature, acknowledging this 
chapter does not reflect an exhaustive account due to the limited scope of this thesis. 
 
2.1.1 Defining primary chronic pain 
 
According to the International Association of the Study of Pain (IASP) (Merskey, 
1986), the need for a universal taxonomy of painful conditions was first highlighted by 
John Bonica in the late 1970s (Bonica, 1979). This resulted in a classification of chronic 
pain issued by the IASP Taxonomy Working Group in 1986, defining pain as: 
 
 “An unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage” (Merskey, 1986, p.226). 
 
Bonica had also previously defined chronic pain as pain which persists past the normal 
time of healing (Bonica, 1954). In practice this may be less than one month, or more 
often, more than six months (Merskey, 1986). For the sake of clarity and simplicity, the 
proceeding chapters of this thesis will refer to primary chronic pain conditions or 
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primary pain where pain is presented as the primary complaint. This is in contrast to 
pain which is specified in relation, or secondary, to a long-term condition (e.g. MS). 
 
2.2 Conceptualising chronic pain 
 
2.2.1 Evolution of a biopsychosocial perspective in chronic pain 
 
One of the earliest explanations of pain was proposed by the French philosopher Rene 
Descartes (Descartes, 1989), who described pain mechanistically, in dualistic mind and 
body terms, and suggested that tissue damage was a necessary condition for pain to 
occur. The prevailing Cartesian view meant that conceptualisations of pain remained 
mostly physiological throughout the early part of the 20th century (Gatchel, Peng, 
Peters, Fuchs, & Turk, 2007). However, the advent of psychoanalytic perspectives saw 
the rise of psychosomatic explanations of pain, which dichotomised painful symptoms 
as either physiological or psychological in nature, where inexplicable remitting and 
relapsing conditions, such as rheumatoid arthritis, were categorised as psychiatric 
‘hysterical conversion disorders’ (Alexander, 1950). The dichotomised view that pain 
either existed in the mind or body was later reflected in research investigating 
predisposing pain personality types of people with medically unexplained pain. This 
included the now widely refuted ‘Conversion V’ and ‘Neurotic Triad’ pain personality 
profiles, derived from the Minnesota Multiphasic Personality Inventory (MMPI) 
(Eccleston, 2011; Pilling, Brannick, & Swenson, 1967), which grew in popularity 
during the 1960s. ‘Conversion V’ depicted a V-shape pattern from composite scores on 
the MMPI, which identified individuals who experienced somatic symptoms in response 
to stress, expressed exaggerated concern over bodily sensations, and were unable to 
recognise their own emotional state. The ‘Neurotic Triad’ reflected a similar pattern, 
except these individuals were described as more demanding and complaining (Leo, 
2007). 
 
Around this time a shift towards a more integrated biopsychosocial understanding of 
pain physiology led to the introduction of gate control theory, proposed by Ronald 
Melzack and Patrick Wall (Melzack & Wall, 1967), and later Kenneth Casey (Melzack 
& Casey, 1968). Gate control theory provided a more complex, integrated 
multidimensional explanation of pain, which drew on both psychological findings 
(Beecher, 1959; Pavlov, Gantt, Volborth, & Cannon, 1941) and a combination of 
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specificity and pattern theories derived from clinical assessments (Hebb & Konzett, 
1949; Livingston, 1943). Together this evidence did not support a one-to-one 
relationship between pain perception and pain intensity of a stimulus, or that observable 
tissue damage was a pre-requisite for pain to occur. In addition, the traditional view that 
“pain receptors” function only by sending afferent messages to the brain was 
challenged. Rather gate control theory proposed that ascending signals related to pain 
and injury could be intensified, reduced or blocked by other incoming stimuli via 
modulatory control systems located within the brain and body before reaching the 
perceptual centres of the brain. The gating mechanisms were hypothesised to ‘open’ and 
‘close’ according to feedback from nerves in the body, including descending impulses 
from the brain activated by specific neural signatures or networks (including e.g. 
attention, emotion or memory processes). Therefore, in conjunction with Melzack and 
Wall’s later neuromatrix theory (Melzack & Wall, 1996), gate control theory 
acknowledged the important role genes, psychological factors or processes, and the 
environment play in the experience of pain. Whilst gate control theory was not 
explicitly described as a “biopsychosocial model”, it was consistent with the later work 
of George Engel (Engel, 1977), who was one of the first to propose that a biomedical 
reductionist philosophy limited understanding of all health problems. Engel proposed 
that a broader biopsychosocial perspective was needed to fully account for determinants 
of health and disease, highlighting that chronic physical illness had previously been 
conceptualised only in terms of underlying physical mechanisms to the exclusion of 
behavioural or psychosocial elements. 
 
Engel’s work and gate control theory provided an important foundation for the 
development of a biopsychosocial model of pain, which viewed chronic pain as a 
dynamic and reciprocal interaction between biological, psychological, social and 
cultural variables that ultimately shapes a person’s response to pain (Turk & Okifuji, 
2002). What followed was an evolution of predominant psychological paradigms (now 
described in terms of ‘waves’) aiming to understand and treat chronic pain, and the 
development of specific therapies. At present there is no single unifying model of 
chronic pain, but several have reasonable empirical support. There are also several other 
specific therapeutic approaches that have been applied to chronic pain, including 
mindfulness, hypnosis, biofeedback and motivational interviewing (Jensen et al., 2009; 
Jensen, Ehde, et al., 2011; Jensen et al., 2003; Kabat-Zinn, 1982; Kabat-Zinn, Lipworth, 
& Burney, 1985; Kaushik, Kaushik, Mahajan, & Rajesh, 2005; Nestoriuc & Martin, 
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2007; Nestoriuc, Martin, Rief, & Andrasik, 2008). However, these are based on, in 
some cases, a broader understanding of psychological phenomena, and are not specific 
to chronic pain. Therefore, this review will only examine the predominant approaches 
that have developed specific theories of chronic pain, which have directly informed the 
development of specific treatments.  
 
2.3 Models and frameworks for understanding chronic pain 
 
2.3.1 “First wave” operant behavioural approaches to chronic pain 
 
Wilbert Fordyce (Fordyce, 1976; Main et al., 2014) was the first to develop a “first 
wave” operant behavioural rationale and treatment for chronic pain (Morley, 2011). 
According to Fordyce, this approach was influenced by Burrhus Frederic Skinner’s 
earlier operant (Skinner, 1963) and Albert Bandura’s social learning theories (Bandura, 
1965). Fordyce’s approach did not dismiss disease or ‘psychogenic’ models of chronic 
pain, but was the first to emphasise the importance of integrating the role of pain 
behaviours within a multidisciplinary treatment context. A central concept of the 
operant approach is “pain-behaviour”. Fordyce defined pain behaviours as both verbal 
and paraverbal (e.g. altering the tone of voice) and nonverbal emissions (e.g. guarding, 
moaning, gasping, limping, rubbing painful areas, grimacing and avoidance of work-
related activities etc.) In Fordyce’s treatment both types of pain behaviour were 
conceived as emissions that, when observed by others, resulted in the observer 
responding contingently, so that over time behaviours become operantly controlled 
(Williams & Daniel, 2012). Specifically, a person’s pain behaviours were argued to 
contribute to a three part contingency referred to as Antecedents, Behaviours and 
Consequences (ABCs), where the individual encounters (A) a situation or 
discriminative stimulus, e.g. a painful sensation (B) responds to the antecedent, e.g. pain 
behaviours, which may (C) interact with a variety of consequences in the social 
environment, e.g. others attempts to relieve the individual of responsibility for even 
basic activities of daily living (Kerns, Sellinger, & Goodin, 2011). The theory suggests 
that over time future patterns of behaviour are learned and reinforced, and directly 
shaped and maintained by the social and cultural context, ultimately resulting in 




Operant treatment focuses primarily on extinguishing pain behaviours, and positively 
reinforcing healthy, adaptive behaviours, such as exercise or work (Henschke et al., 
2010). Within treatment ‘healthy behaviours’ are increased systemically during each 
session by generating an exercise schedule with a specific goal in mind. Incremental 
gains in performance are then maintained and reinforced by regular positive feedback 
and verbal encouragement from both treatment staff, spouse or family members 
(Fordyce, 1976; Main et al., 2014). Taken together recent meta-analytic reviews suggest 
that operant therapy is more effective than wait list controls and usual care for short-
term pain relief, and improving mood in some cases (Henschke et al., 2010; Williams, 
Eccleston, & Morley, 2013). However, available evidence does not show that operant 
therapy is effective in the intermediate or long-term, or that it significantly improves 
functional status. In addition, it certainly does not appear superior in effects on pain or 
depressive symptoms compared to cognitive and combined behavioural therapies, and 
when compared to group exercise treatments over the long-term. However, one 
potentially important criticism of these findings is the lack of large and 
methodologically robust studies evaluating operant behavioural therapy in its purest 
form (Molton, Graham, Stoelb, & Jensen, 2007).  
 
Fordyce’s operant approach to chronic pain has been subject to several criticisms. First, 
researchers suggest the operant approach oversimplifies the role of social contingencies 
on behaviour (Williams & Daniel, 2012). Second, the strength of evidence supporting 
the underlying theory and terms has been described as a limited, highlighting in 
particular the questionable validity and narrow focus of the ‘pain behaviour’ construct 
(McCracken, 2014; Turk, 1996). Third, Fordyce’s approach tended to understate the 
role of cognition and other psychological processes that may contribute to pain and 
related disability. However, it has been suggested that Fordyce’s shared 
conceptualisations, or formulations, with patients means that operant treatment is 
inherently cognitive and behavioural in nature (Sharp, 2001). Finally, although 
Fordyce’s approach claims  roots in operant theory, some have argued it is insensitive to 
social and cultural norms, and underestimates the extent to which a person’s ability to 





2.3.2 “Second wave” traditional cognitive behavioural approaches to chronic 
pain 
 
Around the same time as Fordyce’s earlier work (Fordyce, Fowler, Lehmann, & 
Delateur, 1968), the prevailing view within the wider field of psychiatry and psychology 
was that behavioural approaches generally reflected a purely deterministic perspective 
that de-emphasised individual autonomy (Williams & Daniel, 2012). Operant and other 
behavioural approaches were also criticised for being unable to clearly articulate a fully 
integrated account of human cognition (Chomsky, 1959; O'Donohue, 1998), which 
resulted in the widely held view that behavioural principles required expansion.3 This 
led to second-generation behaviour therapy, and a subsequent paradigm shift to what 
was at one time called the “cognitive revolution”, which included Cognitive Therapy 
(CT) pioneered by Aaron Beck and colleagues (Beck, 1976; Beck, 1979), and Rational-
Emotive Therapy (RET) by Albert Ellis (Ellis, 1980; Ellis & Bernard, 1985). The 
purpose of these approaches was to provide a therapy that could explain and treat 
cognition for people experiencing depression, which unlike its psychoanalytic 
predecessor, could be tested empirically, and was based on testable empirical models 
(Beck, 1979). “Second-wave” approaches incorporated the earlier principles of 
conditioning, and used a computational metaphor to conceptualise cognitive 
mechanisms (Dougher & Hayes, 2000; O'Donohue, 1998). 
 
The cognitive behavioural perspective, a term comprising a diversity of integrated 
approaches (Mahoney & Arnkoff, 1978), was initially applied to chronic pain through 
the work of Dennis Turk and colleagues in the early 1980s (Turk et al., 1983), and is 
still applied in contemporary clinical settings today. Rooted in stoicism (Beck, 1976), 
the cognitive behavioural perspective suggests people have the belief they cannot 
function because of pain and are helpless to improve their circumstances (Turk, 
Swanson, & Tunks, 2008). CBT proponents were opposed to what they saw as more 
deterministic behavioural perspectives, and instead argued that people are not passive 
                                                 
3Noam Chomsky is recognised for his critique of B.F. Skinner’s earlier operant account of cognition, or 
verbally regulated behaviour, which was purely theoretical in nature and attempted to explain rule-
governed or instruction behaviour (Skinner, 1957). However, in more recent years a resurgence of interest 
in the behavioural analytic tradition has resulted in a more comprehensive operant view of language and 
cognition called Relational Frame Theory (RFT) (see section 2.3.3 and (Hayes, Barnes-Holmes, & Roche, 




reactors, but rather active processors of information (Turk et al., 2008). Based on this 
information processing model, an individual’s learning history is assumed to organise a 
“cognitive schema” (or mental structure) representing perceptions of the self, world or 
future (Beck, 1991). When the individual encounters novel or familiar situations schema 
may be activated resulting in appraisals, expectancies or beliefs. Cognitions are 
hypothesised to influence mood, affect, physiological responses, and behaviour, which 
impact on consequences experienced, including social consequences. Each of these 
factors influence the nature and content of a person’s thought processes, such that 
behaviour is reciprocally determined by both the individual and social environment 
(Turk et al., 2008). 
 
Similar to Beck’s Cognitive Therapy (Beck, 1976), the cognitive behaviour therapy 
approach (CBT) in chronic pain is defined as a collaborative psychotherapy, aiming to 
help individuals identify, reality-test and correct maladaptive, or distorted, 
conceptualisations and dysfunctional beliefs about pain and associated distress (Turk et 
al., 1983). Individuals are encouraged to learn a new psychological framework and set 
of terms to re-conceptualise their problem. This involves observing links between 
cognition, affect, physiological autonomic arousal and behaviour, including adaptive 
and maladaptive coping strategies, and their combined consequences (Sharp, 2001), or 
potential to maintain psychological and physical problems. A key focus of CBT is to 
help individuals identify and self-monitor the influence of negative automatic thoughts 
and mental images that maintain maladaptive behaviour, and using cognitive-
restructuring techniques, replace them with more adaptive or beneficial ones (Turk et 
al., 1983). The person is encouraged to test the effects of cognitions and beliefs through 
tailored homework assignments forming part of a goal-oriented, systematic procedure 
(Kerns et al., 2011). Contemporary CBT also combines education and skills training 
related to stress management, including relaxation and distraction techniques, but also 
goal-setting, graded exposure to activity and exercise, pleasant activity scheduling, 
pacing of activities, assertiveness training and problem-solving (Kerns et al., 2011; Turk 
et al., 2008). Individuals are encouraged to reinforce and generalise newly acquired 
skills to a broader range of everyday life situations, and anticipate relapse by 





Whilst there are many potentially modifiable psychological constructs or mechanisms 
within the cognitive behavioural perspective and approach (Jensen, 2011; McCracken & 
Morley, 2014), two of the most studied include pain-related self-efficacy and pain 
catastrophizing. Pain-related self-efficacy relates to the central focus being on problems, 
which are viewed as specific and solvable, rather than vague, undifferentiated and 
overwhelming (Turk et al., 2008). The overarching focus of treatment is to facilitate an 
individual’s perception of self-control by enhancing self-efficacy (Kerns et al., 2011; 
Turk et al., 2008). In the context of chronic pain, Bandura’s self-efficacy concept 
(Bandura, 1977) is defined as the person’s confidence in their ability to engage in a 
course of action sufficient to accomplish a desired outcome, such as control of pain, and 
limiting its impact on one’s life (Turk & Okifuji, 2002). The expectation is that 
individuals will gain mastery over their pain, resulting in improved mood (Thieme, 
Gromnica‐Ihle, & Flor, 2003). Evidence suggests that pain-related self-efficacy is a 
strong predictor of improved outcomes in primary chronic pain populations (Keefe, 
Rumble, Scipio, Giordano, & Perri, 2004; Turk & Okifuji, 2002). Whilst self-efficacy 
has been identified as an important factor in chronic pain, recent theoretical approaches 
have begun to question traditional CBT’s focus on enhancing perceived control and 
emphasis on problem-solving, suggesting that attempts to do so may inadvertently result 
in poorer outcomes (Eccleston & Crombez, 2007; McCracken, 2007; Vowles, McNeil, 
et al., 2007).  
 
Another potentially modifiable psychological construct within traditional CBT for 
chronic pain is pain catastrophizing, defined as an exaggerated negative orientation 
towards pain where a relatively neutral event is irrationally made into a catastrophe 
(Sullivan, Bishop, & Pivik, 1995). Pain catastrophizing has three dimensions, 
comprising magnification, rumination and helplessness. Consistent with pain-related 
self-efficacy, pain catastrophizing has also been defined as the tendency to focus on 
pain and negatively evaluate one’s ability to deal with it (Keefe et al., 2004). However, 
some researchers suggest there are grounds for proposing a general rather than pain-
specific view of catastrophizing (Sullivan, 2001). Three reviews suggests that pain 
catastrophizing is one of the most robust predictors of pain outcomes and behaviours in 
clinical and experimental studies, but the majority have been cross-sectional in design, 
limiting causal interpretation (Edwards, Bingham, Bathon, & Haythornthwaite, 2006; 
Quartana, Campbell, & Edwards, 2009; Sullivan, 2001). However, a growing number of 
studies indicate that pain catastrophizing, along with perceived control in some cases, is 
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an important mediator of pain severity, pain interference, depression and pain behaviour 
in CBT trials, along with other treatments, for chronic pain (Burns, Day, & Thorn, 
2012; Smeets, Vlaeyen, Kester, & Knottnerus, 2006; Spinhoven et al., 2004; Turner 
J.A., Holtzman S., & Mancl L., 2007). However, one criticism is that research on pain 
catastrophizing has mostly been empirical and not based on a systematic theory (Keefe 
et al., 2004). Whilst catastrophizing features in both the traditional CBT and fear-
avoidance models of chronic pain (outlined in section 2.3.2.1), it has been variably 
defined as both an appraisal, attentional and coping-related construct (Sullivan, 2001). 
For example, some researchers have conceptualised pain catastrophizing as a coping 
response designed to deal with negative emotions caused by chronic pain by eliciting 
proximity to, or garnering support from, others (Sullivan, 2001). In addition, others 
have argued that pain catastrophizing may reflect a measure of distress, or a component 
of distress (Turner & Aaron, 2001). Consequently, pain catastrophizing has been 
criticised for being a theoretically multifactorial construct (Severeijns, Vlaeyen, & van 
den Hout, 2004). Despite these limitations, both pain-related self-efficacy and pain 
catastrophizing remain common targets in contemporary CBT treatments. 
 
There is now a large body of evidence suggesting interventions defined as CBT can 
improve function as well as reduce pain severity, pain interference and pain behaviours 
(Turk et al., 2008). Consistent with several other reviews in the field (Bernardy, Füber, 
Köllner, & Häuser, 2010; Dixon, Keefe, Scipio, Perri, & Abernethy, 2007; Henschke et 
al., 2010; Hoffman, Papas, Chatkoff, & Kerns, 2007; Scascighini, Toma, Dober-
Spielmann, & Sprott, 2008), a recently updated Cochrane review of 35 RCTs evaluating 
CBT for chronic pain (Williams et al., 2013) show moderate effects on improved mood, 
and small effects on catastrophic thinking, disability and pain severity. The review also 
found superior effects for CBT compared to variants of operant behaviour therapy. 
However, the review authors concede that many of the so-called “CBT” interventions 
evaluated showed significant sample and treatment heterogeneity, which limits more 
definitive interpretation of the overall effects of the CBT approach for chronic pain. 
 
Several limitations of CBT are highlighted in the chronic pain literature. First, review 
findings in chronic pain are limited by considerable variation in the content of 
interdisciplinary pain management programmes utilising CBT, making it is difficult to 
determine which therapeutic components best predict improvement (Kerns et al., 2011; 
McCracken, Vowles, & Eccleston, 2005; Williams et al., 2013). Second, researchers 
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highlight a lack of coherent theory underlying many intervention studies (Williams et 
al., 2013). At the conceptual level, some have argued there is a lack of organisation for 
the numerous dimensions or mechanisms proposed within CBT models, and that 
scientific assumptions have yet to be stated, but are likely to be varied (McCracken & 
Morley, 2014). Finally, treatment reviews consistently demonstrate that although CBT 
is helpful for many individuals, there are some for whom CBT is not beneficial (Turk et 
al., 2008; Williams et al., 2013). For example, one practice-based evaluation of an 
interdisciplinary chronic pain management programme based on CBT shows that 
between 1 in 3, and 1 in 7 (depending on the outcome measure used), achieve clinically 
significant gains at post-treatment and follow-up, whilst around 1% to 2% of patients 
deteriorate during treatment (Morley, 2008). 
 
2.3.2.1 Fear-avoidance model of chronic pain 
 
Within the broader category of traditional CBT more specific psychological theories of 
chronic pain have developed in recent years. One is the fear-avoidance (FA) model of 
chronic pain (Lethem, Slade, Troup, & Bentley, 1983; Vlaeyen & Linton, 2000), which 
suggests that a person may interpret potentially pain-inducing situations as threatening 
and as causing further harm or damage to the body (Boersma & Linton, 2006; Gatchel 
et al., 2007). Within this model pain-related anxiety, fear and catastrophizing are 
thought to accentuate pain experience (Crombez, Eccleston, Van Damme, Vlaeyen, & 
Karoly, 2012; Crombez, Vlaeyen, Heuts, & Lysens, 1999), contributing to a cycle of 
hypervigilance, behavioural avoidance and inactivity, resulting in greater pain severity 
and pain interference (see Figure 3). Consistent with pain catastrophizing, pain-related 
anxiety or fear-avoidance have also been identified as significant predictors of greater 
pain-related disability in chronic pain populations (Keefe et al., 2004; Turk & Okifuji, 
2002). However, one review suggests that studies testing the FA model within 
longitudinal designs using path-analytic methods has yielded conflicting or null findings 





Figure 3: Fear-Avoidance of Chronic Pain (Vlaeyen & Linton, 2000) 
 
A key strength of the FA model is that it maps directly onto graded in vivo exposure and 
graded activity treatment techniques. These aim to help individuals engage in physical 
activities for the purpose of reducing fear associated with the particular activity (Keefe 
et al., 2004). The evidence-base for graded in vivo exposure is growing, and a recent 
review indicates that it is superior to no treatment at all in the short to intermediate term, 
and is comparable to physical exercise interventions (Macedo, Smeets, Maher, Latimer, 
& McAuley, 2010). Another review (Bailey, Carleton, Vlaeyen, & Asmundson, 2010) 
also suggests that graded in vivo exposure demonstrates comparable efficacy to “third-
wave” approaches, such as Acceptance and Commitment Therapy (ACT) (see section 
2.3.3), and may be more effective in improving disability and reducing fear of pain and 
pain severity compared to wait-list controls, graded activity and mixed protocols of 
CBT. A limitation of this review is that there was considerable inconsistency in study 
protocols and outcomes, which precluded meta-analysis and more definitive conclusions 
regarding efficacy.  
 
Several limitations of the FA model and graded in vivo exposure techniques have been 
identified. First, it has been suggested that the FA model and graded in vivo exposure 
techniques address only one narrow pathway leading to disability, which does not take 
into account other contextual influences (Keefe et al., 2004; McCracken & Morley, 
2014). Other researchers have argued that addressing fear in a cognitive framework 
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needs to be delivered in conjunction with improving the person’s conceptual 
understanding of pain (Williams & Daniel, 2012). It is assumed this understanding 
provides a context to help individuals re-evaluate unhelpful beliefs and fears about 
pain’s causes or triggers, and understand the meaning of fluctuating pain. 
 
2.3.2.2 Avoidance-endurance model of chronic pain 
 
A more recent extension of the FA model of chronic pain has also been proposed. In 
addition to the FA response, the avoidance-endurance (AE) model of chronic pain 
incorporates two alternative pathways hypothesised to result in greater disability 
(Hasenbring, Hallner, & Rusu, 2009; Hasenbring & Verbunt, 2010). First, the distress-
endurance (DER) response is characterised by attempts to suppress pain, which may 
increase anxiety or depression, followed by an increase in task persistence behaviour, 
ultimately leading to physical overuse and overload, chronic pain and reduced 
functioning (see Figure 4). Second, the eustress–endurance response (EER) suggests 
that some individuals use focused distraction, which can result in positive mood in the 
short-term despite pain, followed by task persistence. These individuals are thought to 
recover from pain in the short-term, but develop chronic problems in the long-term 
(Hasenbring, Chehadi, Titze, & Kreddig, 2014). The model also suggests that a more 
adaptive responder will oscillate flexibly between these avoidant behavioural responses 


















Figure 4: Avoidance-Endurance Model of Chronic Pain (Hasenbring et al., 2014) 
 
To date the FA element of the AE model has received significant research attention, 
although there are currently only a limited number of studies investigating the DER and 
EER pathways. Studies examining these elements have tended use longitudinal designs 
(Hasenbring et al., 2014) and, consistent with qualitative accounts of people with 
chronic pain (Andrews, Strong, Meredith, Gordon, & Bagraith, 2015), offer preliminary 
evidence for both types of responding. One experimental study has shown that greater 
fear-avoidance responding is associated with increased cortisol levels in healthy adults 
during a cold-pressor procedure, whilst endurance responding was not (Sudhaus et al., 
2015). As hypothesised by AE model, this suggests endurance responding may be a 
positive way of coping with pain at least in the short-term. However, results from 
healthy individuals subjected to transient pain exposures within lab-based studies may 
not always generalise to chronic pain populations. One intervention study has shown 
that two versions of CBT, one specifically targeting pain-related avoidance (n = 93), 
and the other persistence responses using activity pacing techniques (n = 97), resulted in 
improvements in physical and psychological functioning in both treatment groups 
compared to controls (Van Koulil et al., 2011). Effects on psychological functioning in 
each treatment group were mediated by hypothesised changes in either pain avoidance 
or persistence responding. However, only the effects observed in physical functioning 
















































One limitation was that both treatments also showed significant improvements in other 
relevant cognitive behavioural factors or processes (e.g. pain-related fear, 
hypervigilance, worry, acceptance and helplessness), which were not tested for 
mediation alongside avoidance and endurance variables. Therefore, it remains unclear 
which factors or processes reflect the most important targets in CBT.  
 
The AE model also has limitations. Whilst it offers two alternative explanations of pain-
related disability, expanding the narrower focus of the FA model, it has been argued that 
elements in both pathways reflect more specific topographical, or “surface level”, 
descriptions of potentially unhelpful cognitions, emotions and behaviours, and fail to 
clearly take into account the functional dimension of behaviour (McCracken & Morley, 
2014). Consistent with Hasenbring’s argument that healthy functioning may reflect a 
flexible movement between these avoidance responses (Hasenbring et al., 2014), it 
might be that an individual’s avoidance or persistence behaviour may actually reflect an 
‘adaptive’ response to pain in certain circumstances. Therefore, a broader class of 
experiential avoidance behavioural processes may better account for the function, rather 
than description, of a person’s behaviour in a given context. Another related criticism of 
both the AE and FA models is that they do not adequately explain the potentially 
important role of motivational or recovery processes in chronic pain (McCracken & 
Morley, 2014). 
 
2.3.2.3 Common sense model of illness perceptions applied to chronic pain 
 
The cognitive models of chronic pain have also led to an interrelated body of research 
looking at pain-related beliefs more broadly, which have also been shown to be 
associated with key outcomes. Some of these studies have been less guided by a clear 
theory of chronic pain (Jensen, Karoly, & Huger, 1987; Jensen, Romano, Turner, Good, 
& Wald, 1999; Jensen, Turner, Romano, & Lawler, 1994; Turner, Jensen, & Romano, 
2000). In contrast, others have been informed by broader psychological theories that are 
less specific to pain (Foster et al., 2008; Foster, Thomas, Bishop, Dunn, & Main, 2010; 
Moss-Morris, Humphrey, Johnson, & Petrie, 2007), drawing on the common sense 
model of illness perceptions (CSM) proposed by Howard Leventhal and colleagues in 




Briefly, the CSM is a cognitive behavioural model based on self-regulation, which 
explains how individuals interpret, process and manage potential health threats related 
to prevention, adaption and maintenance of behaviours relating to disease (Leventhal, 
Meyer, & Nerenz, 1980; Leventhal et al., 1984). As shown in Figure 5 the CSM 
suggests two parallel, and partly interacting, systems, which are activated in response to 
health threats (i.e. symptoms and other internal or external cues). First, the cognitive 
processing pathway is responsible for generating illness representations, or schema, 
including thoughts related to (a) symptoms attributed to the chronic condition (identity), 
(b) duration of illness (timeline), (c) potential causes (cause), (d) illness severity and its 
potential impact on physical, social and psychological functioning (consequences), (e) 
the extent to which the person believes their illness is curable or controllable, relating to 
efficacy of personal and treatment resources for managing the health threat, and (f) 
overall understanding of illness (illness coherence). Illness representations are thought 
to drive coping strategies or management behaviours to deal with the health threat, 
which in turn are evaluated for their effectiveness. Depending on the nature of this 
“secondary appraisal”, the individual may continue with a specific coping strategy or 
adopt an alternative. With new information, illness perceptions are thought to be 
constantly updating and coping behaviours continuously appraised for their efficacy. 
The emotional processing system (emotional representation) is also thought to be 
activated by illness representations and other internal (e.g. physical sensations) and 
environmental cues. Once activated this can also result in the implementation of 
potentially helpful or unhelpful self-management behaviours or coping strategies (e.g. 
avoidance, expression or suppression of feelings), which ultimately aim to reduce or 
















Figure 5: Common Sense Model of Illness Perceptions (Leventhal et al., 2003) 
 
Whilst the CSM is not a dominant theory in chronic pain, a growing body of 
longitudinal evidence indicates that individual’s perceptions related to the 
consequences, chronicity (timeline acute/chronic), personal (and treatment) control of 
chronic low back pain at baseline predicts outcome at six months follow-up (Foster et 
al., 2008). Specifically, individuals who perceived low back pain as chronic, 
uncontrollable and as having serious consequences were more likely to have poorer 
outcomes at 6 months. Another study in primary care has also shown that chronic pain 
patient’s perceptions of illness identify, acute/chronic timeline, personal control, and 
pain self-efficacy at baseline explained a large proportion (56%) of the variance in 
outcomes at 6 months (Foster et al., 2010). Importantly, these illness representations 
remained significant in an adjusted multivariate analysis, whilst other traditional CBT 
factors, including depression, catastrophizing and fear avoidance did not. This suggests 
that whilst psychological constructs share some conceptual overlap, more general CBT 
constructs may be less important when set against pain perceptions specific to the CSM. 
These findings were mostly consistent with a longitudinal study exploring changes in 
cognitive variables across a four week multidisciplinary group pain management 
program based on reactivation, which included components of CBT (Moss-Morris et al., 
2007). Findings indicated significant reductions in perceived consequences and 
catastrophizing were most strongly associated with improved physical functioning, 
whilst reduced pain vigilance and negative emotional representations, and increased 
Representation of 















































coherence of pain, were the best predictors of improved mental functioning. Taken 
together these findings offer promising support for the idea that pain perceptions from 
the CSM are likely to be important targets within CBT treatments for chronic pain. 
However, these factors have yet to be examined in mediation analyses within the 
context of RCTs specifically evaluating CBT treatments for chronic pain. 
 
2.3.3  “Third wave” contextual cognitive behavioural approaches to chronic pain 
 
Chronic pain was one of the first problems addressed by so-called “third-wave”  
approaches, including Mindfulness-Based Stress Reduction (MBSR), pioneered by Jon 
Kabat-Zinn in the early 1980s (Kabat-Zinn, 1982, 1994). However, some have argued 
there has been little robust evaluation of MBSR in chronic pain since this time (for 
recent reviews see Chiesa & Serretti, 2011; Teixeira, 2008), and even fewer theoretical 
developments informing key mechanisms of action, despite becoming increasingly 
widespread in clinical environments (Williams & Daniel, 2012). In contrast, a newer 
form of CBT, called Contextual Cognitive Behavioural Therapy (CCBT) (McCracken, 
2006), synonymous with ACT (Hayes, 1999), has received increasing research attention 
in the context of chronic pain since the late 1990s (McCracken, 1998). ACT first 
appeared in the wider field of clinical psychology in the early 1990s for mood disorders 
(Zettle, 2005), and was informed by a basic scientific account and research programme 
that began around a decade before this time, leading to the development of relational 
frame theory (RFT). Briefly, RFT is a post-Skinnerian operant account of human 
language and cognition (Hayes et al., 2001), centring around notions of experiential 
avoidance, generalised response classes and “relational responding” (McCracken, 2014) 
(see Torneke, 2010 for a more comprehensive summary). RFT and ACT are founded on 
the philosophical assumptions of functional contextualism, which applies a pragmatic 
truth criterion to scientific enquiry (Hayes et al, 2006). Contextualism is defined as a 
world view, or hypothesis, with an underlying root metaphor of the "act in its context", 
whereby any event is interpreted as an ongoing act inseparable from its current and 
historical context (Pepper, 1942). This means all actions are viewed as whole events, 
which have meaning only with reference to their context. The truth criterion of 
contextualism is therefore defined as a “successful working” toward one's analytic 
goals, whereby the truth and meaning of a concept lies in its function or utility, rather 
than in how well it is said to describe, represent, or mirror reality (Hayes, 1993). 
Consistent with philosophical pragmatism (James, 1909), a contextual analysis can be 
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said to true or valid if it leads to effective action, or achieves some pre-specified goal. 
Together RFT and ACT aim to provide a functional contextual account of human 
behaviour that focuses on the prediction and influence of psychological events, with 
precision, scope, and depth, within the behaviour of the person interacting in and with a 
context considered historically and situationally (Hayes, Levin, Plumb-Vilardaga, 
Villatte, & Pistorello, 2013) (for a recent summary of the philosophical assumptions of 
RFT and ACT see Vilardaga, Hayes, & Schelin, 2007). Specifically, from a functional 
contextual perspective, an interpretation of human behaviour is said to have precision, 
scope and depth when it possesses the following qualities: (1) identifies variables that 
permit prediction (of the events in question) and influence (i.e. can be manipulated to 
affect the probability of an event occurring), (2) has a limited number of concepts (i.e. 
specific in how it applies), (3) but is broad in situations to which it is relevant (e.g. 
across health problems or diagnostic groups), (4) coheres with different levels of 
analysis (e.g. experimental or applied science) and other branches of science, and (5) 
has the built-in feature of being ‘‘constantly updating’’, which means the philosophy is 
held consistently out of choice, but the model and treatment methods that emerge from 
it are held lightly, with the expectation that they will, at some stage, be shown to be 
limited in some way (McCracken & Morley, 2014). 
 
ACT’s applied or “mid-level” psychological flexibility model has been described as a  
transdiagnostic theory of “normal” human behaviour, which incorporates functional 
dimensions of analysis and “motivational” processes (McCracken & Morley, 2014). 
“Mid-level” refers to the applied constructs, or processes, in the psychological 
flexibility model, which are in themselves derived from the more complex, or finer 
grained, basic level behavioural processes operationalized in RFT. Psychological 
flexibility has been defined as the capacity to persist with, or change, behavior in a 
manner that includes conscious and open contact with thoughts and feelings, appreciates 
what the situation affords, and serves one’s goals and values (Scott & McCracken, 
2015). The psychological flexibility model comprises six integrated psychological 
processes (see Figure 6 below), including acceptance, cognitive defusion, self-as-
observer, present-moment awareness, values, and committed action (Hayes, 1999). The 
six processes are more extensively described in other sources (Hayes, Luoma, Bond, 
Masuda, & Lillis, 2006; Hayes, 1999). Briefly, acceptance is defined as willing 
engagement in activities in a way that includes contact with one’s unwanted 
experiences, such as pain, without defense or attempts to struggle with or control them, 
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when to do this serves one’s goals (McCracken, 2010a; McCracken & Morley, 2014; 
McCracken, 2010b). Cognitive defusion is the ability to experience a distinction 
between thoughts and the things they describe, and to contact experiences directly 
without being dominated by the meaning and influences carried in thoughts 
(McCracken & Morley, 2014). Self-as-observer is closely linked to RFT’s deictic 
relational frames, including I versus You, Now versus Then, and Here versus There, 
which lead to a sense of self as a locus or perspective (Hayes et al., 2006; McHugh, 
2015). It therefore reflects the person’s ability to experience a perspective where they 
are neither defined, nor harmed, by their own thoughts and feelings (McCracken & 
Morley, 2014). Present-moment awareness, or flexible present-focused attention, is 
similar to the qualities cultivated in mindfulness meditation. Unlike goals, values are 
freely chosen qualities of purposive action that we define as important, which are 
ongoing and can never be obtained as an object, but can be instantiated moment by 
moment (Hayes et al., 2006) and can feed into goals (McCracken & Morley, 2014). 
Finally, committed action is the ability to flexibly persist with a course of action guided 
by values and goals, in a way that can incorporate failure and discomfort, and still 
continue, but also be abandoned when unhelpful (McCracken, 2013; McCracken & 
Morley, 2014). The inverse of the six psychological flexibility processes represents a 
model of behavioural problems and suffering, including experiential avoidance, 
cognitive fusion, an inability to take a perspective separate from thoughts and feelings, a 
pre-occupation with the past or future, failures in clarity or pursuit of values, and 




Figure 6: ACT’s Psychological Flexibility Model (Thompson & McCracken, 2011) 
 
A recent review of 66 studies shows there is now a range of laboratory-based 
component research supporting most elements of the psychological flexibility model 
(Levin, Hildebrandt, Lillis, & Hayes, 2012), including many studies examining brief 
pain exposures. In contrast, much of the applied research on the psychological 
flexibility model in chronic pain has focused on the role of pain acceptance and values 
(see Scott & McCracken, 2015 for a recent review). Whilst many studies are cross-
sectional in nature (Reneman, Dijkstra, Geertzen, & Dijkstra, 2010), limiting causal 
interpretation, there is also a growing number of process-level studies using mostly non-
randomised longitudinal treatment designs (Scott & McCracken, 2015). Overall, these 
show that psychological flexibility processes are consistently associated with pain 
severity, pain interference and other relevant domains of functioning. Recently there 
have also been efforts to operationalise other processes within the psychological 
flexibility model, which have demonstrated significant predictive relationships between 
pain outcomes and “decentering”, a similar construct to cognitive defusion (McCracken, 
Gutiérrez-Martínez, & Smyth, 2012), as well as present moment awareness 





Proponents of ACT suggest it is not a theory or scientific model per se (McCracken & 
Morley, 2014). Rather the six psychological flexibility processes map directly onto a set 
of mindfulness and acceptance, or commitment and behaviour change, treatment 
methods or techniques (Hayes et al., 2006). Alongside RFT, the psychological 
flexibility processes offer guidance on how to approach the therapeutic relationship to 
increase psychological flexibility from a pragmatic stance. Experiential exercises help 
clients come into contact with psychological processes more directly, and use of 
metaphorical language, paradoxes, and stories are introduced by the therapist to help the 
person learn to relate to their experience in a more flexible way without constructing a 
new set of rigid rules (Hayes et al., 2013). Movement in the six processes is the 
functional goal and any techniques that shift these processes can form part of an ACT 
intervention (Hayes et al., 2013). However, ACT is not didactic in style and does not 
attempt to directly alter the severity of pain and pain-related emotions, such as fear and 
frustration, nor does it seek to alter the content of thoughts about pain. Rather, it aims to 
alter how the person relates to these experiences to improve the quality and 
effectiveness of action (Scott & McCracken, 2015) and reduce the distressing and 
disabling influences of pain on living life according to one’s values (McCracken et al., 
2005). 
 
Four systematic reviews have examined the efficacy of ACT in the context of chronic 
pain. Whilst one review has been described above (Bailey et al., 2010), a subsequent 
meta-analysis including 22 studies indicates that 9 RCTs for ACT and MBSR show 
small pooled effect sizes for pain severity, anxiety, depression, quality of life, and 
medium effects for depression for pre- and post-treatment changes. These findings are 
comparable to traditional CBT, suggesting both may be good alternatives (Veehof, 
Oskam, Schruers, & Bohlmeijer, 2011). Pooled effects for 13 controlled and 
uncontrolled trials were also in the medium range on most outcomes. One limitation of 
this review was that ACT and MBSR were grouped together as “acceptance-based 
treatments”, making it difficult to disentangle their potentially divergent treatment 
methods. Another limitation was that only two of the seven ACT studies in the review 
were RCTs, since non-randomised studies are more susceptible to bias. More recently, a 
meta-analytic review (Öst, 2014) examining RCTs for ACT for a range of physical and 
mental health problems identified 10 studies for ACT in chronic pain. However, this 
review did not conduct a meta-analysis, but concluded that ACT was “probably 
efficacious” for a number of conditions. However, Öst’s review was recently criticised 
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because it focused exclusively on pain severity as a primary outcome of treatment to the 
exclusion of other relevant emotional, physical and social domains of functioning. Scott 
and McCracken have argued that Öst’s review method contradicts the aims of ACT 
(Scott & McCracken, 2015). Specifically, a more recent review (Hann & McCracken, 
2014) suggests that ACT deviates from the Initiative on Methods, Measurement, and 
Pain Assessment in Clinical Trials (IMMPACT) guidance (Dworkin et al., 2010; 
Dworkin et al., 2008), which reflects a group of academics, regulatory agencies, US 
National Institutes of Health, US Veterans Administration, consumer support and 
advocacy groups, and industry, who develop consensus reviews and recommendations 
for improving the design, execution, and interpretation of clinical trials of treatments for 
pain. In contrast to IMMPACT guidance, physical and social role performance reflect 
primary targets in ACT, and pain severity and emotional functioning are considered 
secondary. The review therefore identified the same 10 studies, and showed that ACT 
was efficacious particularly with regard to improving physical and emotional 
functioning. However, overall many of the reviewed studies evaluating ACT for chronic 
pain were small and included significant risk of bias, and most compared ACT with 
inactive controls. Therefore, improvements observed may in part reflect non-specific 
treatment effects. 
 
The ACT model also has limitations. The psychological flexibility model emphasises 
the central role of understanding contextual influences on the function of a person’s 
behaviour, with the aim of developing theory that coheres with other branches of 
science. However, consistent with other chronic pain models it does not clearly explain 
how biology interacts with these processes, or how other’s behaviour (e.g. the effects of 
stigma, low social support or overly solicitous responses), or the wider social context, 
can have a potentially positive or negative impact on people with chronic pain. In 
addition, whilst the psychological flexibility model focusses predominantly on the role 
of experiential avoidance of private events, it fails to incorporate a clear explanation of 
emotion and emotional processing, and their underlying biological mechanisms (see 
Lumley et al., 2011). Although the fear-avoidance model highlights the negative 
consequences of pain-related fear, other existing chronic pain theories have yet to 
explain the potentially important role of other emotional responses (e.g. positive affect), 
and how positive emotions can play an important role in facilitating awareness, and 




2.3.4 Comparing predominant approaches in chronic pain 
 
Whilst some reviews have compared effect sizes for the different treatments in chronic 
pain (Bailey et al., 2010; Williams et al., 2013), few individual RCTs have directly 
compared the more predominant approaches. Only one study has directly compared 
group CBT with ACT (Wetherell et al., 2011), and another ACT with applied relaxation 
training (Thorsell et al., 2011). Findings indicate that support for the superiority of one 
or the other treatment remains unclear at present, although when ACT was compared to 
CBT (Wetherell et al., 2011), participants in ACT group reported greater satisfaction. 
One challenge in applied research relates to how researchers can identify and separate 
unique and shared components of these different approaches. However, this is likely to 
be difficult since ACT is a form of CBT, and therefore is likely to significantly overlap 
with other underlying therapeutic processes and treatment techniques, such as exposure 
and behavioural activation (Scott & McCracken, 2015).  
 
A potential fruitful avenue may lay in the analysis of treatment process. For example, an 
RCT evaluating ACT in chronic whiplash-associated disorder has shown that positive 
changes in pain-related disability and life satisfaction was mediated by reductions in 
broader measures of psychological inflexibility (Wicksell, Olsson, & Hayes, 2010) and 
not by change in one of a number of potentially competing processes, including fear of 
movement and self-efficacy. However, a recent RCT evaluating traditional CBT has 
also demonstrated that improvements in pain severity, pain interference, and depression 
outcomes were mediated by changes in pain acceptance (Åkerblom, Perrin, Fischer, & 
McCracken, 2015). Overall, it appears at present most chronic pain theories and 
associated treatments demonstrate similar efficacy, and research comparing dominant 














This chapter began by summarising the evolution of approaches that led to primary 
chronic pain conditions being viewed as a multidimensional phenomenon in need of a 
biopsychosocial perspective. A selection of well-established, empirically supported 
psychological theories in chronic pain conditions, and their respective psychological 
constructs, and associated treatments, were discussed. There is currently a wealth of 
empirical support for psychological theories and associated treatment developments in 
chronic pain. There are elements from within each of the theories reviewed that appear 
to be associated with pain severity, pain interference and other relevant functional 
domains. At least three of these models have resulted in the development of efficacious 
treatments for chronic pain (McCracken & Morley, 2014; Turk et al., 1983; Vlaeyen & 
Linton, 2000), demonstrating that targeting specific psychological factors or processes 
may be an effective way of helping people better manage chronic pain.  
 
All chronic pain models appear to share one limitation. After the contribution of gate 
control theory (Melzack & Wall, 1965) greater emphasis was placed on developing a 
“biopsychosocial” model of chronic pain. However, there appears to be distinct lack of 
specific biological factors or processes embedded within the predominant chronic pain 
theories, or at least are made less explicit. Whilst recent efforts have been made to link 
more traditional cognitive behavioural factors or processes of chronic pain to elements 
of neuropsychology (Jensen, 2010) and neurophysiology (Campbell & Edwards, 2009; 
Davis & Moayedi, 2013; Edwards, Campbell, Jamison, & Wiech, 2009), it appears 
chronic pain theories outlined in this chapter do not obviously explain how biological 
factors interact with psychosocial elements. Whilst the diathesis stress model of MS 
pain (Kerns, 2000; Kerns et al., 2002) considers the dynamic nature of a person’s 
adjustment in response to a changing neurobiological context, including new or 
changing symptoms and disease progression, chronic pain theories are yet to clearly 
incorporate these elements. Another related issue is that chronic pain theories have not 
distinguished between different types of pain, where most have focused predominantly 
on musculoskeletal pain. Whilst some researchers have examined the role of 
psychological factors or processes, and the effects of psychological treatments, in the 
context of neuropathic pain (Closs, Staples, Reid, Bennett, & Briggs, 2009; 
Haythornthwaite & Benrud-Larson, 2000; Henwood & Ellis, 2004; Martin, Daniel, & 
Williams, 2014; McCracken & Yang, 2013), few have directly compared neuropathic 
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and non-neuropathic pain. Comparing the different types of pain may be helpful to 
determine whether psychosocial components of existing chronic pain theories can 
explain neuropathic pain in the context of MS, since it may be it may be the case that 
the different types of pain lead to different psychological responses, and that 
psychosocial variables are potentially less relevant in pain of neuropathic origin.  
 
Despite their limitations, the strength of empirical support for second- and third-wave 
interventions at present appears to be comparable, and the literature offers no clear 
indication as to whether one chronic pain theory or treatment is necessarily more 
effective than another, or a combination of approaches. It would therefore appear that 
all chronic pain theories and frameworks outlined may have some relevance to 
understanding and treating MS pain. This view is supported by promising preliminary 
evidence for both CBT and ACT interventions for MS pain outlined in chapter 6. 
Therefore, at this stage drawing from all chronic pain models and treatment approaches 
outlined in this chapter is likely to be helpful in guiding our empirical investigations of 
MS pain and developing a working theoretical model.  
 
To date few attempts have been made to explore the psychosocial correlates of MS pain 
in a systematic way that considers existing empirical evidence in relation to primary 
chronic pain models. This makes it difficult to obtain a reliable overall impression of the 
findings from this growing body of research. A review and synthesis of current research 
also becomes increasingly important as more studies emerge investigating similar 
constructs. Therefore, the following chapter presents a systematic review conducted by 
the author investigating the psychosocial factors or processes associated with pain 
severity and pain interference in MS. As mentioned previously, these reflect two key 
clinical outcomes in the chronic pain literature (Dworkin et al., 2008). The purpose of 
the review was to draw on relevant theory and empirical findings specific to MS to 
bring together a working model of MS pain, of which key elements are further 





Chapter 3 : A Systematic Review of Potentially Modifiable 
Psychosocial Factors in MS Pain. 
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Objective: Pain is a common symptom of Multiple Sclerosis (MS). Biomedical 
treatments achieve only modest reductions in pain severity suggesting this approach 
may be too narrow. The aim of this systematic review was to assess evidence for 
associations between modifiable psychosocial factors and MS pain severity and pain 
interference and use this evidence to develop a preliminary biopsychosocial model of 
MS pain.  
 
Methods: Empirical studies of pain in MS utilising standardised pain severity and pain 
interference measures were included. Online databases (Cochrane, PsychInfo, 
EMBASE, CINAHL, Medline, Web of Science and World Cat) and reference sections 
of included articles were searched, and corresponding authors contacted to identify 
unpublished studies. Information about design, sample size, MS type, time since 
diagnosis, psychosocial and pain measures and key findings were extracted. Thirty-one 
studies were assessed for quality and a narrative synthesis was conducted.  
 
Results: Similar to primary chronic pain, most studies reported small to medium 
associations between several psychosocial factors and pain severity and interference. 
Pain catastrophizing showed consistently strong associations with pain interference. 
Preliminary findings revealed a strong correlation between pain acceptance and pain 
interference. However, fear- avoidance appeared less important in MS, and other forms 
of behavioural avoidance were not explored. 
 
Conclusions: A preliminary model of MS pain outlining specific psychosocial factors is 
presented with a conceptual formulation from both traditional, and contextual, cognitive 
behavioural perspectives. Pain catastrophizing, acceptance, and endurance, as opposed 
to fear avoidance, responses are highlighted as potentially important treatment targets in 












Pain affects around two thirds of people with Multiple Sclerosis (MS) (Nestoriuc & 
Martin, 2007) and is associated with poor quality of life (Hirsh et al., 2011; Hirsh et al., 
2009; Khan, Pallant, Amatya, Young, & Gibson, 2011). Prevalence rates for pain in MS 
are reported to range from 40-80% (Ehde et al., 2006; Hirsh et al., 2009; O'Connor et 
al., 2008). This variability may be explained by the divergent definitions of pain used 
and patient populations studied (O'Connor et al., 2008). A third of people with MS 
describe pain as one of their worst symptoms (Stenager et al., 1991). People with MS 
may experience acute or chronic pain (Indaco et al., 1994) arising from multiple 
aetiologies (Osborne et al., 2007) including neuropathic pain resulting from injury to 
nerve tissue, musculoskeletal pain related to degenerative muscle or joint dysfunction 
and migraine headache (O'Connor et al., 2008), which can be neuropathic in origin or 
secondary to the disease process (Khan & Pallant, 2007; Moisset et al., 2013). 
Neuropathic pain includes extremity pain, trigeminal neuralgia, Lhermitte’s sign and 
painful tonic spasms including paroxysms. People with MS can experience one or more 
of these pain syndromes across their disease course (Douglas, Windsor, et al., 2008; 
Pollmann & Feneberg, 2008), but prevalence does not appear to be associated with age, 
disease duration (Kerns, 2000) or MS subtype (Archibald et al., 1994; Heckman-Stone 
& Stone, 2001).  
 
MS pain is typically treated within a biomedical framework. However, a recent review 
suggests biomedical treatments achieve only modest reductions in pain severity (Beard 
et al., 2003) and a large proportion of people with MS experience ongoing uncontrolled 
pain (Kerns et al., 2002). Pain in MS may benefit from a broader conceptualisation 
including psychosocial factors that may contribute to the experience of pain and 
incorporating these in treatment approaches. There is at least one proposed 
biopsychosocial theory of pain-related interference from MS (Kerns, 2000; Kerns et al., 
2002). Although an important advance, it draws from a more general model of stress 
rather than a model or theory developed specifically from empirical data on pain in MS. 
One way to expand this formulation may be to draw on not only on the empirical MS 
pain literature, but on the extensive theoretical and empirical literature on primary, non-
disease related, chronic pain (Merskey & Bogduk, 1994).  
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The primary chronic pain literature distinguishes between two key outcomes of pain, the 
severity of the pain and physical dysfunction, which includes the extent to which pain 
interferes with activities of daily living, relationships with others and sleep (Turk et al., 
2003). These outcomes are considered separately because pain severity only explains 
some of the variance in the extent to which pain interferes with physical functioning. 
Physical functioning can also improve even in the absence of improvements in pain 
severity (Fordyce et al., 1981; Fordyce et al., 1984). Several potentially modifiable 
cognitive, emotional, behavioural and social factors or processes consistently explain 
variance in physical functioning over and above pain severity in this group (Jensen, 
Moore, Bockow, Ehde, & Engel, 2011). 
 
A range of theoretical models exist which attempt to explain how these modifiable 
psychosocial factors interact to maintain the severity of pain and impact of the pain on 
physical function (pain interference). Early operant behavioural theory (Fordyce, 1976) 
highlighted the negative impact of environmental influences (e.g. overly solicitous 
responses to pain by others) on pain behaviours and outcome. The traditional cognitive 
behavioural model (Turk, et al. 1983) expanded on operant behavioural theory, 
suggesting pain-related emotions, beliefs and coping responses (e.g. anxiety, low mood, 
self-efficacy and perceived social support) also play a crucial role alongside behaviour. 
Pain catastrophizing, defined as an exaggerated negative orientation toward painful 
stimuli during actual or anticipated pain experience (Sullivan, 2001), also emerged as a 
key component of the traditional cognitive behavioural model (Sharp, 2001), and a 
consistent predictor of outcome. Recent expansions to the traditional cognitive 
behavioural model include two specific behavioural pathways: The fear-avoidance 
model (Vlaeyen & Linton, 2000) suggests pain-related fear, defined as interpreting 
potentially pain-inducing situations as  threatening and causing further damage to the 
body, contributes to hypervigilance, behavioural avoidance and inactivity, resulting in 
greater pain and interference (Boersma & Linton, 2006; Gatchel et al., 2007). A recent 
addition to this model suggests another opposing pathway, avoidance-endurance 
(Hasenbring & Verbunt, 2010), characterized by  suppression of pain and increased task 
persistence, leading to physical overuse and overload, greater anxiety, depression and 
ultimately reduced functioning.   
 
More recently, contextual cognitive behavioural theory (McCracken, 2006) or 
acceptance and mindfulness-based ‘third-wave’ approaches have been applied to 
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chronic pain (Hayes, Follette, & Linehan, 2004). Influenced by operant behavioural 
theory and traditional cognitive behavioural model, these draw on six integrated 
processes within the psychological flexibility model (Hayes, 1999). One process, pain 
acceptance, defined as willing engagement in activities in a way that includes contact 
with pain, without defense or attempts to struggle with or control it (McCracken, 2010a, 
2010b), has consistently been identified as a key process of change influencing 
reductions in pain severity and interference (McCracken & Gutiérrez-Martínez, 2011; 
Vowles, McCracken, & O’Brien, 2011). Although there is no single unifying model of 
pain, most have reasonable empirical support (Eccleston, Williams, & Morley, 2009; 
McCracken & Morley, 2014; Morley, Eccleston, & Williams, 1999; Veehof, Oskam, 
Schruers, et al., 2011). There is also a large body of evidence suggesting therapies based 
on these theoretical approaches decrease pain severity, disability and related mood 
disturbance in primary, non-disease-related chronic pain conditions (Eccleston et al., 
2009; Veehof, Oskam, Schruers, et al., 2011).   
 
Whilst primary chronic pain may have a different pathophysiology to pain secondary to 
a neurological condition, exploring psychosocial factors drawn for these models in the 
context of MS pain will provide insight as to any overlap in these conditions.  
 
The purpose of this study is therefore to identify and systematically review evidence for 
potentially modifiable psychosocial factors associated with pain severity and pain 
interference in the MS literature, applying quality ratings when evaluating and 
interpreting study findings. We refer to pain interference specifically rather than the 
broader construct of physical functioning as in the context of MS, the latter is 
potentially effected by a wide range of disease-related symptoms. How these data relate 
to existing theories of primary chronic pain will be explored and a working theoretical 
framework of MS pain proposed. Finally, this review will provide directions for future 












Criteria for Including Studies within the Review  
 
Studies were included if they met both the following two criteria: (a) Studies of adults 
with MS experiencing pain and (b) used quantitative, psychometrically validated pain 
severity and pain interference measures in conjunction with cognitive, emotional, 
behavioural or social factors/processes typically considered modifiable in the context of 
cognitive behavioural models of pain and treatment. Studies were also required to 
either: (c) Explore bivariate relationships between psychosocial factors and pain 
severity or interference, (d) report multivariate statistical models with psychosocial 
factors as predictors and pain severity and interference as outcome variables, (e) test 
group differences, comparing psychosocial variables across pain versus no pain MS 
groups, or MS pain versus other pain-related conditions, or (f) evaluate treatments for 
pain in MS looking at psychosocial mediators of improvement in relation to pain 
severity and interference. Studies were therefore excluded if they failed to meet 
minimum inclusion criteria (a) and (b), and did not report at least one of the statistical 
methods described in criteria (c) to (f). 
 
Studies were also excluded if they (a) were not written in English, (b) were non-
empirical, general discussion or theoretical papers, (c) used qualitative rather than 
quantitative methods, (d) included mixed population groups where MS pain-specific 
data could not be extracted, (e) looked only at quality of life in relation to pain severity 
and interference, since this may be considered an outcome of pain rather than a 
modifiable psychosocial factor, (f) reported multivariate statistical models with pain 
severity and interference as predictors and psychosocial factors as outcome variables. 
 
Selection of Studies 
 
Studies were identified though a systematic online search of CINAHL, Cochrane, 
EMBASE Medline, PsychInfo, Web of Science and World Cat dissertation databases, 
contacting key authors and manual searching of reference lists (see flow-chart diagram 
Fig.1). Database searches were conducted during November 2013 using key search 
terms outlined in supplementary materials: Appendix A. The first and fourth authors 
initially screened all online abstracts independently. Relevant full-text articles from both 
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screens were obtained by the first author and assessed for eligibility, which included 
both published and unpublished studies. The manual search was conducted by the first 
author who hand-searched reference lists of all eligible studies at the full-text screening 
stage, and emailed lead researchers in this area to request any in-press and unpublished 
studies. Please find all excluded studies at the full text screening stage with reasons in 
supplementary materials: Appendix B. 
 
Methodological Quality Assessment 
 
The methodological quality of studies was assessed using an adapted version of Ariëns 
et al’s (Ariëns, van Mechelen, Bongers, Bouter, & van der Wal, 2001) quality 
assessment tool (see supplementary materials: Appendix C). Adapted versions of Ariëns 
et al’s tool have been used across a number of previous reviews (Arden-Close, Gidron, 
& Moss-Morris, 2008; Bogosian, Moss-Morris, & Hadwin, 2010). Since the tool did not 
assess methods of statistical analysis and sample characteristics we added items to 
reflect these domains to meet the needs of this review. The quality assessment tool was 
composed of eight superordinate methodological categories comprising of 15-items 
rated as either ‘positive’ (1) or ‘negative’ (0) to provide a total positive score. Total 
scores were classified as poor (0-8, ≤50%) medium (9-12, 60-80%) and good (13-15, 
≥80%), reflecting cut-offs used within previous reviews (Arden-Close et al., 2008; 
Ariëns et al., 2001; Bogosian et al., 2010). The first and fourth authors assessed the 
studies independently to ensure there was consistency across 10 (30%) of the 31 ratings. 
Minor discrepancies of 4 ratings were resolved in discussion with the second author 
until a consensus was reached. The quality assessment of remaining studies was 













































The combined search yielded 5012 abstracts, after removing duplicates. Thirty-one 
studies (29 published and 2 unpublished) were identified as meeting inclusion criteria 
for this review (Fig. 1) and are summarised in Table 1. Table 2 summarizes the strength 
of psychosocial factors examined in relation to pain severity and interference measures 
across these studies. Supplementary materials: Appendix D provides a full summary of 




The review question precluded meta-analysis for two reasons. First the broad and 
multifaceted nature of the review set out to identify a variety of psychosocial factors 
associated with MS pain severity and interference, rather than focussing on a single 
Manual search: 9 articles identified by 
researchers in the area, including authors of 
included online search articles.  
 
8 articles excluded with reasons  
(No psychological measures n=2; No validated pain 
measures n=3; Unobtainable n=1; relationships between 
psychological factors and MS pain not directly explored 





Online search: 7259 articles identified via Cochrane 
(0), PsychInfo (468), EMBASE (3501), CINAHL (469) 
Medline (1036), Web of Science (1744) & World Cat 
Dissertation (41) databases.  
2247 Duplicates articles removed 
 
5012 abstracts were screened by 
authors 1 & 4 using inclusion & 
exclusion criteria 
  
216 full-text articles searched and 
read by authors 1 & 4  
for eligibility using inclusion 
exclusion criteria  
 
31 studies data extracted for 
narrative synthesis (29 online 
published articles, 1 online 













4796 irrelevant abstracts excluded 
185 articles excluded with reasons  
(Non-empirical n=16; No psychological measures 
n=13; No validated pain measures n=21; Symptoms 
other than MS pain n=3; Unobtainable n=39; 
Systematic or literature reviews n=9; Biomedical n=32; 
Relationships between psychological factors and MS 
pain not directly explored n=24; Not MS n=8; Non-
English publication n=3; Qualitative study n=4; 
Mediating psychological factors not explored n=4; 
Samples comprising other pain conditions n=4; Book 
chapter n=2; Neurocognitive factors only 
n=1;Duplicate =2) 
Figure 1 PRISMA Flowchart Diagram 
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predictor and criterion variable. Eleven psychosocial factors were identified, though 
different instruments were used to measure the same constructs (see Table 1 footnote 
and Table 2). Second, studies were characterised by a large degree of methodological, 
clinical and statistical heterogeneity, sometimes failing to report effect-sizes and 
measures of variability. Narrative synthesis was used to summarise the data in 
accordance with Popay et al.’s (Popay et al., 2006) guidance. This involved 1) 
identifying, listing and tabulating results and organising results with a common 
statistical rubric, 2) considering factors that might explain any differences in direction 
and size of effect across the included studies, and 3) assessing the robustness of the 
synthesis using tabulation and the quality assessment tool and reflecting critically on the 
synthesis process within the discussion.  
 
In order to address the research aims, potentially modifiable psychosocial factors related 
to pain severity and interference were identified and grouped. To relate back to existing 
theories of pain, the results are considered within three sections (see Table 2): (a) 
Factors related to operant behavioural theory and traditional cognitive behavioural 
model of chronic pain, (b) Factors related to contextual cognitive behavioural models of 
chronic pain, and (c) Summary of regression findings. 
 
Where possible bivariate correlations between psychosocial factors and both pain 
severity and interference will be reported, and interpreted as small, medium and large 
according to Cohen (Cohen, 1988), Rosnow and Rosenthal’s (Rosnow & Rosenthal, 
1996) r effect-size thresholds. Simple mean score comparisons of psychosocial factors 
between pain and non-pain MS groups will also be described. Multivariate regressions 
were not comparable across studies since they controlled for different illness and 
predictor variables, precluding useful interpretation. However, where bivariate analyses 
could not be extracted from the papers or through contacting relevant study authors, 
regression statistics will be presented with a description of type of regression and other 
control variables. To avoid mixed interpretations regressions will not be presented 








Table 1 Included Studies 
Ref. no. (for Table 2), 
name, country & date 
Study design MS pain or 
mixed MS sample 
& comparator (n) 
Recruitment Pain measures 
1. Alschuler et al. USA 
2013 ( same sample as 
Kratz et al. 2011) 
 
Cross-sectional 161 (mixed MS) University of Washington MS 
research and rehab training centre 
Pain severity  
(0-10 NRS) 
2.  Brochet et al., France 
2009 
Longitudinal   69 (mixed MS) Newly diagnosed community-
based patients in Southern France 
 
Pain severity 
(SEP-59 & NRS) 
3. Bruce and Arnett, USA 
2009 
Cross-sectional 50 (mixed MS) 
45 (healthy matched 
controls) 
Recruited from state college or 
community in in Central 
Pennsylvania 
 
Pain severity and 
interference  
(BPI) 
4. Bruce, Polen & Arnett, 
USA, 2007 
Cross-sectional 91 (mixed MS) MS support groups and the state 
college in Central Pennsylvania. 
 
Pain severity and 
interference  
(BPI) 
5. Douglas et al., Australia 
2008 
Cross-sectional 105 (mixed MS) Queensland’s MS Society 
database: from a larger study by 
the authors 
 









7. Glowacka, UK, 2011 
(Dissertation) 




8. Grasso et al., Italy, 2008 
 
 
Cross-sectional  61 (mixed MS) 
67 (healthy matched 
controls) 
Outpatient service Pain severity & 
interference  
(MPQ) 




Cross-sectional 49 (headache) 
44 (no headache) 




10. Holden & Isaac UK, 
2011 
Cross-sectional 234 (mixed MS) 
89 (Rheumatoid 
Arthritis) 
Online self-reported MS 
diagnosis MS Society UK 
Pain severity & 
interference  
(MPQ) 
11. Kalia and O’Connor, 
Canada 2005 
Cross-sectional 99 (mixed MS) Outpatients service in Toronto Pain severity  
(SF-MPQ) 
12. Khan & Pallant, 
Australia, 2007 




(SDPS & Chronic 
Pain Grade) 
13. Khan et al., Australia 
2011 





14. Kratz et al., USA, 
2011 
Cross-sectional 114 (mixed MS) University of Washington MS 
research and rehab training centre 
 
Pain severity & 
interference  
(0-10 NRS) 
15. Michalski et al. 
Germany, 2011 
Cross-sectional 38 (mixed MS) Department of Neurology 
University of Leipzig 
 
Pain severity 0-10 
(NRS: Price et al. 
1994) 
16. Moisset et al. France 
2013 
  
Cross-sectional 673 (mixed MS)  
529 (MS pain) of 




(ICHD-2)   
 





17. Motl and McAuley, 
USA, 2010 
Longitudinal 291 (mixed MS – 
ambulatory) 
Midwestern chapters of the MS 
Society. 
Pain severity  
(SF-MPQ) 
18. Motl et al. USA 2010 
 
Cross-sectional 269 (mixed MS 
RRMS only) 
National Multiple Sclerosis 
Society (NMSS 





19. Motl, Snook & 
Shapiro, USA 2008 
 
Cross-sectional 133 (mixed MS) Midwestern chapters of the MS 
Society. 









Pain scales. BPI (Brief Pain Inventory), DN4 (Douleur Neuropathique 4 interview questionnaire), HSS (The intensity of MS-related 
Headache Scale), ICHD-2 (International Classification of 
Headache Disorders) MPQ/SF-MPQ (McGill Pain Questionnaire & Short Form Version), NPS-10 (Neuropathic Pain Scale 10-items), NRS 
(Numerical Rating Scale), PES (Medical outcomes study Pain Effects Scale), PIR (adapted from the Pain Evaluation Questionnaire), SDPS 
(Simple Descriptive Pain Scale), SEP-59 (Self-administered quality of life questionnaire), SF-36 
(Short-Form 36), VAS (Visual Analogue Scale),WHOQOL-100 (World Health Organisation 100). 
Psychosocial scales. 
1. Perceived social support: CPI (Community Participation Index), MSSS (Medical outcomes Study Modified Social Support Scale). 
2. Perceived solicitude: MSPSS (Multidimensional Scale of Perceived Social Support), SOPA (Pain Attitudes Scale). 
3. Pain-related self-efficacy and perceived control: CSQ (Coping Strategies Questionnaire), MPRCQ (Multidimensional Pain Readiness to 
Change Questionnaire), SOPA (Pain Attitudes Scale). 
4. Pain-related catastrophizing: CSQ (Coping Strategies Questionnaire), CBSQ (Cognitive and Behavioural Responses to Symptoms 
Questionnaire), PCS (Pain Catastrophizing Scale). 
5. Pain-related fear-avoidance & avoidance, resignation and distraction behaviours: CBSQ (Cognitive and Behavioural Responses to 
Symptoms Questionnaire), FSR (Pain related behaviour). 
6. Pain-related thought suppression: KPI-AEM PCR (Kiel Pain Inventory Avoidance Endurance Questionnaire — Pain-related Cognitive 
Responses subscale). 
7. Illness perceptions: IPQ-R (Illness Perceptions Questionnaire Revised). 
8. Pain constancy: PBPI (Pain Beliefs Perception Inventory). 
9. Depression: BDI–II (Beck's Depression Inventory), CES-D (Centre of Epidemiological Studies Depression Scale), CMDI (Chicago 
Multidimensional Depression Inventory), GHQ-28 
(General Health Questionnaire), HADS (Hospital Anxiety and Depression Scale), MADRS (Montgomery and Asberg Depression Rating 
Scale), MDI (Major Depression Inventory), MDS (Resident Minimum Dataset), MHI (Mental Health Inventory), PHQ-9 (Patient Health 
Questionnaire). 
10. Anxiety and worry: HADS (Hospital Anxiety and Depression Scale), MHI (Mental Health Inventory), PSWQ (Pennsylvania State Worry 
Questionnaire), STAI (State-Trait Anxiety Inventory). 
11. Pain-related acceptance: CPAQ (Chronic Pain Acceptance Questionnaire). 
 
Table 1 continued 
Ref. no. (for Table 2), 
name, country & date 
Study design MS pain or 
mixed MS sample 
& comparator (n) 
Recruitment Pain measures 
20. Newland et al. USA, 
2005 
 





Minimum Dataset (MDS) for 
residents admitted to community-
based long-term care in Missouri 
 
Pain severity 
(Resident  dataset 
MDS scale 
referenced) 
21. Newland et al. USA, 
2009 
Cross-sectional 40 (mixed MS – 
women with RRMS) 
40 (healthy controls) 
University MS Centre (Mid-West 
Metropolitan community) 
 





22. Newland et al., USA, 
2012 
Cross-sectional 40 (mixed MS – 
women with RRMS) 
Secondary data taken from 
Newland (2005) 





23. Osborne et al., USA, 
2006 





24.  Osborne et al., USA, 
2007 
Cross-sectional 125 (mixed MS) MS Society, King County. 
 
 
Pain severity & 
interference  
BPI) 
25. Rog et al.  UK (2007) Cross-sectional 
instrument 
validation study 
141 (MS pain – 
central neuropathic) 
The Walton Centre regional MS 
clinic 
Pain severity for 
central 
neuropathic pain  
(NPS-10) 
 
26. Sasson Gelman, USA, 
(Dissertation, 2008) 





27. Spain et al Australia 
2007 
 
Cross-sectional 687 (mixed MS) MS Society and outpatient clinics 
in Victoria 
Bodily pain  
(SF-36) 
28. Sullivan and Edgley, 
Canada, 1992 
Cross-sectional 35 (mixed MS) 
35 (chronic lower 
back pain) 




29. Svendsen et al., 
Denmark 2005 
Cross-sectional 50 (MS pain) 
50 (MS no pain) 
47 (healthy controls) 
 
Previous study in Aarhus county 




30. Tedman, Young & 
Williams UK 1997 
Cross-sectional 92 (MS mixed) 
40 (Motor neuron 
disease) 
Walton Centre for Neurology and 
Neurosurgery 
 
Bodily pain  
(SF-36) 
31. White et al., USA, 
2008  
Cross-sectional 107 (MS pain) Mid-Western chapter of the 





Table 1 (continued) 
Ref. no. (for 
Table 2), name, 







Key Findings Quality 
assessment 
score (1-15) & 
major 
limitations 
1. Alschuler et al. 
USA 2013 ( same 
sample as Kratz 
et al. 2011) 
 
Depression (PHQ-9) Chi2 & Odds 
Ratio: No 
Participants meeting depression criteria 
were more likely meet pain criteria 




 Unclear if 
groups were 
matched 






Odds Ratio: Yes 
Depression was worse in the MS pain vs. 
non-pain group. 
Depression status at baseline predicted 













Matching prior to 
correlation: Yes 
 Regression:  Yes 
but IV & DV 
opposite to review 
hypothesis 
Excessive worry was associated with 
greater pain interference (which was 
higher in the MS group). 





Sample size was 













correlation: No  
Regression: IV & 
DV opposite to 
review hypothesis 
No direct relationship between pain and 
depression; with potentially some overlap 





 No adjustment 
for correlation 
5. Douglas et al., 
Australia 2008 






Pain constancy and perceived ability to 
reduce pain were strong predictors of pain 
severity. 
Pain constancy and pain-related 
catastrophizing were strong predictors of 















 Regression: Yes 
People with MS with pain reported 
significant higher levels of depression than 
those without pain. 
Depression was positively related with 
pain interference, but not the multivariate 
level. 
Perceived social support was not a 


















Regression: Yes The predictive role of pain-related 
cognitions in MS pain interference was 
only partially confirmed, since pain 
acceptance remained a significant (strong) 
predictor when entered into the model, 
accounting for variance above and beyond 
other cognitive factors.  
The remaining factors were highly and 





















comparison: Yes  
Regression: No 
Depression and gender (i.e. female) were 













Depression (BDI) Comparisons: Yes No significant difference was found in 
depression scores between patients with 
migraine and tension headache subgroups. 
9 (Medium) No 
aim or 
hypotheses 
10. Holden & 
Isaac UK, 2011 
Depression (CMDI) Within MS 
Comparison: No 
Depressed MS participants reported 
significantly greater pain (combined 
severity & interference score) compared to 
non-depressed MS participants. 
10 (Medium)  







Table 1 (continued) 
Ref. no. (for 
Table 2), name, 







Key Findings Quality 
assessment 
score (1-15) & 
major 
limitations 







Pain severity was positively correlated 
with depression and anxiety. When 
stratified by gender, these correlations 
were present only in women.  
12 (Medium) 










Mann Whitney U, 
Kruskal-Wallis 
and Chi2: No 
Depression scores did not differ between 





influence of key 
variables. 
 






A ‘Dysfunction’ cluster had higher levels 





influence of key 
variables. 
 
14. Kratz et al., 
USA, 2011 






correlation: No  
 
Less pain interference was related to self-
efficacy and readiness for task persistence 














People with MS with pain tended to report 
increased avoidance and resignation 
behaviour compared to those without, but 

















Matching for pain 
group 
comparisons: Yes 
Pain catastrophizing was strongly 
correlated with pain severity and pain 
interference: The non-neuropathic pain 
subgroup had a larger correlation than 
those with neuropathic pain.  














comparison: No  
 
Clusters differed in levels of pain, 
depression and fatigue. Whereby those 






influence of key 
variables. 
 











The combined pain severity and 
interference scores were significantly 
positively associated with the combined 






19. Motl, Snook 
& Shapiro, USA 
2008 
 
Depression (CES-D) Bivariate 
correlation: No 
 
Greater depression was significantly 
associated with greater levels of reported 
pain (combined score).  
13 (Good) 
No adjustment 
for correlation  
20. Newland et 





Odds ratio: No 
Chi2: No 
Regression: Yes 
but IV & DV 
opposite to review 
hypothesis 
The odds of depression in those with pain 
but not MS were higher than those with 






MS groups not 
matched 
21. Newland et 
al. USA, 2009 
Depression (BDI-II) ANOVA: Yes Women with RRMS and healthy controls 
did not differ in terms of depression.  
 
9 (Medium) 




























Table 1 (continued) 
Ref. no. (for 
Table 2), name, 







Key Findings Quality 
assessment 
score (1-15) & 
major 
limitations 
22. Newland et 





Clusters differed in levels of pain and 
depression. Whereby those with more pain 
experienced greater levels of depression. 
Greater pain severity was significantly 
correlated with greater depression. 
 
11 (Medium) 






23. Osborne et 




Regression: Yes  
Bivariate 
correlation: No 
Pain interference was significantly 
correlated with all psychosocial variables. 
Depression severity was a strong predictor 
of pain interference, while perceived 
social support was not. Depression and 
pain interference constructs were shown 





were not stated. 
24.  Osborne et 
al., USA, 2007 







Regression: Yes Pain severity and interference were 
positively correlated with catastrophizing.  
Catastrophizing, illness beliefs and 
affective, social beliefs and task 
persistence were strong predictors of pain 
intensity. Catastrophizing was the only 
predictor of pain interference.  
Pain interference was associated with 













Correlations: No Chronic central neuropathic pain severity 
was associated with higher levels of 
depression and anxiety in MS.  
11 (Medium) 
















correlations:  No 
 
Pain interference positively correlated 
with depression and anxiety, and 






rate and source 
population not 
well described. 







Regression: Yes Greater number of MS perceived 
symptoms (identity), consequences and 
curability/control of symptoms shared 
small to medium sized relationships with a 
combined pain severity and interference 
score.  
After controlling for age, MS duration, 
EDSS and processing speed, depression, 
and anxiety and identity, timeline and 
external causes illness perceptions were 
significant predictors of  combined pain 









version of Holahan 
& Moos, 1987) 
Depression (BDI-II) 
Bivariate 
correlations:  No 
 
Pain severity was associated with greater 
depression for both the MS and CLBP 
groups.  
13 (Good) 
 The sample 





29. Svendsen et 
al., Denmark 
2005 
Depression (MDI) ANOVA, Chi2, t-
tests: No 
Those with MS pain reported significantly 
higher depression scores compared to 
those without pain and healthy controls. 
11 (Medium) 















Table 1 (continued) 
Ref. no. (for 
Table 2), name, 







Key Findings Quality 
assessment 











Depression and anxiety were both 
significantly associated with the combined 
pain severity and interference score. 
Patients with motor-neurons disease 
demonstrated larger negative associations 






compare groups  
31. White et al., 





Pain interference was significantly 
associated with depression and anxiety.   
14 (Good) 









Table 2 Psychosocial factors examined in relation to Pain Severity (PS) and Pain Interference (PI) in MS 
Model 
 
Psychological Factor Quality Design Study Ref. (Table 1) 
and level of statistical 
techniques applied 
Group differences, r correlations, 
odds ratios of PS & PI across studies - 
Average (range) (n=studies reporting 
sig.) 
ANOVA & Regression (factors in combination 
with other psychosocial predictors & R2 range 
across studies) (n= studies reporting sig.) 
Factors from Operant 
Behavioural and Traditional 
Cognitive Behavioural 
Models of Chronic Pain 
(including Fear-Avoidance 
and Avoidance-Endurance)  
 
 




























PS: -.27 (n=1) 





PI: .29 (n=1) 
Perceived social support was not a sig. predictor 
in PI in all multivariable regressions. 
 









5 (PS*** & PI) 
14 (PS & PI*) 
 
PS r not stated (n=1) 
PI: -.32 (-.28 to -.37) (n=1) 
 
Perceived ability to reduce pain alongside pain 
constancy and were strong predictors of pain 
severity (n=1). 
 






5. Pain-related Fear-Avoidance  
 
 
6. Pain-related Thought Suppression 
 
 















































5 (PS*** & PI***) 
7 (PI***) 
24 (PS*** & PI***) 














5 (PS*** & PI***) 
 
 
PS: .31-.54 (n=2) 
PI: .42 (.41 to .58) (n=3) 
Neuropathic group: PS: .48 PI: .54 Non-
neuropathic  group: PS: .61 PI: .64 (n=1) 
PS: Non-sig. 
 
PI: .27 (n=1) 
 
 








PS r not stated 
PI r not stated 
 
 
Catastrophizing predicted 24% alongside other 
psychosocial variables in PS (n=1).  
Catastrophizing predicted 11-22% alongside 
other psychosocial variables in PI. (n=3) 
 
 
PS vs. fear-avoidance ANOVA statistic not 
reported 
 
Pain-related thought suppression accounted for 
14% with other variables in PI but was a non sig. 
predictor. 
Timeline & external causes illness perceptions 
predicted a further 30% of variance alongside 
fatigue, depression and anxiety after controlling 
disease & demographics in PS+I (n=1). 
 
Pain constancy predicted 26% alongside other 
psychosocial variables in PS (n=1). 
Pain constancy predicted 13% alongside other 




*Uncontrolled bivariate correlation, uncontrolled comparisons (t-test /chi2), principle component / cluster analysis  
**Controlled bivariate correlation or comparisons, uncontrolled regression analysis  
***Controlled multivariate analyses (ANOVA or regression) 
 4PS+PI refers to studies using what appears to be combined pain severity and interference scores 
 5When A.H. contacted this study author to request the PS+I-illness perceptions bivariate correlations, those which were reported as significant were inconsistent with regression findings.  







Psychological Factor Quality Design Study Ref. (Table 1) 
and level of statistical 
techniques applied 
Group differences, r correlations, 
odds ratios of PS & PI across studies - 
Average (range) (n=studies reporting 
sig.) 
ANOVA & Regression (factors in combination 
with other psychosocial predictors & R2 range 
across studies) (n= studies reporting sig.) 






















































































2 (PS***)  
4 (PS & PI*)  
6 (PS & PI***) 
7 (PI***)  
8 (PS*) 
9 (Headache PS*) 
10 (PS+PI combined*) 
13 (PS & PI* cluster) 
17 (PS* k cluster) 
19 (PS+I combined*) 
20 (PS*) 
21 (PS* & PI*)  
22 (PS* cluster) 
23 (PI***) 
25 (Central PS*) 
26 (PI*) 
27 (PS+I combined***) 
29 (PS**) 
28 (PS*) 
30 (PS+I combined*) 
31 (PS* & PI*) 
 
3 (PS & PI*) 
11 (PS*) 




PS: .34 (.27 to .38) (n=5) 
Headache PS: .17 (Non-sig) 
Central PS: .27 (n=1) 
 
Depressed People with MS OR=0.8-
2.070 report worse PS than non-
depressed (n=3); Depression higher in 
women with RRMS (n=1) vs. healthy 
women with and People with MS 
without pain (n=2). 
 
PI: .49 (.28 to .56) (n=4) 











PS: .33 (.26 to .39 to) (n=2) 
Central PS: .22 (n=1)  
PI: .36 (.32 to .42) (n=4) 
PS+I: .32 (n=1) 
 
 
Depression (Log OR) alongside other 
psychological factors predicted PS (n=1). 
 
Depression at inpatient hospital admission was a 
significant predictor of pain severity at two years 
follow-up (n=1) 
 
Depression alone predicted 13% in PI (n=1); 
28% alongside other variables in PI, but was 
non-sig.  
 
Depression predicted a further 30% of variance 
alongside 
Illness perceptions, fatigue and anxiety after 









PI and worry correlation (controlling for state 
anxiety) was no different to uncontrolled 
correlation.  
 
Anxiety predicted a further 30% of variance 
alongside illness perceptions, fatigue and 
depression after controlling disease and 
demographics in PS+I (n=1). 
 Depression & Anxiety (distress 
score) 
 
Medium Cross-sectional 18 (PS+I combined*) PS+I: .42 (n=1)  
Processes from the 
Contextual Cognitive 
Behavioural Model of 
Chronic Pain 
11. Pain-related Acceptance Medium Cross-sectional 7 (PI***) 
 
PI: -.57 (n=1) Pain acceptance predicted an additional 4% 
(unique R2 change) above all other psychosocial 
factors in PI (n = 1). 
84 
 
Factors related to Operant Behavioural & Traditional Cognitive Behavioural 
Models of Chronic Pain  
 
Perceived Social Support and Perceived Solicitude 
 
Within the broader psychological literature (Norris & Kaniasty, 1996) and primary 
chronic pain models (e.g. operant behavioural (Fordyce, 1976) and traditional cognitive 
behavioural model (Turk et al., 1983) perceived social support and perceived solicitude 
have been conceptualized as both helpful and unhelpful psychosocial factors (Cano, 
2004a; Cano, 2004b). Solicitous responding is typically defined as a primary reinforcing 
process by the spouse associated with unhelpful pain behaviours in primary chronic pain 
conditions (Fordyce, 1976). Perceived solicitousness might therefore be described as the 
extent to which the pain sufferer believes that others respond to their pain with interest 
or concern. Perceived social support is defined as the belief that helping behaviors 
would be provided when needed (Norris & Kaniasty, 1996). 
 
Only one good quality study examined the relationship between perceived social 
support and pain severity, identifying a non-significant small, negative relationship 
(Osborne et al., 2007). One medium and three good quality studies found significant 
small to medium negative associations between perceived social support and pain 
interference at the simple bivariate level, such that less perceived social support was 
associated with greater pain interference. Osborne et al (Osborne et al., 2007) also found 
a medium positive relationship between pain interference and perceived solicitude. 
 
Pain-related Self-efficacy and Perceived Control 
 
Two good quality studies assessed self-efficacy, the extent to which a person sees 
himself or herself as having the resources available to cope or have control over pain 
and engage in particular activities. Kratz et al (Kratz et al., 2011), using simple bivariate 
correlations, found pain self-efficacy to have a non-significant, negative relationship 
with pain severity, but a small to medium size negative association with pain 
interference.  Similarly, perceived importance and readiness to change (related to 
healthy exercise behaviour and task persistence) was significantly negatively associated 






Pain catastrophizing plays a pivotal role in the traditional cognitive behavioural (Sharp, 
2001; Turk et al., 1983) and fear-avoidance models of chronic pain (Vlaeyen & Linton, 
2000). Two good (Douglas, Wollin, et al., 2008; Osborne et al., 2007) and one medium 
quality study (Moisset et al., 2013) examined the relationship between pain severity and 
pain catastrophizing. Two studies found medium to large positive bivariate relationships 
between pain severity and pain catastrophizing (Moisset et al., 2013; Osborne et al., 
2007). Moisset et al’s medium quality study also identified similar medium to large 
positive relationships between pain severity and catastrophizing in both neuropathic and 
non-neuropathic pain migraine headache subgroups.4  
 
In terms of pain interference, the same three studies (Douglas, Wollin, et al., 2008; 
Moisset et al., 2013; Osborne et al., 2007) and (Glowacka, 2010) looked at the 
association between pain catastrophizing and pain interference. All four studies reported 
medium to large positive bivariate associations. Moisset et al (Moisset et al., 2013) also 
found consistently large positive relationships between pain interference and 
catastrophizing in both migraine headache neuropathic and non-neuropathic pain 




Pain-related fear-avoidance is central to the fear-avoidance model of chronic pain 
(Vlaeyen & Linton, 2000). Two studies explored the relationship between pain-related 
fear-avoidance and pain severity and interference in MS. A simple bivariate correlation 
in a medium quality study revealed no relationship between fear-avoidance and pain 
severity (Glowacka, 2010), but a small positive relationship with pain interference. In 
contrast, Michalski et al’s (Michalski et al., 2011) low quality study compared self-
reported pain-related fear-avoidance behaviours between two MS groups. People with 
MS with pain reported a significantly greater tendency to engage in avoidance and 
resignation behaviours than those without pain. 
 
                                                 
4 Classified as probable and chronic migraine headaches based on the second edition of the International 
Classification of Headache Disorders (ICHD-2), and assessed as having neuropathic and/or non-





Pain-related thought suppression is a central construct of the avoidance-endurance 
model of chronic pain (Hasenbring & Verbunt, 2010). One medium quality study 
(Glowacka, 2010) found a medium size positive correlation between thought 
suppression and pain interference at the simple bivariate level, such that greater thought 
suppression was associated with greater pain interference.  
 
Illness and Symptom Perceptions 
 
Illness perceptions are a core component of the common sense model of illness 
representations (Leventhal et al., 1984). While no chronic pain theory explicitly 
includes illness perceptions, they have been incorporated into traditional cognitive 
behavioural interventions for other MS symptoms and are often addressed in CBT 
approaches for pain (Knoop et al., 2012). The model assumes each patient has their own 
ideas about the identity, cause, timeline, and consequences of their illness and 
symptoms, which may ultimately influence their ways of coping and outcome. One 
good quality study (Spain, Tubridy, Kilpatrick, Adams, & Holmes, 2007) found small to 
medium size relationships between high identity (the number of symptoms the patient 
attribute to their MS), low control/cure (beliefs about whether one's own actions or 
medical treatment can influence the disease) and high consequences (beliefs about the 
negative consequences of MS) and a combined pain severity and interference score.   
 
Pain constancy, the temporal belief that pain will be enduring (Williams, Robinson, & 
Geisser, 1994), is similar to the concept of chronic timeline defined in the common 
sense model. One good quality study (Douglas, Wollin, et al., 2008) explored the 
relationship between pain constancy, pain severity and interference. A regression 
analysis found, amongst other psychosocial variables, pain constancy was the strongest 
positive predictor of pain severity and pain interference ratings, accounting for 26% and 
13% of the variance respectively. Both models controlled for demographic factors, and 









Depression was a common factor investigated in relation to pain severity and 
interference, occurring in a total of twenty-one included studies (twelve medium and 
nine good in quality). Twelve studies explored the relationship between depression and 
pain severity, and seven pain interference. Three studies also investigated depression in 
relation to a combined pain severity and interference total score. 
 
In terms of pain severity, two medium and one good quality study demonstrated small 
to medium size positive relationships between depression and pain severity using simple 
bivariate correlations (Kalia & O'Connor, 2005; Newland et al., 2012; Sullivan et al., 
1992). One medium quality study looking exclusively at neuropathic MS pain (Rog et 
al., 2007) demonstrated the same result. However, a good quality study (Bruce, Polen, 
& Arnett, 2007) conducted a partial correlation controlling for MS-related disability 
found that depression (using the BDI-II) and pain severity were unrelated. One medium 
quality study (Kalia & O'Connor, 2005) examined correlations for each gender and 
found that only women had a significant medium size positive relationship between 
depression and pain severity. One medium quality study (Hamdy, Amer, Ramzy, Rabah, 
& Ashour, 2009) showed that headache severity and depression (BDI-II) were 
unrelated. In terms of odds ratios, one medium (Alschuler et al., 2013) and one good 
quality study (Brochet et al., 2009) showed MS participants meeting depression criteria 
were 1.196–2.070 times more likely to meet pain criteria (greater severity) relative to 
non-depressed MS participants. 
 
Six studies applied statistical comparisons. Three medium (Brochet et al., 2009; Ehde et 
al., 2003; Svendsen, Jensen, Hansen, & Bach, 2005) and one good (Newland, Wipke‐
Tevis, Williams, Rantz, & Petroski, 2005) quality study indicated people with MS with 
greater pain severity had significantly higher levels of depression compared to matched 
people with MS with no pain, and healthy controls. However, one medium quality study 
showed levels of depression did not significantly differ between women with relapsing-
remitting MS who experienced pain with healthy controls (Newland et al., 2009). 
Furthermore, one medium quality study (Hamdy et al., 2009) found no significant 
differences in self-reported depression between MS migraine and tension-like headache 
subgroups. One poor quality study found that patients with motor-neurons disease 
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demonstrated larger associations between pain severity and depression when compared 
to people with MS (Tedman, Young, & Williams, 1997).  
 
In terms of pain interference, three good and one medium quality study indicated a 
medium to large positive relationship between depression and pain interference at the 
simple bivariate level (ranging from r = .28 to .60) (Glowacka, 2010; Osborne, Turner, 
et al., 2006; Sasson Gelman, 2009; White et al., 2008).  
 
Depression was investigated in relation to a combined pain severity and interference 
total score in one poor (Tedman et al., 1997), one medium (Holden & Isaac, 2011) and 
two good quality studies (Motl, Snook, & Schapiro, 2008; Spain et al., 2007). Two 
studies (Motl et al., 2008; Tedman et al., 1997) indicated a small to medium positive 
relationship between depression and pain severity and interference total score, ranging 
from r = .29-.38. Holden et al (Holden & Isaac, 2011) found depressed MS participants 
reported significantly greater pain severity and interference total scores compared to 
non-depressed MS participants p<0.001).  
 
Anxiety & Worry   
 
Three medium quality studies (Bruce & Arnett, 2009; Kalia & O'Connor, 2005; Rog et 
al., 2007) examined relationships between chronic worry and anxiety and pain severity. 
While two studies (Bruce & Arnett, 2009; Rog et al., 2007) found small positive 
correlations (r = .22 and .26), one (Kalia & O'Connor, 2005) identified a significant 
medium correlation, along with a larger relationship for females when stratified by 
gender.  
 
The relationship of chronic worry and anxiety with pain interference was explored in 
one poor, one medium and two good quality studies (Bruce & Arnett, 2009; Sasson 
Gelman, 2009; Tedman et al., 1997; White et al., 2008). All studies consistently 
demonstrated significant medium size positive relationships between chronic worry and 
anxiety and pain severity at the simple bivariate level (ranging from r = .32 to .42). 
Bruce et al (Bruce & Arnett, 2009) also used a partial correlation to control for trait 




A single medium quality study (Motl et al., 2010) identified a medium size positive 
correlation (r = .42) between a combined depression and anxiety total score and a 
combined pain severity and interference total score.  
 
Factors from the Contextual Cognitive Behavioural Model of Chronic Pain 
 
Pain Acceptance  
 
One medium quality study (Glowacka, 2010) demonstrated a large negative relationship 
between the pain willingness component of the Chronic Pain Acceptance Questionnaire 
(CPAQ) and pain interference at the bivariate level.  
 
Summary of Regression Findings 
 
A number of cross-sectional studies identified associations between pain severity, 
interference and psychosocial variables using multivariate models. Other than perceived 
social support and solicitude (Ehde et al., 2003; Osborne et al., 2007; Osborne, Turner, 
et al., 2006), all psychosocial predictors within regression models, usually in 
conjunction with other psychosocial factors, were significant, accounting for between 4-
30%  of the variance in pain severity and pain interference (Brochet et al., 2009; 
Douglas, Wollin, et al., 2008; Glowacka, 2010; Osborne et al., 2007; Spain et al., 2007). 
All studies (see Table 2) controlled for demographic and disease factors, while three 
controlled for pain severity when pain interference was the entered as the outcome 




Overall Completeness and Applicability of the Evidence 
 
The purpose of this systematic review was to identify and assess quality of studies 
looking at potentially modifiable psychosocial factors associated with MS pain severity 
and interference and synthesise the evidence. Thirty-one studies, most of medium to 
good quality, offer preliminary support for the presence of several treatment modifiable 




In most instances, in line with the primary chronic pain literature (Jensen, Moore, et al., 
2011), correlations between a range of psychosocial factors and both pain severity and 
interference were similar in size. Consistent with traditional cognitive behavioural and 
fear-avoidance chronic pain theories, studies reported small to medium relationships 
between greater anxiety, depression, greater tendency to attribute a wide range of 
symptoms to MS, beliefs about pain constancy, the uncontrollable and serious nature of 
MS and increased pain severity and interference. Pain catastrophizing consistently 
demonstrated a medium to large relationship with pain interference at the bivariate and 
multivariate level. This is consistent with a recent study combining MS with other 
illness groups, which showed that pain catastrophizing was a significant predictor of 
pain severity and interference after controlling for diagnostic groups (Hirsh et al., 2011). 
Pain-related thought suppression shared a medium association with pain interference but 
was not examined in relation to pain severity. Reduced self-efficacy was only related to 
greater pain interference. Smaller and less consistent associations were reported in 
studies looking at relationships between perceived social support, the belief that others 
should respond solicitously and pain outcome, with perceived support having a positive 
effect on pain outcome and solicitousness a negative effect.   
 
Most MS studies incorporated variables drawn from the traditional cognitive 
behavioural and fear-avoidance perspective. One unpublished study focused on 
variables relevant to the contextual cognitive behavioural model. Findings from this 
single study indicated pain acceptance had a strong relationship with pain interference 
and, unlike most factors above, was negatively associated with pain interference, having 
a protective role. The relationship between acceptance and pain severity was not 
examined. Findings from a recent study of patients with chronic pain secondary to 
neurological conditions, including MS (Kratz, Hirsh, Ehde, & Jensen, 2013), showed 
pain acceptance predicts less pain interference and depression, and greater social role 
satisfaction and quality of life. This is consistent with Pakenham (Pakenham & 
Fleming, 2011) and Ferenbach’s unpublished study (Ferenbach, 2011) showing that 
general acceptance, alongside other contextual cognitive behavioural processes, is 
associated with better adjustment in MS. 
 
Taken together, this review suggests a number of cognitive factors appear relevant to 
MS pain. However, there was only tentative evidence for the relationship between fear-
avoidance, a core component of primary chronic pain models and pain severity. Fear-
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avoidance shared a small positive relationship with pain interference, in a relatively 
small unpublished study (Glowacka, 2010). The same study, found a stronger 
relationship between higher levels of pain-related thought suppression and greater pain 
interference. It is possible that people with MS overall are generally less fear avoidant, 
and instead, have a greater tendency to engage in pain-related avoidance-endurance 
behaviours consistent with the avoidance-endurance model (Hasenbring & Verbunt, 
2010). Alternatively, these findings might suggest there is a smaller subgroup of pwMS 
who experience pain-related fear. However, since review findings are preliminary, and 
fear avoidance is a consistent predictor of outcomes in primary chronic pain conditions 
(Crombez et al., 2012), it would be helpful to determine its relevance to MS pain in 
future research.  
 
Preliminary findings for the relationship between psychosocial factors and MS pain 
from different aetiologies were identified. One study (Rog et al., 2007) identified a 
small to medium size association between central neuropathic pain severity, depression 
and anxiety. Another study (Moisset et al., 2013) demonstrated large positive 
correlations between pain catastrophizing and pain severity and pain interference in 
both neuropathic and non-neuropathic subgroups. Moisset et al (Moisset et al., 2013) 
also found those with migraine headache reported greater pain severity, interference and 
pain catastrophizing compared to those with tension headache. In terms of disease 
characteristics, only one study looked at relapsing-remitting disease (Newland et al., 
2009) but no other subtypes. Therefore, clarifying potential differences between painful 
syndromes and MS subtypes in relation to psychosocial factors may also be helpful to 
guide treatment development.   
 
Preliminary Conceptual Model 
 
In Figure 2 we outline a working conceptual model of MS pain to inform future 
research and interventions in this area. Our model expands on Kerns’ biopsychosocial 
diathesis stress model of MS pain (Kerns et al., 2002) by specifying the psychosocial 
factors that may be important in magnifying or perpetuating the pain and associated 
disability. In particular, the figure elaborates on cognitive, emotional, behavioural and 
social factors or processes related to pain severity and interference, informed by 
empirical studies. These factors derive from well-established, empirically supported 
psychological theories and treatments within primary chronic pain. As with Kerns’ 
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conceptualisation, our model argues that biological factors, including neuropathic and 
musculoskeletal processes, medication and other painful syndromes unrelated to MS, 
interact with psychosocial elements in contributing to both pain severity and 
interference. Where relevant, factors have been further divided into helpful or unhelpful 
in terms of their influence on pain severity and pain interference. These biospychosocial 
factors sit within a context of predisposing experience, current MS symptoms and the 
social environment. While reviewed studies suggest psychosocial factors associated 
with MS pain are similar to other chronic pain populations, it is important to 
acknowledge the wider interactive context of pain in relation to other inherently painful 
(e.g. optic neuritis and spasticity) or non-painful MS symptoms (e.g. fatigue and 
immobility). As one example, MS fatigue is also associated with a variety of unhelpful 
potentially modifiable psychosocial responses (Knoop et al., 2012). Like Kerns, our 
model also recognises pain can potentially be exacerbated by use and overuse of both 
generic MS treatments (e.g. steroids) and medications prescribed for pain-relief.   
 
The model also attempts to integrate the traditional cognitive behavioural and 
contextual cognitive behavioural approaches in relation to our findings. From a 
traditional cognitive behavioural perspective, an unhelpful catastrophic response, or 
belief that pain will persist no matter what, may lead to the experience of worry, anxiety 
and depression and inward self-focus behaviours. It may be that the nature of avoidance 
for the majority of people with MS reflects “endurance”, comprising thought-
suppression and regular over-exertion, as opposed to fearful withdrawal or deactivation 
responses. As indicated in grey, it is important to note that few MS studies have 
specifically explored other forms of avoidance behaviours (Hasenbring & Verbunt, 
2010) (except avoidance in the context of fear), and are hypothesised behaviours drawn 
from studies of people with primary chronic pain. It was also the case that few studies 
examined social factors in relation to pain. From a contextual cognitive behavioural 
psychological flexibility perspective, the observed role of pain catastrophizing and fear, 
thought suppression and overexertion might reflect a broader pattern of experiential 
avoidance. Being the opposite of avoidance, pain acceptance has a significant 
behavioural component and, therefore, is represented as both a cognitive and 
behavioural process in our model. An individual’s unwillingness to have pain (non-
acceptance), alongside their inability to de-literalise from pain-related thoughts and 
associated distress (cognitive fusion), may result in a lack of present moment awareness. 
This may lead to repeated failed attempts to control or reduce pain, to the exclusion of 
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pursuing valued life activities (committed action). In either conceptualisation, this may 
ultimately lead to greater pain severity and pain interference, physical and social 

















Bold text = strong evidence, with many studies conducted with studies consistently supporting this role.  
Normal text = weaker evidence, where findings appear to be consistent but studies are few. 
Grey text = factors that may play an important role in primary chronic pain theories but have not been 
investigated.  




Implications for Therapy 
 
Given that our current MS findings show only few differences from those with primary 
chronic pain conditions, it may be that current psychological treatments offered to 
primary chronic pain patients (Eccleston et al., 2009; Veehof, Oskam, Schruers, et al., 
2011) may equally translate to improved functioning for people with MS. However, the 
potential differences observed in fear-avoidance may have implications for the goals of 
treatment, such that fear-avoidance therapeutic techniques may fit less well to people 
Wider social environment (perceived 
solicitude and social support) & MS 







 Cognitive Factors 
 
Potentially Helpful 
Self-efficacy / Perceived control 
over pain  
Pain Acceptance 
Perceived Social Support  




Negative beliefs about identity, 
control/curability & consequences 
of MS  



















Fear Avoidance  
Over-exertion  
 
            Biological Factors 
Pain of Neuropathic origin (due to a 
primary lesion or disease of the central 
nervous system)  
Pain of Non-neuropathic origin (due to 
actual or threatened damage to non-
neuronal tissue) 
Migraine Headache (with mixed 
neuropathic and non-neuropathic 
characteristics) 
Non MS-related pain (e.g. due to 
Wider social environment (perceived 
solicitude and social support) & MS 
contextual factors (i.e.  Other 
symptoms) 
 
Figure 2 Preliminary Conceptual Model of MS Pain 
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with MS. There are at least two possible current cognitive behavioural approaches in 
pain management, traditional cognitive behavioural (CBT) and contextual cognitive 
behavioural therapy, or Acceptance & Commitment Therapy (ACT). Despite having 
divergent scientific principles, both therapies aim to address cognitive and emotional 
facets of chronic pain and disability, albeit using different approaches. In CBT, 
unhelpful thoughts and behaviours are replaced with more helpful alternatives. In ACT 
thoughts are viewed functionally and their functions are targeted for change, such as 
whether they are followed or allowed to exert influence. ACT aims to loosen the 
exclusive influences of thoughts over behaviour patterns and to increase the influence of 
direct features of the situation at hand and one’s goals and values. Considering which of 
these processes are more amenable to change and likely to have the greatest positive 
benefit for people with MS is important, as is the question of which will lead more 
easily to future treatment developments. Overall, the similarities and differences 
outlined between CBT and ACT are not merely semantic, since they inform how the 
clinician encourages the patient to approach the problem of pain and the design of future 
interventions. 
 
Preliminary therapy trials in MS indicate both approaches may have value in managing 
pain in MS. A small uncontrolled trial of a cognitive restructuring hypnotic intervention 
for MS was associated with significant reductions in catastrophizing, pain intensity and 
interference (Jensen, Ehde, et al., 2011). A recent uncontrolled pilot trial of ACT for 
MS was associated with a reduction in thought-suppression and pain interference 
(Sheppard, Forsyth, Hickling, & Bianchi, 2010). While two RCTs assessing the efficacy 
of CBT interventions for people with MS are underway (Ehde, unpublished; Kerns, 
unpublished), more theory-based developments are needed. By defining key therapeutic 
mechanisms, and testing mechanisms of change in larger trials, we will be able to refine 
our conceptual model and key processes to address in future MS pain interventions. 
 
From the point of view of care providers, it may also be important to understand how 
pain interacts with other MS symptoms (e.g. ambulation, fatigue and sleep) within a 
multi-morbid, integrated biopsychosocial model that informs the development of 





Limitations and Directions for Future Research 
 
This review is limited by the cross sectional nature of the studies so the direction of the 
relationships between pain and modifiable psychosocial factors is unclear. The focus on 
bivariate findings and the potential for confounding in relation to disease severity means 
interpretation ought to be met with a degree of caution. 
 
The reviewed studies had several limitations. While three studies (Brochet et al., 2009; 
Motl & McAuley, 2010; Newland et al., 2005) provided longitudinal evidence 
investigating trends in people with MS pain-related depression and anxiety over time, 
studies investigating other psychosocial factors were mostly cross-sectional, limiting 
causal interpretation. Nevertheless, studies were helpful in identifying factors as 
relevant targets for psychological interventions as relationships can be reciprocal. 
 
Small sample sizes may have limited the ability to detect relationships (Bruce et al., 
2007; Glowacka, 2010; Michalski et al., 2011; Newland et al., 2012; Sullivan et al., 
1992), while better powered studies sampled US male military veterans, a non-
generalizable cohort not reflecting the higher prevalence of women observed in 
epidemiological studies (Alonso & Hernán, 2008; Compston & Coles, 2008).  
 
Most studies did not refer to a psychological theory or hypothesis as a rationale for 
selecting psychosocial factors, making it difficult to derive a consistent picture of how 
constructs are theoretically related and which may be most important. In this paper, we 
have proposed a conceptual model to help structure future work in this area. Future 
research should include large samples so that associations and multiple pathways can be 
reliably tested. No studies examined psychosocial differences across MS subtypes, and 
few explored whether there are differences between neuropathic and non-neuropathic 
pain. Once a clear theory base is developed, interventions can be designed accordingly 
and tested in randomised controlled trials (RCTs). RCTs should examine not only pain 
outcomes but also mechanisms of action by taking into account potential mediating and 
moderating psychosocial factors. These process analyses can then feedback and if 
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Supplementary Materials: Appendix A Search Strategies (Continued) 
 
Web of Science November 2013 
 
Topic=(Multiple Sclerosis OR MS OR Demyelinating disease OR Disseminated 
sclerosis OR Encephalomyelitis disseminate) AND Topic=(Pain OR Dysesthetic OR 
Lhermittes sign OR Trigeminal Neuralgia OR Low$ Back Pain OR Muscle spasms OR 
Tonic Spasms OR Neuropathic pain OR Headache) AND Topic=(Psycholog$ OR 
Psychosocial factors OR Psychological factors OR Adjustment OR Depression OR 
Anxiety OR Mood OR Social adjustment OR Social function OR Quality of Life OR 
Coping OR Belief OR Cognition OR Perception OR Fear avoidance OR Interference 
OR Catastrophi?ing OR Acceptance OR Willingness OR Mindfulness OR Endurance) 
OR Model OR Biopsychosocial 
Refined by: Document Type=( ARTICLE ) AND Languages=( ENGLISH )  
Timespan=All Years. Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH.  
Lemmatization=On   
World Cat Search November 2013 
Keywords: kw:Multiple Sclerosis kw:Pain OR Dysesthetic OR Lhermitte’s sign OR 
Trigeminal Neuralgia OR Lower Back Pain OR Muscle spasms OR Tonic Spasms OR 
Neuropathic pain OR Headache OR Severity OR Intensity kw:Psycholog$ OR 
Psychological factors OR Adjustment OR Emotional Response OR Depression OR 
Anxiety OR Fear avoidance OR Interference OR Catastrophizing OR Acceptance OR 
Willingness OR Mindfulness OR Endurance OR Coping beliefs OR Cognition OR 
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First online abstract screen by authors 1 & 4 
 
7259 after removing 2247 duplicates = 5012 abstracts. 4796 were irrelevant and so excluded: 
Second online full paper sought to be screened by authors 1 & 4 
Of 216 k=185 were excluded + 8 manually identified articles = 192 (references listed below): 
 
Total/Online/Manual Full article exclusions with reasons:  
 
Non-empirical k=16/16/0 
No psychological measures k=15/13/2 
No validated pain measures k=24/21/3 
Symptoms other than MS pain k=3/3/0  
Unobtainable k=40/39/1 
Systematic or literature reviews k=9/9/0 
Biomedical k=32/32/0 
Relationships between psychological factors and MS pain not directly explored k=25/24/1 
Not MS k=8/8/0 
Non-English publication n=3/3/0 
Qualitative study n=4/4/0  
Mediating psychological factors not explored n=5/4/1 
Samples comprising other pain conditions n=4/4/0 
Book chapter n=2/2/0 
Neurocognitive factors only n=1/1/0  
Duplicate k =2/2/0 
 
Grand Total of included studies k= 31 
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1 Anagnostou E and Mitsikostas D. Time 
perception in migraine sufferers: An experimental 
matched-pairs study. Cephalalgia. 2005; 25: 60-7. 
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2 Al-Smadi J, Warke K, Wilson I, et al. A pilot 
investigation of the hypoalgesic effects of 
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low back pain in people with multiple sclerosis. 
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Biomedical  
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(2013). Co-occurring Depression and Pain in 
Multiple Sclerosis. Physical Medicine and 
Rehabilitation Clinics of North America. 
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(2012). The Association of Depression with Pain‐
Related Treatment Utilization in Patients with 
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(2012). Defining mild, moderate, and severe pain 
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"Pain prevalence, severity and impact in a clinic 
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MS pain but biomedical  
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Haggiag S and Strano S. Painful and involuntary 
multiple sclerosis. Expert Opinion on 
Pharmacotherapy. 2011; 12: 763-77. 
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Pain syndromes in patients with multiple 




10 Barwick, F., P. Arnett, et al. (2009). "Managing 
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Coping, and Quality of Life." Archives of Clinical 
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available only 
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located 
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KM. Pain and sensory complaints in multiple 
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33 (2) (pp 173), 2010. Date of Publication: 2010. 
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Ivan R. Molton, PhD2  Provided by the Jensen 
No psychological 
measures in 
conjunction with pain 
measures 
 
4. Linl, C. P., Kupperl, A. E., Gammaitonil, A. R., 
Galerl, B. S., & Jensenl, M. P. (2011). Frequency 
of chronic pain descriptors: Implications for 
assessment of pain quality. European Journal of 
Pain, 15(6), 628-633. 
No pain measures  
5. Macleod, L. and G. Macleod (1998). "Control 
cognitions and psychological disturbance in 
people with contrasting physically disabling 
conditions." Disability and Rehabilitation: An 
International, Multidisciplinary Journal 20(12): 




6. Mills, N. and & Allen, J.(2000) Mindfulness of 
movement as a coping strategy in multiple 
sclerosis: 
a pilot study. General Hospital Psychiatry 22, 
425–431 Identified by third author. 
Not enough info about 
the measures used and 
their validity 
 
7. Rosenberg, D.E., Bombardier, C.H., Artherholt, 
S.B., Jensen, M.P., & Motl, R.W. (in press). 
“Self-reported depression and physical activity in 
adults with mobility impairments”. Archives of 
Physical Medicine and Rehabilitation. (Manual 
search Grey Literature paper identified by 





looking at MS alone. 
Nor did it use any 
pain severity or 
interference measure 
 
8. Sheppard, S. C., Forsyth, J. P., Hickling, E. J., & 
Bianchi, J. (2010). A novel application of 
acceptance and commitment therapy for 
psychosocial problems associated with multiple 
sclerosis: Results from a half-day workshop 




not explored, no 
direct correlations or 
comparisons between 






Supplementary Materials: Appendix C Quality Assessment Tool 
 
(All Items scores as 0 = not present or 1 = present)      
Scoring 0-15: ≤8 (53%) Poor; 9-12 (≥60-≤80%) Medium; 13-15 (≥86.6%) Good. 
 
                                                           Item Definition 
Rationale- aims 1: Positive if the objective of the study was sufficiently 
described (question or hypothesis with either direction) 
and/or based of a theoretical model. 
Demographic variables 
 
2: Positive if information was reported on participant’s 
gender, age, disease type/course, disease severity, time 
since diagnosis, current MS status (at least 3 of these)  
Suitability of the design to 
answering the research question 
3: Positive if appropriate research design was used, e.g. 
positive if control group was used when comparing 
psychopathology to the healthy population, if cross 
sectional design was used to find associations among the 
variables (not suggest causality or predictors), or 
qualitative methods were used to investigate in depth 
experiences of adults. 
4: Positive if control group was equivalent in age, sex and 
socioeconomic status (comparative studies)  
The Sample 5: Positive if the source of the subjects studied is stated 
6: Positive if response/participation rate relative to non-
participation was stated (how many questionnaires the 
researcher got back) 
7: Positive if the sample size was justified in relation to a 
power calculation and/or the number of independent 
variables utilised (a recognised rule of thumb is 10 times 
the number of IVs within a regression analysis: including 
control and psychological factors). 
Statistical analysis 8: Positive if appropriate statistical methods of analysis 
were used for the data (specific to the context of the 
studies aims) 
9. Positive if an appropriate statistical adjustment was 
performed on factored into the design (confounders)  
10. Positive if the authors stated if normality distributions 
were met, and if not, whether data transformation was 
conducted prior to analysis (if required). 
Presentation of the analysis 11: Positive if the graphs and tables were easy to 
understand, e.g. presenting a table for regression analyses 
including R2 values and β weights 
12: Positive if confidence intervals or p values were given 
for the main results 
Measures used 
 
13: Positive if all the questionnaires used were 
standardized, defined as questionnaires that had been 
validated and published or psychometric properties of new 
measures were presented 
Conclusions 14: Positive if the conclusions were justified based on the 
research findings 




Supplementary Materials: Appendix D Characteristics of Included Studies 
Study Characteristics Number (%) 
Sample Recruitment Sources: 
 MS Community & University Settings 
 Inpatient, outpatient & Rehabilitation Centres 
 
   14 (45%) 













  16  
   4  
   4  
   1 
   2  
   1  
   1  
   1  
   1  
 
Design: 
    Longitudinal 









Demographic & Clinical Characteristics  
Mean Age (n=27): 




Mean % of females (n=29) 74.38%  
 
Mean % of White Caucasians (n=12) 92.16% (Excl.one Egyptian study) 
 
Mean MS Subtype % (pain & no pain samples)  




Mean MS Subtype % (pain only subgroups or samples)                                









 7 (53.91%) 
 5 (17.8%) 
 5 (29.52%) 
 
 Mean Neurological Disability EDSS (mixed pain and 
no pain samples) 
 
Mean Neurological Disability EDSS (pain only 
samples and subgroup  






Mean time since diagnosis (years) 12.09 (n=19) 
 
Mean % prevalence of pain across mixed pain and no 
pain MS samples 
 
58.34% (n=12) 
Mean % employment status (full or part-time) pain and 
no pain samples 
 








END OF PUBLISHED ARTICLE 
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3.3 Systematic review erratum 
 
Two studies included in the review (Kratz et al., 2011; Osborne et al., 2007) explored 
relationships between psychosocial factors and pain outcomes. However, some of the 
bivariate findings were not included in Table 2 and the main text of the published article 
because some of the more detailed subscales for pain-specific cognitions and behaviours 
were missed. Therefore, the following section will briefly summarise these findings, 
which will be discussed in relation to some of the decisions made for the cross-sectional 
study in chapter 5, and added to the updated MS pain model in chapter 6.  
 
The erratum Table 1 shows the additional bivariate findings. The first outlines findings 
from a good quality study described in detail in chapter 1 (Kratz et al., 2011), which 
showed small to moderate bivariate negative correlations between pain interference and 
readiness to change (or maintain) task persistence behaviour. Specifically, pwMS who 
reported greater readiness to change in task persistence behaviour were more likely to 
report lower pain interference. 
 
Second, as indicated in Table 1 of the published article, one good quality study 
(Osborne et al., 2007) showed that illness beliefs, affective and social beliefs, and task 
persistence/exercise coping behaviour, alongside other psychosocial factors, were strong 
predictors of pain intensity in a multivariate regression accounting for demographic and 
disease variables. However, the bivariate correlations were not presented in Table 2. 
Therefore, erratum Table 1 shows that pain severity shared a small significant negative 
correlation with pwMS’ perceived control over pain, measured using the Survey of Pain 
Attitudes (SOPA) (Jensen et al., 1987), and was positively associated with the belief 
that one is disabled by pain. Pain interference shared a small to medium sized 
significant positive correlation with the pwMS’ attitude that others should be solicitous 
in response to their pain behaviours. A medium sized negative association between pain 
interference and pwMS’ belief that their emotions influence pain (considered to be an 
adaptive response), and a large positive association with perceived disability were also 
identified.  
 
In terms of self-reported coping responses, measured using the Chronic Pain Coping 
Inventory (CPCI) (Jensen, Turner, Romano, & Strom, 1995), pwMS who rested more in 
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response to pain showed small to medium significant associations with greater pain 
severity and pain interference. Pain interference also shared a small to medium negative 
relationship with task persistence and exercise coping strategies, and a small to medium 
positive association with use of coping self-statements. In addition, medium to strong 
sized significant positive associations with guarding and resting coping responses were 
also identified. Other coping responses on the CPCI, such as asking for assistance, 
relaxation, seeking social support and pacing, did not show significant relationships 
with either pain outcome. 
 
Overall, many of the bivariate relationships summarised were non-significant. However, 
those that were are incorporated into the refined model in chapters 5 and 6 to provide 
greater detail about some of the possible cognitions and behaviours that may contribute 
to pain and related disability in MS. Chapter 2 briefly highlighted there have been 
several ways of operationalizing pain-beliefs in MS, which are likely to overlap. 
Therefore, pain-beliefs that are similar to those identified in the SOPA were 
investigated using different measures in chapter 5. 
 
These findings provide further support for the original MS pain model, highlighting the 
potentially important role of cognitive, emotional, behavioural and social factors, or 
processes in maintaining pain and related disability. The current model differs from 
Kerns’ (Kern’s 2000; 2002) broader stress and coping conceptualisation in several 
important respects. First, the model incorporates the content specificity of chronic pain 
models outlined in chapter 2 (Hasenbring & Verbunt, 2010; McCracken & Morley, 
2014; Turk, Meichenbaum, & Genest, 1983; Vlaeyen & Linton, 2000), by including 
specific potentially modifiable cognitive, emotional, behavioural and environmental 
factors based on empirical findings from existing MS studies. Second, rather than 
focusing predominantly on predisposing vulnerability factors, the current model 
identifies factors or processes that are likely to maintain pain and related disability, and 
explores whether they are potentially helpful or unhelpful. Finally, the model explicitly 
distinguishes between neuropathic and non-neuropathic (musculoskeletal) pain 
subtypes, highlighting potential differences in the way pwMS respond psychologically 





Table 1 Systematic review erratum: Psychosocial factors examined in relation to Pain Severity (PS) and Pain Interference (PI) in MS  
Model 
 
Psychological Factor Quality Design Study Ref. (Table 1) and 
level of statistical 
techniques applied 
Group differences, r correlations, odds ratios of 
PS & PI across studies - Average (range) 
(n=studies reporting sig.) 
ANOVA & Regression 
(factors in combination with 
other psychosocial 
predictors & R2 range 
across studies) (n= studies 
reporting sig.) 
Factors from Operant 
Behavioural and 
Traditional Cognitive 
Behavioural Models of 
Chronic Pain (including 
Fear-Avoidance and 
Avoidance-Endurance, 
Motivational interviewing)  
 
 

















4. Pain coping (CPCI) 
Guarding  
Resting 




























































24 (PS* & PI* as scales 







24 (PS* & PI* as scales 
used in regression unclear) 
 
 
PI: ns   
PI: -.30  
 
 




PS:-.27 PI: ns   
PS: .27  PI: .52 
PS: ns PI: ns   
PS: ns PI: .29  
PS: ns PI:  ns 
PS: ns  PI: .29 
PS: ns  PI:  ns 
 
 
PS: ns  PI: .45 
PS:.25  PI: .35 
PS: ns  PI:  ns 
PS: ns  PI:  ns 
PS: ns PI: -.24  
PS: ns  PI: -.19  
PS: ns PI:  .27 
PS: ns PI:  ns 











 CPCI: The Chronic Pain Coping Inventory; SOPA: Survey of Pain Attitudes; ns: non-significant. 
*Uncontrolled bivariate correlation, uncontrolled comparisons (t-test /chi2), principle component / cluster analysis  
**Controlled bivariate correlation or comparisons, uncontrolled regression analysis  
***Controlled multivariate analyses (ANOVA or regression) 
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Chapter 4 : A Qualitative Interview Study Investigating Pain and its 
Management from the Perspective of People with Multiple 
Sclerosis. 
 
4.1 Chapter overview  
 
In chapter 3 the systematic review demonstrated there is a growing body of empirical 
evidence focusing on the psychosocial correlates or predictors of pain severity and pain 
interference in MS. The majority of studies were cross-sectional in nature presenting 
mostly bivariate findings, although some accounted for key demographic and disease 
variables using multivariate analyses. The synthesis of evidence contributed to the 
development of a preliminary working cognitive behavioural model of MS pain. The 
model indicated that pain outcomes, including pain severity and pain interference, may 
interact with a range of potentially modifiable contextual and cognitive behavioural 
factors or processes, including pain-related catastrophizing, self-efficacy / perceived 
control, depression and anxiety. It also showed that pain acceptance, illness perceptions, 
thought suppression and perceived social support may also be important. However, in 
contrast to primary chronic conditions, fear-avoidance did not appear to be strongly 
associated with pain outcomes in MS. 
 
Whilst the synthesis of reviewed evidence suggests that cognitive behavioural 
treatments may be beneficial for pwMS, there was generally a lack of good quality 
studies using temporal designs to investigate psychosocial factors or processes in 
relation to pain outcomes (Brochet et al., 2009; Khan, Amatya, & Kesselring, 2013; 
Newland et al., 2009). Therefore, we have little understanding of pwMS’ experience of 
pain in relation to psychological responses across time. This is important because most 
pwMS are likely to experience a variety of potentially fluctuating and interfering painful 
symptoms (Seixas et al., 2014). This degree of unpredictability may influence pwMS’ 
psychological responses in different ways and at different times, particularly as they 
encounter new or worsening symptoms. One way of capturing this dynamic process 
might be to conduct a longitudinal study investigating psychosocial factors and pain 
outcomes over time. However, another approach would be to use qualitative methods to 
ask pwMS about their lived experience of pain, and explore in greater detail their 
cognitive and behavioural reactions or responses, and efforts to manage pain. Most of 
the studies reviewed in chapter 3 investigated MS pain with quantitative designs, whilst 
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few have used qualitative methods (Douglas, Windsor, et al., 2008; Saverino & Solaro, 
2010). In contrast to quantitative designs, qualitative methods are useful because they 
allow for a more open-ended exploration of pwMS’ experience and beliefs about pain 
and associated treatments, which can highlight additional psychosocial factors or 
processes that have yet to be explored in previous quantitative studies. This is not only 
important to advance the development of the conceptual model and intervention, but 
may also improve our understanding of common themes and individual differences. The 
latter will allow us to think more carefully about developing patient-centred clinical 
approaches that aim to reduce the negative impact of pain and improve pwMS’ 
engagement in other treatments. The current chapter presents a published article 
reporting on this next qualitative phase of work.  
 
The preliminary MS pain model presented in systematic review was useful in 
highlighting the importance of several cognitive behavioural factors or processes in 
relation to pain outcomes. However, many studies explored depression in relation to 
pain, whilst fewer studies examined the role of more specific cognitive behavioural 
factors and processes. Correlational findings across the more specific factors and 
processes were also mixed, prompting several theoretical questions. First, the 
behavioural element of the model identified either non-significant or small effect sizes 
for fear-avoidance in relation to pain. This finding was surprising given that pain-related 
fear reflects a common response in primary chronic pain populations described in 
chapter 2. It may be this finding reflects the fact that two studies investigating this 
construct were either underpowered or of low quality. In addition, no studies in the 
review had explored other potentially unhelpful forms of behavioural avoidance, such as 
over-exertion or endurance responding. This was felt to be important in MS pain since 
research in MS fatigue had indicated “all-or-nothing” behaviour was a significant 
contributor to reduced functioning (Knoop et al., 2012; Skerrett & Moss-Morris, 2006). 
On the other hand, pain acceptance was identified as a potentially helpful response that 
shared a strong association with pain interference in one underpowered and unpublished 
study. Furthermore, although Kratz’ et al.’s motivational model explored 'adaptive’ task 
persistence and exercise management behaviours (Kratz et al., 2011), no  studies had 
investigated other potentially helpful behavioural responses that may tap motivation, 
such as pwMS’ flexible persistence with, or shifting to, a course of action guided by 
values and goals even in spite of pain (i.e. committed action). Therefore, asking pwMS 
more general qualitative questions about what they do in response to pain might 
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elucidate whether these behavioural responses were necessarily important in 
maintaining pain and related disability in MS. 
 
Second, the cognitive part of the MS pain model indicated that pain catastrophizing was 
the strongest correlate of both pain severity and pain interference. Self-efficacy or 
perceived control also appeared to be relevant but to a lesser degree. However, whilst 
the model indicated that illness perceptions related to identity and chronicity may be 
important, no studies had explored beliefs specific to pain informed by Leventhal’s 
common sense model of illness perceptions (Leventhal et al., 2003). Therefore, greater 
emphasis was also placed on developing open-ended qualitative questions around 
pwMS’ pain-related beliefs in order to find out more about these, and other, perceptions 
that may be pertinent to MS pain. To develop a more integrated picture of PwMS’ 
responses to pain, it was also felt that asking them how they think about pain in 
conjunction with what they do might be informative for the model. 
 
Although a few studies in the review showed that correlational findings for neuropathic 
and non-neuropathic pain subgroups were mostly comparable, another gap in the model 
centred on the limited understanding of how a person may differentially respond to 
painful symptoms. It was therefore unclear whether one particular symptom stood out as 
being more problematic than others. In addition, the review provided very little 
information about how pain may interact with other MS symptoms, which was 
emphasised in Kerns’ earlier diathesis stress model (Kerns et al., 2002). Therefore 
questions also explored both of these aspects. Finally, although the operant behavioural 
elements related to perceived solicitude or social support were identified in the review, 
they only shared small to medium associations with pain outcomes. It was therefore felt 
that exploring other people’s reactions in response to pwMS’ pain might provide more 
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Abstract   
 
Background: Pain affects around 63% of people with Multiple Sclerosis (pwMS). 
Biomedical treatments demonstrate limited efficacy. More research is needed to 
understand pain from the individual’s perspective in order to better inform a patient-
centred approach that improves engagement, self-management and outcome. 
 
Objective: To explore pwMS’ experience and responses to pain, and their perspectives 
on pain management.  
 
Methods: Twenty-five, in-depth, semi-structured, telephone interviews were conducted. 
Interviews were audiotaped, transcribed and analysed using an inductive thematic 
analysis approach with elements of grounded theory. 
   
Results: Key themes included vivid descriptions of pain and beliefs that pain is 
unpredictable, a sign of damage and may worsen. Anger was a common emotional 
response. Two dominant pain management themes emerged: one related to pain 
reduction and another to acceptance. Those focussing on pain reduction appeared to 
engage in cycles in which they struggled with symptoms and experienced continued 
distress. 
 
Conclusion: Findings identify pain-related beliefs, emotional reactions and disparate 
pain-management attitudes. All may influence pwMS’ responses to pain and what they 
ask of their clinicians. Uncovering pwMS’ personal beliefs about pain, and introducing 
a broader biopsychosocial understanding of pain in the clinical context, may provide 
















A recent meta-analytic review estimates pain affects around 63% of people with 
Multiple Sclerosis (pwMS) (Foley et al., 2012). MS pain can be broadly classified as 
either neuropathic, directly caused by a primary lesion or disease of the somatosensory 
nervous system (including Lhermitte’s sign and trigeminal neuralgia), or non-
neuropathic, arising from actual or threatened damage to non-neuronal tissue including 
activation of nociceptors (musculoskeletal) (Merskey & Bogduk, 1994; O'Connor et al., 
2008). Pain can be indirectly related to MS, coincident, or caused by other MS 
symptoms and treatments (Pöllmann & Feneberg, 2008). A third of pwMS describe pain 
as one of the worst MS symptoms (Stenager et al., 1991). Many experience 
uncontrollable pain (Kerns et al., 2002) and current biomedical treatments demonstrate 
limited efficacy (Beard et al., 2003). 
 
MS pain is yet to be carefully understood or extensively studied within a broader 
biopsychosocial framework (Douglas, Windsor, et al., 2008). Whilst there is a growing 
body of evidence for psychosocial factors associated with MS pain (Douglas, Wollin, et 
al., 2008; Osborne et al., 2007; Osborne, Turner, et al., 2006), few studies have engaged 
patients in direct discussion about their experience. Two qualitative studies offer useful 
insights into pwMS’ descriptions of pain and its impact (Douglas, Windsor, et al., 2008; 
Saverino & Solaro, 2010). However, little is known about pwMS pain-related beliefs, 
which may be important since the way individuals conceptualise their MS symptoms 
(Jopson & Moss-Morris, 2003; Riazi, Thompson, & Hobart, 2004; Vaughan, Morrison, 
& Miller, 2003) and treatments (Martin et al., 2014) can determine self-management 
behaviour and outcome. Therefore, using qualitative methods to better understand how 
individuals perceive pain may guide the development of patient-centred clinical 
approaches that improve engagement in specific treatments. 
 
The aim of the current study was to explore pwMS’ experiences of pain and their beliefs 








Participants and methods 
 
The project was approved by the Berkshire Research Ethics Committee. 
 
Participants were included if (a) they were over eighteen years of age, b) diagnosed with 
MS, and c) had experience of pain in the context of MS. PwMS were excluded if they 
were non-English speakers. 
 
Recruitment was via national advertising and through National Health Service (NHS) 
MS clinics. Potential participants were invited to complete a screening questionnaire, 
including demographics, Self-report Leeds Assessment of Neuropathic Signs and 
Symptoms (S-LANSS) (Bennett, 2001), MS subtype pictorials (Lublin & Reingold, 
1996) and Self-administered Expanded Disability Status Scale (Bowen, Gibbons, 
Gianas, & Kraft, 2001). Once returned, purposive sampling was used to select a diverse 
range of participants. Thirty-two responders to study advertisements returned the 
screening questionnaire and 26 from MS clinics. Twenty-five participants were 
interviewed (Table 1): 12 from the MS Society and 13 from NHS specialist clinics. 
Interviewing ceased once data saturation was reached, defined as the point at which no 





Table 1  Characteristics of the sample (n=25) 














4   (16) 
5   (20) 
5   (20) 
5  (20) 
6  (24) 
Ethnicity: 
    White-British 
    Black African-British 
    Black Caribbean-British 
    Asian-British 
    Mixed (White-Asian) 
 
17 (68) 
2   (8) 
2   (8) 
2   (8)    
2   (8) 
Years of education:  
    1-11 
    >12 
 
3   (12) 
22 (88) 
Employment Status: 
    Full-Time 
    Part-Time 
    Full-Time Education 
    Unemployed 
    Retired 
 
2   (8) 
9   (36)  
1   (4) 
7   (28) 
6   (24) 





3   (12) 
6   (24) 
16 (64) 
Experiencing current relapse: 
    Yes 
    No 
    Not Sure  
 
1   (4) 
22 (88) 
2   (8) 
Neurological Disability Self-Report EDSS:  Mean (SD) (Range) 
5.68   (.98)  (4-7) 
Current MS Symptoms: 
Fatigue 
Bowel or bladder dysfunction 
Balance disruption 
Cognitive impairment 
Blurred or double vision 
Difficulties with Speech 
Difficulties with swallowing 




















7   (28) 
5   (20) 
Pain Severity 11-point Numerical Rating Scale (0 ‘no 
pain’ and 10 ‘pain as severe as it could be’) 
Mean (SD) (Range) 
6.58 (Moderate) (1.98)  (3-10) 




8   (32) 
17 (68) 
Recruitment Source: 
   NHS Specialist Clinics 




1 This is an approximation based on a self-report measure not yet validated in the MS population 
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Participants included six men and nineteen women, with a mixture of ethnic 
backgrounds, ages and occupational status. PwMS reported an average pain severity 
rating of 6.5 on the S-LANSS 11-point scale suggesting pain in the moderate to severe 




Non-directive, semi-structured telephone interviews were conducted by A.H. to elicit 
accounts of participant’s experience. The interview schedule (Table 2), piloted and 
edited by three patient and public involvement members with MS, included seven open-
ended questions, encouraging individuals to share issues that were important to them. 
Questions were provisional and modified if more clarification was required. Telephone 
interviews were used to improve access to pwMS who might otherwise be excluded due 
to severe disability. Interviews ranged from 30-60 minutes in duration, and were digital-
audio recorded and transcribed verbatim. Once data saturation was reached, those who 
consented but were not interviewed were thanked for their time, and given the 
opportunity to participate in future studies in this research programme. 
 
Data analysis  
 
Data were analysed following established guidelines for inductive thematic analysis 
(Braun & Clarke, 2006) and procedures from Grounded Theory (Glaser & Strauss, 
2009), used specifically to gain psychological insights to guide the next stages of the 
MS pain treatment research programme. 
 
A.H. listened to interviews, and repeatedly read transcripts to become immersed in their 
content. Coding was undertaken with regular discussion with authors A.B. and R.M.M., 
who read and coded excerpts from four transcripts to ensure AH’s coding was grounded 
in the data. Each unit of coding was assigned a descriptive name on Nvivo 10 software, 
and wherever possible, reflected participant’s vocabulary (Glaser & Strauss, 2009). 
Codes were redefined and combined, and new and alternative codes were generated 
(Glaser & Strauss, 2009). Broader themes were identified and organized into a 
preliminary framework. A.H.’s written accounts and diagrams of themes and their 
interrelationships were repeatedly checked against transcripts to ensure they accurately 
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represented the data (Patton, 1990). An audit trail of coding and thematic developments 
was maintained. 
 
Table 2 Interview Schedule 
Questions Prompts 
 
Can you tell me about the pain you experience? 
 
 
How would you view your pain in relation to other MS 
symptoms? 
 
Health care professionals have certain views and 
beliefs about pain. I am interested to hear about your 
personal beliefs or views about your pain?  
 
Tell me what you usually do when you experience 
pain? 
 




How do others (i.e. family or friends) react to your 
pain?  
 
What do you think could be done to help you with 
your pain? 
 
How would you compare these different kinds of 
pain? 
 
Where does pain fit in? How do you rate you pain 
compared to other symptoms? How does pain affect 
your day-to-day life compared to other symptoms? 
Things that make pain worse or better, causes 
curing or controlling, consequences, how long do 
you think you will have MS-related pain?  
 
How would you usually react, similar reactions for 
different types of pain? 
 
Concrete example / a typical day, most helpful 
things, least helpful, how effective, similar for all 





Do you think anything else should be offered to 
you? What should be addressed in treatment? 
How might services assist you? What might a 
treatment look like / target? How might you expect 
to feel after a fictitious pain management 









































5. Attitudes & 
Beliefs about Pain 
Management 
 
2. Vivid & 
Paradoxical 
Descriptions 
4. Dealing with 








pain can be 
difficult 
and elusive 





I’ve tried most things & 













Being careful  
not to over-exert 
 
Common ways of 
managing pain 
 










Figure 1 summarises five key identified themes and their subthemes: 1) Pain in the 
context of MS, 2) Vivid & paradoxical descriptions, 3) Pain beliefs, 4) Dealing with 
frustration and anger, and 5) Attitudes & beliefs about pain management.5 Each of these 



































                                                 
5 More detailed information of all the themes can be obtained from the authors [see 




Table 3 Key Themes: additional Examples 
Themes and Subthemes Example Quotations 
 




“I think it is all just swirled into one… MS pain is wrapped 
up with a lot of other things.” 
 
“Everything comes together. They [symptoms] all happen 
around the same time, and that normally starts to occur the 
more tired I get.” 
 
2. Vivid and Paradoxical Descriptions 
 
 
“Like pins sticking into my toes.” 
 
“Feels like somebody has just stood on my hands.” 
 
“Imagine a hundred times worse than you could squeeze in a 
bear hug.” 
 
“It's really hard to describe these things!” 
 
“I am not too sure how it feels or how to describe it… I think 
that I have only recently understood how it feels.” 
 
3. Pain beliefs 
 
























“The lesions on the brain… they are putting pressure on 
certain parts of the brain, I think that causes a bit more pain 
in that certain area.” 
 
“When I have the lower back pain, it's obviously got 
something to do with the nerves in that area, it can't be 
anything else.” 
 
“Pain is like the brain or my nerves are saying, okay you 
need to do something different.” 
 
“So I’m taking it [Simvastatin], not for pain but for high 
cholesterol, and it may have affected my pain.” 
 
“It's so unpredictable and you have no idea when and 
where, if and how.” 
 
“There is no way I could point to a diary and say it is going 
to happen then it's just decides “okay, we are going to do 
this today.” 
 
“I envisage it getting worse.” 
 
“I think I see it every day, you know what that path is, I am 
not getting any better, and the intensity is a bit more as time 
passed.” 
 
4. Dealing with frustration & anger 
 
 
“When I get my everyday pain, as I call it, it’s just like – it’s 
an annoyance, it’s just there and it’s like, oh, okay then!” 
 
“Oh, I just find it frustrating because I can’t do the things 
that I want to do.” 
 
“I went to the pictures the other day to see a film and you 
get involved in it for a certain time and then your mind 
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“It's been hard to control because there is… something that 
will work on me, and then there are some things that don’t, 
and they will work for a certain amount of time, and then it 
won't work.” 
 
“Well if it is really bad, I just stay in bed and I rest.” 
 
“Find me a wonder drug for pain.” 
 
“I’m not very good at giving in to things and… I’m not very 
sensible sometimes.” 
 
“The actual painkillers and medication you take can end up 
debilitating you just as much as the pain.” 
 
“I will have to adapt to leading my life with it there”. 
 
 
1. Pain in the wider MS context 
 
This first theme explains that many participants viewed pain as the worst symptom of 
MS. PwMS described pain as inherent to other MS symptoms, including optic neuritis, 
spasms and sensory dysfunction. The co-occurrence and interaction between pains, 
fatigue and sleep disruption were also highlighted. A few pwMS suggested that pain had 
become a common label to identify or describe other MS symptom experience. 
 
I think it’s all just swirled into one… MS pain is wrapped up with a lot of other MS 
symptoms. All symptoms around my legs seem to have some sort of pain attached to 
them… I think a lot of my symptoms have now become about pain. (Female, 46 RRMS)  
 
2. Vivid and Paradoxical Descriptions  
 
Although many patients said pain was hard to describe, most in fact provided clear 
descriptions. Many of these descriptions also included strong imagery.  
 
In my feet, you know, I could say that um it feels as though somebody is um hammering 
my feet with a claw hammer, a metal hammer… but how do I know that because that 
has never happened to me?  




3. Pain beliefs 
 
Three types of pain-related beliefs were prominent.  
 
Pain is unpredictable. Many participants suggested their pain had no discernible 
pattern, arising randomly from day-to-day and changing unpredictably across the 
disease course.  
 
It changes quite a lot with MS. I get these feelings in my toes… it feels like there are 
pins sticking in… and the pains change as well, and all the feelings in the feet change. 
It’s become more painful over the last year than it was before. (Female, 58, RRMS) 
 
Personal causal beliefs. PwMS expressed a variety of personal causal beliefs about 
pain, ranging from the use of cholesterol medication to having a stressful lifestyle.  
 
I would definitely say… the main thing is stress… stress really flares it up. (Male, 35, 
RRMS) 
 
Pain was sometimes assumed to be a direct result of damage to nerves and viewed as a 
sign or omen of worsening pain, further damage, relapse and disease progression. Some 
pwMS felt this explanation came from HCPs.  
 
I have been told by neurologists it’s to do with the scarring on the right-hand side of my 
brain [headaches]. I’ve had quite a few MRI scans that have shown up where the areas 
of the… damage, the myelin sheath are, and I experience quite serious headaches… I 
don’t know whether I believe if it’s a pain more telling me to calm things down a bit or 
whether it’s something going wrong with my nerves. (Female, 42, SPMS) 
 
PwMS sometimes referred to vivid causal descriptions of the central nervous system 
being confused or faulty.  
 
I know that a lot of it is caused by… the electrical cable of  your nerves, the myelin has 
holes in the plastic sheath around a cable and so it isn't working properly, some of the 





Pain will get worse. Most pwMS’ felt that pain would worsen over time. 
 
Well, I’m expecting… it does, it has got worse… over the past say five or six years, 
walking distances is more and more difficult. So I’m imagining that it will get worse, 
hopefully not too quickly because my progress has been quite steady over the years. 
(Male, 52, RRMS) 
 
4. Dealing with frustration & anger 
 
The fourth subtheme reflects the idea that pain is an unwanted companion for pwMS, 
often resulting in frustration and anger. Many described these difficult feelings were due 
to pain’s intrusive and unrelenting nature, becoming a central focus in their awareness.  
 
The discomfort causes frustration.  The best way to describe it is… when… something is 
just… like a dripping tap or something, it's just like, ‘Oh god why is this…?  Just go 
away!’ kind of thing.  
(Male, 35, RRMS)  
 
Most reflected on pain’s ability to prevent spontaneous or planned engagement in 
enjoyable activities. This aroused frustration and anger, and some highlighted a 
tendency to dwell on pain and an inability to disengage from angry feelings. 
 
If I go for a walk with my friend… after half an hour, I know I can feel pain 
increasing… I can feel myself getting upset and cross and then I have to sit down and 
wait… that makes me really angry … if I go home and dwell on that… and if it doesn’t 
recede, then I get more angry and upset. (Female, 46, RRMS) 
 
Some described becoming short-tempered towards others, which resulted in socially 
isolating behaviour to manage pain and preserve relationships.  
 
I get really grumpy… to the point where nobody can talk to me because I’m so 
‘ahhhhhhh, leave me alone!’ and let them know everything is painful. I feel guilty about 




Other causes of anger and upset arose from disappointment with recurrent, unsuccessful 
attempts to reduce pain with medications. A few felt treatments specifically addressing 
anger may be helpful.  
 
5. Attitudes & beliefs about pain management  
 
The fifth subtheme illustrates how pwMS shared mixed successes in attempts to reduce 
pain. 
 
I’ve tried most things and it’s a case of hit and miss. PwMS used a variety of 
treatments and management strategies, ranging from medications and self-administered 
physical strategies (e.g. bathing or stretching) to mental visualization or distraction 
techniques.   
 
With my headaches, it's been quite hard to control because there is… something that 
will work on me, and then there are some things that don’t, and they will work for a 
certain amount of time, and then it won't work. (Female, 18, RRMS) 
 
Common ways to self-manage. While a minority of pwMS used exercise to reduce pain 
arising from standing or sitting still, the majority identified two common ways to self-
manage, including taking pain medications (even if ineffective) and being careful not to 
over-exert themselves by stopping and resting regularly.   
 
Pain reduction agenda. When asked about expectations of future treatments, many 
professed adherence to a pain reduction agenda, reflecting an eagerness to try new 
‘wonder drugs’ and learn new ‘mental tricks’. 
 
Just relief from the pain… so I don’t have it anymore, or if I do, that it's less than what I 
have been experiencing that has to be the ultimate goal, I can't think of anything else… 
I would want the pain to be less or non-existent - it has to be! (Female, 38, RRMS) 
 
Catch-22. Consistent with the reduction agenda, pwMS often described unique ‘Catch-
22’ situations or unhelpful ‘cycles’ that undermined common ways to self-manage. 
Figure 2 shows how one lady’s attempts to manage or reduce pain (avoiding 
movement), in combination with other debilitating symptoms (fatigue), tended to result 
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in worsening pain and symptoms, and additional problems (weight gain). This often 





















Fighting talk. The same pwMS often described themselves as ‘fighters’, suggesting 
they needed to think positively or be a ‘positive person’. For some, motivation for their 
struggle reflected the desire to remain independent and overcome the inclination to 
avoid everyday activities. 
 
I don’t like that idea at all [loss of independence], that is to me the worse consequence 
and … I mustn’t think about it because… I’m a fighter and I will fight as much as I 
can… Now, once I can't… that doesn’t bear thinking about. (Female, 62, PPMS) 
 
For others fighting was about problem-solving their pain and MS, or an internal battle 
focussing on the pushing away of thoughts related to their disease progression, 
sometimes rejecting advice offered by HCPs and family members (e.g. over-exerting 
when resting has been prescribed). One participant with long-standing pain explained 




around due to 
pain & fatigue 
symptoms 
Pain from not 
moving around 
Lack of exercise 
Weight gain 
Become more 
unfit with greater 
pressure on legs  
Additional pain 
Figure 2: Catch-22 example (60 year-old Female, RRMS) 
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You can’t fight it; you just go with it. When I talk to a friend of mine about her 
problems, I say to her well… today is one of the days you can’t work through it, you 
have just got to go with it. We’re not these kind of defeatist people, we like to… hold our 
own… but you can’t. (Male, 45, SPMS) 
 
Managing and accepting agenda. In contrast others felt adapting or planning a lifestyle 
to fit with pain was more realistic. This reflected the view that curing pain and MS was 
unlikely. Accepting pain as part of life, being in touch with the body and knowing one’s 
limits were viewed as integral to improved management. 
 
The thing is you can't cure it can you, so it is all about management… managing 
yourself and knowing what medications to take at what time… a lot of it is pain 




This study provides a unique insight into the experience of pain in the context of MS. 
PwMS identified pain as part of a conglomerate of interacting symptoms where it was 
often hard to separate pain from sensations such as numbness, stiffness and fatigue. 
   
Most pwMS interviewed for this study provided vivid and sometimes dramatic 
descriptions of their pain to convey the intensity of the pain experienced. PwMS viewed 
pain as unpredictable, uncontrollable and attributed a variety of potential causes. 
Detailed descriptions of damage to nerves or ‘wiring’ were often recounted, sometimes 
in conjunction with ominous beliefs about worsening pain, other MS symptoms and 
disease progression (Douglas, Wollin, et al., 2008). Pain catastrophizing is associated 
with poorer outcome in patients with chronic low back pain (Foster et al., 2008). A 
recent study has shown patient’s MS illness perceptions are associated with pain 
severity and interference (Spain et al., 2007). However, pain-specific illness perceptions 
have not been explored in relation to MS pain. 
 
Consistent with the primary chronic pain literature (Fernandez & Turk, 1995), pwMS 
frequently reported frustration and anger, which worsened when faced with limitations 
preventing planned and spontaneous activity. Anger was expressed in conjunction with 
themes of unpredictability, dissatisfaction with pain medications and HCP interactions. 
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Some described an inability to disengage from difficult feelings, expressing a desire to 
manage anger more effectively.  
 
PwMS employed a range of management strategies to reduce pain or associated distress, 
often with mixed results. This is consistent with the finding that  medications for 
neuropathic pain may benefit some, but not all individuals, with other chronic pain 
conditions (Kalso et al., 2013), and a study (Heckman-Stone & Stone, 2001) showing 
that pwMS ranked pain medication as the most effective and ineffective coping strategy, 
and exercise, rest and sleep were identified as common ways to self-manage. More 
importantly, our findings revealed pwMS’ attempts to manage pain using these common 
strategies often resulted worsening of others and unhelpful ‘catch-22’ vicious cycles.  
 
Attitudes towards management were split between those who focused on reduction of 
pain, where pain was viewed as something to be fought, and those who felt management 
was about acceptance and adapting to a life with pain. Acceptance is a key predictor of 
adjustment in MS (Pakenham & Fleming, 2011). Pain acceptance, defined as willing 
engagement in activities, in a way that includes contact with pain, without attempts to 
struggle with or control it, is also a predictor of better functional outcome in primary 
chronic pain conditions (McCracken, 2007; McCracken & Velleman, 2010). PwMS 
who talked more about acceptance expressed a preference for a more holistic 
biopsychosocial approach to pain management. In contrast, the majority held a more 
mechanistic biological account of cause (e.g. ‘bad nerves’, lack of medication, external 
stressors) and talked more about the need for ‘wonder drugs’. This split in attitudes 
might also reflect a recent study showing that chronic pain subgroups held distinct 
models of causal interpretation of pain that were consistent with views of how it should 
be treated (Martin et al., 2014). It therefore seems important to examine the role of pain 
acceptance and broader causal schemas of pain and management in MS.  
 
Implications for treatment   
 
Some pwMS explained their biomedical interpretations of pain were provided by HCPs 
(particularly related to causes and control beliefs). Such interpretations may influence 
patient’s to rely on medications which to date show limited efficacy. While health 
professionals are unlikely to have the time to replicate an in-depth interview exploring 
pain, it may be beneficial to provide a broader biopsychosocial understanding by asking 
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a few targeted questions centring on pain and management beliefs. For example, a 
patient with recurrent (perhaps vivid) thoughts that pain is associated with increased 
damage to nerves (e.g. ‘if I push myself I’m going to damage myself even more’) may 
begin to avoid everyday activities. While such thoughts may be protective in certain 
contexts (e.g. not over-exerting during an exacerbation), they are likely to be unhelpful 
if followed as generalised rules. Therefore, orienting patients to a biopsychosocial 
perspective of pain via psychological interventions that actively target pain beliefs and 
distress by exploring their validity (an aim of traditional Cognitive Behavioural 
Therapy, see Eccleston et al., 2009), or changing the person’s relationship to their 
mental and bodily experience (Acceptance-based approaches, see Veehof, Oskam, 
Schreurs, & Bohlmeijer, 2011), may lessen their influence on behaviour, by interrupting 
catch-22 cycles. Since pwMS describe pain as interacting with other MS symptoms 
within vicious cycles (with some possessing their own psychosocial consequences 
(Knoop et al., 2012), it may be that a broader symptom management strategy, rather 
than a pain-specific one, is necessary.  
 
There were several limitations with this study. A single data-gathering period cannot 
elucidate the variable and every changing presentation of MS pain. Therefore, future 
research may benefit from an ongoing assessment across the course of illness by 
conducting a series of interviews tracking the individual’s beliefs across time, 
identifying factors pertinent to functioning. Because recruitment focused specifically on 
participants with pain participants may have experienced higher than average pain 
severity.  Pain ratings in this study were in the moderate to severe pain on average. 
Other MS studies using similar measures commonly report average pain ratings of ‘mild 
to moderate (Osborne, Turner, et al., 2006). As with all qualitative research interviewer 
demographic characteristic could have influenced the interview process. However, use 
of telephone interviews, carefully constructed open questions and the fact that the 
interviewer was independent of patients’ health care will have reduced this bias. It is 
also possible that prior knowledge of psychological models of pain may have influenced 
the salience of certain themes reported potentially resulting is less emphasis being 
placed on alternative explanations for the data collected. The exclusion of non-English 





Overall, our data indicate there may be benefits to talking through pain- and treatment-
related beliefs with pwMS. This process may uncover pain-related anger, and provide 
the opportunity to rectify idiosyncratic pain-beliefs, which influence ineffective 
management strategies and perpetuate vicious cycles of distress and reduced 
functioning. Future quantitative research would enhance our understanding of these key 
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4.3 Qualitative study erratum 
 
 
One aim of the qualitative study was to develop a better sense of how pwMS perceived 
other’s responses to their pain. However, a sixth theme centring on the social aspects of 
pain was omitted from the published article because of the short word limit imposed by 
the journal. It was also the case that this theme had already been well described in the 
previous qualitative literature (Douglas, Windsor, et al., 2008). For the purposes of this 
thesis, and intervention development, the following section briefly describes these 
additional findings, which are incorporated within the refined MS pain models in 
chapters 5 and 6. 
 
6. Pain is invisible to others 
 
When pwMS were asked either about the impact of pain or others responses to it, many 
said that they felt that pain was invisible to others.  They often explained that the lack of 
clear visual physical damage or injury to the body often resulted in others failing to 
understand or appreciate the extent of their pain.  
 
“Because it’s something people can’t see... You know, if somebody’s walking around 
with an arm in a sling or plaster on their arm or leg, people go, oh you’ve broken your 
leg.” (Female, 63, SPMS)  
 
“I will tell you one thing, work can be difficult, one of the biggest problems with going 
to work is that people don’t understand it, they can't see it because you know when 
people have got pain they have normally got a sling on, or an eye patch, or they have 
got stitches, you know, something to represent their pain, and when you go in and you 
look healthy, and you try to say to people, well I don’t feel well, they will say, well you 
look fine to me.” (Female, 55, RRMS) 
 
In some cases pwMS felt that the invisibility of pain often lead to them feeling as 
though others were questioning the legitimacy of their experience, which even occurred 




“But looking at me, listening to me, pain and anything else… No, I don’t think it goes 
in, it doesn’t, it's what people can see and they judge you on what can be seen rather 
than what you’re telling them.”  
(Male, 35, RRMS)  
 
Although the invisibility of pain was distinct from other themes identified in Figure 1 of 
the published article, it was closely linked to pain being difficult to describe, and often 
related to feelings of anger and frustration. This theme also encompassed another 
subtheme, which reflected pwMS’ tendency to be more selective in their decision to 
‘conceal or reveal’ pain to others.  
 
“Um, well [chuckling] they react differently I suppose, my close friends, it's about how 
much you tell someone isn't it, so some people I chose to tell and others I don’t and so 
they can never understand if I don’t tell them, I don’t want - I am sort of torn between, it 
sounds ridiculous, because how can they help me if I don’t tell them but I don’t see that 
everybody needs to know about the MS or the pain.” (Male, 45, SPMS) 
 
Sometimes pwMS ‘concealed’ pain because they felt others would not understand, or 
were concerned about what others would think about them.  
 
“Purely because pain – like fatigue – is one of those things that people can’t see so they 
can’t relate. They can see you might have pain, the expression on your face, but a lot of 
MS sufferers, if they get pain, they try and hide it. So they are fighting it on that level 
and then they are fighting it from people seeing it at another level. So I think that makes 
people worse because they are worried what people are going to think.”  
(Male, 45, SPMS) 
 
On the other hand, a few pwMS felt that talking about pain was unfair on others, 
particularly when it was potentially distressing for them.  
 
“I don’t like people to know that I’m suffering pain because, I mean, it’s just not fair for 
other people to do that [I: Can you say more about that?] …When I’ve talked to other 
people about this I’m very reluctant, as you have gathered to talk about how the 
intensity of the pain and how much I feel and whatever, I just don’t like it to impinge on 
my life or on the life of others and that’s my main objection to it… They’ve [family] 
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seen it over the years and they’ve watched me cope with it and they can't help and that’s 
very distressing for them at times.” (Female, 53, RRMS) 
 
In addition, some individuals said they were uncertain why they had been so reluctant to 
share their experience. 
 
“When I do experience pain and I have been unwell, I don’t really go out and I don’t 
think I am open with my MS or my pain, I’m quite a closed person, it's not something 
that I would tell anybody else, unless I have a good relationship with them, like I don’t 
really open up about it. (Crying) [I: May I ask why that might be, from your 
perspective?] Um, I am not sure, I didn’t think it was deliberate, I don’t know why, I 
haven't really thought about it.” (Female, 28, RRMS) 
 
However, in some cases pwMS felt that selectively ‘revealing’ their pain experience to 
others had some benefit, including making them feel less depressed and helping them to 
work around pain when taking part in shared social activities. 
 
“Most of my friends have been really supportive and understanding, they find it quite 
hard to get their heads around it. So the girl I have just been out with this morning, 
she’s a really good friend, so she completely knows that I can only walk X far, so we 
only walk to the tree that we have earmarked that we can go to, you know, and then we 
get a coffee and that’s all fine because that’s what we always do. So that feels, that’s 
not, somehow that’s not depressing and I talk a lot about the MS with her, and I have 
got five or six really, really close friends that I talk to about it a lot, and then I  have got 
other friends I don’t talk to about it at all.” (Male, 45, SPMS) 
 
Overall, the finding that pwMS felt pain was invisible to others, or should be concealed 
in certain situations, may have some important emotional (e.g. frustration, anger and 
depression) and behavioural consequences (e.g. not expressing emotions related to pain, 
angry outbursts or withdrawal). Therefore, these themes have been incorporated into the 
updated pain model in chapters 5 and 6 to improve our understanding of how some of 
the potential social behaviours and emotional consequences may interact and contribute 
to worsening pain and related disability in MS. Collectively, these findings also 
contributed to the development of a new treatment. 
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Chapter 5 : A Cross-sectional Study of Cognitive and Contextual 
Behavioural Correlates of MS Pain. 
 
5.1 Chapter overview 
 
In the previous chapter the qualitative study explored pwMS’ experience of pain and 
how they manage it in greater detail. Several important findings emerged from this 
work, which have been incorporated within the updated working theoretical model of 


















Bold text = strong evidence, with many studies conducted with studies consistently supporting this role.  
Normal text = weaker evidence, where findings appear to be consistent but studies are few. 
Grey text = factors that may play an important role in primary chronic pain theories but have yet to be 
investigated. 
Strike-through text = moved or considered less important and therefore removed  
Highlighted text = new factors, processes and other findings in the model 
Blue text = salient qualitative themes from chapter 4. 
The above maintenance model is assumed to be interactional rather than unidirectional 
*Pain acceptance and present moment awareness have a significant behavioural component and, 
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Figure 7: Updated Conceptual Model of MS Pain (Diagram taken from Harrison,  




The original model from the systematic review indicated that several behavioural 
responses may potentially be important in the context of MS pain. First, one of these 
responses included experiential avoidance of pain (the inverse of pain acceptance) from 
ACT’s psychological flexibility model, which is an important correlate in primary 
chronic pain samples (McCracken & Morley, 2014). A collection of themes and 
subthemes from the qualitative study around pwMS’ disparate pain management 
attitudes suggested that pain acceptance may be a protective process in MS. On the one 
hand, many individuals sought pain reduction, tried different pain management 
strategies, often with limited success, took medications even when they found them to 
be ineffective, and struggled with pain or feelings of anger, which often made them feel 
worse. On the other hand, a few individuals felt that factoring pain into their lives 
without trying to “fight it” were less likely to report feeling caught up in vicious cycles 
that amplified other MS symptoms and distress (i.e. “Catch-22”).  
 
Second, whilst fear-avoidance appeared less important in the original model based on 
the review and qualitative study, most pwMS suggested they were “careful not to over-
exert” themselves either for fear of making pain worse or needing to rest for prolonged 
periods afterwards to recover. It was therefore unclear whether pwMS had problems 
with avoidance in the context of fear, were persisting with tasks to the point where it 
was unhelpful, or engaged in both responses. Whilst effects for fear-avoidance were 
generally small or non-significant in the review, other studies indicated that avoidance 
behaviours may be important (e.g. guarding and resting). Therefore, it is possible that 
avoidance is not only related to fear of activity, but rather it could also be related to 
other thought processes. For instance, avoidance might be driven by fear of making 
symptoms worse, catastrophic thoughts about pain and other symptoms, beliefs that 
resting is helpful, or negative affect (e.g. frustration or anger). It may also be influenced 
by cognitions related to motivation, which is consistent with two studies in the 
systematic review (Kratz et al., 2011; Osborne et al., 2007) showing that when pwMS 
felt less inclined to change, or maintain, their persistence with everyday tasks they 
experienced greater pain interference. Similarly, greater perceived importance relating 
to task persistence was also correlated with less pain interference, although these 
correlations were generally small. It may therefore be important to measure cognition 
and activity avoidance separately to clarify the role of avoidance behaviours. Although 
fear-avoidance incorporates a combination of cognitive and behavioural elements 
148 
 
(Vlaeyen & Linton, 2000), it was initially placed within the behavioural part of the 
model in the systematic review. However, it was felt that fear-avoidance reflected a 
more cognitive and affective construct, rather than a specific behaviour, and therefore 
has been moved to the cognitive part of the model.  
 
Third, it was also felt that cognitive fusion might be a different way of looking at fear-
avoidance in MS pain. However, unlike traditional CBT factors, thoughts and 
behaviours in ACT are not conceived as separate entities. Cognitive fusion does not 
specify the nature of a thought, but rather attempts to capture a broader process (or 
response class) that integrates cognition and behaviour. Cognitive fusion occurs when 
an individual’s behaviour is “caught up” in or dominated by their thoughts or mental 
images to the extent that they fail to come into contact with other (non-verbal or other 
cognitive) contingencies in their immediate environment. For example, an individual 
might be fused with the belief that “exercising when in pain may worsen MS”, which 
may lead to avoidance of physical activity. Over time this may result in further 
deconditioning, and the person may rarely experience the positive reinforcing effects of 
taking gentle exercise. 
 
Therefore, it was felt that exploring the potentially protective role of pain acceptance, 
and potentially unhelpful role of pain-related avoidance-endurance, avoidance of 
physical and social activities (which do not include a component of fear), and cognitive 
fusion, in relation to pain severity and pain interference would determine which 
behavioural responses were most important. MS studies investigating these responses 
have mostly used small samples. Therefore, examining these behavioural responses 
within a larger cross-sectional study would allow us to clarify the mixed findings 
observed in the review and qualitative findings. It was the first study to examine the role 
of cognitive fusion and avoidance of physical and social activities in the context of MS 
pain, which may elucidate new avenues for intervention development in the future. For 
example, it may be that helping pwMS to step back from their pain-related beliefs, by 
using exercises from ACT or mindfulness treatments, corresponds with shifts in 
cognitive fusion and acceptance processes, lessens their influence on potentially 
unhelpful behavioural responses to the improvement pain outcomes. 
 
The cognitive element of the model initially emphasised the predominant influence of 
pain catastrophizing and the potentially important role of other pain-related beliefs (i.e. 
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perceived control, chronicity or disability), in determining pain and related functioning 
in MS. In accordance with this finding, themes around pwMS’ vivid descriptions of 
pain were thought to be related to either a verbal or visual form of pain catastrophizing. 
In addition, consistent with Leventhal’s CSM framework and the illness perceptions 
identified in the systematic review (Leventhal et al., 2003), qualitative questioning 
related to pain-specific beliefs resulted in many pwMS expressing that pain was 
“unpredictable”, had varied “causes”, would “worsen” over time and was a sign of 
further damage or disease progression. Therefore, further examining the potentially 
important role of pain catastrophizing and pain-related beliefs informed by the CSM, 
was considered to be a useful line of investigation in the cross-sectional study. 
 
The majority of studies in the review showed medium to large sized correlations 
between depression and anxiety and pain outcomes. However, few examined specific 
cognitive and behavioural factors or processes outlined in chronic pain theories in 
chapter 2. Whilst anxiety and depression reflect broader modifiable treatment targets in 
traditional CBT in MS (Mohr & Goodkin, 1999; Mohr et al., 2000), it was felt that 
conceptualising and targeting potentially modifiable pain-specific beliefs and 
behavioural responses in addition to anxiety and depression may be an optimal 
approach. It was therefore hypothesised that pain-related disability in MS is not only 
due to negative mood. Since anxiety and depression were expected to overlap with 
specific contextual and cognitive behavioural factors or processes in the model, efforts 
were made to account for their influence in regression analyses to determine if finer-
grained mechanisms were important in explaining pain severity and pain interference 
outcomes.  
 
Finally, the qualitative study offered a better sense of how biological factors may 
interact with other elements in the model. PwMS felt that pain was usually caught up in, 
or influenced, by other MS symptoms, which often resulting in “Catch-22” vicious 
cycles. In addition, pwMS use of pain medications sometimes perpetuated these cycles 
rather than improved the situation. Another key biological factor that did not appear to 
influence particular themes was the type of pain pwMS experienced. Whilst one person 
described the traumatic impact of severe trigeminal neuralgia (including shouting and 
grinding one’s teeth during acute episodes), pwMS often reported experiencing a variety 
of painful symptoms that appeared to result in common cognitive and behavioural 
responses. Although findings indicate few differences in psychological responses 
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between people with neuropathic and non-neuropathic pain in chronic pain populations 
(McCracken & Yang, 2013), there is currently a lack of evidence exploring potential 
differences between these groups in MS. This was surprising given that the prevalence 
of neuropathic pain is generally higher in MS compared to other chronic pain 
populations (O'Connor et al., 2008). Therefore, the current cross-sectional study further 
investigated the interactive role of pain and other MS symptoms, and examined 
potential differences in the way pwMS think, feel, and behave in response to both types 
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Background and purpose:  Pain affects around two-thirds of people with Multiple 
Sclerosis (pwMS). Biomedical treatments show limited efficacy. A recently developed 
cognitive behavioural model of Multiple Sclerosis (MS) pain suggests several 
psychosocial factors may worsen pain and related disability. The current study 
investigated whether psychosocial factors drawn from this model explain significant 
amounts of the variance in pain severity and interference over and above measures of 
disease severity and pain subtype.  
 
Methods: 612 pwMS experiencing pain completed a UK wide cross-sectional survey 
including valid and reliable psychometric questionnaires. Hierarchical regressions 
determined the relative contribution of disease severity and psychosocial factors to 
predicting pain severity and interference. 
 
Results: All psychosocial factors including distress, negative beliefs about pain and its 
consequences, and avoidance of activity, were related to pain outcomes, explaining a 
further 24% and 30% of the variance in pain severity and interference after controlling 
for demographic and disease variables.  Findings were similar for neuropathic and non-
neuropathic pain subgroups. 
  
Conclusion: All pwMS reported significant pain and associated disability even though 
over 90% were taking pain medication. Psychosocial factors identified as important in 
predicting pain severity and, to a greater extent, pain interference are potentially 


















Pain affects around 63% of people with Multiple Sclerosis (pwMS) (Foley et al., 2012). 
MS associated pain is typically classified as either neuropathic or non-neuropathic in 
origin (O'Connor et al., 2008). Between 5% and 32% of pwMS regard pain as their most 
severe symptom (O'Connor et al., 2008). Current biomedical treatments demonstrate 
limited efficacy (Beard et al., 2003) and many pwMS experience uncontrollable pain 
(Kerns, 2000).  
 
A recent systematic review (Harrison, McCracken, et al., 2015) proposed a cognitive 
behavioural model of MS pain based on existing pain theories (Hasenbring & Verbunt, 
2010; McCracken & Morley, 2014; Vlaeyen & Linton, 2000) and a synthesis of existing 
empirical MS studies (see Figure 1). The model suggests that whilst disease factors 
trigger pain, a range of non-disease factors significantly determine its severity, extent 
and resulting disability. These factors include the individual’s cognitive (thinking), 
emotional, and behavioural responses to pain, and social influences, such as level of 
social support. A recent qualitative study provided some support for this model by 
showing that pwMS fear worsening pain, perceive their pain as unpredictable, and 
interpret it as a sign of damage (Harrison, Bogosian, Silber, McCracken, & Moss-
Morris, 2014). Many focus on trying to reduce or control pain, using a variety of 
strategies often resulting in worsening rather than lessening of pain. Whilst a number of 
quantitative studies have revealed relationships between some of the identified 
psychosocial factors in the model, such as depression and catastrophizing about pain 
(Harrison, McCracken, et al., 2015), few have looked at multiple psychosocial factors 
conjointly to examine which are most important. In addition, to date certain aspects of 
the model such as beliefs about controllability of pain, and avoidance have not been 
looked at in published studies of MS. Consequently, there is no coherent understanding 
of how psychosocial factors fit together in MS associated pain and how they interact 
with relevant disease variables. It is also unclear as to whether psychological correlates 
of pain are the same for neuropathic and non-neuropathic pain. To date most cognitive 
behavioural models of and treatment for chronic pain are based on musculoskeletal 
(non-neuropathic) pain groups, and very few have directly compared neuropathic and 
non-neuropathic pain. Although there is preliminary evidence showing that pain 
subtypes are unlikely to be different in MS (Harrison, McCracken, et al., 2015), it may 




The current study aims to (a) describe the type and severity of pain experienced by 
pwMS, how interfering pain is in relation to other symptoms, and use of medications to 
control pain, (b) determine the contribution of several potentially modifiable cognitive, 
behavioural and emotional factors drawn from our  previous MS pain model (see Figure 
1) (and described in the methods section) to pain severity and pain interference when 
controlling for  measures of disease severity, and (c) conduct sensitivity analyses to 
determine the contribution of the cognitive and behavioural variables when negative 
mood (anxiety and depression) is removed (d) examine potential differences in patterns 





Biological (Trigger) Factors 
    Pain of Neuropathic origin (due to a primary lesion or disease of the central      
     nervous system) 
Pain of Non-neuropathic origin (due to actual or threatened damage to non-neuronal 
tissue) 
Migraine Headache (with mixed neuropathic and non-neuropathic characteristics) 
Non MS-related pain (e.g. due to medication side-effects, or a result of other health 
conditions) 












Self-efficacy / Perceived control over pain  
Pain acceptance* 
Present moment awareness 





Negative beliefs about identity, 
control/curability and consequences of MS 
Negative beliefs about coherence, 
chronicity, control/curability and 
consequences of pain 
Thought suppression 
Perceived solicitude 
Increased Self-focused Attention 
Cognitive fusion 
 







Avoidance of social activities  







The boxes highlighted in grey reflect psychosocial factors considered in relation to self-reported pain severity and 
pain interference where: 
Normal text: strong evidence, with many studies conducted with studies consistently supporting this role;  
Grey text: weaker evidence, where findings appeared consistent but studies were few; 
Bold text: factors that may play an important role in MS and primary chronic pain theories that will be tested in the 
current study; 
Italicised text: factors that may play an important role in primary chronic pain theories but have not been investigated 
in the current study. 
The above factors are assumed to interact with one another rather than be unidirectional. 
*Pain acceptance has a significant behavioural component and, therefore, is represented as both a cognitive and 
behavioural process in our model. 
 
Figure 1: Interacting biopsychosocial factors hypothesised to contribute to the severity 
and impact of Multiple Sclerosis pain (adapted from Harrison, McCracken, et al., 2015) 
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Participants and methods 
 
This multicentre cross-sectional survey study was approved by the Queen Square 
London Research Ethics Committee (13/LO/1429). 
 
612 pwMS experiencing pain completed a nationwide cross-sectional study using valid 
and reliable psychometric instruments. Participants were recruited from a number of 
sources, including 15 National Health Service (NHS) outpatient clinics. The study was 
also advertised on the MS Society website and emailed to members of MS UK Register 
reporting pain. Of the 759 patients with a neurologist confirmed MS diagnosis 
approached in NHS clinics, 361 (47.5%) completed the postal or online questionnaire. 
Fifty-one participants from the MS Society website, and 205 (25.6%) of the 800 
participants emailed by the MS UK Register responded. We obtained informed consent 
and completed questionnaires from 617 participants during the period from December 
2013 to July 2014. Those participants who could not speak English were excluded. Nine 
questionnaires were excluded from the final analyses: Four participants reported no 
pain, two submitted questionnaires with substantial missing data and three were 
duplicates.  
 
The questionnaire included demographics, disease severity variables, psychosocial 
instruments drawn from our MS pain model (Harrison, McCracken, et al., 2015) and 
qualitative interview study (Harrison et al., 2014), and pain severity and interference 
outcomes. 
  
Disease Severity Measures 
 
Self-administered Expanded Disability Status Scale (EDSS-S) (Bowen et al., 2001). 
Because of the length of the EDSS-S questionnaire, the mobility scale of the EDSS-S 
was used as a shorter proxy measure for level of neurological disability, as reported in 
other studies (Bowen et al., 2001). 
 
MS subtype was determined using established MS subtype pictorials (Bamer et al., 
2007) accompanied by lay descriptions. Years of disease duration, and the level of 
interference caused by other MS symptoms on a 1 to 10 point numerical rating scale, 




Years of pain duration and pain medications were recorded, and degree of pain-relief 
from these medications was assessed using a 0% to 100%  numerical rating scale from 
the Brief Pain Inventory (BPI) (Cleeland & Ryan, 1994). 
  
The Self-report Leeds Assessment of Neuropathic Signs and Symptoms (S-LANSS) 
(Bennett, Smith, Torrance, & Potter, 2005) was used to identify patients whose pain is 
dominated by neuropathic mechanisms. The S-LANSS is designed to differentiate 
participants with pain of predominantly neuropathic origin and those with nociceptive 
pain using a case identification cut-off score (≥12). It was selected over the Neuropathic 
Pain Scale (NPS) (Rog et al., 2007), which although validated in MS provides a 
continuous measure rather than a categorical cut-off (Bennett et al., 2005; Cruccu et al., 
2004; Rog et al., 2007). The S-LANSS positive score demonstrates good convergent 
validity with neuropathic items of the NPS (Bennett et al., 2005).   
 




Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983) was used to  
measure self-reported anxiety and depression and has good psychometric properties in 
the MS population (Skerrett & Moss-Morris, 2006). Higher scores indicate greater 
levels of psychological distress. 
 
Cognitions processes and thought patterns 
 
Pain Catastrophizing Scale (PCS) (Sullivan et al., 1995) was used to assess the extent to 
which pwMS magnify or exaggerate the threat value or seriousness of pain sensations. 
The PCS is a valid and reliable instrument (Rosenstiel & Keefe, 1983). The 13-items 
reflect rumination, magnification and helplessness, with higher scores reflecting greater 
pain catastrophizing.  
 
Illness Perceptions Questionnaire-Revised (IPQ-R) (Moss-Morris et al., 2002) was used 
to  measure perceived time-course of MS pain (timeline acute/ chronic and timeline 
cyclical), consequences, symptoms involved (identity), control or curability and how 
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understandable pain is (coherence). The IPQ-R demonstrates good psychometric 
properties in several illness populations, including MS (Moss-Morris et al., 2002).  
 
Cognitive Fusion Questionnaire (CFQ) (Gillanders et al., 2014) assesses the degree to 
which a person’s experience and behaviour is “caught up” in or dominated by their own 
thoughts. This is similar to assuming thoughts are facts, taking thoughts too seriously, 
or being unable to see beyond one’s own beliefs, such as can happen when a person is 
distressed and experiencing exaggerated or unrealistic thoughts. Cognitive fusion 
reflects a dimension in human experience where the actions are strongly influenced by 
the thoughts they are having. The 7-item scale demonstrates good validity and reliability 
in the MS population, with higher scores reflecting greater levels of cognitive fusion. 
 
Behaviours and Behavioural processes  
 
Avoidance-Endurance Questionnaire Pain-related Behavioural Responses Scale (AEQ) 
(Hasenbring et al., 2009) is a valid and reliable scale used to assess pain-related 
behaviours in response to pain, including avoidance of physical and  social activities, 
and a contrasting endurance response, where people continue with activity despite the 
pain. Higher scores reflect greater levels of avoidance and endurance behaviours. 
 
Chronic Pain Acceptance Questionnaire (CPAQ-8) (McCracken, Vowles, & Eccleston, 
2004) comprises two parts, including activity engagement (doing activities in the 
presence of pain) and pain willingness (refraining from attempts to control or reduce 
pain). The CPAQ-8 has shown good validity and reliability in recent studies (Fish, 
Hogan, Morrison, Stewart, & McGuire, 2013). Higher scores reflect greater acceptance 




Brief Pain Inventory Short Form (BPI) (Cleeland & Ryan, 1994). The BPI is a valid and 
reliable (Osborne, Raichle, et al., 2006) instrument assessing two components, including 
pain severity and pain interference scales, which are standard primary outcomes in all 
chronic pain clinical trials (Turk et al., 2003). A pain severity index score is calculated 
using the mean of four severity ratings, including present pain, pain at its worst, least 
and average in the last 24 hours. The interference scale has seven life domains, 
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including general activity, mood, mobility, work, relationships, sleep and enjoyment of 
life. A pain interference index score reflects the mean of all seven domains. Similar to 
previous studies (Osborne, Turner, et al., 2006) we used a modified short form of the 
BPI, and we replaced the interference scale item “walking ability” with “mobility 




Bivariate correlations, two-tailed t-tests and ANOVAs were used to examine 
relationships between pain severity and pain interference outcomes and participant 
demographic and disease characteristics. Two hierarchical regression analyses were 
conducted to determine if psychosocial factors drawn from our MS pain model 
(Harrison, McCracken, et al., 2015) predicted pain severity and pain interference 
outcomes after controlling for relevant demographic and disease variables, including 
type of pain. The same regression analyses examined moderation, using all psychosocial 
variables and pain type interaction terms in the third step to see if the pattern of results 
observed in the hierarchical regression were similar for pwMS with neuropathic pain 
compared to those with non-neuropathic pain. Finally, four hierarchical regressions 
were conducted to examine whether psychosocial factors accounted for a similar 
amount of variance in pain severity and pain interference outcomes for neuropathic and 
non-neuropathic pain groups after demographics and disease factors. All statistical 
analyses were conducted using SPSS Version 22 (IBM Corp., New York). 
 
Power analysis for sample size 
 
An a priori power calculation using G*Power version 3.1 (Faul, Erdfelder, Lang, & 
Buchner, 2007) indicated that a minimum sample size of n=128 would be sufficient to 
detect a medium R2 effect size =.15, based on data from a previous studies looking at 
several psychological constructs (Harrison, McCracken, et al., 2015), with a power =.80 
at a two-tailed alpha level = .05. This included twelve psychosocial predictor variables 
within a multiple linear regression fixed model with R2 increase after including nine 








Table 1 shows the disease and demographic characteristics of the MS pain sample 
(n=608). Participants included 156 men and 452 women. The sample was 
predominantly middle-aged and white in ethnic background with varied occupational 
status. Forty-seven percent of participants classified themselves as having relapsing 
remitting disease, while the remainder were equally divided into secondary and primary 







































Table 1 MS Sample Characteristics (n=604)a 
 
Mean Age  
 
52.4 ± 11b (95% CIs 51.5 to 53.2) 
Gender female n (%) 452 (74.3) 
Ethnicity white n (%) 581 (95) 
Unemployed n (%) 406 (66.7) 








Mean disease duration years 12.8 ± 9.4 (95% CIs 12.1 to 13.6) 
Mean EDSS-S Mobility  5.9 ± 1.3 (95% CIs 5.8 to 6) 
Current relapse n (%) 
Relapse not applicable 
99 (16.2) 
129 (21.2) 
Mean HADS Depression ≥11 15.6 ± 7.0 
Pain severity (BPI) (Alschuler et al., 2012b) clinical cut-









an = 604 due to missing data. 
bValues are mean ± SD   
Abbreviations: BPI: Brief Pain Inventory Short Form; EDSS-S: Self-report Expanded Disability Status Scale; MS: 
multiple sclerosis; HADS: Hospital Anxiety and Depression Scale; PPMS: primary progressive multiple sclerosis 
RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis.  
 
On average participants reported a pain severity score of 4.5±2.26 (95% CIs7 4.3 to 4.6), 
which according to recognised cut-offs (Alschuler et al., 2012b) reflects pain of 
moderate severity. Eighty-five percent reported a pain severity score in the moderate 
and severe ranges. One-hundred and thirty pwMS (27.3%) experienced constant pain, 
165 (27.1%) intermittent pain, and 311 (51.1%) both. Five-hundred and eighty six 
participants (96.3%) reported chronic pain lasting longer than six months in duration 
(Merskey, 1986). Ninety three percent of participants reported using a variety of pre-
defined pain medications (see Figure 2), of which 72% (n=409) reported using two or 
more. On average pwMS indicated that pain medications provided 49.7% ± 29.6 (95% 
CIs 47.2 to 57.1) of pain relief. 
                                                 
6 Values are mean ± SD  




NSAIDs: Non-steroidal anti-inflammatory drugs; SNRIs:  Serotonin–norepinephrine reuptake inhibitors. 
 
Figure 2 Reported Pain Medications 
 
The average pain interference score was 4.8 ± 2.5 (95% CIs 4.6 to 5). Relative to other 
MS symptoms pain was the most commonly reported and the fourth most interfering 
symptom (6 ± 2.5 95% CIs 5.8 to 6.2), after fatigue, sexual dysfunction and balance 
difficulties (see Figure 3). See Table S1 for further correlations between pain and other 









































n: number of participants reporting symptom; NRS: symptom interference 1-10 point numerical rating scale using the 
Brief Pain Inventory (BPI) format. 
 
Figure 3: Frequency of MS symptoms reported and level of interference n: number of 
participants reporting symptom; NRS: symptom interference 1-10 point numerical 
rating scale using the Brief Pain Inventory (BPI) format. 
 
The role of psychosocial factors in MS pain severity and pain interference  
 
All psychosocial factors were correlated at the bivariate level with either pain severity 
or pain interference (see Table 2). Two hierarchical regression analyses were conducted 
to determine how much variance psychosocial variables accounted for in pain severity 
and pain interference after controlling for demographic and disease variables (see Table 
3). Demographic and disease variables were entered in the first step and psychosocial 
factors in the second step. The first hierarchical regression showed that demographic 
and disease variables accounted for 19% (F=14.63, p<.001) of the variance in pain 
severity. Psychosocial variables explained a further 24% (F=19.01, p<.001). Similarly, 
the second regression demonstrated that demographic and disease variables accounted 
for 26% (F=22.29, p<.001) of the variance in pain interference, whilst psychosocial 
variables explained a further 30% (F=31.77, p<.001). When removing depression and 


















































behavioural factors still accounted for 23% (F=20.35, p<.000) and 28% (F=31.77=, 
p<.000) of the variance in pain severity and pain interference respectively. All 






Table 2  Psychosocial Correlates of Pain Severity and Pain Interference (BPI) 




Anxiety and depression (HADS) .35**  
(95% CIs .25 to .41) 
.52** 
(95% CIs .45 to .57) 
Pain catastrophizing (PCS) 38** 
(95% CIs .32 to .43) 
.51** 
(95% CIs .44 to .56) 
Pain acceptance (CPAQ) -.29** 
(95% CIs -.26 to -.22) 
-.50** 
(95% CIs -.43 to -.55) 
Cognitive fusion (CFQ) .11** 
(95% CIs .03 to .19) 
.31** 
(95% CIs .23 to .38) 
Avoidance-endurance behaviour (AEQ) 
Avoidance of social activities .23** 
(95% CIs .16 to .29) 
.45** 
(95% CIs .37 to .50) 
 
Avoidance of physical activities  
 
.19** 
(95% CIs .12 to .25) 
 
.34* 





(95% CIs -.02 to -.14) 
 
-.09* 
(95% CIs -.01 to -.16) 
Pain perceptions (IPQ-R)   




(95% CIs .36 to .49) 
 
-.09* 






(95% CIs -.01 to -.16) 
 
.45** 





Personal control  
(95% CIs .38 to .51) 
 
-.22** 
(95% CIs -.14 to -.29) 
(95% CIs .57 to .67) 
 
-.20** 
(95% CIs .12 to .27) 
Psychosocial predictors: AEQ: Avoidance-Endurance Questionnaire; CFQ: Cognitive Fusion Questionnaire; CPAQ:  
Chronic Pain Acceptance Questionnaire; IPQ-R:  Illness Perceptions Questionnaire; PCS: Pain Catastrophizing Scale  
Pain outcomes: BPI: Brief Pain Inventory Short Form. 
**Correlation is significant at the 0.01 level (2-tailed). 
*Correlation is significant at the 0.05 level (2-tailed). 
95% CIs:  95% Confidence Intervals 
n range = 593-607. 
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Table 3 Psychosocial Predictors of Pain Severity (n=567) and Pain Interference (n=568) (BPI)  
 Pain Severity Pain Interference 
 Beta p ∆R2 Beta p ∆R2 
Step 1: Demographic and disease variables   .19  
(F=14.63, p<.001) 
















Gender .05 .12 -.01-.11 .07 .01 .01-.13 
Employment status .03 .33 -.04-.11 .06 .05 -.01-.13 
RRMS (Ref) vs SPMS subtype -.03 .34 -.09-.05 .007 .83 -.07-.09 
RRMS (Ref) vs PPMS subtype -.05 .24 -13-.03 -.001 .98 -.07-.09 
No current relapse (Ref) vs Current relapse .08 .02 <-.01-.16 -.08 .007 -.16-<.01 
No current relapse (Ref) vs Not applicable -.02 .60 -.08-.06 -.05 .10 -.13-.03 
Mobility (EDSS-S) .18 <.001 .09-.25 .19 <.001 .10-.26 
Pain type (S-LANSS) .12 <.001 .03-.20 .05 .05   -.03-.13 
BPI: Brief Pain Inventory; Ref: Reference group; Beta: Standardized Coefficients; ∆R2: R-squared change; Overall R2: Total effect in regression model; p:  95% 
significance value; NS: Non-significant parameters; 95% CIs: 95% Confidence Intervals for standardised Beta.  
Demographic and disease variables: Employment status: Employed vs unemployed; EDSS-S: Self-report Expanded Disability Status Scale; HADS: Hospital Anxiety 
and Depression Scale; PPMS: primary progressive multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis. 
Psychosocial predictors: AEQ: Avoidance-Endurance Questionnaire; CFQ: Cognitive Fusion Questionnaire; CPAQ: Chronic Pain Acceptance Questionnaire; IPQ-R: 
Illness Perceptions Questionnaire; PCS: Pain Catastrophizing Scale  











Table 3 Psychosocial Predictors of Pain Severity (n=567) and Pain Interference (n=568) (BPI) Continued 
 Pain Interference Pain Severity 
 Beta p ∆R2 Beta p  ∆R2 
Step 2: Psychosocial factors   .24  
(F=19.01, p<.001) 
95% CIs 
  .30 
(F=31.71, p<.001) 
95% CIs 
Anxiety and depression (HADS) .09 .06 -.01-.19 .19 <.001 .10-.28 
Cognitive fusion (CFQ) -.14 .002 -.23 to-.05 -.08 .03 -.16-<.01 
Pain acceptance (CPAQ) .06 .23 -.04-.17 .01 .76 -.08-.10 
Avoidance of social activities (AEQ) .05 .29 -.04-14 .11 .006 .3-.20 
Avoidance of physical activities (AEQ) -.02 .52 -11-.05 -.01 .74 -.09-.06 
Behavioural endurance (AEQ) .12 .001 .05-.20 .06 .05 .01-.13 
Pain catastrophizing (PCS) .20 <.001 .11-.30 .13 .002 .04-.21 
Timeline (IPQ-R) .24 <.001 .16-.32 .07 .04 .01-.14 
Timeline-cyclical (IPQ-R) -.07 .05 -.13-.01 .01 .54 -.07-.09 
Consequences (IPQ-R) .21 <.001 .11-.30 .35 <.001 .28-.44 
Personal control  (IPQ-R) -.05 .14 -12-.01 -.05 .07 -.12-.01 
Coherence (IPQ-R) -.07 .03 -13--.01 -.004 .90 -.05-.05 
Step 3: All psychosocial factors and pain type 
(S-LANSS) interaction terms  





Overall R2 =.56 
             (F=33.98, p<.001) 
BPI: Brief Pain Inventory; Ref: Reference group; Beta: Standardized Coefficients; ∆R2: R-squared change; Overall R2: Total effect in regression model; p:  95%  
significance value; NS: Non-significant parameters; 95% CIs: 95% Confidence Intervals for standardised Beta.  
Demographic and disease variables: Employment status: Employed vs unemployed; EDSS-S: Self-report Expanded Disability Status Scale; HADS: Hospital Anxiety  
and Depression Scale; PPMS: primary progressive multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis. 
Psychosocial predictors: AEQ: Avoidance-Endurance Questionnaire; CFQ: Cognitive Fusion Questionnaire; CPAQ: Chronic Pain Acceptance Questionnaire; IPQ-R:  
Illness Perceptions Questionnaire; PCS: Pain Catastrophizing Scale  






Neuropathic and non-neuropathic pain in MS  
 
Initial t-tests demonstrated pwMS with pain of predominantly neuropathic origin (≥12 
on the S-LANSS) reported significantly higher levels of pain severity (t=8.3, p<.001, 
Mean difference 1.4, 95% CIs 1.07 to 1.74) and pain interference (t=7.0, p<.001, Mean 
difference 1.4, 95% CIs 1.02 to 1.82), and less pain-relief from pain medications (t=-2.3 
p<0.02, Mean difference -5.7, 95% CIs -10.72 to -.83) compared to those with non-
neuropathic pain. Our second aim was to conduct moderation analyses by adding 
psychosocial factors and pain subtype interaction terms as a third step within the first 
two hierarchical regressions (see Table 3). The interaction step did not significantly 
explain any additional variance in pain severity or pain interference [see thesis 
Appendix G], suggesting the pattern of results were similar across the neuropathic and 
non-neuropathic pain subgroups.  
 
We also conducted separate hierarchical regression analyses for the neuropathic 
(n=342) and non-neuropathic pain subgroups (n=225) [see thesis Appendix H and I]. 
For those with neuropathic pain, demographic and disease variables (including MS 
subtype, current relapse, EDSS-S gait, and disease duration) accounted for 16% 
(F=7.72, p<.001) of the variance in pain severity and 27% (F=15.22, p<.001) in pain 
interference, while psychosocial factors accounted for a further 20% (F=8.32, p<.001) 
and 25% (F=14.21, p<.001) respectively. For those with non-neuropathic pain, 
demographic and disease variables accounted for 9% (F=2.75 p=.006) of the variance in 
pain severity and 15% (F=4.61, p<001) in pain interference, while psychosocial factors 
accounted for a further 36% (F=11.37, p<.001) and 44% (F=18.16, p<.001) 
respectively. Together demographic, disease and psychosocial variables explained 8% 
and 10% more variance in pain severity and pain interference for pwMS reporting non-




This is the largest published study to date specifically investigating pwMS’ experiences 
of pain (Harrison, McCracken, et al., 2015). Consistent with previous MS studies (Ehde 
et al., 2006; Osborne, Turner, et al., 2006), the current sample of people with MS 
associated pain showed that 85% of respondents reported clinically significant levels of 
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moderate to severe pain, whilst 96% reported chronic pain lasting longer than six 
months. Relative to other MS symptoms pain was the fourth most interfering symptom. 
Almost all respondents (93%) reported using some form of prescribed pain medication, 
but on average only achieved 50% of pain-relief when using them. These initial findings 
suggest that pain is an important problem and biomedical approaches to MS associated 
pain may benefit from a broader perspective.    
  
In accordance with our biopsychosocial model of MS pain (Harrison, McCracken, et al., 
2015) the results indicated that potentially modifiable cognitive, behavioural and 
emotional factors are likely to play a significant role in the maintenance of increased 
pain severity and pain interference in MS, accounting for 24% and 30% of the variance 
respectively, after taking into account relevant demographic and disease variables. The 
moderate to large effect sizes observed in these multiple regressions are consistent with 
findings reported in other physical disabilities (Jensen, Moore, et al., 2011) and primary 
chronic pain conditions (Pincus, Burton, Vogel, & Field, 2002). Sensitivity analyses 
revealed that even after removing the emotional factor (anxiety and depression) from 
these analyses the remaining cognitive and behavioural factors still explained a similar 
amount of the variance in both pain outcomes suggesting that the effects are not just due 
to negative mood. The bivariate findings suggest all the identified psychosocial factors 
were associated with pain severity or pain interference, while the regression analyses 
indicate that certain psychological factors were more pronounced than others after 
controlling for demographic and disease variables. Specifically, pwMS with higher 
levels of pain severity and pain interference may have a greater tendency to magnify or 
exaggerate the threat or seriousness of pain sensations (catastrophic thought processes) 
and are more affected or influenced by the content of their own thoughts (cognitive 
fusion, see Gillanders et al., 2014 or McCracken & Morley, 2014 for more in depth 
discussion of this variable). Greater pain is also associated with a tendency to avoid 
physical and social activities when in pain, with greater anxiety and depression, and 
with viewing pain as persistent over time and having serious consequences. It is also 
worth noting that persisting with activity (endurance) either showed small negative 
correlations with pain or no relationship suggesting that maintaining activity does not 
worsen pain whilst avoidance does. Many patients are told by health professionals to 




Predictive models are helpful to quantify relationships between pain, disease and 
psychosocial variables. However, clearly this is a cross sectional study and causation 
cannot be inferred. From a clinical perspective, disease factors interact in a reciprocal 
way with the psychosocial factors. For example, consistent with accounts from our 
qualitative interview study (Harrison et al., 2014), it may be that pwMS engage in 
vicious cycles when in pain, where they view pain as always harmful, as having serious 
consequences or equating to worsening MS. This may result in a struggle to reduce pain 
by avoiding physical movement and/or social situations, and frequent use of pain 
medications, even if ineffective or inconsistent in providing adequate pain relief (Beard 
et al., 2003; Heckman-Stone & Stone, 2001; Kalso et al., 2013). There were also 
medium to strong-sized correlations between the interference caused by pain and other 
MS symptoms. Whilst this might suggest that pain and other MS symptoms are 
correlated and share the same disease process, there is a risk that behavioural efforts 
employed by pwMS to avoid or reduce pain may also inadvertently exacerbate other 
MS symptoms. For example, if someone were to rest for long periods because they 
believed pain was harmful and overused pain medications, this may result in physical 
disuse and deconditioning, and unpleasant side-effects, which may worsen fatigue, 
stiffness and spasms. Therefore, certain management choices may increase pwMS’ 
emotional distress and become potentially disabling over time. 
 
Implications for treatment   
 
Our findings suggest it may be helpful to understand and treat MS associated pain 
drawing from the broader biopsychosocial, patient-centred approaches developed in 
primary chronic pain. The psychosocial factors identified in the current study reflect 
specific targets of well-established traditional and contextual cognitive behavioural 
treatments, which demonstrate good efficacy in primary chronic pain populations 
(McCracken, 2006; Turk et al., 1983) and when applied to MS fatigue (Knoop et al., 
2012). There is also preliminary support for both cognitive behavioural approaches in 
reducing pain severity and pain interference in MS associated pain (Jensen, Ehde, et al., 
2011; Sheppard et al., 2010). However most of these studies are small, uncontrolled and 
have not been informed by an empirically supported theoretical model of MS associated 
pain. By defining key therapeutic mechanisms in larger trials, we will be able to refine 
our conceptual model. In practice, such approaches aim to assist pwMS in identifying 
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and rectifying potentially unhelpful pain- and treatment-related beliefs and management 
behaviours that are likely to influence poorer outcome. 
 
Our second aim was to examine potential differences between pwMS with neuropathic 
and non-neuropathic pain and explore patterns of hierarchical regression findings 
between pain subgroups. The pain subgroup analyses demonstrated that pwMS with 
neuropathic pain reported significantly higher pain severity, pain interference and lower 
levels of pain relief from biomedical treatments. However, moderation analyses 
indicated no significant differences in the pattern of results for the two groups, 
suggesting the psychosocial correlates are relevant in both types of pain. However 
subgroup analyses revealed that disease variables explained more variance in pain 
outcomes for pwMS with neuropathic pain compared to those with non-neuropathic 
pain. In addition, disease and psychosocial factors together explained slightly less 
variance in pain outcomes for those with neuropathic pain compared to those with non-
neuropathic pain. This finding is largely consistent with two studies in our MS pain 
review (Harrison, McCracken, et al., 2015), and in other painful conditions (McCracken 
& Yang, 2013), which indicate few differences in psychological characteristics between 
pain subtypes. This suggests that while both pain subgroups are likely to benefit from 
psychosocial interventions, those with non-neuropathic pain may benefit from an 




The cross-sectional nature of this study limits causal interpretation of the relationships 
between self-reported pain and psychosocial factors. However, based on what we know 
about primary chronic pain treatments, it is likely we can modify these factors and 
improve outcomes for pwMS. One limitation is that all disease factors were collected 
via self-report instruments (including MS subtype, current relapse, EDSS-S gait, disease 
duration and pain type), which may be susceptible to either exaggeration or under-
reporting by participants, where a clinician rating would have provided greater 
accuracy. Second, the importance of non-significant psychosocial factors within the 
regression models may also be underestimated due to common-method variance and 
conceptual overlap with other psychosocial factors. Third, although the sample size was 
large, response rates were relatively low, which may limit generalisability of findings. 
Lastly, the measure used to identify neuropathic pain (S-LANSS) (Bennett et al., 2005) 
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is yet to be validated in the MS population. Therefore, the moderation and subgroup 
analyses in this study should be considered preliminary. However, the few studies 
reporting prevalence of neuropathic pain in MS indicate a large range between 28 to 
58%, which may reflect the different clinical evaluations used. Despite the limitations, 
this study reflects the largest MS associated pain sample to date investigating a variety 
of potentially modifiable psychosocial factors, guided by a clear theoretical model, 
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Table S1: MS Symptom Interference NRS Bivariate Correlations 
 
 Fatigue Sexual 
dysfunction 



















































NRS: Numerical Rating Scale; 95% CIs: 95% Confidence Intervals 
**Correlation is significant at the 0.01 level (2-tailed). 
*Correlation is significant at the 0.05 level (2-tailed). 
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Chapter 6 : Development of the self-management psychological 
intervention for MS pain. 
 
6.1 Chapter overview 
 
 
The previous chapter reported on a study of cross-sectional associations between 
contextual and cognitive behavioural variables and pain outcomes in MS. These 
findings led to further changes in the working theoretical model of MS pain outlined in 
the systematic review. The updated conceptual model of MS pain is presented in Figure 
8.  
 
The review and qualitative study presented contradictory evidence for the role of 
avoidant behavioural responses in the context of MS pain. Low quality studies in the 
review indicated that fear-avoidance shared small or non-significant associations with 
pain severity and pain interference, whilst qualitative themes indicated that pwMS 
tended to rest in response to pain and were concerned that over-exerting would lead to 
worsening pain or disease progression in some cases. The cross-sectional findings 
examined more specific forms of behavioural avoidance, which offered further support 
for the idea that pwMS’ avoidance of physical movement and social activities in 
response to pain may result in greater pain severity and pain interference. However, 
pwMS’ tendency to endure with activities in response to pain appeared less important, 
indicating that greater avoidance-endurance responding may be neither helpful nor 
unhelpful in the context of MS. Therefore, the model was refined in two ways. First, 
rather than including fear-avoidance as a potentially unhelpful behaviour (which 
includes both a cognitive and affective component), avoidance of social and physical 
activity were incorporated to reflect the cross-sectional data. Second, the ‘potentially 
unhelpful’ nature of over-exertion was de-emphasised in the model as there was only a 
very small but positive effect between endurance behaviours and pain interference. In 
the context of MS, it appears that endurance behaviours may be neither helpful nor 
unhelpful in relation to pain outcomes. 
 
The cognitive elements of the model were also updated. Consistent with findings in the 
review, pain catastrophizing was once again a strong predictor of both pain outcomes 
and was retained in the model. The distinction between verbal- and imagery-based 
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catastrophic patterns of thinking, observed in our qualitative study, was not examined 
because no validated instruments had been developed in chronic pain to assess these 
differences. Therefore, this remains a gap in our knowledge. The cross-sectional study 
was the first published study with a large sample to confirm the potentially protective 
role of pain acceptance. In addition, the earlier qualitative accounts relating to pwMS’ 
pain beliefs were also confirmed to some extent. Perceived consequences and chronicity 
of pain were strongly correlated with pain outcomes, but perceived control appeared to 
show only small effect sizes. This finding was less consistent with the pain-related self-
efficacy measures used in the systematic review. Similarly, cognitive fusion 
demonstrated small to medium associations with pain outcomes, which was surprising 
given that this process appeared to share some conceptual overlap with both unhelpful 
catastrophic thinking patterns and other pain-related beliefs, and behavioural avoidance. 
 
In line with the systematic review and qualitative data, the cross-sectional study 
provided further confirmation that the different cognitive, behavioural or emotional 
correlates of neuropathic and non-neuropathic are similar, although disease factors 
appears to play a stronger role in neuropathic pain. This suggested that both groups 
were likely to benefit from a contextual or cognitive behavioural intervention that 
targeted elements within the model, but that effects may be stronger for non-
neuropathic pain. In addition, consistent with recent MS studies (Day et al., 2015; 
Shahrbanian et al., 2015), the significant correlations between pain and other symptom 
interference ratings in the cross-sectional study to some extent supported the qualitative 
findings that pwMS may engage in “Catch-22” vicious cycles, where pain and an 
individual’s responses appear to interact with other MS symptoms in a reciprocal way. 
 
In summary, the refined model proposes that whilst disease factors trigger pain, a range 
of cognitive, emotional and behavioural responses may worsen its severity and interfere 
with daily functioning. Specifically, pwMS with greater pain severity and pain 
interference tend to view pain as serious, struggle in their attempts to control or reduce 
it, can be overwhelmed by their pain, and may avoid physical movement and social 
activities. In addition, those who experience stronger negative emotional reactions to 
pain, and have thoughts around pain being chronic, uncontrollable, and as having 
serious consequences, also report poorer outcomes. It is hypothesised that these 
psychological processes interact with pain in a reciprocal way, forming vicious cycles 




Although the cross-sectional findings suggest that several psychological factors or 
processes may be important in explaining pain severity and pain interference outcomes 
in MS, the study design could not explore temporal hypotheses, or determine whether 
changes in key psychosocial variables preceded changes in pain outcomes over time. 
An important recommendation of the systematic review was that more longitudinal 
investigations of change within the context of treatment trials would help to elucidate 
temporal relationships between potentially important psychological factors or processes 
and pain outcomes.  
 
The current chapter will therefore describe the development of a cognitive behavioural 
treatment manual informed by the MS pain model. This was developed with the aim of 
evaluating the intervention to further test the model. First, a rationale for the self-
management treatment approach adopted is provided, and the aims of the programme 
are specified. This is followed by a short summary of the aims and content of the eight 
treatment sessions, and how they link back to the working theoretical model of MS pain 
in Figure 8. The role of the expert research team and MS Society patient and public 
involvement members (PPI) in providing feedback for the treatment manual are also 
described. A few examples of revisions to the treatment manual in response to this 
feedback are outlined. The current chapter closes with a brief conclusion, leading into 
chapter 7, which evaluates the potential efficacy of the intervention across individuals 
























Bold text = strong evidence, with many studies conducted 
with studies consistently supporting this role.  
Normal text = weaker evidence, where findings appear to be 
consistent but studies are few. 
 
Strikethrough text = factors or processes that have been 
investigated but may be less important for pwMS 
 
Highlighted text = new factors, processes or other findings in 
the model 
 
*Pain acceptance, present moment awareness, committed 
action and values processes from ACT have a significant 
behavioural component and, therefore, are represented as 














Pain of Neuropathic origin (due to a primary 
lesion or disease of the central nervous system) 
(more related to disease factors) 
Pain of Non-neuropathic origin (due to actual 
or threatened damage to non-neuronal tissue) 
(more related to psychological factors) 
Migraine Headache (with mixed neuropathic 
and non-neuropathic characteristics) 
Non MS-related pain (e.g. due to medication 







Self-efficacy / Perceived control over 
pain  
Perceived importance & Readiness to 
change (or maintain) behaviour 
Belief that emotions influence pain 
 
Potentially Unhelpful 
Pain Catastrophizing  
Fear Avoidance 
Negative beliefs about consequences, 
and timeline of pain (i.e. viewing pain 
as chronic).  
Negative beliefs about MS  
about identity, control/curability and 
consequences of MS  
Cognitive fusion 











Avoidance of social activities 




Neither Helpful nor Unhelpful 
Over-exertion / endurance 
     
Wider social environment 
(Perceived solicitude, social support) 
& MS contextual factors  
(i.e.  Other symptoms) 
 




Session 1: What is MS Pain? 
Introduction to the model 
Session 8: Preparing for the future  
Session 3: The natural tendency to avoid 
unwanted pain and setting goals  
 
Session 4: Doing what matters: Thinking 
about goals in relation to values 
 
Session 2: Breaking vicious cycles: 
patterns of rest and activity 
 
Session 6 Option 2: Stepping 
back from pain and related 
thoughts and feelings  
 
Session 6 Option 1: Using 
alternative thoughts 
 
Session 5: Identifying 
unhelpful thoughts 
 





As mentioned in chapter 2, many of the psychosocial factors and processes identified in 
our MS pain model (Harrison, Silber, McCracken, & Moss-Morris, 2015) have been 
shown to be potentially modified in the context of well-established CBT and ACT 
approaches for primary chronic pain conditions (Veehof, Oskam, Schruers, et al., 2011; 
Williams et al., 2013) and MS fatigue (Knoop et al., 2012; Moss-Morris et al., 2012; 
van Kessel et al., 2008; van Kessel et al., 2015).  
 
To date only three pilot studies  (Garinger, 2007; Jensen, Ehde, et al., 2011; Sheppard et 
al., 2010) and one RCT (Ehde, Elzea, et al., 2015) have evaluated cognitive behavioural 
interventions designed specifically to help pwMS better manage painful symptoms. Of 
these studies one indicated that a 10 week CBT group programme significantly reduced 
emotional distress at follow-up, but there were no clinically or statistically significant 
reductions in pain severity (Garinger, 2007). Another demonstrated that self-hypnosis 
was superior to cognitive-restructuring training (a key component of CBT), but that a 
combination of both components was most effective in reducing pain severity and pain 
catastrophizing, defined as the extent to which pwMS magnify or exaggerate the threat 
or seriousness of pain sensations (Sullivan et al., 1995), from baseline to post-treatment 
(Jensen, Ehde, et al., 2011).  
 
The only RCT was published shortly after completing our case-series intervention study 
outlined in chapter 7. This large single-blinded RCT evaluated the efficacy of an eight 
week (eight 1 hour session) telephone-delivered CBT self-management treatment (n = 
75) to reduce fatigue impact, pain interference, and depression, compared to a telephone 
delivered education intervention (n = 88) (Ehde, Elzea, et al., 2015). The authors 
compared the response rate (%) of those pwMS who achieved a reduction in any one of 
the three target symptoms between the groups. A responder was someone who achieved 
a >50% reduction in one or more of the target symptoms. Both groups improved in one 
or more target symptoms at post-treatment. Specifically, the CBT group achieved a 58% 
response rate, whilst the education group was 48%. Whilst both groups showed 
significant improvements from baseline to treatment, which were maintained at 12 
months follow up, the difference between the groups was not statistically significant. 
Within-group comparisons showed both interventions resulted in statistically significant 
reductions in fatigue impact, pain interference, and depression, but effects were 
generally small for pain interference. In addition, pain severity did not significantly 
change within the CBT treatment group, but did increase slightly at follow-up. In 
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contrast, significant reductions were observed in the education group at 6 and 12 
months.  
 
Finally, one study evaluated a short five hour workshop based on ACT for n = 15 
pwMS (Sheppard et al., 2010). ACT and CBT are described in more detail in chapter 2. 
The workshop showed significant improvements in pain interference and QoL, along 
with reductions in depression and pain-related thought suppression, at 3 months follow-
up. Together these studies indicate that either CBT or ACT treatments may help pwMS 
better manage pain, and potentially lead to reductions in pain severity and pain 
interference. Only three of the studies examined psychological variables, including pain 
catastrophizing and thought suppression, self-efficacy, resilience and negative affect or 
depression, which improved in conjunction with pain outcomes (Ehde, Elzea, et al., 
2015; Jensen, Ehde, et al., 2011; Sheppard et al., 2010). However, none of these 
treatments were based on a clear conceptual model of MS pain, and other potentially 
important contextual and cognitive behavioural factors or processes identified within 
the previous empirical chapters were not investigated.  
 
Traditionally researchers have evaluated CBT or ACT approaches, and their dominant 
underlying theories, independently. However, previous empirical studies in this thesis 
indicate that variables from both models explain important variance in pain outcomes, 
and it is not clear whether CBT or ACT would be more or less helpful. One study in 
primary chronic pain has examined the potential efficacy of a treatment combining 
second- and third-wave psychological approaches. This study showed that significant 
improvements in pain outcomes may be mediated by pain catastrophizing, a key factor 
identified in the MS pain model (Linton & Fruzzetti, 2014). Therefore, it may be 
beneficial to evaluate an intervention guided by the MS pain model that combines key 
elements from both CBT and ACT, which aims to promote pwMS’ choice of using 
techniques from either approach. 
 
6.1.1 Rationale for the development of a self-management intervention 
 
When developing an intervention in the context of MS, consideration of how a 
treatment may be integrated within current services is important because access to 
psychological resources is often limited. PwMS may encounter two important barriers 
when attempting to access current psychological treatments in the UK. First, recent 
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evidence suggests that pwMS may have limited access to specialist care for symptom 
management or mental health issues (see MS Society UK, 2015 for full report), which is 
likely to include access to clinical psychologists and other psychological therapists 
trained specifically in pain management. Traditionally CBT in the NHS is delivered 
face-to-face on a one-to-one basis by a highly trained clinical psychologist across 5 to 
20 sessions lasting up to one hour (NHS Choices, 2015). However, these therapist-
intensive delivery methods may be considered too costly by most health care providers 
in the current economic context. It is therefore, possible that most pwMS will have 
limited access to CBT for symptom management. The recent introduction of improving 
access to psychological therapies (IAPT) (Clark, 2012; Clark et al., 2009) and the role 
out of this programme for people with long-term conditions means that there will be an 
increasing workforce of newly trained clinicians with varying levels of psychological 
expertise who may be available to facilitate this intervention. It may therefore be 
possible to refer pwMS to low intensity IAPT workers (e.g. assistant psychologists, 
psychological wellbeing practitioners or primary care mental health workers), who in 
time may form part integrated care pathways for pwMS. On the other hand, simple, 
low-intensity psychological interventions could potentially be nurse-led, perhaps with 
some training, in the context of MS specialist services. A second important issue is that 
pwMS with greater levels of disability may have difficulty attending sessions due to 
poor mobility, and may not take into account acute episodes of severe pain or 
fatigability, cognitive impairment and concentration difficulties (Dennison & Moss-
Morris, 2010). Trying to overcome these potential barriers to access may be important 
to achieve successful implementation of effective treatments in the long-term. 
  
Face-to-face therapy is also a common model of treatment delivery in the broader 
chronic illness literature. However, in the last fifteen years there has been an increasing 
shift towards self-management approaches (Barlow, Wright, Sheasby, Turner, & 
Hainsworth, 2002; Bodenheimer, Lorig, Holman, & Grumbach, 2002; Jovicic, Holroyd-
Leduc, & Straus, 2006; Newman, Steed, & Mulligan, 2004; Ramadas, Quek, Chan, & 
Oldenburg, 2011; Stinson, Wilson, Gill, Yamada, & Holt, 2009), which can either be 
manual or web-based. One definition of self-management in this literature includes: 
 
“The tasks that individuals must undertake to live with one or more chronic conditions. 
These tasks include having the confidence to deal with medical management, role 
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management, and emotional management of their conditions” (Carnes et al., 2012, p. 
344). 
 
Most self-management approaches in the chronic illness literature appear to be optimal 
if they have some support, typically using either telephone or email methods. However, 
at present there appears to be less evidence indicating what the optimal clinical and 
cost-effective dosage of support is in the context of psychological interventions for 
long-term conditions.  
 
In addition to the telephone-delivered intervention for pain outlined in the previous 
section (Ehde, Elzea, et al., 2015), in the context of MS web- or telephone-based self-
management interventions have been introduced as one way to address the problem of 
cost and availability of CBT. They offer greater flexibility when tailoring treatment 
content and sessions to varying levels of need and disability. One review of 39 MS 
studies suggests that telephone- or internet-delivered self-management interventions, 
including CBT, may improve clinical outcomes, quality of life, and reduce health care 
costs (Rae-Grant et al., 2011). This is consistent with a more recent review suggesting 
there is growing evidence for the effectiveness of psychological interventions to 
improve pwMS’ management of several symptoms using a variety of delivery methods 
(Pagnini et al., 2014). Of the 22 studies in this review, one of the largest treatment 
effects was demonstrated by a study aiming to improve pwMS’ management of fatigue 
using a face-to-face and telephone supported eight week CBT intervention reviewed in 
chapter 1 (van Kessel et al., 2008). Two small pilot studies have subsequently tested a 
web based version of this intervention, where one used minimal telephone and the other 
email support (Moss-Morris et al., 2012; van Kessel et al., 2015). Both of these low 
intensity interventions were efficacious, although improvements in fatigue and related 
interference are unlikely to be as large as those observed using high-intensity face-to-
face delivery methods. However, it is difficult to disentangle effectiveness of treatment 
content from intensity, because studies have used different comparison groups, ranging 
from treatment as usual (which in many cases may be no treatment at all) to 
interventions attempting to control for non-specific therapist effects. One way to 
separate the effectiveness of treatment content from intensity would be to directly 




There is also a growing body of evidence for self-management psychological 
interventions in the context of chronic pain. Recommendations from a recent review 
evaluating the delivery methods of 46 RCTs (of which 38 were psychological 
interventions) indicate that self-management interventions lasting for less than eight 
weeks may be an optimal approach (Carnes et al., 2012). However, at present there are 
no published studies investigating the efficacy of a more time limited self-management 
intervention based on a combination of CBT and ACT approaches for MS pain using 
these alternative delivery methods. Therefore, developing a low-intensity telephone 
supported self-management intervention for MS pain may be a pragmatic approach in 
the current context. Specifically, for the purposes of this preliminary treatment trial, it 
was felt that using a detailed self-management manual alongside three one hour 
treatment sessions offered via telephone or Skype, with a therapist who has a limited 
amount of training and is not a qualified clinician, may be more realistic in terms of 
achieving long-term implementation. 
 
6.1.2 Aims of the current self-management intervention 
 
Our main aim was to develop a treatment manual that maps sessions directly onto 
relevant aspects of the newly developed model. The titles of each session, and which 
part of the model they most relate to, are mapped onto the model in Figure 8. Although 
most of the sessions focused on cognitive or behavioural aspects of the model, it is 
assumed that changes in these will also directly impact on negative emotions. The 
details of each session are described in Table 2 below. Given the similar pattern of 
findings for pwMS with different type of pain identified in the systematic review and 
cross-sectional study (Harrison, McCracken, et al., 2015; Harrison, Silber, et al., 2015), 
the intervention was designed to broadly target pwMS with neuropathic and non-
neuropathic pain. 
  
Consistent with guidance in the chronic pain literature (Turk et al., 2003), the current 
intervention was designed specifically to target psychological factors or processes 
within our MS pain model to (a) improve pwMS’ engagement in everyday, or other 
meaningful, life activities by reducing pain interference, (b) reduce their levels of pain 
severity, and (c) help pwMS to learn and retain a new set of self-management skills, or 
strategies, to manage pain and assist them in the future. Currently there is insufficient 
evidence to support the efficacy of biomedical treatments (Beard et al., 2003; De Santi 
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& Annunziata, 2012; Jawahar et al., 2013), although some pwMS report some benefit 
from using pain medications (Ehde, Alschuler, et al., 2015; Harrison, Silber, et al., 
2015). Therefore, the current programme was designed to be supplementary to 
biomedical treatments in order to promote choice for pwMS. The programme was 
designed to be delivered alongside biomedical treatment if it was being received. This 
meant that participation in the programme did not require that pwMS either to reduce or 
stop taking altogether their current pain medications. 
 
6.1.3 Overview of eight session treatment manual 
 
Treatment sessions included a range of didactic, experiential, skills training, and 
educational elements, using materials adapted for pwMS from CBT and ACT 
interventions in chronic pain (McCracken, 2006; Otis, 2007; Thorn, 2004) and MS 
fatigue (van Kessel et al., 2008). Aspects of transdiagnostic treatment manuals 
combining CBT and ACT approaches were also included (Harris, 2009; McKay, 
Fanning, & Ona, 2011). The manual was developed by the author of the thesis and 
incorporated feedback from his supervisors and three MS Society PPI members on the 
usability, usefulness and acceptability of information (this is process is described in 
more detail in section 6.1.4). The “Guided cognitive behavioural self-management 
Treatment for MS pain (GIFT)” manual included eight weekly modules summarised in 
Table 2. All sessions were designed to be interactive and tailored to the individual, 
including self-assessments, a separate task sheets booklet, and a CD with optional audio 
exercises. Optional exercises throughout the manual allowed participants to focus on 
aspects which they felt were more relevant to them, and ignore those which were less 
relevant. Each session also included homework tasks within the task sheets booklet, 
which were designed to be completed over the following week and reviewed in the next 
session. The protocol for the use of the manual included only minimal therapist contact. 
PwMS received three telephone or Skype sessions throughout the eight week 
programme, each lasting up to one hour. The telephone sessions were scheduled so that 
the first one took place after participants completed session 1 to review this chapter 
(week 2); the second after session 4 to review chapters 2 to 4 (week 4); and the third 
after session 7 to review sessions 5 to 8 (week 7). All telephone sessions were 
collaborative in style, using Socratic questioning, guided discovery and validation 




Two treatment models were outlined in section 6.1.1, which would either involve 
support from low-intensity IAPT therapists or MS nurses. To date no studies have 
directly compared the efficacy of CBT treatments delivered by other health 
professionals traditionally employed by MS services, low intensity IAPT therapists and 
highly trained clinical psychologists (Dennison & Moss-Morris, 2010). Therefore, all 
telephone sessions were delivered by the author of the current thesis, a third year health 
psychology PhD student, and previously an assistant psychologist, who has completed 
some training in both therapeutic approaches. The author’s level of clinical expertise is 
therefore assumed to be comparable to that of an assistant psychologist or low-intensity 
IAPT therapist receiving appropriate training and supervision. The detailed content of 
each session will now be summarised in the following section.  
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Table 2 Outline  of the hybrid traditional cognitive and contextual behavioural guided self-help treatment (GiFT) manual 
 
Chapters Focus  
1. MS Pain explained What is Multiple Sclerosis (MS) associated pain?  
A summary of gate control theory, including physiological explanations of different types of pain. 
Understanding the biological, cognitive, emotional, social/environmental factors triggers and how these can maintain pain. 
Developing a personal cognitive behavioural model. 
2. Breaking vicious cycles: patterns of rest 
and activity 
 
Levels of activity, rest, and pain are reviewed in relation to individual’s models and / or vicious cycles. Information explains 
how patterns of rest and activity or over-activity affect the body and pain. The importance of consistency in activity and rest is 
emphasised, and benefits of moderate physical exercise suggested (activity scheduling and self-monitoring).  
3. The natural tendency to avoid unwanted 
pain and setting goals 
The natural tendency to experientially avoid pain and associated thoughts and feelings is discussed, along with acceptance-
based metaphors and an optional audio exercise (Observe, Breathe Open up). 
A workability analysis of behaviour (i.e. short- and long-term consequences) is considered in relation to the person’s model and 
vicious cycles.  
Setting goals related to either activity or avoidance is suggested, and choosing specific and achievable goals is emphasised. 
4. Doing what matters: Thinking about 
goals in relation to values. 
 
Thinking about underlying motivation by exploring the differences between values and goals. 
Identifying values, including the optional Eightieth birthday exercise, and linking to them to goals.  
Setting values-based goals. 
5. Identifying unhelpful thoughts. Explanation of how perceptions of events can influence a person’s responses to pain.  
Identifying unhelpful thoughts and feelings and considering common traps or ‘errors’ in thinking. 
6. Option 1: Using alternative thoughts  
 
 
   Option 2: Stepping back from pain and     
   related thoughts and feelings.    
Explanation of how to weighing-up a ‘negative’ thought and learning how to consider possible alternatives to help with levels 
of distress and limit unhelpful behaviour. 
 
The problems with suppressing pain, thoughts and feelings are discussed. 
Defusion exercises are introduced (Lemons, lemons, lemons and “I notice I’m having the thought that…”) to understand the 
potential influences of thoughts on behaviour, and to get distance from them without trying to change them.  
7. Contacting the present moment. An explanation of the importance of getting present in order to be more open to pain and to pursue values-based goals. 
Mindfulness exercises are introduced, including audio (Body Scan). 
8. Preparing for the future. Developing a future management plan and setting long-term values-based goals with smaller objectives. 
Exploring potential barriers and identifying physical or emotional warning signs of relapse and normalizing these. 
Thinking about reconnecting with values and trying again to keep a commitment, or part of a commitment, to values-based 
goals. 




6.1.3.1 Session 1: MS Pain explained 
 
The aim of session 1 was to engage pwMS in a behavioural intervention by helping 
them to develop (a) a biopsychosocial understanding of MS pain, and (b) create a 
personal five-part cognitive behavioural model of MS pain, which provided a rationale 
for treatment. The review and previous empirical studies indicated that several factors 
or processes are involved in MS pain. Therefore, psycho-education provided a rationale 
to help pwMS understand the potentially reciprocal relationship between all aspects of 
the model that may contribute to, and maintain, pain. This included a detailed summary 
of the role of potentially important biological, behavioural, cognitive, emotional and 
environmental factors or processes. A dominant theme in the qualitative study was that 
pwMS generally felt that pain was difficult to understand or describe. Therefore, to 
improve their understanding session 1 firstly provided detailed information about the 
biological aspects of pain, including the different types of painful symptoms in MS and 
possible causes (e.g. lesions from demyelination or gait problems). The S-LANSS 
instrument (Bennett et al., 2005) was inserted to help pwMS determine whether their 
pain was either neuropathic or non-neuropathic in nature, which allowed them to refer 
to more relevant sections in the chapter and ignore those that were less relevant. In 
addition, a lay explanation of chronic pain and gate control theory was provided, which 
emphasised the cyclical relationship between pain and stress (Otis, 2007). Given that 
many pwMS reported using pain medication even when they were ineffective in the 
cross-sectional and qualitative studies, a brief section describing the evidence of pain 
medication in MS, their potential side-effects and consequences of over-use were also 
outlined.  
 
When introducing the importance of other elements of the model, many explanations of 
how cognitive, emotional, behavioural and social factors influenced pain were 
supported by illustrative quotations of pwMS from the qualitative study. The quotations 
aimed to normalise pwMS’ experience of the sometimes challenging situations they 
may face, including e.g. potentially unhelpful overly solicitous or stigmatising reactions 
of others. After each element of the model was discussed pwMS were encouraged to 
complete short interactive self-assessments, which were designed to help them identify 
some of their own ways of thinking about pain and emotional reactions, and how they 
and others tend to behave in response to their pain. At the end of the chapter, pwMS 
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were encouraged to reflect on their self-assessments to create their own personal MS 
pain model, which explored potential interactions between these key elements. 
Importantly, the personal model was formulated in collaboration between pwMS and 
the therapist, where guided discovery was used to ensure the model reflected pwMS’ 
experience. The homework required pwMS to re-read the chapter, or specific sections, 
in order to consolidate their learning and refine their model in preparation for the next 
session.  
 
6.1.3.2 Session 2: Breaking vicious cycles: patterns of rest and activity 
 
The primary aim of session 2 was to reinforce pwMS’ learning of their personal model 
by providing detailed examples of how vicious cycles may develop. Some of the 
examples drew on pwMS “Catch-22” experiences described in the qualitative study. 
The examples aimed to illustrate in greater detail how vicious cycles can potentially 
become problematic for pwMS with ranging levels of disability and different life 
circumstances to engage pwMS. As seen in Figure 8, the qualitative study suggested 
that pwMS were “careful not to over-exert”, “took medications” and engaged a variety a 
strategies to reduce pain with sometimes limited success. In addition, cross-sectional 
findings suggested pwMS’ may have a tendency to either avoid physical or social 
activities when experiencing pain, and that enduring with activity when in pain may not 
necessarily be harmful. Therefore, a particular emphasis in session 2 was placed on 
unhelpful behaviours in response to pain by describing how patterns of excessive rest 
and over-activity (in select cases) over the short- and longer-term may affect pain and 
the body more generally. In addition, the importance of consistency with rest and 
activity was emphasised, and moderate physical exercise was encouraged. Again, 
pwMS were asked to complete interactive self-assessments specifically related to 
patterns of rest and activity and other behavioural responses (e.g. over-using pain 
medications, alcohol or drugs, or hiding pain from others). PwMS were then 
encouraged to incorporate these responses and their impact into their personal model 
from session 1. The session homework required pwMS to use a pain and stress diary to 
self-monitor their weekly activities, which specifically explored how fluctuating levels 
of stress and pain may influence each other. The dairy was then reviewed at the start of 
the following session (forming part of the first telephone session with the therapist) in 




6.1.3.3 Session 3: The natural tendency to avoid unwanted pain and setting 
goals 
 
The aim of session 3 was to help pwMS to recognise when they were struggling with 
pain and related thoughts and feelings when to do so may be potentially unhelpful. 
Consistent with other studies in the literature (Ehde, Alschuler, et al., 2015; Heckman-
Stone & Stone, 2001), a large proportion of pwMS in the cross-sectional study reported 
using biomedical treatments, but pain-relief appeared to be modest and pain was often 
persistent. In addition, pain acceptance was related to better pain outcomes in the cross 
sectional data. The qualitative findings also showed that pwMS had a “pain reduction 
agenda”, reflecting a narrower focus on trying to control or reduce pain even when the 
short- and long-term effects were not always helpful. One consequence of the pain 
reduction agenda appeared to be that pwMS’ withdrew from engagement in other 
meaningful life activities. The qualitative study also indicated that pwMS tended to 
“fight” or struggle with their pain or emotional experience. There was also some 
evidence in the review to suggest that pwMS had a tendency to suppress their pain-
related thoughts. Conversely, pwMS who had a “management and acceptance agenda” 
appeared to make room for pain in their life and were seemingly less distressed by it. 
Therefore, session 3 focused on pwMS pain-related behaviours with a particular 
emphasis on pain acceptance. This session was split into two parts. In part 1 pwMS 
were introduced to the consequences of experiential avoidance (again, illustrative 
quotes and examples were used throughout the chapter), and then were asked to 
examine the workability of their behaviour (i.e. a lay version of a functional analysis). 
In part 2 participants were then assisted with developing skills in goal-setting.  
 
Part 1: Experiential avoidance (the inverse of pain and general acceptance) in this 
section was conveyed to pwMS as the natural tendency to avoid unwanted pain, 
thoughts and feelings. An acceptance metaphor from ACT was used to normalise 
pwMS’ tendency to avoid uncomfortable private experiences (‘Quicksand metaphor’, 
see Harris, 2009), aiming to help them understand how avoidance can amplify pain and 
other problems in the long-term. PwMS were also encouraged to examine the 
workability of their pain-related behaviours, which involves writing down short- and 
long-term consequences or “pay-offs” of engaging in a particular behaviour. They were 
then encouraged to incorporate their findings from the workability analysis into their 
updated personal model from session 1. 
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Part 2: PwMS were then encouraged to set workable goals related to issues in their 
personal model, which were emphasised as an important way to break vicious cycles of 
pain, or “Catch-22” problems, and related distress. They were asked to set stepped goals 
to gradually increase meaningful activities (including exercise) in a consistent way. 
These goals were then monitored closely throughout the programme by the individual 
and therapist to enhance self-efficacy. The potential link between engaging in goal-
directed behaviour and acceptance was also emphasised, where pwMS were asked to 
complete an optional experiential audio exercise on acceptance (‘Observe, Breathe, 
Open up’). The rationale for acceptance within this exercise was introduced to pwMS as 
a method to “open up” to their pain sensations, thoughts and feelings to help them 
engage more fully in meaningful life activities or goals.  
 
6.1.3.4 Session 4: Doing what matters: Thinking about goals in relation to 
values 
 
Session 4 aimed to help pwMS clarify their values, explore how their current pain-
related behaviour may prevent them from acting in the service of their values, and 
derive personally meaningful values-based goals. Values or committed action have yet 
to be tested in conjunction with MS pain. However, studies investigating ACT in 
chronic pain show that values, in combination with acceptance and mindfulness 
techniques, are associated with reductions in anxiety and may increase motivation, 
helping individuals to commit to sustainable behaviour change in the long-term 
(McCracken & Keogh, 2009; McCracken & Velleman, 2010; McCracken & Vowles, 
2008). The emphasis on motivation appeared to be consistent with one study in the 
systematic review, which suggested that motivational elements, such as greater 
perceived importance of, and readiness to change (or maintain), self-management 
behaviour, were associated with less pain interference (Kratz et al., 2011). Values were 
included in the intervention because they seemed particularly relevant for chronic 
illness populations. Values are not in themselves ends. Rather they can be worked 
towards, but unlike goals, are never fully achievable. For example, an individual might 
value “caring for others”, which even in the face of serious disease progression, relapse 
or changes in functioning can still be worked towards in many different ways. Values 
emphasise flexibility that is sensitive to context. Therefore, an individual might be 
encouraged to consider a number of values-congruent actions or goals based on their 
level of disability, ranging from even the smallest gestures of care (e.g. telling someone 
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they love them or making them a cup of tea) to bigger goals or longer-term projects 
(e.g. supporting their child with school homework or going on holiday). With the help 
of fictitious examples, pwMS were encouraged to complete self-assessments, including 
the forty common values checklist (Harris, 2009) and Values Bull’s-eye, which explore 
the extent of a person’s remoteness from their values (Dahl & Lundgren, 2008). An 
experiential audio exercise (‘Eightieth Birthday’, see Harris, 2009) was also introduced 
to help pwMS identify what is ultimately important to them. Homework tasks from this 
session up until end of treatment asked pwMS to set a number of values-based goals, 
which were reviewed in each of the following sessions and discussed with the therapist 
in the second telephone session.  
 
6.1.3.5 Session 5: Identifying unhelpful thoughts 
 
Session 5 aimed to help pwMS identify their thoughts and feelings in response to pain, 
explaining how both can have a potentially important role in maintaining vicious cycles 
of pain and distress. CBT has traditionally targeted more general patterns of thinking of 
the self, world or future related to anxiety and depression, including catastrophic 
predictions and negative beliefs about coping abilities (Beck, 1991). However, the 
empirical findings in this thesis repeatedly confirmed the important role of pain-related 
catastrophic thinking in MS, which may either be verbal or imagery-based in nature. In 
addition, beliefs around negative consequences, chronicity, and low control of pain to a 
lesser extent, were also associated with worse pain outcomes. Qualitative themes, 
including “Pain is unpredictable”, “Pain will get worse” / is progressive, and the variety 
idiosyncratic personal beliefs about the causes of pain also reinforced the idea that pain 
perceptions informed by Leventhal’s CSM model of illness perceptions (Leventhal et 
al., 1984; Moss‐Morris, 2013) played an important role.  
 
Therefore, consistent with a recent CBT intervention for MS fatigue (van Kessel et al., 
2008), session 5 targeted both general and pain-specific beliefs. For the latter this meant 
helping pwMS complete self-assessments to identify pain-related catastrophizing, and 
appraisals of chronicity, negative consequences (sometimes in conjunction with pain 
catastrophizing), and potential causes of pain. Illustrative quotes and examples informed 
by the qualitative study explained how these cognitive events may result in negative 
emotional responses and potentially unhelpful self-management behaviours. In the 
second telephone session the therapist also explored appraisals that may be triggered by 
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acute (e.g. transient unpleasant painful symptoms, or changes in treatment or exercise 
habits) and chronic health threats (e.g. disease progression, worsening chronic 
symptoms, loss of function). PwMS were also introduced to common types of thinking 
errors from traditional CBT to label their pain-specific or general beliefs. In addition, 
the ACT acceptance metaphor ‘Passengers on the Bus’ was used to consolidate pwMS’ 
understanding of the process of thought identification and labelling. Along with the 
self-assessments, pwMS were encouraged to update the thoughts section of their 
personal five-part model. Finally, pwMS were also introduced to thought records in 
session 5 with worked examples informed by the qualitative data. Thought records were 
also used for homework tasks to help pwMS identify situations in which pain-specific, 
or more general negative beliefs, may lead to potentially helpful or unhelpful 
behavioural and emotional responses that may worsen pain. They were also asked to 
label the thoughts according to the common types of thinking list. This work was 
reviewed in the following session, where again the therapist used a more Socratic style 
of questioning to continue the collaborative formulation process where guided 
discovery was encouraged.   
 
6.1.3.6 Session 6: Using alternative thoughts or Stepping back from pain and 
related thoughts and feelings    
 
The aim of session 6 was to introduce skills to help pwMS better manage their 
potentially unhelpful pain, or more general negative thoughts, identified in their 
personal model and previous session. This was with the aim of limiting their influence 
on potentially unhelpful behaviours outlined in session 2 and 3. Cognitive techniques in 
traditional CBT suggests individuals unrealistically overestimate negative outcomes, 
which can result in unhelpful coping behaviours (Beck, Emery, & Greenberg, 1985). 
Therefore, a combination of thought-challenging and exposure-based methods are 
commonly used to help individuals overcome anxiety, “enabling them to find more 
adaptive alternatives in thinking, habituation and de-catastrophization of feared 
predictions or expectations” (Greer, Park, Prigerson, & Safren, 2010, p. 6). As indicated 
in our model, pwMS may also monitor and inaccurately interpret painful symptoms as 
harmful, perhaps as representing worsening disease. However, it was also recognised 
that pwMS may have realistic fears related to pain and disease exacerbations or 
progression, and changes in function or treatments. Therefore, in addition to traditional 
CBT’s thought-challenging techniques it was felt an alternative approach might be 
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helpful to address negative thought patterns specific to MS pain that might be 
considered ‘rational’, but which may still be intrusive and distressing. It was also the 
case that cognitive fusion was significantly associated with pain interference in the 
cross-sectional study. 
 
Therefore in this session pwMS were given the option to try out (i) thought-challenging 
(i.e. weighing up a thought and finding useful alternatives) from traditional CBT, or (ii) 
cognitive defusion exercises from ACT to address unhelpful or distressing thoughts. 
Defusion and thought challenging methods have divergent aims (Harris, 2009). Thought 
challenging is primarily interested in modifying the content of pain-related thoughts or 
beliefs and seeking alternatives, whilst defusion exercises focus more on changing the 
person’s relationship to their thinking or context, without directly attempting to modify 
or control thought content. One can therefore defuse from thinking, irrespective of 
whether a thought it is necessarily ‘true’ or not (Harris, 2009). More specifically: 
 
In option 1 pwMS were given worked examples of thought diaries, and were asked a 
number of key questions to help them weigh-up pain-related or general beliefs 
identified in their model or previous thought records. The therapist also actively 
engaged pwMS in this process, sometimes using in situ examples, within the second 
telephone session. This involved asking the individual to provide empirical data on how 
distressed they were before and after challenging their thinking. In addition, pwMS 
were reinforced with praise for trying out the task and for testing out different 
behavioural responses in the presence of thoughts that had previously exerted greater 
influence over them. They were also encouraged to praise and reward themselves when 
they tried to do this. 
 
In option 2 the same process was applied using thought records but instead used ACT’s 
cognitive defusion methods. These included explanatory experiential exercises (e.g. 
lemons, lemons, lemons) in combination with other techniques, including saying aloud 
and silently the phrase “I notice I’m having the thought that…” before a potentially 
unhelpful pain-related, or more general, thought. The rationale for defusion methods 
were also supplemented by acceptance (e.g. ‘Polygraph Metaphor’) and paradoxical 
thought suppression exercises (e.g. ‘don’t think about a cup of tea’). Homework tasks 
for both options aimed to reinforce learning by using thought-challenging or defusion 
exercises as an additional step within weekly thought records. 
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6.1.3.7 Session 7: Contacting the present moment 
 
Session 7 aimed to teach pwMS present moment awareness or mindfulness skills from 
ACT. This was described to pwMS as another way to manage pain and related thoughts 
and feelings when embarking on values-based (i.e. committed) actions or goals. 
Currently there is no empirical evidence in the MS pain model for associations between 
pain outcomes and present moment awareness or mindfulness processes. However, a 
recently identified unpublished study (n = 139) suggests lower levels of mindful 
awareness is significantly associated with greater pain severity and pain interference in 
MS (Senders, Yadav, & Shinto, 2014). In addition, a small study evaluating a 
meditative intervention for pwMS (n = 17) has demonstrated significant reductions in 
pain severity compared to controls (Tavee, Rensel, Planchon, Butler, & Stone, 2011). 
Furthermore, a recent pilot study evaluating the efficacy of a Skype distance-delivered 
eight week mindfulness intervention for MS adjustment has also demonstrated small but 
significant reductions in pain severity at post-treatment, with moderate improvements 
observed at three months follow-up (Bogosian et al., 2015). It has also been argued that 
cognitive defusion in ACT’s psychological flexibility model, in combination with 
present moment awareness and acceptance, are essentially defined as key processes of 
mindfulness (Hayes et al., 2013). Therefore, this session provided a rationale for 
improving present moment awareness to help pwMS open up to pain and difficult 
thoughts and feelings, when to do so allows them to engage more fully in valued 
activities or goals. In combination with exercises conducted during the third telephone 
session, several exercises from ACT, including ‘Notice Five Things’ and three audio 
exercises (‘Leaves on a Stream’, ‘Tracking Thoughts in Time’, ‘Free Choice Body 
Scan’), aimed to help pwMS gain an experiential understanding of mindfulness that 
could be usefully applied to their everyday routine. A self-assessment was also used to 
help pwMS identify thinking that may interrupt their attempts to engage in these tasks, 
which again fed back into their model. PwMS were encouraged to listen and practice 
those exercises that they found most helpful for five to ten minutes a day. They were 
also asked to set themselves random reminders on their mobile phones to engage in the 






6.1.3.8 Session 8: Preparing for the future 
 
The final session focused on helping pwMS formulate long-term values-based goals, 
and related sub-goals, to work towards in the future. Potential barriers or setbacks to 
achieving goals were also explored in greater detail, and a relapse prevention plan was 
introduced to help pwMS to anticipate potential problems (e.g. pain flare-ups, 
exacerbations, disease progression, depression, social issues etc.) to help them manage 
pain more successfully. Individuals were also encouraged to reflect on newly acquired 
skills from all previous sessions that might be employed when working towards values-
based goals. This session also focuses on ACT’s values and committed action 
processes, despite the fact that neither had been directly tested in the MS pain model. 
However, other motivational beliefs did appear to be important. PwMS were 
encouraged to monitor their commitment to values-based goals in a way that normalised 
the experience of breaking commitments, but also highlighted the cumulative impact of 
quitting: Including feeling bad about quitting, fearing making commitments, and giving 
up on making commitments. In contrast, pwMS were encouraged to identify when they 
break a commitment in the future, and were encouraged to try again to keep the 
commitment, or part of the commitment. Finally, pwMS were encouraged to change 
their long-term goals or actions if considered unworkable, and re-clarify their values, 
particularly if they discover that they are less important to them than initially thought. 
 
6.1.4 Expert feedback and patient and public involvement 
 
The GIFT manual content was developed by the author of this thesis with feedback 
from his supervisors. His first supervisor, R.M.M., is a qualified registered health 
psychologist and an expert MS researcher, specialising in cognitive behavioural models 
of adjustment. His second supervisor, L.M., is a consultant clinical psychologist and 
lead for a chronic pain inpatient service, and an expert ACT and chronic pain 
researcher. Several drafts were submitted to both supervisors, who offered feedback on 
the structure and content of sessions, but also commented on language to promote 
pwMS understanding of sometimes complex concepts or exercises. For example, 
behavioural elements of the model were introduced at the start of the programme so as 
not to alienate pwMS with explanations related to cognition. It was felt that starting 
with cognitive components may potentially be misinterpreted by pwMS as the research 
team suggesting that pain is ‘not real’ or ‘all in one’s head’. Therefore, this order may 
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be perceived by pwMS as less stigmatising, aiming to promote better engagement. In 
addition, terms such as “willingness” and “openness” are used throughout the manual, 
rather than “acceptance”, in order to avoid potentially negative connotations 
surrounding acceptance equating to resignation or quitting (McCracken, Carson, 
Eccleston, & Keefe, 2004).  
 
The manual also incorporated a second iteration of revisions. This included feedback 
from three MS Society PPI members, who were asked via email or telephone to 
comment on the usability, usefulness and acceptability of information in the 
programme, and provide suggestions for possible improvements for all eight sessions 
and associated materials. All three pwMS agreed to participate in several manual and 
audio exercises and offered experiential feedback. Based on this feedback, and 
discussions with the research team, a number of adjustments were made to the manual. 
For example, more fictitious examples of people with progressive MS were included, 
along with examples of realistic exercise-based goals for wheelchair users in part 1 of 
session 3. In addition, larger text was used in the manual to assist pwMS with visual 
problems. Some of audio exercises were re-recorded with simpler and slower 
instructions to help pwMS with cognitive impairments. In addition, the longer 
mindfulness exercises were shortened from around 25 to 15 minutes to ensure pwMS 





The current hybrid contextual and cognitive behavioural self-management intervention, 
based on the MS pain model (Harrison, McCracken, et al., 2015; Harrison, Silber, et al., 
2015), aims to reduce pain severity and pain interference in pwMS. One RCT, and a 
few small pilot, non-randomized and uncontrolled studies have evaluated cognitive 
behavioural interventions to help pwMS better manage pain. Although promising, the 
content of these treatment developments were not guided by an empirically supported 
model of MS pain. In addition, little consideration has been given to limited resources 
and use of self-management methods. Furthermore, interventions appeared to provide 
less information about painful syndromes in MS. In contrast, our tailored treatment, 
informed by our model, targets specific issues related to MS pain, and related 
biological, cognitive, emotional and behavioural influences. The self-management 
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methods adopted mean that the GIFT programme has the potential for more pragmatic 
low-intensity delivery, and could be facilitated by MS specialist nurses or low-intensity 
therapists, or even be used as a stand-alone self-help resource.  
 
At this stage of development several potential limitations of the GIFT programme were 
identified. First, the breadth and depth of the programme’s content was felt to 
potentially be too burdensome for pwMS who experience a greater level of disability, 
cognitive impairment or fatigue. A related issue was that potential burden of the 
programme was not highlighted by the three PPI members, which might suggest that 
patient involvement at this stage of development was insufficient. Specifically, all three 
of the PPI members who contributed to the development of programme were highly 
educated and motivated individuals from the MS Society. Therefore, in the future it 
might be helpful to obtain feedback from a wider pool of PPI members from different 
sources who have varied demographic and disease characteristics. This might go some 
way to ensure that programme materials are appropriate and accessible for pwMS with 
a range of difficulties. Despite these limitations, it was felt that one advantage of the 
self-help format was that it could easily be modified for future roll out, by either 
reducing or simplifying the content for those pwMS who might experience difficulty in 
successfully completing the programme in its current form. Given the complexity of 
some of the content in the GIFT manual, a final important consideration was whether it 
could actually be delivered reliably by staff with minimal training. It was therefore felt 
that in the future it might be helpful to develop a brief staff training programme, and 
competency assessment, which alongside the manual and regular supervision from a 
clinical or health psychologist, may translate to improvements in therapist adherence to 
the manual, and fidelity to the model. A future trial could compare delivery by staff 
with minimal training versus those with high level of expertise to compare the relative 
clinical and cost-effectiveness of these approaches. 
 
The next chapter will summarise a preliminary investigation into the potential efficacy 
of the more widely targeted GIFT programme with seven pwMS with a range of 
demographic and disease characteristics. This evaluation aims to provide useful 
information about pain outcomes, and targeted psychological factors or processes from 





Chapter 7 : A Case-series Study to Evaluate the Potential Efficacy of 
a Cognitive and Contextual Behavioural Intervention for MS Pain. 
 
7.1 Chapter overview 
 
 
The current chapter reports on a small, unpublished empirical study investigating the 
potential efficacy and feasibility of the GIFT intervention for pwMS with different 
types of pain and a broad range of demographic and disease characteristics. A version 
of this chapter, incorporating relevant information from chapter 6, has recently been 
submitted for publication to the British Journal of Health Psychology. 
 
Conducting a preliminary evaluation of the GIFT intervention aimed to further revise 
the treatment and MS pain model. The case series method does not reflect a naturalistic 
group-based longitudinal design (Barlow & Hersen, 1984). However, it was a useful 
way to explore how pwMS’ pain severity and pain interference change in relation to 
psychological responses over time in the context of an intervention. Therefore, this 
study explored temporal relationships between pain outcomes and potentially important 
contextual and cognitive behavioural mechanisms of change. The current chapter first 
outlines the aims of the study and provides a brief rationale for the case series method 
adopted. A more detailed description of methods used to evaluate the GIFT programme 
is then described. Key findings are then summarised, and the chapter closes with a 
discussion around theoretical and treatment implications.  
 
7.1.1 Study aims 
 
The purpose of the current study was to investigate the potential efficacy of a telephone-
supported hybrid CBT and ACT self-management intervention for pwMS with pain 
based on our conceptual model (Harrison, McCracken, et al., 2015) using mixed 
methods. Specific aims were to (a) test the intervention using individual case series to 
assess potential changes in pain severity and pain interference for a range of pwMS with 
different demographic and illness characteristics, and (b) evaluate potential 
psychological processes of change from the model. The systematic review and cross-
sectional study (Harrison, McCracken, et al., 2015; Harrison, Silber, et al., 2015) 
indicated that the strongest psychological correlates of pain severity or pain interference 
were pain-related catastrophizing, acceptance, perceptions and negative emotional 
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representations, and avoidance of social activities. Therefore, these processes were 
specifically targeted in the intervention. The study also aimed to (c) explore pwMS’ 
experiences of the treatment programme within a post-intervention qualitative telephone 
interview, and (d) inform recommendations for revising and modifying the intervention 
in the future.  
 
7.1.2 Use of for single-case methodology 
 
Single case series designs provide a quasi-experimental approach to evaluating 
treatment effectiveness in a single subject or small group of subjects, in which 
individuals serve as their own controls (Backman & Harris, 1999). Many treatments 
have been evaluated using more conventional group-based designs, however it has been 
argued these findings may be misleading because they assume effects at the group level 
apply to the individual (Weinstein, 2007). Compared to group-based designs the single-
case method also allows for a cost-effective investigation of processes of change in 
psychological interventions (Kazdin, 2011), and provides a more detailed analysis of 
both “responders” and “non-responders” to treatment (Barlow & Hersen, 1984). 
Therefore, rather than conducting a group-based pilot trial, a single-case design was 
used because it allowed us to test how our broadly targeted treatment may work at an 
individual level for pwMS with a range of demographic and illness characteristics (i.e. 
disease subtype, level of neurological disability and type of pain). The single case series 
design was supplemented with qualitative methods to gauge participant’s acceptability 
of the intervention and explore potential processes of change in greater detail to further 




7.2.1 Ethical considerations 
 
The study was approved by the Camden & Islington Research Ethics Committee 
London in December 2014 (14/LO/1909) and informed consent was collected from all 









A replicated single-case time series A-B-A design with a four week baseline, eight 
week treatment and four week follow-up period, with four-day intervals between 
assessments, was used to evaluate the potential efficacy of the eight-week telephone-
guided hybrid CBT and ACT self-management programme for pwMS.  
 
7.2.3 Recruitment and participants 
 
Participants were selected from a previous UK-wide cross-sectional survey study 
(n=608) (Harrison, Silber, et al., 2015), which recruited pwMS from National Health 
Service (NHS) MS specialist neurology clinics, and online through the MS UK Register 
and MS Society. Those participants who expressed a preference to be re-contacted 
about the current study were mailed an initial invitation letter, information sheet and 
consent form by the first author. In conjunction with the eligibility criteria below, 
eleven people were initially invited to take part in the current study based on their 
demographic and illness data (see Figure 9 CONSORT flow diagram). Specifically, the 
first author (A.H.) reviewed the available cross-sectional survey data to select 
potentially eligible participants based on age, gender, ethnicity, MS subtype, level of 
disability, pain severity and pain interference, pain onset and type of pain. The cross-
sectional dataset did not include many younger pwMS, and few were in the early stages 
of pain onset. Therefore, people with different genders and types of pain were 
purposefully sampled people with different genders and types of pain, to ensure disease 
subtypes and varying levels of neurological disability were represented. 
 
7.2.4 Screening and eligibility criteria 
 
Of the eleven participants re-contacted from the previous cross-sectional study (n=608) 
one person had died. Therefore 10 pwMS provided informed consent to complete a 
brief telephone screening assessment with A.H. The screening assessment included the 
Telephone Interview for Cognitive Status Modified (TICS-M) (Brandt et al., 1993) 
where a score of ≥20 was required. The TICS-M is an English modification of a brief 
standardised ten minute telephone interview procedure that assesses cognitive status. 
Based on the Mini-Mental State Examination (MMSE) (Folstein, Folstein, & McHugh, 
1975), it was originally used to identify cases of dementia, but has been shown to be a 
helpful tool for identifying people with and without cognitive impairment in studies 
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where other testing methods are too expensive or impractical (Crooks, Clark, Petitti, 
Chui, & Chiu, 2005). The assessment comprises 19 items assessing basic cognitive 
functions affected by dementia, including orientation, concentration, memory, naming, 
comprehension, calculation, and reasoning. Compared to other brief, in-person 
neuropsychological examinations, the TICS-M has good interrater reliability, high 
sensitivity and specificity for the detection of dementia, and is strongly correlated with 
the MMSE in clinical samples (Brandt et al., 1993). The following eligibility criteria 
were also assessed during the telephone screen: 
 
Participants were included if they (a) had participated in our previous cross-sectional 
study, (b) were ≥18-years of age with any subtype of MS, (c) in line with IMMPACT 
recommendations for all chronic pain trials (Dworkin et al., 2010), experienced pain 
regularly for at least three months with a current pain severity and pain interference 
score of at least ≥3 (moderate severity, Alschuler et al., 2012b) assessed using the Brief 
Pain Inventory (BPI) (Cleeland & Ryan, 1994), and (d) onset of pain needed to have 
occurred at the time of diagnosis or after a diagnosis of MS. 
 
Participants were excluded if they (a) could not speak and understand English to an 
acceptable level in order to participate in assessments, reading and telephone sessions, 
(b) reported previous serious psychological disorders, or (c) showed severe cognitive 
impairment (≥20 on the TICS-M), or were either (d) starting a new pain medication 
regimen or (e) psychological therapy for pain during the study period, and (f) had 
experience of prior formal experience in CBT or ACT approaches. 
 
One person was excluded post-screen because they were expected to start on a new pain 
medication regimen during the study period, whilst another reported pain related to a 
bone fracture. The remaining eight participants were sent a confirmation letter asking 
them to complete an online or paper version of the Self-administered Expanded 
Disability Status Scale (EDSS-S) (Bowen et al., 2001) to assess their level of 
neurological disability, MS subtype pictorials (Bamer et al., 2007) and Self-report 
Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) (Bennett 
et al., 2005) to identify any changes in disease variables since the cross-sectional study. 
The S-LANSS provided a case identification cut-off score (≥12) to identify participants 
whose pain was dominated by neuropathic mechanisms. The S-LANSS has good 
convergent validity with neuropathic items of the MS-validated Neuropathic Pain Scale 
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(Rog et al., 2007). All eight individuals were enrolled on the guided cognitive 
behavioural self-management treatment programme for MS pain (GIFT) study from 
December 2014 to May 2015. One participant withdrew from the study due to 
commitments with full-time education. At the end of the study the seven completers of 








All participants completed online valid and reliable self-report instruments assessing 
pain outcomes and psychological processes every four days during baseline (4 weeks), 
treatment (8 weeks) and follow-up phases (4 weeks). The four-day interval for ratings, 
and use of shorter validated instruments, aimed to maximise validity and minimise 
participant burden. Measures were drawn from our MS pain model (Harrison, 
McCracken, et al., 2015). All measures demonstrated acceptable internal reliabilities in 
the previous cross-sectional study (Cronbach’s α ≥.80) (Harrison, Silber, et al., 2015). 
Three MS Society UK patient and public involvement (PPI) members assisted with the 
design of the online ratings, providing feedback on their acceptability and usability. 
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Every four days during the 16-week period participants were sent e-mail and text 
message reminders by an independent assessor (K.J.) asking them to complete their 
online ratings. At 12 weeks participants were invited to take part in a semi-structured 
qualitative telephone interview with K.J. to explore their experience of the treatment 
programme (see Appendix N for interview schedule). 
  
7.2.5.1 Primary outcome measures 
 
Brief Pain Inventory Short Form (BPI).  
The BPI (Cleeland & Ryan, 1994) is a valid and reliable instrument for pwMS 
(Osborne, Raichle, et al., 2006) assessing pain severity and pain interference. As part of 
the four-day ratings, the single-item pain severity ‘pain now’ scale, ranging from 0 (“no 
pain”) to 10 (“pain as bad as you can imagine”), and a modified ‘general’ pain 
interference scale for a given day, ranging from 0 (“does not interfere”) to 10 
(“completely interferes”), were used. Recent cut-offs specific to MS suggest an average 
pain severity score of 1 to 2 (mild), 3 to 5 (moderate) and 6 to 10 (severe) (Alschuler et 
al., 2012b). Guidance in chronic pain suggests that a clinically meaningful change for 
pain severity reflects a 2-point shift in mean scores, whilst a “substantial change” is 4, 
and a “minimal change” 1 (Dworkin et al., 2008). The BPI also assesses participant’s 
perceptions of effectiveness of current pain treatments in the last 24 hours, ranging from 
0% (“no relief”) to 100% (“complete relief”). 
 
7.2.5.2 Secondary process measures 
 
Cognitions processes and thought patterns 
 
Pain Catastrophizing Scale (PCS)  
The PCS was used to assess the extent to which pwMS magnify or exaggerate the threat 
or seriousness of pain sensations (Sullivan et al., 1995). The short 13-item scale 
incorporates rumination, magnification and helplessness, with items ranging from 0 
(“not at all”) to 4 (“all the time”), with higher scores reflecting greater pain 
catastrophizing. Scores of >20 indicate elevated risk for problematic recovery 
warranting further clinical attention (Wideman & Sullivan, 2011). 
 
Brief Illness Perceptions Questionnaire (BIPQ) 
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Four of the eight items from the BIPQ assessed pwMS’ perceived time-course, 
consequences, control and emotional representations of pain were included. The scale 
items were modified by replacing the word “illness” with “MS-related pain”. Individual 
items of the BIPQ demonstrate good test–retest reliability and concurrent validity with 
relevant measures in pwMS (Broadbent, Petrie, Main, & Weinman, 2006). 
 
 
Behaviours and behavioural processes  
 
Avoidance-Endurance Questionnaire Pain-related Behavioural Responses Scale (AEQ)  
The AEQ is a valid and reliable scale used to assess pain-related behaviours in response 
to chronic pain (Hasenbring et al., 2009). To minimise burden the 6-item avoidance of 
social activities subscale (ASAS) was selected rather than the avoidance of physical 
activities subscale (APAS) because it had stronger associations with pain outcomes in 
our cross-sectional study (Harrison, Silber, et al., 2015). The ASAS usually assesses 
individual’s behaviour in response to both “mild” and “severe” pain, although the 
subscale was modified to ask pwMS about their avoidance of social activities in 
response to pain on a given day. Items range from 0 (“never”) to 6 (“always”) with 
higher average scores reflecting greater levels of socially avoidant behaviour. 
 
Chronic Pain Acceptance Questionnaire (CPAQ-8)  
The CPAQ-8 assesses acceptance of pain, including pain willingness (refraining from 
attempts to control or reduce pain) and activity engagement (doing activities in the 
presence of pain). The 8-item scale is a modified version of the CPAQ-20 designed for 
people with chronic pain (McCracken, Vowles, et al., 2004; Vowles, McCracken, 
McLeod, & Eccleston, 2008). Each item is rated on a scale ranging from 0 (‘‘never 
true’’) to 6 (‘‘always true’’), with higher scores reflecting greater acceptance of pain. 
The CPAQ-8 demonstrates good validity and reliability in chronic pain populations 




The “Guided cognitive behavioural self-management Treatment for MS pain (GIFT)” 
manual was based on the updated model of MS pain, which was described in detail in 
the previous chapter. All treatment sessions were delivered by the thesis author, a third 
year health psychology PhD student who was guided by the content of the treatment 
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manual and attended training sessions in both approaches. During the treatment phase 
he was supervised fortnightly by his supervisor R.M.M, a qualified registered health 
psychologist. Other supervisory specific issues related to treatment methods were 
discussed conjointly with his second supervisor L.M., a lead consultant clinical 
psychologist for a chronic pain service in London and specialising in ACT. All sessions 
were audiotaped for fidelity checking by the fifth author throughout the study and used 
for supervision.  
 
7.2.7 Statistical analyses 
 
Time series data were plotted and visually inspected for each participant to explore 
differences in pain outcomes at pre-treatment (phase A), treatment (phase B), and 
follow-up (phase C). Whilst visual inspection of plots is recommended by experts in the 
field (Kazdin, 2011; Perone, 1999), recent studies show this method, and use of 
conventional statistics, can overestimate effects of interventions because time series 
data is autocorrelated (Borckardt & Nash, 2014; Borckardt et al., 2008). Therefore, 
Simulation Modelling Analysis (SMA) software Version 8.8.3 (Borckardt & Nash, 
2014) was used to generate effect sizes and autocorrelation (AR) adjusted p-values 
related to (a) the mean difference between baseline and intervention phase, and (b) rate 
of change in ratings from the start of treatment. To explore if changes in pain were 
maintained, or continued to improve at one month post-treatment, the same analyses 
compared baseline (phase A) and follow-up ratings (phase C). In the current study 
10000 resamples were conducted for each test. Pearson’s r values were converted to 
Cohen’s d to aid interpretation. Whilst other conventional approaches for analysing time 
series data were considered (see Box & Jenkins, 1970; Crosbie, 1993; McKnight, 
McKean, & Huitema, 2000; Robey, Schultz, Crawford, & Sinner, 1999), simulations 
indicate SMA protects against Type I error, whilst providing greater than 80%  power to 
detect effects with 5 to 30 data points per phase (Borckardt et al., 2008).  
 
All secondary psychological variables were visually plotted and the same phase- and 
slope-effect analyses were conducted using SMA. All valid instruments were scored 
allowing for 20% of missing data. Missing data was minimal (<0.01% across the 
sample), and dealt with using a last observation carried forwards imputation method. 
The distribution for each individual’s data was checked to determine whether it met the 
assumption of approximate normality. This did not indicate any extreme outliers across 
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participants, which is partly due to the restricted response range of instruments. As such 
the mean is unlikely to be overly biased as an indicator of central tendency even where 
the distributions are skewed. Furthermore, whilst the distribution of data streams were 
platykurtic in some cases, this is likely to result in SMAs tests being more conservative. 
 
Finally, the post-treatment qualitative interview exploring the individual and group 
perspectives of the programme were analysed by A.H. following established guidelines 
for inductive thematic analysis. First, key themes were derived for each individual, 
which were then linked to their quantitative data, and themes common to all participants 
were then explored. Due to time constraints only A.H. was involved in the process of 
identifying key individual and group themes. Therefore, coding and thematic 
developments were not cross-checked by another person. However, K.J. conducted an 
independent content analysis of all interview transcripts as part of her intercalated BSc 
project, which was subsequently used to explore similarities and discrepancies with 




Of the seven participants completing treatment, four were recruited from NHS 
outpatient neurology clinics in the UK, two from the MS UK Register and one from the 
MS Society. As seen in Table 3, four participants were women and three men, ranging 
from 37 to 65 years of age, were predominantly White-British, with varied occupational 
status. There was almost even split of pwMS reporting neuropathic and non-neuropathic 
pain, and each participant experienced pain of moderate to severe intensity in a variety 
of locations according to recent cut-offs (Alschuler et al., 2012b), for a substantial 
amount of time (ranging from 2.5 to 15 years). At initial assessment all pwMS were 
using at least two pain medications (see Appendix O), reporting varied levels of pain 
relief from their medications. Whilst there was a variety of disease subtypes, all 
participants experienced moderate to severe levels disability. Participant’s level of 
neurological disability ranged from being fully ambulatory without aid, despite 
relatively severe disability, to essentially being restricted to a bed, chair, or wheelchair.  
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ID: Participant identification number;  
Disease variables: RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis PPMS: primary progressive multiple sclerosis; EDSS-S: Self-report  
Expanded Disability Status Scale; S-LANSS: Self-report Leeds Assessment of Neuropathic Signs and Symptoms; N: neuropathic pain; NN: non-neuropathic pain. 
Pain outcomes: BPI: Brief Pain Inventory Short Form on entering the study.   
1Bamer et al’s (2007) MS subtype pictorials with lay descriptions. 
2All participants reported a pain severity score of 3 or greater, which according to recognised cut-offs (Alschuler, Jensen and Ehde, 2012) reflects pain of moderate to severe intensity.  
3This is an approximation based on a self-report measure not yet validated in the MS population: A score of 12 or greater indicates pain of neuropathic origin (Bennett et al, 2005).
Table 3 Participant characteristics at recruitment 
 
























1 42 Female White-
British 






2 37 Male Mixed-
White and 
Asian 





3 47 Female White-
British 














5 45 Male White-
Scottish 




























In this section primary pain outcomes are summarised, followed by secondary 
psychological processes. Qualitative themes for each individual and the wider group are 
briefly described alongside these findings (see Table 4 for more detail). 
 
7.3.1 Primary effects 
 
 
Figure 10: Four-day pain severity and pain interference ratings (0–10) Brief Pain 





Visual plots presenting four-day pain ratings (BPI) for all participants during the 16 
week period are summarised in Figure 10. Whilst qualitative findings suggest that all 
pwMS felt the programme was “beneficial”, individual pain ratings were variable. 
Three out of seven participants (1, 4 and 7) showed significant improvements in pain 
severity and pain interference from baseline to treatment, or treatment to follow-up, 
whilst two pwMS reported unchanging scores (2 and 3), and two got worse (5 and 6). 
Descriptive statistics, effect-sizes, autocorrelation estimates (AR), and AR-adjusted p-
values for pain outcomes are presented in Appendix P.1 and P.2. Participant 1 had 
RRMS with neuropathic pain, reported decreases in both pain outcomes, with a large 
clinically (see Dworkin et al., 2008) and statistically significant phase change in pain 
severity ratings from baseline to treatment (Phase A, M = 6.63, Phase B, M = 4.5, d = 
1.42, p = .029), and when comparing baseline to follow-up, after controlling for AR 
(Phase A, M = 6.63, Phase C, M = 3.88, d = 1.67, p =.007). A similar finding was 
identified for pain interference (Phase A, M = 6.63, Phase B, M = 3.38, d = 1.50, p = 
.030; Phase A, M = 6.63, Phase C, M = 3.50, d = 1.42, p = .013). 
 
Whilst participant 4 showed a clinically significant mean reduction of 2.3 in pain 
severity across phases, and significant slope change from baseline to treatment (r = -
0.54, p = .017), all phase comparisons were not statistically significant. Participant 4 
had SPMS and non-neuropathic pain, and decided to reduce her pain and spasticity 
medications (Gabapentin by 300mg and Baclofen 10mg per day) at the start of 
treatment (day 36), and moved house on day 64, reporting increased levels of stress 
related to this activity. She also reported a large 2.5 point mean reduction in pain 
interference at the onset of treatment after baseline, although this finding was only 
significant for slope (r = -.77, p=.019) rather than phase change (Phase A, M = 5.38, 
Phase B, M = 1.81, d = 1.50, p = .100). However, she showed clinically and statistically 
significant improvements in pain interference when comparing baseline to follow-up 
ratings (Phase A, M = 5.37, Phase C, M = 1.12, d = 2.58, p =0.003). Similarly, 
participant 7 had PPMS and neuropathic pain, showing only slope change decreases for 
pain severity from baseline to treatment (r = 0.81, p = .018) and follow-up (r = -0.74, p 
= .023). However, she demonstrated large clinically and statistically significant 
improvements in pain interference from baseline to treatment (Phase A, M = 8.12, Phase 
B, M = 5.81, d = 1.44, p = .044), which were maintained at follow-up (Phase A, M = 




Consistent with visual plots, two participants with RRMS and neuropathic pain (2 and 
3) did not appear to show any statistically significant improvements in pain severity or 
pain interference during the 16 weeks. Whilst participant 2 showed a non-significant 
trend of improvement in pain interference at follow-up (Phase A, M = 4.00, Phase C, M 
= 2.88, d = 1.35, p = ns), participant 3’s pain severity and pain interference mean scores 
were mostly unchanged. This was consistent with participant 2’s view that his pain had 
not improved despite his efforts to change it (see Table 4), whilst participant 3 reported 
that she did not apply her new skills when experiencing higher levels of pain. Both 
participants were employed full time, and expressed they found it quite challenging to 
“play catch-up” with the GIFT homework tasks due to work.  
 
Pain outcomes worsened for two cases (5 and 6). Participant 5 showed a non-significant 
trend of increasing pain severity and interference of around 1 to 2 points respectively. 
This person had PPMS and was severely disabled, experiencing several health problems 
during the programme, including severe trigeminal neuralgia. Consequently, his 
gabapentin was increased from 100mg to 400mg daily in the first few weeks of 
treatment, and from day 24 this increased to 1200mg over the following six weeks. At 
the time he and his carer reported that the increase of medication adversely affected his 
concentration and fatigue, preventing him from absorbing some of the session content 
in the treatment booklet. At day 84 (follow-up) participant 5 was also prescribed 
tramadol 50mg daily, and was later hospitalised with Pneumonia during the follow-up 
period (day 114). His deteriorating health was consistent with his view that examples 
provided in the booklet were not adequately tailored to his greater levels of physical 
disability (see Table 4). 
 
Participant 6 had SPMS and severe non-neuropathic pain preventing him for walking. 
He also reported gradually worsening pain severity (slope change r = 0.81, p =.018) and 
pain interference (r = .59, p = .052) from baseline to treatment, demonstrating a large 
significant increase in pain severity at follow-up (Phase A, M = 3.75, Phase C, M = 
7.25, d = 3.40, p = .02). However, he also reported low mood related to feeling socially 
isolated. At day 66 he contacted the first author to report that he felt increasingly 
depressed and demotivated, and was bed-bound for two days despite experiencing a 
period of improvement with graded exercise goals in the previous week. On completing 
his final telephone session (day 80) he had only completed session 4 of the eight week 
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programme, and therefore did not attempt any of the cognitive strategies in later 
sessions. In contrast, all remaining participants completed both optional cognitive 
modules in the programme booklet. 
 
In some cases SMA produced small, and a few negative, phase and slope AR estimates 
for pain outcomes (see Appendix P.1 and P.2). In discussion with a local statistician 
(S.N.), and through email correspondence with a cofounder of SMA, it was felt that the 
design and structure of the data could potentially lead to underestimation of the AR in 
pain outcomes. Low and negative AR estimates may be problematic because they can 
potentially bias the model in favour of finding differences that may not exist (Type I 
error). More conventional single case series approaches typically analyse a greater 
number of data points per phase or slope using daily ratings, which may produce more 
accurate AR estimates. Therefore, sample AR estimates for pain outcomes were 
calculated by combining all seven pwMS’ data streams using SPSS Version 22 (IBM 
Corp., New York, NY, USA). This resulted in an overall lag-1 or AR =.42 estimate for 
pain severity, and AR=.56 for pain interference. 
 
A sensitivity analysis was then conducted for those phase and slope simulations that 
indicated statistical significance, but had an AR=<.40. A more conservative estimate 
was achieved by manually imputing AR estimates of .40 into SMA simulations for both 
pain severity and pain interference. The + symbol in Appendix P.1 and P.2 indicates 
which simulations remained significant at the p=.05 level after these analyses. For 
pwMS who showed significant phase and slope effects for pain severity with an AR = 
<.40, six sensitivity analyses indicated that when an AR=.40 was imputed 50% of 
effects (3 out of 6) remained significant at the p=.05 level (see Appendices P.1). 
Similarly, 40% of effects (2 of 5) remained significant when an AR=.40 was manually 
entered for pain interference (see Appendices P.2).  
 
7.3.2 Secondary processes 
 
Five participants reported changes in secondary psychological processes, despite only 
three showing significant trends of improvement in pain outcomes. First we summarise 
the three participants who improved (1, 4 and 7), followed by those who did not (2, 3), 
and those who got worse (5 and 6). The visual plots for the four-day ratings (z-scores) 
for pain catastrophizing (PCS), pain acceptance (CPAQ-8) and avoidance of social 
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activities (ASAS) for each participant over the 16-week period are presented in Figure 
11, with corresponding SMA outputs in Appendices Q.1 to Q.3.  Perceptions and 
emotional representations of pain (BIPQ) are presented in Figure 12 with statistical tests 











Figure 11: Four-day ratings of Pain Catastrophizing (PCS), Pain Acceptance (CPAQ-8) 
and Avoidance of Social Activities (AEQ-ASAS) at baseline, treatment, and follow-up 




Visual plots and analyses for participant 1 show several psychological processes 
changed in parallel with reductions in pain outcomes. She experienced mostly large 
significant reductions in pain catastrophizing, negative emotional representations, and 
perceived consequences and chronicity of pain when comparing baseline to treatment, 
and baseline to follow-up, ratings after controlling for AR. However, participant 1 did 
not show a statistically significant change in pain acceptance, social avoidance or 
perceived control. The latter was inconsistent with her qualitative data (see Table 4), 
where she felt the intervention increased her sense of control over pain. She also treated 
goals as “mini projects”, linking them to her values and self-worth, and found 
behaviours she practised in the service of goals gradually became a natural part of her 
routine. 
 
Participant 4 experienced large significant increases in pain acceptance, and large 
statistically significant reductions in pain catastrophizing, avoidance of social activities, 
negative emotional representations, and perceived pain as less chronic at follow-up. 
Consistent with these changes, she described how she learned to pace and prioritise her 
goals, which resulted in less anger, and mindfulness exercises helped her to “let go of 
difficult thoughts and feelings”. Whilst she reported a non-significant trend towards 
perceiving more serious consequences of pain from baseline to treatment, this trend 
reversed at follow-up. She also experienced no change in perceived control.  
 
At follow-up participant 7 showed significant reductions in perceived consequences of 
pain and avoidance of social activities. She experienced gradual slope reductions in 
negative emotional representations, perceived chronicity and pain catastrophizing, and 
an increase in pain acceptance, from baseline to follow-up. This was consistent with her 
view that mindfulness exercises and writing down thoughts “stopped her from acting on 
her thoughts, fears and anxieties” related to pain, allowing her to focus on goals. She 
started a new romantic relationship near to the end of the treatment phase, which she 
suggested in combination with the treatment, increased her confidence to “lead a more 
normal life”. She also experienced no change in perceptions of control. 
 
Whilst participants 2 and 3 did not show significant improvements in pain outcomes, 
they did report changes in psychological processes. Participant 2 had large significant 
reductions in pain catastrophizing and negative emotional representations of pain, 
perceiving pain as less chronic and as having less serious consequences from baseline to 
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treatment, and at follow-up. This appeared to be consistent with his view that the 
treatment was mostly about “changing his attitude”. Whilst he also showed a 
statistically significant increase in pain acceptance at follow-up, this is unlikely to 
reflect a clinically significant change (McCracken, MacKichan, & Eccleston, 2007).  
 
Participant 3 experienced a small reduction in pain catastrophizing, consistent with her 
view that she no longer “completely panics” when experiencing pain (see Table 4). 
However, whilst she viewed pain as having less serious consequences during treatment, 
she subsequently perceived pain as more having serious consequences at follow-up. She 
also viewed her pain as significantly less chronic from baseline to treatment, and 
increased levels of pain acceptance at follow-up, although these changes were small. 
Whilst this was consistent with her description of re-engaging in valued activities 
despite pain, she also reported a significantly greater tendency to avoid social activities 
at follow-up. Her unchanging negative emotional feelings towards pain was also 
inconsistent with her view that she was getting less drawn into vicious cycles and 
experienced a positive change in her “state of mind”, although she did report a non-
significant 1-point increase in perceived control. 
 
Participant 5 and 6 showed no changes in psychological processes. However, 
participant 5 felt the programme kept his brain occupied and learnt new distraction 
techniques. Participant 6 reported experiencing complete control (BIPQ) over his pain 
throughout the 16 weeks, despite having significantly worse pain outcomes. However, 
he said he learned “not to battle with pain” and was “less frightened”, but was also 
“shocked” at how remote from his values he had become (e.g. being creative), 
suggesting that recurrent physical health problems (i.e. urinary infection) and fear of his 









Figure 12: Four-day ratings (0–10) on the Pain Perceptions Questionnaire (BIPQ) at 





Table 4 Key themes specific to individuals and the sample with examples 
ID Themes Example Quotations 
1 1. Getting over the initial, “Oh my 
god... there’s so much to do!” 
 
















6. Seeing reductions made me feel less 
anxious and more in control  
“There was quite a lot of information to read and understand, and I felt a bit overwhelmed in the beginning. Only because I was 
thinking, oh my god, there's so much to do and read and bits of tasks and things I needed to do.” 
 
“It was just like having a little mini-project to manage... I'd noticed that on a few days when I didn't get round to doing it [goals], 
for whatever reason, I could feel the difference. So it was then giving me the motivation to go back and start again… Let's get 
motivated again and let's get back on track.” 
 
“I probably think its [pain] changed because it was part of my goal-setting activity, and therefore when you do something and 
repeat it over and over, it just becomes part of your routine… One change would be certain things that I started out as having as 
goals have now been sort of slotted naturally into my life.” 
 
“Also the other thing which came out very early on… probably in the first kind of phone call I had with [A.H.] was about self-worth 
and feeling valued. Because I'm no longer working he helped me to think about it differently and… coming at it from a different 
angle and somebody saying, actually, just because you're not working doesn't mean to say you can't bring a value to x, y or z.”  
 
“The human interaction side of things… I think that was again a very useful thing. To have somebody to talk to at the start of the 
programme, and then towards the middle or the end of the programme. So that you knew what you were doing, what was expected 
and that you were on the track.  Otherwise, I think I'm not sure how you would motivate people to stay on track. 
 
“I think it was a case of, oh actually there might be more to this than I first thought. I think, even if I can get my pain to be a four 
out of five most days, that has got to be a big upside to it being up to a nine some days and has me in tears. So I think noticing that I 
was less anxious about my pain levels… I felt that I'd gained a bit of control over it.” 
2 1. Pushing yourself does not always 
mean worse pain 
 
 






“I used to be like oh if, it’s like it said in the thing [booklet] if you overdo it, you think to yourself ‘you are going to feel worse 
tomorrow’ but it’s not necessarily true really, the whole thing of don’t overdo it, like I said and going to bed all the time, just 
saying, “You know what I am going to try and…” and it has been successful in a lot of ways.” 
 
“Like I said it’s stuff that I thought about and tried anyway [strategies] without being like, oh I know it all, because I don’t. It’s just 
that I have realised myself that small changes in your attitude and not just thinking ‘oh you know I am going to take my medicine 
and that is all I can do to deal with MS.” Because I think a lot with MS is your attitude… I think changes in mental attitude and just 
trying to look after your health, your mental health and your physical health, exercise and eating and stuff like that it makes such a 












5. Being told something different is 
motivating 
 
“It’s been hard to keep up with things because it’s been a lot more than I thought it would be, working as well full time, it’s been 
difficult, but yeah I found it quite useful but, to me it’s been more of just like, more of an attitude towards things rather than specific 
exercises itself… I have still yet to do the CD.” 
 
“I guess it’s the type of person, it’s the way that your mind works… I did have to discuss it [booklet] a little bit, you know working 
through the whole thing, this kind of programme you can’t just do it with books really can you, it does have to involve a bit of 
talking. 
 
[A.H] would say to me try this week to do some of the things that you maybe would have given up on before. It’s just nice to have 
somebody pushing you in a way. You know, it’s like I said, say if I speak to my mum, she is always telling me to go to bed, just go to 
bed take it easy all the time, and it’s just refreshing to speak to somebody and they say, you know what just try and do a few things 
and see how you feel, it’s refreshing to have that kind of motivation.” 






















5. Not completely panicking 
 
“I think it's helped me with the planning, it's helped with me, with my feelings towards the planning. It's helped me with my state of 
mind. It's helped me sort of find a way to approach doing those things without just feeling flattened by it afterwards and going back 
into one of those awful negative cyclical acts.” 
 
“The other thing I thought was really good was, as well as like giving, setting goals and tasks, was trying to identify the ways that 
you think. Because I knew that I was thinking in a very strange way and I knew I was behaving- I knew what was happening in this 
kind of negative cycle but I hadn't really identified, or I hadn't got the sort of titles to name those ways of thinking.” 
 
“My exercise goals too - I really wanted to achieve that because that is part of my identity and very much linked-up with my values 
and the way I want to live my life… I think instead of my days just being about work and collapse, it feels like I've got work, and 
then I try quite hard to then fix on the other things.” 
 
“You know there's a whole chapter on your values and making sure that your goals linked with your values - the ways that you live 
your life. That was a whole different way of looking at it for me. So, that's what I've tried to do. Bring in more of those things. So 
going to art galleries and going out into nature, seeing more friends that aren't local to where I live. Those are all part of my 
values.” 
 
“It's pretty dull being on an exercise bike. Trying to fill the time up with, like, quite often I think about my work or jobs I've got to 
do, so I almost start kind of reliving my work. So, I tried to stop doing that and tried to focus on my, you know my legs going round 
on the pedals, actually doing the sort of living in the moment of being on that exercise bike and listening to the outside sounds and 
enjoying that.” 
 
“One thing is that doing the exercise does often make the pain worse initially. So I've tried to look at that and think, instead of just 




6. Changing the way you think and act 






7. Playing catch up 
 
 
8. When pain ramps up it’s harder to 
apply 
it.” 
“It is quite hard and it is quite a challenge to change the way that you think and the way that you act in eight weeks. I don 't know 
why but labelling them and then trying to think in a different way - I found that enormously difficult, but I could do it. You know, 
that would be such an achievement, and I'm not saying I have, at all, but I'd like to.” 
 
“I tried to also include some ones [goals] that approached my sort of thinking. I've been less good at those. But what I've been quite 
good at is noticing when I'm doing it – although I'm not sure how good I've been at sort of putting them to one side.” 
 
“I had a lot of work building up in the middle of it and a [current job role] and, as I said to [A.H.], it would have been so easy to 
just stop because I just thought, oh my god, you know, when I get home  I've got to do this, and I'm behind and the mad catch up!” 
 
“I think that, you know, for me this course is absolutely fine when the pain is at one level. The second it sort of ramps up, that 
should be really the time that you imply this book, that you apply this book, isn't it? But somehow, when the pain increases, I find it 
harder and harder to stick to the book.” 
4 1. Encouragement with goals spurs 
you on 
 








3. Putting it into words 
 
 
4. Mindfulness helped me to let things 
go 
 
5. Getting other’s viewpoint 
 
 
6. Writing about your feelings was 
challenging 
“He [A.H] sort of encourages you and says, yeah, that's brilliant, we're on the right track. So, that spurs you on.” 
 
 
“I pace myself more… So if I've got more important things to get done, I get those done and not struggle on. So if I do lots and then 
I make myself tired, and I can't do the important things and then I get angry with myself, because I haven't done them. So, it is 
making me pace myself more.” 
 
“I've realised the difference of just being in [pain], and obviously it's really horrible. But if the pain is the predominant thing then I 
find it helpful that I don't stop and just rest and do nothing because then I do focus on it and it makes me more anxious and that 
increases my pain - That opens the gate more [referring to gate control theory]. 
 
“Because I've always liked that, you know when other people put it in their words and it's sort of what you you've been thinking, or 
trying to put into words.”  
 
“On the CD, I liked the one on the river, the leaves on the river. I find that, I found that very, um, I've been doing that a lot, 
because, because I can just sort of let unhelpful things go, you know.” 
 
“If there was something I found difficult, I'd go talk to my husband and he's very good. So it's quite good to have somebody else's 
viewpoint, isn't it? Somebody that knows you very well.” 
 
“I sort of, I found they [task sheets] were hard. But it's just basically because it's writing about yourself, isn't it? A lot of it is your 
feelings and, I suppose, that, you don't really do that after school.” 
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5 1. Examples were rarely applicable 
 
 













5. Using distraction  
“It is such a varied disease or condition, but I know you’ve got to cover all, so that’s why maybe somebody who’s less able than 
somebody else, maybe having more coverage for them.” 
 
“Some of the books were a bit awkward…The workbooks were probably the one thing that I had the most difficulty with. I think my 
[carer] did more on the workbooks than I did… I wanted to fill them in, but I just couldn’t fill them in because they just, you know, 
about being able to get up and walk around.” 
 
“Rather than see a telephone call, a telephone call just not would’ve been the same, whereas face-to-face, it’s much better, you get 
a chance to meet the person, know what they’re like and they get to know you as well. Uh, so I think the Skype idea is definitely one 
of the best things to do.” 
 
“I was looking towards what’s next session, you know? The next questionnaire, the next Skype call, I was always preparing for 
these things. So it’s given me an, it’s given me something to be more interested in.  It’s given me something to think about, use the 
old grey matter, which is starting to diminish quite a bit… So I used to work a lot and now I don’t I feel I get quite lazy... This 
programme has given me something to think about and I’m now using my brain a lot more and I feel better for it.” 
 
“Now if something does happen and I do get a bit of pain, then I automatically think back to the process that you’re doing and try 
some of the exercises that [A.H.] gave me. You know, using my mind, trying to think of other things and things like that. It’s 
certainly helping me… If you get a pain, it’s too easy to just think oh, I’ve got a pain.  I just can’t keep my mind off it, whereas now 
I try and distract myself, think about other things.” 
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2. Fear of disapproval when working 
towards valued goals 
 
 
3. I learnt to absorb or accept pain and 













5. Physical health problems can mean 
two steps back 
“Some were a bit shocking when you had to actually write them down. When you actually see them graphically, as plain as day in 
front of you it’s- The quick exercise on values on page seventy-eight [values bulls-eye]… Work, education etc. each question I 
answered for leisure, relationships, personal growth, were right on the circumference. When you have the circle and you’re trying 
to work your way into the centre of the circle, and graphically you see how far away from it you are.” 
 
“I wanted to paint a lot but I don’t want to do it because, I know this sounds crazy, but I won’t do it because of my wife. Because of 
what she’d say, she’d tear me to shreds - I know she’d criticise whatever I did… that’s the hardest bit, my wife coming and saying, 
what the hell are you doing that for? You know. That’s what I’ve got to get over.” 
 
“Try and live with it and absorb it… you can’t fight it and I’m one of these people and I’ve lived with this all my life, I’m a bit of a 
bull at a gate and I get cross with myself. I try and fight things. It’s the opposite you’ve got to do. It taught me to back-off and go 
the opposite way of what I normally do.” 
 
“It teaches you to look into yourself. To accept pain and it’s not finished. You know, life… it dominates you so much and you’ve got 
to-. You shouldn’t fight it in the way I used to fight it. You’ve got to absorb it more and that’s not to let it dominate you all the 
time.” 
 
“It’s rather like being on an island and you’re a fish that’s been thrown up onto this island out of the stream and everybody’s in the 
stream and this island is circular and the river’s going round and round this island. All your friends, your colleagues, everybody is 
swimming in the right race. You’ve been just thrown up onto the island and you can see them, and every now and then, they wave at 
you or they might hop on and say, “hello”, but that’s all and then they go back and swim. You know that you’ll never join them and 
swim again. You will never be in that life again.”  
 
“I went into another urine infection on Sunday evening. They’re terrible, I thought I’d had it for three years and it puts you into, 
virtually an epileptic fit and I had to wait until Monday morning before I got antibiotics… You are completely shattered, you know, 
you could be paralysed and then within five days you’re almost- You’ve got back to where you were [referring to exercise-based 
goals].” 




2. Mindfulness exercises helped 
ground anxiety and set goals 
 
 
3. Unhelpful thought records made me 
“I’m, sort of stopping myself from doing things, you know related to my thoughts, fears and anxieties… and it’s has made me 
change my behaviours a lot.” 
 
“I found the leaves on a stream exercise very helpful, I’ve used that a lot, and I can use that without the CD now in my head, so I 
found that was very powerful, which is something that I will do when I’ve got a moment on my own. I will sit and use that to sort of 
bring me back down to where I should be if I’m starting to get anxious or trying to avoid pain or setting any goals. So I find that 
really helps me.” 
 




think “Crikey, is this me?” 
 
 
4. A new romantic  relationship and 
treatment helped  
more what I was trying to achieve, you know, it was a situation as such. But in the end it actually helped me, but at the time I felt, 
you know I sat back and read it to myself and I thought, ‘Crikey, is this me?’ you know.” 
 
“I’m feeling far more positive about life really, because I have met somebody new, and I do put part of that positivity down to the 
programme actually. It all sort of came at the same time, so I think it helped me. When I look back at it now, and you know, start 
reading the notes I’ve written, I can see that my life has improved since those few weeks ago, and I seem to be coping more with the 
pain and am more able to rise above it and lead a more normal life.” 
Themes across the sample 
 
          1. Goals tapped motivation 
 
 





          3. Create an online version please! 
 
 
“One of the ones [goals] is the exercise. I really wanted to achieve that because that is part of my identity and very much linked up 
with my values and the way I want to live my life.” (Participant 3, RRMS) 
 
“Speaking to [A.H.], he sort of encourages you and says, ‘yeah that's brilliant!’ we're on the right track. So, that spurs you on.” 
(Participant 4, SPMS) 
 
“Talking to someone that is just going to say, “Oh give it a go” it is more of an objective for you I suppose.” (Participant 2, RRMS) 
 
“If the whole thing was on a website, you could just click onto the website and choose what you wanted to do. Or if you wanted to 




7.3.3 Group Themes 
 
Three dominant themes were consistent across participants (see Table 4). First, many 
found setting values-based goals tapped their motivation. Second, the majority 
emphasised that personal telephone contact with A.H. during the programme was 
instrumental in keeping them motivated. Third, most pwMS found the treatment 
booklets initially overwhelming and slightly overcomplicated, and frequently suggested 
a web-based version would be less daunting more accessible, particularly for people 
with greater levels of disability. Whilst pain ratings did not change for many pwMS, it 
appears most talked about key therapeutic processes and techniques in an insightful 
way. However, the varied knowledge and skills described by participants suggests they 




The current study aimed to evaluate the potential efficacy of an eight-week telephone 
supported pilot intervention (GIFT) based on CBT and ACT designed to reduce pain 
severity and pain interference in pwMS using mixed methods. Underlying 
psychological factors and processes drawn from an empirically supported model of MS 
pain were also explored as potential mechanisms of change over 16-weeks. 
 
In relation to our first question, three of the seven participants (1, 4 and 7) showed 
statistically significant 2 to 3 point reductions in pain severity and, to a greater extent, 
pain interference after controlling for the influence of autocorrelation, which according 
to guidance in chronic pain reflects a clinically meaningful improvement (Dworkin et 
al., 2008). These findings were consistent with other pilot studies (Garinger, 2007; 
Jensen, Ehde, et al., 2011; Sheppard et al., 2010) and one RCT (Ehde, Elzea, et al., 
2015) evaluating cognitive and contextual behavioural interventions for MS pain. The 
more robust improvements in pain interference is, to some extent, consistent with 
chronic pain research indicating that functioning can improve independently from pain 
(McCracken & Morley, 2014). The larger effect sizes observed in pain-related 
interference for two pwMS (4 and 7) at follow-up might also indicate that they 
gradually became more competent in practising newly acquired skills, or found 




Two of the seven participants (2 and 3) did not appear to benefit from the programme. 
However, there are possible explanations for this. These participants reported milder 
levels of disability in the sample and worked full-time, explaining that balancing the 
programme with their busy working lives was challenging. Participant 2 also reported a 
much higher level of pain relief from medications at initial assessment compared to 
pwMS in recent MS studies (Ehde, Alschuler, et al., 2015; Harrison, Silber, et al., 
2015), suggesting his pain was already well managed with pharmacological treatments. 
 
Two participants (5 and 6) reported worse pain following treatment. Participant 5 had 
PPMS and was severely disabled, and his poorer outcomes may have stemmed from his 
declining physical health during the programme. Participant 6 reported periods of 
depression and demotivation, which also appeared to be related to recurrent health 
issues and feeling socially isolated. It is therefore possible that his problems were too 
complex for a low-intensity self-management intervention focusing solely on pain. 
Overall, the mixed findings in pain outcomes across the group are consistent with 
practice-based evaluations of interdisciplinary chronic pain management programmes 
based on CBT, which show that between 1 in 3, and 1 in 7 (depending on the outcome 
measure), achieve clinically significant gains at post-treatment and follow-up, whilst 
around 1% to 2% of patients deteriorate during treatment (Morley, 2008).  
 
With respect to our second question, three pwMS (1, 4 and 7) experienced reductions in 
pain and improvements in secondary psychological processes drawn from our MS pain 
model (Harrison, Silber, et al., 2015), including pain catastrophizing, negative 
emotional representations of pain, pain beliefs, avoidance of social activities and, to 
lesser extent, pain acceptance. Pain catastrophizing was the most robust process of 
change, where two participants showed decreases at follow-up falling below recognised 
clinical cut-offs (Wideman & Sullivan, 2011). Findings are consistent with a pilot 
hybrid emotion-focused exposure intervention for chronic pain (Linton & Fruzzetti, 
2014), evidence for potential mediators of change in CBT trials for chronic pain (Turner 
J.A. et al., 2007; Van Koulil et al., 2011; Williams et al., 2013) and MS fatigue (Knoop 
et al., 2012). Changes in pain acceptance for pwMS who significantly improved on pain 
outcomes were mixed. Whilst participants 4 and 7 showed significant increases in pain 
acceptance at follow-up, participant 1 did not, which is somewhat inconsistent with 
evidence showing pain acceptance is an important predictor of improved functioning in 
ACT interventions for chronic pain (McCracken & Morley, 2014). However, this 
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finding might be explained by participant 1’s relatively high acceptance scores at 
baseline, or that different psychological processes change for individuals. 
 
Participants 2 and 3 also reported large reductions in pain catastrophizing and perceived 
chronicity of pain in absence of any significant improvements in pain outcomes. It is 
possible the cognitive elements of the programme were more relevant to these higher 
functioning participants, whilst pwMS with moderate levels of disability seemed to 
benefit from cognitive and behavioural activation components.  
 
Perceived control of pain is likely to tap self-efficacy (Bandura, 1977), which reflects 
an important predictor of outcomes in traditional CBT for chronic pain (Kores, Murphy, 
Rosenthal, Elias, & North, 1990; Turk & Okifuji, 2002; Turner J.A. et al., 2007). 
However, contrary to some pwMS’ experience of “having a greater sense of control”, 
perceptions of control measured by the BIPQ did not change for any participant. When 
considered in relation to the mixed findings for pain acceptance, this may highlight key 
differences in the way CBT and ACT address the problem of pain (McCracken & 
Morley, 2014). Traditional CBT encourages participants to set goals, sometimes related 
to symptom reduction, which may involve scheduling relaxation, rest or physical 
activity (Turk et al., 1983). In contrast, ACT encourages the person to take an open and 
willing stance towards pain in order to pursue valued life activities and deemphasises 
the importance of pain reduction or control (McCracken, 2006). Therefore, whilst these 
therapeutic approaches complement each other to an extent, it is possible that our 
attempts to integrate elements inadvertently conveyed conflicting aims of enhancing 
control and acceptance. For example, cognitive strategies within ACT and CBT (e.g. 
defusion and thought challenging) have divergent aims (Harris, 2009). Thought 
challenging is primarily interested in modifying the content of pain-related thoughts or 
beliefs and seeking alternatives, whilst defusion focuses more on changing the context, 
or person’s relationship to their thinking, without directly attempting to modify or 
control thought content. From a practical perspective, developing skills in either 
strategy is likely to require regular practise. Whilst participants were given the option to 
focus on one or both of these strategies in the programme, learning numerous 
techniques from both approaches may have diluted opportunities for more targeted 
learning and practise in either method. Testing a hybrid treatment also makes it difficult 




Our final aim was to explore participant’s views of the GIFT programme within a post-
treatment qualitative telephone interview. Individual themes were not entirely consistent 
with quantitative findings. Whilst all pwMS found the programme “beneficial”, only 
three reported significant improvements in pain outcomes, and five in psychological 
processes. Other non-specific treatment factors may have contributed to this, including 
helping participants make sense of their pain (“Putting it into words”). Group themes 
tended to focus on delivery methods. Most participants described the treatment booklet 
as initially overwhelming and overcomplicated. However, qualitative themes indicated 
that most individuals understood key concepts or techniques specifically taught within 
the programme. It may be that the limited time affected motivation and precluded 
learning of new skills in those pwMS who were more likely to benefit. The majority of 
pwMS expressed a preference for a more user-friendly web-based version of the 
treatment booklet. However, “Human contact” with the therapist during the programme 
was highlighted as an important factor in maintaining motivation. This is consistent 
with a pilot RCT evaluating an online CBT intervention for MS fatigue with limited 
telephone support (MSInvigor8) (van Kessel et al., 2008), showing large significant 
improvements in fatigue severity, anxiety and depression, and quality-adjusted life 
years compared to standard care (Moss-Morris et al., 2012). Van Kessel et al (van 
Kessel et al., 2015) recently conducted an RCT comparing MSInvigor8 with or without 
personalised email support, where pwMS receiving support experienced significantly 
greater reductions in fatigue severity and impact. Therefore, given the limited resources 
in most healthcare settings, and disease-related obstacles to access, developing a web-
based version of the GIFT programme may improve usability, optimise skills-learning, 
and reduce pain and related disability in pwMS.   
 
Consistent with our MS pain model (Harrison, McCracken, et al., 2015; Harrison, 
Silber, et al., 2015) and other chronic pain conditions (McCracken & Yang, 2013), there 
were no obvious patterns of change related to disease characteristics (i.e. type of MS or 
pain). Factors affecting individual’s negative outcomes appeared to be more associated 
with social and work factors (participants 2 and 3), and other complex consequences of 
illness (e.g. pneumonia and depression in the case of participants 5 and 6), rather than 
nature of pain, level of pain-related disability or MS subtype. Whilst these factors may 
have contributed to lower levels of participation, it is also possible that pain severity 




7.4.1 Treatment Implications  
 
Findings offer some support for a telephone-delivered guided self-management hybrid 
ACT and CBT intervention based on an empirically-supported conceptualisation of MS 
pain (Harrison, Silber, et al., 2015). Because participants talked about the complexity of 
the intervention, it might be that giving pwMS more time to complete each session will 
help them to practise key skills. Eight weeks may have been too time-pressured, 
particularly for those pwMS with full- or part-time work commitments. Findings also 
suggest that pwMS with more complex problems might not benefit from a low-intensity 
programme. Given that two people got worse, it may be these broader social contextual 
issues reflect important barriers to participation in this low-intensity intervention. 
Therefore, adding these factors to MS pain model may better guide future 
implementation by screening for work, social and other complex health issues prior to 
treatment to avoid poor outcomes. Specifically, pwMS who work may benefit from 
having more time to complete the programme, since self-management approaches can 
be more flexible in this regard. On the other hand, individuals with more complex social 
problems may benefit from a higher intensity intervention with greater therapist contact. 
 
In any case findings warrant further investigation within a larger RCT. The changes 
observed in psychological processes indicate that RCTs should test theoretically-guided 
mediators and moderators of treatment and outcome to better understand how they 
work, and for whom. Although our cross-sectional data (Harrison, Silber, et al., 2015) 
indicated variables from both ACT and CBT models explained important variance in 
pain outcomes, embedding choice within the intervention by combining potentially 
divergent treatments may have diluted key mechanisms of action specific to each 
approach. Therefore, it may be helpful to evaluate CBT and ACT independently in the 
context of MS pain, or provide tailored or optional pathways for one or the other within 
a web-based programme.  
 
7.4.2 Limitations  
 
This study has several limitations. The incompletely controlled and non-randomised 
nature single case series studies preclude definitive causal interpretation and are limited 
in reliability and generality until they are replicated and extended. However, RCTs are 
at risk of aggregation bias, which assumes the average characteristics of a group apply 
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to individuals (Johnston & Johnston, 2013). Therefore, whilst not definitive, the current 
study does explore if, how, why and when the current intervention is effective for 
particular individuals (Borckardt et al., 2008). Self-report ratings, disease measures and 
interview responses may be susceptible to measurement, non-specific treatment or 
therapist effects, and exaggeration or under-reporting. Using group-validated scales 
may also reduce their reliability, and the neuropathic pain measure (S-LANSS) (Bennett 
et al., 2005) is yet to be validated in the MS population. Interpretation of findings 
related to pain subtype should therefore be considered preliminary.  
 
SMA has several limitations (Borckardt & Nash, 2014). First, the autocorrelated 
adjusted p-values may be too stringent (Nash & Borckardt, 2011) and further research 
needs to verify it is capable of reliable Type-I and -II error performance with short 
autocorrelated data. Second, SMA assumes simulations generated are representative of 
the “population” of data streams from which one’s actual data is drawn. However, there 
is a lack of standardised indices regarding the fidelity of simulations generated, so 
caution must be exercised when making inferences (Borckardt & Nash, 2014; Nash & 
Borckardt, 2011). Third, there is a lack of evidence to verify SMA’s performance with 
skewed data or data with extreme outliers. Fourth, simulations of SMA show reliable 
AR estimates with 5 to 30 data points per phase. These ratings are typically recorded at 
daily intervals, suggesting a standard length of baseline and treatment may range 
between 5 to 30 days (around 1 to 4 weeks). Therefore, the small phase-n sizes and 
four-day interval between ratings within the 4 week baseline, 8 week treatment and 4 
week follow-up phases in the current study may have produced inaccurate AR estimates. 
Potentially inaccurate AR estimates might explain why only 40% to 50% of identified 
effects remained significant when imputing a more conservative AR estimate. However, 
other available statistical methods also have weaknesses. For instance, evidence 
suggests ITSACORR (Crosbie, 1993) does not match SMA’s ability to protect against 
Type I errors whilst providing sufficient power to detect effects (Borckardt et al., 2008). 
In addition, other approaches (McKnight, McKean, & Huitema, 2000; Box & Jenkins, 
1970) require a much larger number of data points per phase (>30), and some do not 
appear to have been widely tested or adopted in the case series literature (McKnight, 







A low-intensity eight-week telephone supported self-management intervention, drawing 
on techniques from traditional CBT and ACT approaches, may potentially reduce pain 
severity and pain interference in some pwMS. Whilst the programme was acceptable to 
all participants, pwMS with milder disability in full time occupations apparently did not 
have sufficient time to engage in the programme to gain benefit, whilst pwMS with 
severe physical disability and more complex psychological problems had worse 
outcomes. Future research may benefit from evaluating the two therapeutic approaches 
independently, using a web-based format with therapist support that can reach a larger 




Chapter 8 : Discussion 
 
8.1 Chapter Overview 
 
 
This final chapter first provides a brief summary of the main findings from each of the 
empirical studies. The novel contributions of the overall research programme are then 
summarised, followed by a discussion of the theoretical implications for understanding 
the psychosocial predictors of pain in MS in relation to the previous literature. Potential 
limitations of studies are then discussed. Finally, possible avenues for future research 
and clinical practice to improve pwMS’ management of pain are outlined.  
 
8.1.1 Summary of main findings 
 
This thesis aimed to develop a conceptual model to guide the development and 
evaluation of a treatment to support pain management for pwMS. It began by 
introducing MS and provided a brief overview of evidence for psychological 
approaches aiming to better manage this complex and heterogeneous condition. Chapter 
1 also indicated that psychological approaches for a number of symptoms, including 
depression, adjustment and fatigue, appeared to be beneficial for pwMS in reducing the 
severity of symptoms and their negative impact. However, the review highlighted that 
there had been few attempts to develop an empirically supported theoretical model of 
MS pain to guide the design of treatments aiming to improve pain management. 
 
The critical review of psychological approaches for primary, non-disease related 
chronic pain conditions in chapter 2 showed that there were many ways of 
conceptualising psychological responses to pain. Specifically, there appeared to be 
several theories of chronic pain, which were potentially useful to explain how 
psychological factors or processes influence pain and related disability in the context of 
MS, elucidating possible targets for psychological treatments. The review indicated that 
whilst the majority of research had evaluated traditional CBT in chronic pain, evidence 
for more recent theoretical frameworks, including ACT’s psychological flexibility 
model appeared to be comparable. It also concluded that no single theory provided a 
comprehensive explanation of chronic pain that fully integrated all potentially important 
psychological variables in the chronic pain cognitive behavioural literature. Therefore, 
rather than testing a single existing chronic pain model in the context of MS, this thesis 
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focused on developing a more integrated model and treatment for pwMS using a more 
inductive approach to inform the design of empirical studies. Ultimately, it was hoped 
this approach would promote greater choice for pwMS. 
 
As several psychological factors or processes were thought to be involved in MS pain, a 
working theoretical model was developed to begin to organise key elements of existing 
theory and research. The systematic review in chapter 3 (Harrison, McCracken, et al., 
2015) investigated psychosocial factors in MS pain. These findings led to the 
development of a preliminary model, which showed that several potentially modifiable 
psychosocial factors were associated with greater pain and related disability in MS. 
Specifically, those pwMS who viewed pain as serious or harmful, long-lasting, or felt 
they had a reduced control over pain, and tried to suppress pain-related thoughts, tended 
to report greater pain severity and pain interference. In addition, greater reporting of 
perceived solicitude on the part of others and higher levels of worry, anxiety and 
depression, were also related to greater pain and related disability. In contrast, pwMS 
who tended to focus less on trying to reduce or control their pain, pursued meaningful 
activities in spite of pain, and had more supportive relationships, reported less pain and 
higher functioning. Avoidance in the context of pain-related fear appeared to be less 
important in MS pain than has been shown in primary chronic pain. A small number of 
studies showed that correlates were similar for pwMS with neuropathic and non-
neuropathic pain. Consistent with the chronic pain literature reviewed in chapter 2, 
findings offered support for the idea that several psychological theories might help to 
explain or predict pain in MS and may be amenable to change in the context of CBT 
and / or ACT interventions. The weight of evidence was more robust for traditional 
CBT factors. However, the fact that CBT variables were more carefully and frequently 
researched compared to other theoretical frameworks did not in itself suggest that the 
CBT model was necessarily better at explaining pain in MS. 
 
The three remaining empirical studies within this thesis adopted a range of methods to 
investigate different questions about the psychosocial factors and processes involved in 
MS pain. First, the qualitative interview study in chapter 4 suggested that pain 
interacted with other MS symptoms, and pwMS used vivid descriptions to convey their 
painful experience to others. PwMS also described how they viewed pain as 
unpredictable, or as a sign of worsening MS, and difficulties with managing frustration 
and anger as a consequence of pain were particularly common. Consistent with findings 
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in the systematic review (Harrison, McCracken, et al., 2015), the inductive thematic 
analysis suggested that pwMS either attempted to manage pain by attempting to control 
or reduce it, or incorporated pain into their life. Those who struggled to control or 
reduce painful symptoms appeared to get caught up in vicious cycles of worsening MS 
symptoms and distress. The qualitative findings also indicated that pwMS may have a 
tendency to avoid everyday activities when in pain, but avoidance in the context of fear, 
which has a larger cognitive and affective component, appeared to be less important. 
This distinction is important because avoidance may reflect pwMS’ beliefs that 
behaviours are potentially helpful or unhelpful, rather than a reaction to fear. 
 
The cross-sectional study presented in chapter 5 demonstrated that a number of 
cognitive and contextual behavioural factors or processes, drawn from chronic pain 
models, were significantly associated with pain severity and pain interference in MS. 
Consistent with findings in the wider chronic pain literature, negative catastrophic 
beliefs about pain and its consequences and chronicity (Moss-Morris et al., 2007; 
Sullivan, 2001), avoidance of physical and social activities due to pain (Hasenbring et 
al., 2014) and low mood were the strongest correlates of worse pain outcomes. 
Conversely, greater pain acceptance was strongly associated with lower levels of pain 
severity and pain interference. Overall, psychological variables shared stronger 
associations with pain interference compared to pain severity. Taken together 
psychological factors accounted for almost a third of the variance in both pain outcomes 
after controlling for demographic and disease variables. In addition, contextual and 
cognitive behavioural variables still accounted for a significant proportion of the 
variance in pain and related disability even after removing anxiety and depression from 
the equation. Moderation and subgroup analyses also indicated that the pattern of 
psychosocial correlates observed were similar for neuropathic and non-neuropathic pain 
subgroups, but the neuropathic pain was more strongly related to disease factors as well. 
Most pwMS reported significant pain and associated disability even though over 90% 
were taking pain medication. Pain was considered the fourth most interfering MS 
symptom, and was significantly correlated with all other symptom interference ratings.  
 
Finally, chapters 6 and 7 outlined the development and evaluation of telephone 
supported hybrid CBT and ACT self-management intervention for pwMS with pain 
based on the updated model. The GIFT intervention was targeted to a broad range of 
pwMS because the previous empirical studies did not indicate any clear distinction 
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between pwMS with different types of MS or pain. Whilst other empirical studies in the 
thesis supported the MS pain model, the intervention study produced mixed results. 
Findings showed large improvements in pain outcomes for three pwMS, whilst two did 
not change, and two worsened. The mixed outcomes appeared to be related to the varied 
levels of participation in the treatment across individuals. Participation appeared to be 
influenced by extraneous factors, such as occupational commitments for non-
responders, and additional health issues and complex social circumstances for those 
who worsened, rather than type of pain or MS. Whilst three pwMS observed changes in 
both pain and psychological processes that were consistent with the model, two reported 
positive changes in targeted psychological processes even in absence of changes in pain 
outcomes. The most robust change was in pain catastrophizing, but improvements in 
pain outcomes appeared to be related to changes in different psychological factors or 
processes across individuals. The qualitative interviews following treatment indicated 
pwMS had good insight into treatment techniques or methods, although qualitative 
comments about improvements related to the programme were not always consistent 
with quantitative outcomes. Specifically, qualitative data indicated that pwMS applied 
several strategies taught within the intervention, and felt they experienced changes in 
pain outcomes or relevant factors and processes. However, the quantitative findings did 
not always indicate this. The day-to-day variability in pain reports may, to some extent, 
explain this inconsistency. It may also be the case that pwMS felt they were managing 
pain better even though it was not reflected in their pain outcomes. PwMS also felt 
overwhelmed with the GIFT manual, and expressed a preference for a shorter web-
based version of the intervention. Overall, findings showed that developing a low-
intensity hybrid treatment using telephone delivery methods, informed by an 
empirically supported model of MS pain, may improve pain outcomes for some pwMS. 
 
8.1.2 Contributions to the literature 
 
The studies outlined in the current thesis make a distinct contribution to the literature.  
 
The systematic review had an important role in identifying all existing research 
examining relationships between psychosocial factors and pain severity and pain 
interference in MS. Whilst one systematic review had focused on pain in several 
physical conditions and identified two MS studies (Jensen, Moore, et al., 2011), no 
previous review had specifically investigated MS pain. Assessing the methodological 
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quality of the 31 empirical studies provided useful insight into those studies that made 
the most valid and reliable contributions to understanding the role of psychosocial 
factors in MS pain. In contrast to previous reviews, the synthesis of evidence brought 
together variables from several theoretical frameworks in chronic pain and MS research 
to inform the development of a preliminary cognitive and contextual behavioural model 
of MS pain. Whilst Kerns had proposed a broader biopsychosocial conceptualisation of 
MS pain (Kerns, 2000; Kerns et al., 2002), no previous research had provided an 
empirically supported model that described the possible contribution of specific 
biological, cognitive, emotional, behavioural and environmental factors. The model also 
distinguished between those factors or processes that may be more or less helpful in this 
context.  
 
The review adds to the existing MS pain literature by putting into context several 
research studies. Alone many of these studies only examined a couple of psychological 
variables in isolation, and did not provide a coherent explanation of how these factors or 
processes interact to maintain worsening pain and related disability. The model was also 
novel because it incorporated a range of possible biological factors as key components 
that may interact with other components. In contrast to some chronic pain theories, the 
MS pain model suggests there may be a dynamic and reciprocal relationship between 
elements of the model and MS-specific factors, including the presence of other 
symptoms, relapse and disease progression. As far as we know this is the only MS pain 
model that has integrated all existing psychological targets that may be amenable to 
change within cognitive behavioural interventions. It is hoped that future research will 
further investigate the role of key mechanisms within the model, and move towards a 
more fully integrated account of MS pain, to inform the development of novel clinical 
interventions in this area.  
 
Previous qualitative studies in MS offered useful insights into how pwMS’ describe 
their pain and its impact (Douglas, Windsor, et al., 2008; Saverino & Solaro, 2010). 
However the qualitative study in this thesis was the first to ask pwMS about their 
responses to pain and how they try to manage it. Most of the inductively-derived themes 
were consistent with psychosocial variables identified in the systematic review, which 
provided support for the idea that the model represented a helpful way to conceptualise 
MS pain. The study also added further coherence to the model, where our previous 
understanding was limited only to quantitative sources. The qualitative study also 
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enriched our understanding of MS pain by providing new insights that had not been 
identified in the previous MS literature, including management behaviours related to 
pain acceptance and reduction, frustration and anger, and beliefs related to pain’s 
unpredictability, causes, and progression. This study highlighted the potential 
importance of additional psychological factors or processes that might predict and 
explain pain outcomes. It was the first qualitative study to purposefully sample pwMS 
with a range of demographic and disease characteristics, which was important because 
it showed that themes were similar across individuals. It was also the first to explore 
themes related to psychological responses across pwMS with neuropathic and non-
neuropathic pain, but that further quantitative investigation was needed. Exploring 
potential differences in pain of neuropathic and non-neuropathic origin was important 
because most psychological theories in chronic pain appeared to be based on non-
neuropathic (musculoskeletal) pain, and did not distinguish between the two groups.  
 
Several psychological variables identified in both reviews, and qualitative study 
appeared to be important in MS pain, but had received less research attention to date. 
The large cross-sectional study directly tested key elements of the model by 
investigating whether a range of contextual and cognitive behavioural variables 
correlated with pain severity and pain interference in MS. No previous MS studies had 
examined cognitive fusion, pain beliefs and different types of behavioural avoidance in 
MS. In contrast to many studies in the systematic review, the cross-sectional study 
examined psychological factors or processes conjointly to provide a more coherent 
picture of how they fit together in MS pain, and how they interact with relevant disease 
variables. The cross-sectional study also identified those variables that might be more or 
less important in explaining pain severity and related functioning. In line with the 
review chapters, findings showed that a range of potentially modifiable psychosocial 
factors or processes from chronic plain theories played an important role in the context 
of MS pain. Therefore, this study further reinforced the idea that the integrated 
conceptual model outlined in the systematic review represented a helpful way to 
understand MS pain. The cross-sectional survey was also the first to show that the 
pattern of psychosocial correlates of pain were similar across pain subtypes. The cross-
sectional study therefore offered further support for the idea that a more widely targeted 




A final important contribution of the current thesis was that it showed improvements in 
pain severity and interference outcomes were often related to changes in a potentially 
modifiable psychological factors or processes drawn from the model in the context of a 
hybrid cognitive behavioural intervention. These findings were mostly consistent with 
other CBT and ACT intervention trials in chronic pain, which show that pain 
catastrophizing is an important mediator of treatment and outcome (Trompetter, 
Bohlmeijer, Fox & Schreurs, 2015; Turner, Holtzman & Mancl 2007). Whilst the 
literature showed that three preliminary studies (Garinger, 2007; Jensen et al., 2009; 
Jensen, Ehde, et al., 2011) and one RCT (Ehde, Elzea, et al., 2015) investigating the 
CBT and ACT interventions for MS pain were potentially efficacious, most were 
therapist-intensive. In contrast, this was the first study to evaluate a hybrid CBT and 
ACT self-management intervention for MS pain informed by an empirically supported 
model. It was also the first hybrid intervention study to explore whether the role of pain-
related acceptance, pain beliefs and avoidance behaviours were potentially important 
processes of change related to improvements in pain outcomes. A recent study tested an 
eight session telephone-delivered CBT intervention to improve pain interference in MS 
(Ehde, Elzea, et al., 2015). However, the GIFT study was unique because it was the first 
to explore the potential efficacy of a low-intensity self-management intervention with 
only three sessions of telephone support to address potential economic barriers to long-
term implementation. 
 
8.1.3 Theoretical implications 
 
The updated MS pain model in chapter 6 resembled a more traditional five-part CBT 
framework (Beck, 1991), which showed that biological aspects of pain, and potentially 
helpful and unhelpful modifiable cognitive, emotional, behavioural and social or 
environmental factors were important determinants of pain severity and reducing 
functioning in MS. In contrast to some chronic pain theories (Hasenbring & Verbunt, 
2010; Vlaeyen & Linton, 2000), relationships between key elements in the model were 
hypothesised to interact in a reciprocal way to maintain pain and related disability, 
rather than following any specific causal pathway. The model was less explicit about 
how an individual’s response to MS pain depends on their learning history, personality, 
critical events or life circumstances, and pre-existing vulnerabilities. However, 
consistent with Kerns’ earlier conceptualisation (Kerns, 2000; Kerns et al., 2002), and 
most psychological theories described in this thesis, the model incorporates basic 
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learning principles and assumes predisposing factors are important. The model also 
acknowledged the wider interactive context of pain in relation to other inherently 
painful (e.g. optic neuritis and spasticity) or non-painful MS symptoms (e.g. fatigue and 
immobility), and suggested that pain can potentially be exacerbated by use and overuse 
of both generic MS treatments (e.g. steroids) and medications prescribed for pain-relief. 
The empirical studies in this thesis mostly supported the MS pain model. Consistent 
with the chronic pain literature, the model offered no clear indication that elements 
drawn from any single dominant chronic pain theory were necessarily more important 
in explaining MS pain. Therefore, whilst the model offered further support for the idea 
that either traditional CBT or ACT treatments may be effective for pwMS, it was less 
clear which approach was likely to be more helpful.  
 
The hybrid GIFT intervention produced somewhat inconsistent findings, which may 
have important theoretical and treatment implications (for treatment implications see 
section 8.1.5). Specifically, pain acceptance and, to a lesser extent, perceived control, 
were robust correlates of pain outcomes in the systematic review and cross-sectional 
study. In addition, themes around pain management behaviour in the qualitative 
interviews reinforced the idea that reduced pain acceptance and perceived control were 
important processes (Harrison et al., 2014). However, whilst the GIFT intervention 
indicated the most robust change was pain catastrophizing, consistent with the CBT for 
chronic pain intervention literature (Burns et al., 2012; Smeets et al., 2006; Spinhoven 
et al., 2004; Turner J.A. et al., 2007), the programme did not appear to alter pain 
acceptance or perceived control. This finding was inconsistent with processes of change 
observed in studies evaluating CBT or ACT interventions in the wider chronic pain 
literature (Åkerblom et al., 2015; Kores et al., 1990; McCracken & Gutiérrez-Martínez, 
2011; Turner J.A. et al., 2007). Therefore, this might suggest that our intervention was 
not as effective as it could have been, or perhaps was deficient in some way. There may 
be several explanations for this. First, the intervention was facilitated by the author of 
the thesis, who is neither a qualified or experienced CBT or ACT therapist, nor a 
qualified clinical or health psychologist, which is likely to have impacted on treatment 
competence. Second, there were other important factors that appeared to impact 
negatively on participation, including comorbidities, work commitments and complex 
social problems. To expand on just one of these factors, recent studies indicate that MS 
pain and related functioning tends to be associated with several other comorbidities 
unrelated to the MS disease process (Fiest et al., 2015; Newland, Lorenz, Budhathoki, 
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& Jensen, 2015). Whilst the MS pain model considers the wider MS context, it did not 
adequately capture comorbidity. Given the overlap between symptoms and 
comorbidities found in MS, it is perhaps unsurprising that other researchers have 
developed and evaluated telephone-delivered CBT interventions to address pain in 
combination with several other symptoms, showing some improvement in pain, fatigue 
and depression outcomes (Ehde, Elzea, et al., 2015). 
 
Third, combining techniques from both CBT and ACT treatments may have been 
potentially overwhelming or confusing for pwMS. Fourth, eight weeks may have been 
too short to observe change and three support sessions too few, where pwMS may have 
benefited from having more time to complete the eight week programme at their own 
pace. This was consistent with the qualitative findings showing that participants felt the 
GIFT programme included too much information and expressed a preference for a more 
concise web-based format. A related explanation for the mixed findings might be that 
pain acceptance, or perceived control, may be less amenable to change in the context of 
MS. However, a more likely explanation could be that whilst CBT and ACT approaches 
share some overlap, the combination of divergent treatment techniques in the GIFT 
programme may have conveyed potentially conflicting messages about controlling and 
accepting pain. In addition, the MS pain model attempted to organise a variety of 
factors and processes from both approaches within a traditional CBT maintenance 
model, but it is important to note there are differences between factor and process 
theories. Key constructs and techniques within CBT and ACT stem from different 
scientific assumptions (Dougher & Hayes, 2000), which are debated in the wider 
clinical psychology literature (Hayes, 2008; Hayes & Brownstein, 1986; Vilardaga et 
al., 2007). Therefore, it might be that our attempts to arbitrarily integrate and target 
variables from both approaches may have partly contributed to the mixed outcomes 
observed. 
 
Another interesting finding in the cases series intervention was that a few individuals 
experienced reductions in cognitive and behavioural factors even in absence of any 
clinically or statistically significant change in pain outcomes. These findings are 
somewhat inconsistent with the MS pain model and chronic pain theories, which 
suggest that shifting or changing specific cognitive and behavioural factors or processes 
(e.g. pain catastrophizing or acceptance) should correspond with reductions in pain 
severity or pain interference. It might be that inconsistencies observed between the 
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qualitative and quantitative findings in the case series reflect non-specific effects. 
Alternatively, the intervention may have modified other possible pathways to improve 
wellbeing in MS, which might occur irrespective of improvements in pain, such as 
reducing emotional distress. It might be that skills or techniques taught within the GIFT 
programme may have been applied in a more general way by these participants. 
Another explanation might be that potentially relevant psychological factors or 
processes described by pwMS in the qualitative interviews had actually improved but 
were not captured in quantitative measurements used. The intervention included present 
moment awareness and motivational elements (i.e. values and committed action), which 
may have corresponded with changes in these processes and promoted more general 
improvements in emotional wellbeing. For instance, these participants might have 
committed to valued actions but were not necessarily more accepting of their pain, nor 
did they report any perceptible change in pain severity or pain interference. 
 
A related gap in the MS pain model is that it focused exclusively on pain-specific 
outcomes. Pain interference attempts to capture pwMS pain-related functioning across 
several life domains in order to disentangle its impact relative to other MS symptoms. 
However, the qualitative data suggested pain is usually caught-up in several other 
troublesome or disabling symptoms. Therefore, examining the relationship between 
pain and broader emotional, physical and social-role functioning, or healthcare 
utilisation, outcomes might tell us something more about its wider impact and whether 
these change in the context of treatment. One aim of the GIFT intervention was to 
improve pwMS’ engagement in everyday, or other meaningful, life activities by 
reducing pain interference. However, in reality this is very difficult to evaluate because 
self-reporting of pain interference cannot provide any certainty that pwMS were 
actually engaging in more activity. One way to overcome this problem in future trials 
might be to use other technologies to measure activity, such as pedometers or 
smartphone apps. These more objective measures could then be triangulated with self-
report instruments to provide a more comprehensive picture of potential changes in 
activity as result of the intervention. However, a large component of goal setting in the 
GIFT programme focused on values-based goals (e.g. participant 5 acted on his value to 
be “more sociable” by inviting two old school friends to his home for dinner and 
drinks). Therefore, more objective measures of physical activity may not always capture 
goals related to more subtle social activities, and other values-based actions (e.g. being 
more loving or caring towards a partner by talking about feelings more openly). An 
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alternative way to address this issue would be to obtain the views of the individual’s 
family, carer, or friends who could also report on pwMS progress with goals. However, 
this would pose an important ethical issue related to patient confidentiality, and may be 
particularly problematic if the individual experiences complex social dynamics in the 
home or work context (e.g. an overly solicitous, or unsupportive, partner or employer).    
 
The model also explained less about the social and biomedical aspects of MS pain and 
how we might intervene in this regard. It still remains less clear if, and how, social 
factors contribute to worsening or improved pain and related disability in MS. Whilst 
relatively small correlations between perceived solicitude, social support and pain 
outcomes were incorporated into the model after the review, a key theme in the 
qualitative study appeared to centre on concerns surrounding potential stigma related to 
pain (i.e. “concealing and revealing”). It is possible this theme reflects pwMS’ 
perceived or actual experiences of stigma, or may be a consequence of self-stigmatising 
responses. Both appear to be a common experience for people with chronic pain 
(Cohen, Quintner, Buchanan, Nielsen, & Guy, 2011; Holloway, Sofaer-Bennett, & 
Walker, 2007; Jackson, 2005; Lennon, Link, Marbach, & Dohrenwend, 1989; Marbach, 
Lennon, Link, & Dohrenwend, 1990; Slade, Molloy, & Keating, 2009; Werner, Isaksen, 
& Malterud, 2004). However, few psychological treatments have attempted to directly 
address these problems and it less clear whether chronic pain and MS populations differ 
in this regard. Similarly, the relationship between biomedical factors and elements in 
the model also remain unclear. For instance, much less is known about disease 
progression and pain, or the short and long-term psychological consequences of taking 
several pain medications, including potentially painful injectable DMTs. 
 
A final weakness relates to the lack of biology in the MS pain model. The model draws 
on the traditional Beckian cognitive therapy model (Beck, 1991), and therefore 
recognises the important role of biology. Empirical studies in this thesis aimed to 
explore the interaction between aspects of all three elements in the broader 
“biopsychosocial” framework in some way. Specifically, the model attempted to build 
on Kerns’ earlier biopsychosocial conceptualisation (Kerns, 2000; Kerns et al., 2002), 
by exploring the role of disease variables, such as relapse and disease status, and level 
of neurological disability, in conjunction with psychological factors or processes and 
pain outcomes. Since neuropathic pain was found to be more prevalent in MS compared 
to other chronic pain populations (Bouhassira, Lantéri-Minet, Attal, Laurent, & 
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Touboul, 2008; Harrison, Silber, et al., 2015; O'Connor et al., 2008; Torrance, Smith, 
Bennett, & Lee, 2006), the model also set out to examine potential differences between 
pwMS with neuropathic and non-neuropathic pain. However, as with all chronic pain 
theories, there remains a paucity of evidence to explain the role of biological factors in 
the MS pain model. 
 
The earlier biopsychosocial gate control and neuromatrix theories (Melzack & Casey, 
1968; Melzack & Wall, 1996; Melzack & Wall, 1967) attempted to link the role of 
ascending and descending neuronal connections, supraspinal and cortical mechanisms, 
as well as biochemical processes. Although the MS pain model has investigated broader 
disease characteristics related to biology, the current thesis did not investigate 
neurophysiological mechanisms. An interesting question is whether psychological 
interventions can actually influence pain physiology directly leading to decreased 
severity of pain, or whether decreases in pain perception are more directly related to 
psychological processes. In the context of chronic pain, researchers have started to 
examine the links between specific cognitive behavioural factors or processes and 
neurophysiological variables (Campbell & Edwards, 2009; Edwards et al., 2009). In 
contrast, only one MS study has speculated that lesion sites are associated with 
neuropathic pain (Österberg, Boivie, & Thuomas, 2005), whilst another has shown that 
GABA receptor system dysfunction is related to greater extremity pain (Herman, 
D'Luzansky, & Ippolito, 1992). However, no studies to date have examined the 
relationship between neurophysiological variables and psychological factors or 
processes in MS pain. Therefore, investigating relationships between pain physiology 
and psychological processes may be an interesting avenue for future research. 
 
A related issue is that neurocognitive factors were not examined in the MS pain model. 
Whilst one review has proposed a neuropsychological model of chronic pain (Jensen, 
2010), only a few MS studies indicate that neurocognitive impairments are associated 
with pain, and findings have generally been mixed (Brochet et al., 2009; Demakis & 
Buchanan, 2010; Miller, Basso, Candilis, Combs, & Woods, 2014; Newland et al., 
2012; Newland et al., 2005; Shahrbanian et al., 2015; Stenager et al., 1991). For 
example, one study found no impairments in working memory (Stenager et al., 1991), 
whilst another suggested prospective memory impairments (i.e. remembering to 
remember) were associated with greater pain severity after controlling for disease 
factors (Miller et al., 2014). It might be that correlations between the presence and 
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severity of pain (particularly of neuropathic origin) and global neurocognitive 
impairments may simply reflect the wider impact of the disease process. Alternatively, 
Miller et al’s finding might indicate that memory impairments in MS could either be 
due to pain’s demand on cognitive resources, such as attention, or that pain directly 
affects brain structures that contribute to memory (Miller et al., 2014).  
 
Another area relates to information processing and negative affective memory bias 
(AMB). Consistent with the chronic pain literature (Crombez, Van Ryckeghem, 
Eccleston, & Van Damme, 2013), MS researchers have suggested that AMB potentially 
reflects a pre-existing cognitive vulnerability to depression, showing that greater AMB 
is associated with higher levels of pain and depression in MS (Bruce et al., 2007). 
Overall, in contrast to the conceptual model of MS fatigue (van Kessel & Moss-Morris, 
2006), which assumes demyelination and inflammation are predisposing factors, it is 
still unclear whether neurophysiological, neurocognitive and information processing 
variables function as either predisposing or perpetuating factors (or both) in pain, and if 
they are potentially modifiable in cognitive behavioural treatments.  
 
On completion of the case series evaluation it was felt the final model should retain 
most of the elements outlined in chapter 6 (Figure 8). The variable changes in 
psychological factors or processes across individuals, paired with no change in pain 
outcomes for two pwMS, and worsening pain for two others, provided little clarity on 
which psychological variables were more or less important. However, it may also mean 
that processes related to changes in pain are different across individuals. The consistent 
reductions in pain catastrophizing for some participants strengthened support for its 
position as one of the most potentially important unhelpful factors in the model. This 
was also true for pain perceptions (related to perceiving more consequences and 
viewing pain as long lasting), emotional representations and avoidance of social 
activities, but to a slightly lesser extent. For reasons previously discussed, the lack of 
change in perceived control and pain acceptance for all pwMS more likely points to 
deficiencies with the treatment programme itself, rather than either variable being 
necessarily unimportant. This is supported by evidence showing these variables 
consistently share significant moderate to strong associations with pain outcomes in the 
systematic review and cross-sectional study, and have been shown to be modifiable in 
the context of treatment for primary chronic pain (Trompetter, Bohlmeijer, Fox & 




Consistent with the cross-sectional study, the case series intervention revealed few 
differences between neuropathic and non-neuropathic pain, level of disability and MS 
subtype. Whilst these elements could be removed from the model, it was felt the small 
sample of the case series, combined with the limited validity of the neuropathic pain 
measure (S-LANSS) in both the case series and cross-sectional studies, precluded any 
definitive conclusions about their role. Therefore, whilst the model continues to 
highlight the potential importance of most variables outlined in chapter 6, it also 
suggests future studies should further evaluate the role of disease and pain-related 
variables, and investigate other potentially important factors or processes from CBT 
(e.g. self-focused attention) and ACT (e.g. committed action, values, present moment 
awareness), particularly if these approaches are evaluated separately at a later stage. 
Finally, although the case series highlighted the potentially negative role of 
comorbidity, work and complex social problems in contributing to reduced participation 
in treatment and poorer outcomes for some pwMS’, there is currently insufficient 
evidence to support these relationships. Therefore, future research may benefit from 




8.1.4.1 Systematic review 
 
The studies presented in this thesis have several limitations. The broad inclusion criteria 
for the systematic review, whilst appropriate for the research aims, resulted in the 
identification of several heterogeneous studies, precluding a more definitive meta-
analysis. Most studies were small, cross-sectional and presented only bivariate findings, 
which along with a general lack of quantity and quality of evidence, limited robust 
conclusions about the impact of psychosocial factors on pain outcomes. Whilst the MS 
pain model assumes relationships between these variables are reciprocal in nature, 
reflecting relevant targets for cognitive behavioural interventions, it is expected that 
more high quality longitudinal studies will examine temporal relationships to address 
causal hypotheses in the future and meta-analyses will then be possible. Finally, whilst 
the review provided a synthesis of quantitative studies investigating MS pain, existing 
qualitative studies were excluded (Douglas, Windsor, et al., 2008; Saverino & Solaro, 
2010) and a meta-synthesis was not conducted. However, the divergent quality 
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assessment processes for each method would have meant that the weight of quality 
ratings would not have been equally considered. In addition, the purpose of the review 
was to examine MS pain confined to definitions of pain severity and pain interference 
within quantitative studies, but neither definition had been directly explored in the 
qualitative literature. 
 
8.1.4.2 Qualitative study 
 
After completing the literature and systematic reviews, the qualitative study’s inductive 
analysis was conducted to inform the use of questionnaires within the cross-sectional 
study. It is therefore possible that prior knowledge of psychological models of pain may 
have influenced the researcher’s interview questions, expectations and hypotheses, 
resulting in the salience of certain themes being reported with less emphasis being 
placed on alternative explanations. On the other hand, the reviews provided a useful 
starting point to develop open-ended interview questions, which could potentially elicit 
information related to key elements of the model. The ordering of studies also guided 
theoretical sampling, which explored potential differences between pain types and other 
disease characteristics. Furthermore, themes identified in the qualitative study were 
repeatedly checked against the data, and by the researcher’s first supervisor and Dr 
Angeliki Bogosian, to ensure they were grounded in the data. Whilst this method was 
consistent, it might have been more helpful to include multiple perspectives from 
people with differing expertise, including PPI members and other non-psychologist 
researchers or clinicians. Finally, pain syndromes in MS can be varied and highly 
unpredictable. Therefore, studying pwMS’ experience of pain at different time points 
might have provided useful insights into pain and related functioning, and psychological 
responses, particularly as the context of relapses, disease progression, and increasing 
disability changes over time. Whilst this was beyond the scope of the current thesis, it 
would make a valuable contribution to the literature in the future.  
 
8.1.4.3 Cross-sectional study 
 
The cross-sectional study was sufficiently powered to examine the contribution of 
several psychological factors or processes in relation to pain outcomes across pain 
subtypes (Faul et al., 2007; Tabachnick & Fidell, 1996). However, the importance of 
non-significant psychological factors or processes within the regression models may 
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have been underestimated due to common-method variance, and path-analytic methods 
were not used to determine the unique contribution of separate chronic pain models. 
However, in most cases the psychological variables selected represented only a small 
proportion of any one model. Therefore, directly comparing the weight of evidence 
based on an incomplete set of variables may have potentially resulted in a bias towards 
candidate models with a greater number of factors or processes investigated. Another 
limitation was the cross-sectional nature of the study, which limits causal interpretation 
of the relationships between self-reported psychosocial factors and pain. However, 
evidence from primary chronic pain treatments (Åkerblom et al., 2015; Kores et al., 
1990; Moss-Morris et al., 2007; Turk & Okifuji, 2002; Turner J.A. et al., 2007; 
Wicksell et al., 2010) offered support for the idea that these psychological factors or 
processes could be modified in the context of MS. 
 
8.1.4.4 Case-series study 
 
The case-series used mixed methods to explore in detail potential processes or change 
and overall feasibility of the GIFT programme. However, using inductive thematic 
analysis (Braun & Clarke, 2006) to identify themes at the individual and group level for 
seven post-treatment interviews may not be considered robust, where experts in the 
field suggest saturation typically occurs within the first twelve interviews (Guest et al., 
2006). Whilst this limits interpretation of key findings, the themes identified provided 
richer insights into processes of change, and highlighted inconsistencies between 
qualitative and quantitative findings at the level of the individual. In the future use of 
larger samples and established qualitative methods specific to case series intervention 
designs (Chamberlain, Camic, & Yardley, 2004) may better capture pwMS’ experience 
of cognitive behavioural interventions. Another limitation of the single case series study 
is that it cannot make any definitive causal interpretations about the efficacy of the 
GIFT programme, and is limited in reliability and generality. However, due to the 
exploratory nature of this thesis, the single case series method was helpful to examine 
the potential efficacy of the intervention for pwMS with a range of demographic and 
disease characteristics, which can now be refined and extended before being replicated 
within a larger definitive controlled trial or RCT. Finally, time constraints placed on the 
thesis resulted in using relatively short data streams over four-day intervals. Whilst 
statistical procedures used attempted to reduce this problem (Borckardt & Nash, 2014; 
Nash & Borckardt, 2011), these methods are in the early stages of development. 
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Therefore, findings should be interpreted with caution, and use of more conventional 
time series analyses with a greater number of data points would be an optimal method 




All studies in the thesis were successful in recruiting pwMS with a range of 
demographic and disease characteristics from the NHS and several voluntary sector 
organisations, including the MS UK Register. Although the sample size for the cross-
sectional study was large, response rates were relatively low, which may limit 
generalisability of findings. However, an important strength of this study was that 
research information was sent directly to all pwMS experiencing pain on the MS UK 
Register. Recruitment from the register may be more representative of the MS 
population, particularly when compared to studies that have only recruited pwMS who 
are currently in contact with health professionals or voluntary organisations. To some 
extent this would have reduced the potential for self-selection bias highlighted in 
previous MS research (Dennison, Moss-Morris, et al., 2010; Ferenbach, 2011). Given 
the large recruitment numbers to the cross-sectional study, and the limited number of 
temporal designs identified in the systematic review, it may also have been possible to 
recruit pwMS to a longitudinal design that accounted for high attrition rates. This could 
have then explored hypotheses for causal relationships between psychological factors 
and pain outcomes to further test elements of the model. However, limited time and 
resources meant this was not possible.   
 
In addition, the sample for the qualitative study tended to be older than quantitative 
samples (24% ≥ 61 years of age), and progressive MS subtypes might be viewed as 
being over-represented. However, representative sampling is not a concept used in 
qualitative methods. Rather, in accordance with standard qualitative practice (Coyne, 
1997; Mays & Pope, 1995), two younger pwMS were purposefully sampled to ensure 
the views of younger patients were incorporated, and those with progressive forms of 
MS and men were deliberately oversampled to enhance our understanding of their 





8.1.4.6 Self-report of disease characteristics 
 
A further limitation was the self-report instruments used to measure disease variables in 
all empirical studies. Disease variables, including MS subtype, current relapse, EDSS-S, 
disease duration and pain type may have been susceptible to either exaggeration or 
under-reporting by pwMS. Obtaining confirmation from neurologists about pwMS’ 
disease subtype or severity, and relapse status, on entry to these studies would have 
provided greater accuracy. However, this method would have also been costly and time 
consuming, increasing participant burden. In addition, there is now reasonable evidence 
to suggest that pwMS’ self-reported disease status is comparable to neurologist 
assessments (Bamer et al., 2007; Bowen et al., 2001; Gulick, Cook, & Troiano, 1993; 
Ratzker et al., 1997). One exception was the S-LANSS (Bennett et al., 2005), a self-
report measure assessing neuropathic pain used in all studies, which has yet to be 
validated in the MS population. Therefore, subgroup analyses in all studies should be 
considered preliminary. However, whilst an MS-validated neuropathic measure has 
been developed (Rog et al., 2007), it did not provide a cut-off score to define pain 
subgroups. It was also the case that the proportion of pwMS with neuropathic pain 
reported in the cross-sectional study fell within the range of other existing MS 
prevalence studies using different clinical evaluations (O'Connor et al., 2008). Further 
validation of the S-LANSS in the wider MS population would therefore improve the 
accuracy of self-reported neuropathic pain within clinical assessment and future MS 
research. 
 
8.1.4.7 Self-report psychometric instruments 
 
A final limitation relates to the self-report questionnaires used to assess psychological 
constructs in the cross-sectional study and case series evaluation. Most scales used in 
these studies have been validated in the MS population, whilst others have not, 
including the PCS (Sullivan et al., 1995), CPAQ-8 (McCracken, Vowles, & Eccleston, 
2004), and AEQ (Hasenbring et al., 2009). It is therefore less clear whether these 
assessments are measuring the construct they claim to be measuring in the MS pain 
population. However, these scales showed acceptable reliabilities in the cross-sectional 
study, and produced correlations with pain outcomes that were consistent with studies 
in primary chronic pain. A related issue is that all measures used in the case series have 
only been validated in group-based studies, and have yet to be validated for their use in 
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single case designs. The frequent completion of these self-report assessments over the 
trial period may also have resulted in practice effects and self-presentation bias.  A final 
issue was the AEQ total score used in the cross-sectional study. This score was 
calculated by taking a combined average for mild and severe pain for both the 
avoidance of physical and social activity subscales. A.H.’s subsequent email 
correspondence with the author of the AEQ (Monika Hasenbring) suggested these 
subscales should ideally remain separate to be consistent with the assumptions of the 
AE model. However, when checking the cross-sectional data initially, correlations 
between avoidance behaviours, for mild and severe pain subscales, and pain outcomes 
were very similar to the combined mild and severe average scores. Overall, further 
validation of these psychometric instruments in future MS empirical studies would 
provide greater confidence that they are actually measuring those constructs they intend 
to measure. 
 
8.1.5 Future directions and treatment implications 
 
In addition to the methodological issues in the previous section, which future research 
should try to address, the current thesis identified important avenues for future research. 
These are outlined in the following section.  
 
Despite the potential differences between CBT and ACT treatments, the MS pain model 
was useful in showing both are likely to be helpful for pwMS. However, the effects in 
the case series relating to pain acceptance and perceived control were mixed. Therefore, 
future intervention studies may benefit from evaluating treatments separately. 
Specifically, other empirical studies in the thesis offered strong support for the idea that 
pain acceptance is an important process in MS pain. It is also evident that pain 
acceptance is amenable to change that is associated with improvements in pain-related 
functioning in the context of  both ACT (McCracken & Gutiérrez-Martínez, 2011; 
McCracken et al., 2005; Vowles, McCracken, & Eccleston, 2007) and CBT 
interventions for chronic pain (Åkerblom et al., 2015).  
 
Therefore, on the one hand it might be useful to develop an intervention for pwMS that 
has a larger acceptance component, such as a purer form of ACT. This would more 
accurately determine if pain acceptance, along with cognitive fusion, can be altered in 
the context of MS. In addition, the emphasis on values, committed action, and present 
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moment awareness within the GIFT intervention and pwMS’ qualitative data, suggests 
these processes from the psychological flexibility model may also be important 
mediators of change within an ACT intervention. However, none of these processes 
have been tested using quantitative methods in MS pain. Therefore, investigating these 
additional constructs in preclinical observational and intervention studies evaluating 
ACT (or CBT) interventions would establish if they are pervasive in MS, and whether 
they are amenable to change. 
 
On the other hand, the processes of change observed in the case series were generally 
more weighted towards traditional CBT factors. Therefore, it would also be useful to 
develop and test a more traditional CBT intervention for MS pain, which focuses more 
on challenging catastrophic and other pain-specific beliefs and actively promotes self-
efficacy. Pain catastrophizing and other pain beliefs, avoidance behaviours, and to a 
lesser extent self-efficacy, were important correlates and potential mechanisms of 
change in both pain outcomes in MS. Therefore, focusing on these factors would be 
particularly helpful if the role of modifying, or reducing, unhelpful responses as 
mechanisms for reducing pain and related dysfunction is replicated in the context of 
either a hybrid or more traditional CBT interventions. One additional cognitive factor in 
the model that has yet to be tested in MS is self-focused somatic attention or symptom 
focusing, which has been shown to reduce in relation to functional outcomes after a 
CBT intervention for MS fatigue (Knoop et al., 2012). This cognitive response may also 
be helpful in explaining MS pain and reflect a potentially important target in the context 
of CBT for MS pain. 
 
Furthermore, in light of qualitative findings in chapter 4, future observational and 
intervention research may also benefit from investigating the social element of the MS 
pain model by exploring the potentially unhelpful role of perceived stigma or self-
stigma, and effective ways of changing these. In the broader mental health literature 
there have been recent efforts to reduce stigma or self-stigmatising attitudes in the 
context of sexual orientation, depression and substance misuse counselling using ACT 
and CBT approaches (Griffiths, Christensen, Jorm, Evans, & Groves, 2004; Hayes, 
Bissett, et al., 2004; Masuda et al., 2007; Yadavaia & Hayes, 2012). These interventions 
show promise. Therefore, it may also be useful to add a stigma component within either 
a CBT or ACT treatment for MS pain in the future. Alternatively, it might be helpful to 
develop brief interventions to shift potentially unhelpful attitudes or behaviours of 
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pwMS’ family, friends or health care professionals. The ACT literature has recently 
introduced a new intervention method called Focused ACT (FACT), which is 
specifically designed to shift psychological flexibility processes in the context of short 
health care consultations (Strosahl, Robinson, & Gustavsson, 2012). Interventions like 
FACT may have useful applications in this area. 
 
Irrespective of the treatment approach investigated, it seems likely that a broader web 
format with minimal telephone and / or email support, where pwMS have the choice of 
participating in one therapy or the other, or a combination, may be an optimal approach. 
It might be that this choice can be determined solely on a patient preference basis. 
However, since pwMS may have little knowledge of CBT and ACT, treatment 
allocation might be more reliably informed by a carefully designed clinical triage or 
assessment process. The MS pain model is broad and flexible enough to inform such a 
process, and may also be useful in developing a more tailored formulation and treatment 
for pwMS that is customised to their pain and current circumstances. Given that some 
pwMS got worse in the case series, one important question in both the chronic pain 
(Williams et al., 2013) and MS literature (Thomas et al., 2006) is who is likely to 
benefit from psychological interventions. The case series also raises the question of 
when would low- or high-intensity interventions be more appropriate, and should 
psychological treatments address multiple symptoms or comorbidities, rather than pain 
alone. These areas are likely to be useful focus of future research. Consistent with CBT 
trials for MS adjustment (Moss-Morris et al., 2013), disease status and neurological 
disability did not appear to be associated with improvement in the GIFT intervention. In 
addition type of pain did not appear to be particularly important. However, findings 
showed that it may be useful to screen pwMS for other potentially important contextual 
factors, such as occupational status, comorbidities, and complex social issues, and 
perhaps neurocognitive problems in line with neuropsychological correlates of MS pain. 
PwMS with more complex issues may require higher intensity intervention, and those 
with neurocognitive impairment a simpler approach, or more time, to complete sessions.  
 
In addition, the variable changes observed in psychological processes for both 
responders and non-responders in the GIFT study suggests that screening for unhelpful 
beliefs and behaviours at the start of treatment could not only promote choice, but also 
help the clinician to weight more relevant components of the intervention to the 
individual’s needs. In line with recent findings investigating how people with chronic 
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pain understand their neuropathic pain (Martin et al., 2014), it may also be important to 
assess an individual‘s readiness to engage in an intervention and gauge their perception 
of its relevance to them. In terms of overall acceptability of the intervention, most 
pwMS felt the programme was informative and found the therapist contact important 
for motivation. They also appeared have a good knowledge of the exercises or skills 
taught, and found most of them helpful. In addition, no pwMS reported feeling 
threatened or stigmatised by the treatment rationale and content, and most said they 
would recommend it to others. Given that pwMS found the intervention and level of 
support acceptable, future investigations would also benefit from exploring the clinical- 
and cost-effectiveness of the either an ACT or CBT, or perhaps a hybrid, intervention in 
the context of a larger RCT.  
 
Several other issues related to implementation were highlighted after the case series. 
First, most pwMS found the breadth and depth of the programme content too 
burdensome, which was particularly true for those who were working full time, had 
other comorbidities or experienced complex social problems. Second, the patient 
involvement in the development of the intervention may have been insufficient. 
Therefore, in the future it might be helpful to obtain feedback from a wider pool of PPI 
members from different sources with a range of demographic and disease 
characteristics. Despite these issues, it was felt that one advantage of the guided self-
help format was that it could easily be modified for future roll out, by either reducing or 
simplifying the content for those pwMS who might experience difficulty in successfully 
completing the programme in its current form. Given the complexity of some of the 
content in the GIFT manual, another important consideration is whether it could 
actually be delivered reliably by staff with minimal training. In the future it might be 
helpful to develop a brief staff training programme, and competency assessment, which 
alongside the manual and regular supervision from a clinical or health psychologist, 
may translate to improvements in the therapist’s fidelity to the model and adherence to 
the manual. A future trial could also compare delivery by staff with minimal training 
versus those with high level of expertise to compare the relative clinical and cost-
effectiveness of these approaches. 
 
There is generally lack of understanding of how psychosocial processes may directly 
interact with biological elements of the MS pain model. In order to further develop a 
broader biopsychosocial understanding of MS pain, future research may benefit from 
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focussing on three potentially important areas that were not examined in the current 
thesis. First, it may be useful to investigate how psychosocial processes may directly 
impact on pain physiology (i.e. psychoneuroendocrinology), and whether treatments can 
actually alter neural pathways. Investigating potential neurophysiological mediators of 
change in combination with psychological factors or processes from the model in the 
context of treatment may be a useful approach. For example, MRI studies investigating 
the effects of cognitive behavioural interventions for chronic fatigue (De Lange et al., 
2008), or neurobiological features of mindfulness meditation more broadly (Chiesa & 
Serretti, 2010), have been helpful to explain if and how treatments work. Similar 
methods may apply to MS pain, which might incorporate measuring changes in disease 
progression using MRI scans, physical deterioration and symptom changes, and changes 
in treatments, in relation to psychological factors or processes in the context of RCTs. 
 
Second, it may be important to consider the implications for theory and treatment in 
terms of neurocognitive impairments, such as problems with concentration and 
memory. As one example, prospective memory may limit a person’s ability to organise 
their engagement in meaningful activities, and follow-up on homework tasks or goals 
set in the context of treatment. Therefore, it might be helpful for researchers and 
clinicians to assess pwMS’ prospective memory, and incorporate this within the 
formulation process, in order to better tailor the intervention to the individual. This 
might also involve developing shorter and simpler interventions and giving pwMS more 
time to complete them. In addition, teaching pwMS compensatory (e.g. simple 
smartphone reminders), or remedial neuropsychological strategies, in parallel with 
cognitive behavioural treatments, may help them to remember to complete homework 
tasks or apply previously learnt skills or techniques in their day-to-day lives.  
 
Third, it may be helpful to further investigate the potential role of information 
processing biases in the context of MS pain. Similar to research in chronic pain 
(Crombez et al., 2013; Grumm, Erbe, von Collani, & Nestler, 2008; Pincus & Morley, 
2001), this could potentially involve developing cognitive bias modification 
interventions that help pwMS attend to pain-related stimuli differently, and enhance the 
effectiveness of cognitive behavioural treatments. This area of research may also link 
up well with interventions in the chronic pain literature that aim to reprocess potentially 





Finally, the role of predisposing vulnerability factors in MS pain remains unclear. It 
might therefore be useful to understand the impact of early experiences and pre-morbid 
cognitive and behavioural factors or processes on current cognitive and behavioural 
responses to pain and key outcomes. Ideally prospective longitudinal designs would 
elucidate the role of these factors. However, the low prevalence of MS would mean that 
enormous samples would be required to do this. One way of overcoming this problem 
would be to employ retrospective longitudinal designs to provide some indication of the 




The current research programme underlines the importance of understanding MS pain 
from a broader biopsychosocial perspective. However, many pwMS have access to 
biomedical treatments, the emotional burden and impact of pain on individuals and their 
families may be overlooked in preference for more biological explanations. As the 
empirical chapters in this thesis have demonstrated, MS pain appears to be 
multifactorial in nature and pwMS may have a range of psychological responses to pain, 
which may amplify its severity and have an adverse impact on functioning. No single 
existing chronic pain theory adequately accounts for all relevant aspects of MS pain. 
However, a cognitive behavioural conceptualisation that attempts to integrate a range of 
potentially helpful and unhelpful cognitions and behaviours from existing theories 
appears to show good utility in terms of understanding pain and informing the 
development of interventions to improve pain outcomes. The two classifications of pain 
did not appear to have any clear differential psychological responses associated with 
them, although disease variables explained neuropathic pain more than non-neuropathic 
pain.  
 
The preliminary intervention informed by the model demonstrated mixed findings, but 
modifying specific cognitions and behaviours within the intervention appeared to 
improve pain outcomes in some cases. Although evidence suggested that changes in 
psychological responses to pain may follow different pathways for different individuals. 
The current thesis provides a clear foundation with specific treatment targets from 
which future intervention research for MS pain can build upon. This work also 
considered how appropriate interventions should be designed and delivered in the 
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context of MS to overcome potential barriers to implementation. Research efforts 
should continue to focus on developing a better understanding of the most relevant 
factors or processes that influence pain, and which are most amenable to change in 
relation to pain and other important outcomes. Designing and evaluating either separate 
or integrated treatment methods to shift these elements may lead to more effective 





INFORMATION SHEET FOR PARTICIPANTS 
 





YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET 
‘Tell me about your pain…’ Pain in Multiple Sclerosis (PiMS study)  
 
You are being invited to take part in a research study. Before you decide whether you want to take 
part, it is important for you to understand why the research is being done and what your participation 
will involve. Please take time to read the following information carefully and discuss it with family 
members or friends if you wish. Please contact me if anything is unclear or if you would like more 
information. Take time to decide whether or not you wish to take part. Thank you for reading this. 
 
Who is conducting the study?  
This study is part of a larger research project that is being conducted by researchers at The Section 
of Health Psychology, Institute of Psychiatry at King’s College in collaboration with the MS Society 
UK. The study is being conducted as part of the Principal Investigator (Anthony Harrison’s) doctoral 
studies in conjunction with Lead Investigators Professors Rona Moss-Morris and Professor Lance 
McCracken. Anthony is being supervised by the Lead Investigators with all aspects of the project.  
 
What is the purpose of the study?  
Research has shown that people with MS experience different kinds of pain, but there is little 
research into how this symptom is experienced by people with MS. We are interested in how people 
with MS understand their pain, how much it affects them, and how they deal with it from the day-to-
day. The researchers also want to talk to people with MS pain about their views on improving pain 
management, service provision and any other related issues that are important to them. At the 
conclusion of the study, we will provide you with a newsletter summarising the main findings.  
 
Why have I been chosen?  
You have been approached about this study because you have Multiple Sclerosis and have reported 
to us that you experience some form of pain. We have invited those people with a variety of MS pain 
symptoms to take part in the project. Unfortunately, volunteering by providing us with your completed 
questionnaires may not necessarily result in you being interviewed. While we do understand you may 
feel discouraged by this decision, this is because we aim to recruit 20 people with a variety of illness 
characteristics to determine if they have different views about MS pain.  
 
Do I have to take part?  
No. It is up to you to decide whether to take part or not. Whether or not you take part will not affect 
the standard of care you receive. If you agree to take part you may be asked whether you are happy 
to be contacted about participation in future studies. However, your participation in this study will not 
be affected should you request not to be re-contacted. 
 
What will happen to me if I take part?  
After reading this information sheet you must take at least 24 hours to consider if you wish to take 
part. If you do agree to take part by completing and returning the three enclosed questionnaires and 
contact details form Anthony Harrison will contact you to arrange a convenient time to conduct a 
telephone interview. You will be asked to provide verbal consent before starting the interview. The 
interview will last somewhere between 30 minutes to one hour. The interviewer is not in any way 
connected with the team involved in your treatment. Anthony will ask you some questions about how 




you view your pain, how it affects your life, how you deal with your pain, and what sort of support you 
find helpful. There are no right or wrong answers - the researchers want to find out about your views 
and experiences. The interview will be recorded so that the researchers can write these up at a later 
date. After the interview Anthony will then briefly ask about your demographic and MS characteristics 
and offer to send you a study debriefing statement either to your home address or personal email.  
 
 
Will You Compensate Me for My Time? 
No. While we very much appreciate your help, and you may find the experience useful, you will not 
benefit financially from the research.  
 
Are there any costs? 
The research will take between 30 minutes and one hour of your time but there are no costs to 
participants associated with the project. 
 
What are the possible disadvantages and risks of taking part?  
The risks involved in participating are minimal. It is possible that some people might find it distressing 
to talk about their experiences of pain and MS in general. If you get upset you can skip questions, 
take a break or decide not to continue with the interview. If you are very distressed we will offer you 
some sources of support.  
 
What are the possible benefits of taking part?  
There may not be any immediate or direct benefits to you by taking part. However, some people may 
find it helpful or interesting to talk about their illness and how it affects them. Your participation will 
help us to develop a better idea of how we can help people who experience MS pain. At the 
conclusion of the project, we will send you a newsletter describing the major findings and alerting you 
to any research publications we have generated from the project. 
 
If this study has harmed you in any way…  
In the unlikely event that you are unhappy with the way that the research is conducted complaint 
mechanisms are available to you. In the first instance please contact Professor Rona Moss-Morris 
rona.moss-morris@kcl.ac.uk. If you are not satisfied with this process, we advise you contact the 
Patient Advice and Liaison Service (PALS), at Guy’s and St. Thomas’ Hospital’s PALS KIC Ground 
floor, North Wing, St Thomas' Hospital, Westminster Bridge Road London SE1 7EH (tel. 
02071888801 or 02071888803 or email pals@gstt.nhs.uk). Kings College Hospital PALS, King's 
College Hospital, Denmark Hill, London SE5 9RS (tel. 020 3299 3601 or email kch-
tr.PALS@nhs.net). Queen Mary’s PALS, Frognal Pl, Sidcup, Kent DA14 6LT (Tel: 020 8308 5449 
email: slh-tr.qm-pals@nhs.net) Bromley Hospitals PALS, Princess Royal University Site, 
Farnborough Common, Orpington, Kent BR6 8ND (Tel: 01689 863252 email: slh-tr.br-pals@nhs.net) 
Queen Elizabeth PALS, Stadium Road, Woolwich, London SE18 4QH (Tel: 020 8836 4592 email: 
pals.qeht@nhs.net).  
 
Will my taking part in the study be kept confidential?  
Yes. All information about your participation in this study will be kept confidential in accordance with 
the Data Protection Act 1998. Once the interview is complete, your name on the interview audiotape 
and the transcript data will be replaced with a participant ID number making it completely 
anonymised. Your information will be stored on secure computers, locked within offices and in locked 
file cabinets, and will only be available to members of the research team. This information will only be 
used for the purposes of the current study. Your study data will be retained for a minimum of 5-years 
and subsequently disposed of securely. Once the study is written up and published some quotes from 
your interview may be used as examples of what people have said. If we use any quotes from your 
interview they will not contain your name or any identifiable information about you as an individual 
(e.g. your town or workplace). Your responses to our questions will remain completely confidential 
unless you tell us something to indicate that your own health and safety are currently in danger. Your 
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anonymised data will be shared with other researchers and may be used for other research purposes. 
Please note the deadline to request withdrawal of your data from the study will be 1st June 2013. 
 
What will happen if I don’t want to carry on with the study?  
You are free to withdraw from the study at any time without having to give a reason even if you 
decide to take part initially. 
 
What will happen to the results of the research study?  
The results will be used to help the researchers better understand MS pain with a view to developing 
future treatments. The study will be presented at scientific conferences and be written up for 




Who is organizing and funding the research?  
The study is funded by the Multiple Sclerosis Society. It is being organized and conducted by 
researchers from The Health Psychology Department, Institute of Psychiatry, King’s College London.  
 
Who has reviewed the study?  
The study has been reviewed by the Reading NHS (13/SC/0165) and the Psychiatry, Nursing and 
Midwifery Research Ethics Subcommittee (PNM/12/13-65), King’s College London, as well as the 
research and development team at the UK Multiple Sclerosis Society.  
 
What if I have questions about the project? Contact details for further information  

















Name: Mr Anthony Harrison  
Job title: Principal Investigator (Doctoral Student) 
Telephone number: 07936 448 926 Email address: anthony.harrison@kcl.ac.uk  
Address: Department of Health Psychology, Institute of Psychiatry, Kings College London, 5th Floor 
Bermondsey Wing, Guys Campus, London SE1 9RT 
ALTERNATIVELY: Fill in the attached contact details form, return it in a stamped addressed envelope 
and one of the researchers will contact you  
 











                                        CONSENT FORM 
 
‘Tell me about your pain…’ Pain in Multiple Sclerosis (PiMS study) (Study ethics 
Ref: 13/SC/0165) 
 
Name of Researcher: ______________________________  
 
 
Please initial at the end of each statement to confirm   
  
1. I confirm that I have read and understand the information sheet (dated 12 November 
2012, version 1) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily                     ..….. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected                                                                                                                                                                           
                      …….  
3. I consent to the processing of my data in accordance with the Data Protection Act 
(1998)                         ……. 
 
4. I give permission for the interview I take part in to be audiotaped                        ...….. 
  
5. I understand that when the research is published it may include direct quotations from 
my interview but that I will not be identified as an individual                                   …… 
 
6. I agree to take part in the above study               …… 
 
7. I give permission for my unidentifiable data to used for future research               …… 
    
Name of Participant___________________ Date____Signature__________ 
 
Name of Person taking consent_______________ Date____  
 
Signature___________  




When completed, 1 copy for the patient; 1 for researcher’s file 
 
 




Self-report Version of the Leeds Assessment of Neuropathic Symptoms and Signs 
pain scale (S-LANSS) (Bennett et al., 2005) 
 
About your MS and the pain you experience 
 
I believe my pain is due to: 
1. The effects of MS treatment. 
 Yes  No  
 
2. My MS. 
 Yes  No 
 
3. A medical condition unrelated to MS.  
 Yes  No 
 
 This questionnaire can tell us about the type of pain that you may be experiencing. 
This can help in deciding how to treat it. 
 
 Please draw on the diagram below where you feel your pain. If you have more 
than one area, only shade in the main area where your worst pain is. 
 
 
On the scale below, please indicate how bad your pain (that you have shown on the 
above diagram) has been in the last week where: 
‘0’ means no pain and ‘10’ means pain as severe as it can be. 
 
NONE  0     1      2      3     4      5      6     7     8     9    10   SEVERE PAIN 
 
 
 On the other side of the page there are 7 questions about your pain (the one in the 
diagram). 
Think about how your pain that you showed in the diagram has felt over the last 
week. Please circle the description that best match your pain. These descriptions 
may, or may not, match your pain no matter how severe it feels. 
 Please only tick the responses that describe your pain. Please turn over. 




1. In the area where you have pain, do you also have ‘pins and needles’, tingling 
or prickling sensations? 
 
a)  NO – I don’t get these sensations  
b) YES – I get these sensations often   
 
2. Does the painful area change colour (perhaps looks mottled or red) when the 
pain is particularly bad? 
 
a)  NO – The pain does not affect the colour of my skin 
b)  YES – I have noticed that the pain does make my skin look different from normal. 
 
3. Does your pain make the affected skin abnormally sensitive to touch? Getting 
unpleasant sensations of pain when lightly stroking the skin might describe this. 
 
a)  NO – The pain does not make my skin abnormally sensitive to touch. 
b)  YES – My skin in that area is particularly sensitive to touch. 
 
4. Does your pain come on suddenly and in bursts for no apparent reason when 
you are completely still? Words like ‘electric shocks’, jumping and bursting 
might describe this. 
 
a)  NO – My pain doesn’t really feel like this. 
b)  YES – I get these sensations often.  
 
5. In the area where you have you pain, does your skin feel unusually hot like a 
burning pain? 
 
a)  NO – I don’t have burning pain 
b)  YES – I get burning pain often 
 
6. Gently rub the painful area with your index finger and then rub a non-painful 
area (for example, an area of the skin further away or on the opposite side from 
the painful area). How does this rubbing feel in the painful area? 
 
a)  The painful area feels no different from the non-painful area. 
b)  I feel discomfort, liker pins and needles, tingling or burning in the painful area 
that is different from the non-painful area.  
 
7. Gently press on the painful area with your finger tip then gently press in the 
same way onto a non-painful area (the same non-painful area that you chose in 
the last question). How does this feel in the painful area? 
 
a)  The painful area does not feel different from the non-painful area. 








Self-administered  Multiple sclerosis  
Disease Course Questionnaire (Bamer et al., 2007) 
 




Attacks (exacerbations, relapses) come on over a 
few hours or days, last from one day to several 
weeks, but once they are over, you feel the same as 





Attacks (exacerbations, relapses) come on over a 
few hours or days, last from one day to several 
weeks. After some attacks, your symptoms are 
worse than before. The symptoms that remain after 





At the start of the disease, attacks (exacerbations, 
relapses) occur. You may feel your symptoms get 
worse because of these attacks. Then even between 
the attacks, you feel you are getting worse.  In 
some cases, attacks cease, yet your symptoms 





Symptoms worsen from the beginning. Your 
symptoms may be stable for a time, gradually 
worsen, or deteriorate rapidly, but attacks 





Symptoms gradually worsen from the beginning. 
Your symptoms may be stable for a time at the 
beginning, or may deteriorate rapidly. Attacks 
(exacerbations, relapses) did not occur at the start, 























    Time 
Worse
No
Symptoms     Time
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Self-report EDSS (EDSS-S) (Bowen et al., 2001) 
WALKING DISTANCES 
We would like to know how well your body functions on an average day, not your 
worst days and not your best days. Please tick the box that most closely matches your 
abilities.** 
 
On an average day I can: 
 
  Walk more than 500 metres (about 530 yards) without stopping to rest. 
 (This is approximately 5 football field lengths.) 
    I would need    no help    a cane     two canes     a walker 
 
  Walk 300 metres (about 350 yards) without stopping to rest.  
          (This is approximately 3 football field lengths.)  
    I would need     no help     a cane     two canes     a walker 
 
  Walk 200 metres (about 200 yards) without stopping to rest.  
   (This is approximately 2 football field lengths.)  
    I would need     No help    A cane    Two canes    A walker 
 
 Walk 100 metres (about 100 yards) without stopping to rest.  
     (This is approximately 1 football field length.) 
    I would need     No help     A cane    Two canes    A walker 
 
  Walk 20 metres (about 60 feet) without stopping to rest. 
    I would need     No help      A cane    Two canes   A walker 
 
  Walk 5 metres (about 15 feet) without stopping to rest 
    I would need     No help     A cane     Two canes   A walker 
 
  Walk a few steps. 
    I would need     No help     A cane     Two canes     A walker 
 










If you use a wheelchair please tick one of the following 4 statements: 
 
1.   On an average day, I can bear my weight with my legs (stand up and 
move) and get myself from one chair to another. 
2.  On an average day, I can bear my weight (with the strength in my arms) 
and lift myself from one chair to another. 
3.  On an average day, I cannot bear any weight or get myself from one 
chair to another. 
4.   On an average day, I cannot sit up in a chair. 
 
STRENGTH  
When answering the following questions, please think about an average day for 
you (not a particularly good, or bad day) then think of the “best” part of that day. 
(Maybe the best part of your day is in the morning, or maybe later, after you 
have moved around a bit.)  
On an average day, at my best, my strength is: 
 The same 
as before 
I had MS 
Almost the 
same as 
before I had 
MS 
Can barely 




not raise it 




Right arm      
Left arm      
Right leg      
































I must get 
help, use a 
mechanical 
device, or 







s even with 
help. 
Right arm      
Left arm      
Right leg      




For touch, pain, cold, or heat, please mark the appropriate box in the table 
below. Use the worst – the one that has lost the most sensitivity – of the 
four sensations (touch, pain, cold, or heat) to answer each question. Please 
think of an average day.  
(For example: your left hand has very little sensitivity to pain, mild sensitivity to 
touch, and normal for heat and cold, then you would mark “can feel very little” 
on the line for left hand.) 
 
 Same as 
before I had 
MS 






Right hand     
Right arm     
Left hand     
Left arm     
Right foot     
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Left foot     
Left leg     
 
BLADDER 
On an average day, I have: 
Yes No  
  A normal bladder 
  Urgency (once I need to go I have a hard time holding it) 
  Hesitancy (I feel I need to go but nothing happens) 
  Accidents (incontinence) occasionally but once a week or less 
  Accidents (incontinence) twice a week or more, but less than 
daily 
  Accidents (incontinence) daily 
  Use self-catheterization 
  Use continuous catheter (indwelling or condom catheter) 
 
VISION 









   
 
9 3 7 8 2 6 
 
 
   4 2 8 3 6 5 
















Cannot read any 
of the lines above 
  
 
2.  I see double (two things, where there is really only one) 
 
     Never        About once a week       Almost daily         
     Constantly 
 
3.  On an average day, my eye movements are unsteady 




On an average day, my speech is: 
  The same as before I had MS   
  Slightly Slurred  
  Moderately Slurred  




On an average day, my swallowing is: 
   Normal      
   Occasional choking        




Although some people may wish to consider thinking and memory separately, 
we need you to combine them and tick one box below. 
 
On an average day, my thinking and memory is: 
   Is the same as before I had MS 
   Is almost the same as before I had MS 
   Occasionally causes a problem in my daily life 
   Frequently causes a problem in my daily life 





To be completed over the telephone by the researcher. 
Your year of birth: ........................ 
What is your gender:  
 Female  Male 
 
What is your ethnicity: 
 White - English / 
Welsh / Scottish / 
Northern Irish / British 
 Mixed / Multiple ethnic 
group  - White and Black 
Caribbean 
 Asian / Asian 
British – Indian 
 Black / African / 
Caribbean / Black British – 
African 
White - Irish  Mixed / Multiple ethnic 
group  - White and Black 
African 
 Asian / Asian 
British – Pakistani 
 Black / African / 
Caribbean / Black British – 
Caribbean 
White - Gypsy or 
Irish Traveller  
 Mixed / Multiple ethnic 
group - White and Asian 
 Asian / Asian 
British – 
Bangladeshi 
 Black / African / 
Caribbean / Black British – 
Any other Black / African / 
Caribbean background 
White - Any Other 
White background 
 Mixed / Multiple ethnic 
group - Any Other Mixed / 
multiple ethnic background 
 Asian / Asian 
British – Chinese 
 Other ethnic group – 
Arab 
   Asian / Asian 
British - Any other 
Asian background 
 Other ethnic group – 
Any other ethnic group 
    Not known/not provided 
 
What is your marital status (at present) 
 Single  Married  Widowed  Separated/Divorced 
 
How many years of education have you completed..................................... 
 
Which of the following best describes your current job status? 
 Employed outside the home, full-time 






If unemployed, are you not working due to your MS?  Yes  No  
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What type of MS do you have?………………………………………………………………………… 
Are you currently experiencing a relapse?  Yes     No 
How long have you had MS?………………………………………………………………………….. 
 
What other MS symptoms do you experience currently: 
 Fatigue 
 Bowel or bladder dysfunction 
 Balance disruption 
 Cognitive impairment 
 Blurred or double vision 
 Difficulties with Speech 
 Difficulties with swallowing 
 Stiffness and spasms in muscles  
 Tremor  




Do you take medication for your MS pain?      Yes     No 
If yes, which? 
………………………………………………………………………………………………………………. 
 
Do you take non-medical drugs for your MS pain?      Yes     No 
If yes, which? 
………………………………………………………………………………………………………………. 
 
Other health conditions: 
 
Have you ever experienced (or currently have) any other physical condition other than MS? 
 Yes  No 
 
If yes, what is the condition/s:……………………………………………………………….. 
 
Have you ever experienced, or currently experience, any psychiatric condition/s (e.g. depression, 
anxiety, schizophrenia)?  
 Yes  No 






Appendix E. Chapter 4 Qualitative Study: Coding Manual 
Theme label Subtheme labels and 
definitions 
Examples/locations (by line number) 
1. PAIN IN THE 
WIDER MS 
CONTEXT 
“Top of the league” 
for some, but for 
not all…  
 
Painful symptoms 
described in relation 
to other MS 
symptoms, which 
might either be 
highlighted as the 
worst symptom, or 
comes secondary to 
others. 
P4 “Oh this is, um, well this is top of 
the league really, is that what you 
are asking? [I: Yeah] It’s 
unrelenting. That’s the word I would 
use 114.” 
 
P5 “If the pain could be sorted out 
everything 105 else [symptoms] 
would be manageable every day but 
getting to the point of the pain to be 
sorted out is where hopefully stuff 
will come in the future.” 
 
P20 “I would probably say on a 
scale of one to ten, it's probably 
about a two because it's there, it's 
bothering me, you know it's there all 
the time, that I can't 270 do a great 
deal about it, I just have to manage 
it, I think my eyes and my legs are 
my bigger problem, you know they 
kind of over shadow pain.” 
 
P13 “The main thing about my 
illness, is not actually the pain so 
much as the tiredness, um that’s 
what I find the worse, the absolutely 
worse think in my illness 195” 
Every move is MS 
move 
 
Pain described as 
resulting in a 
disruption, or 
slowing down, of 
everyday activities, 
to the extent that 
constant planning is 
required. In some 
cases this subtheme 
relates to “common 
ways to self-
manage” because the 
person may say they 
need to plan 
activities carefully 
P10 “I have got to think twice about 
if I was walking around to the shop 
312, [I: Mm] I might take the car 
instead [I: Mm] or I might spend 
more time sitting down, if it is 
particularly bad.” 
 
P14 “Okay so if I have to, if I’m 
doing an installation which takes 
concentration and will take me three 
hours and I’ve allocated that three 
hours [I: Mm] I expect it, in my 
working life to actually take me 
three hours [I: Mm] but if I suddenly 
get an, um err a pick axe or err pins 
and needles and I know something is 
going to start to not work probably 
or I’m going to get pain, then 95 
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and schedule rest 
breaks. 
that interrupts my schedule and I 
have to allocate time to that and to 
deal with that.” 
 
P17 “It sort of affects your day to 
day life because your, because you 
are aware of it all the time, you tend 
to change what you do, you tend to 
know your limits and know what you 
are able to do [I: Mm], you know as 
far as walking distances is 
concerned, that’s a no, no because 
but then I do get, not only tired but 
the pain that will come in the lower 
60 back and the backs of my legs as 
well.” 




statements about the 
problem of pain 
sitting within a wider 
context of other 
problems, such as 
low mood or other 
health conditions. 
P4 “It's all related to the MS that 
you have got and you are not going 
to be able to get rid of it, I don’t 
think I am going to be able to get 
through this, um, you know nothing 
is going to happen in my life time 
let’s say, so it really gets you down 
199.” 
 
P8 “Well, um, I have the 
hypermobility, um but I also have, 
um, I have glaucoma 135 as well 
and it is just a mountain of things 
that suddenly you know you realise 
that, oh, you are not young any 
more, you are not agile, you just 
carry on with what you perceive to 
be life, you know, as much as you 
can.” 
 
P5 “There are symptoms that I have, 
apart from the neurological ones 
and the like um, which are not a 
pleasant thing to deal with either 
100.” 
Pain affects you 
because it’s always 
there 
 
Suggestion that some 
forms of pain being 
pervasive and very 
difficult to push out 
of consciousness.  
P10 “I do get quite a lot of 
headaches as well but I think 
because it is on my feet, I think I am 
more conscious of it all the time. I 
mean I live with it and I still work 
two afternoons a week and I still do 
most things that I want to do 
because it does get quite tiring 
having the pain all the time 144.” 
 
P4 “Because it's with you 200 all 
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the time, every move you make is an 
MS move, it doesn’t, there is no way 
you are going to get any time off 
from it, you can't relax.” 
 
P13 “Pain fits in daily… I mean I’m 
in pain every single day 65.” 
Pain swirls in with 
everything else 
 
Reports that pain 
tends to come with a 





loss of strength and 
mobility, and in 




revolve around pain 
in the sense that it 
influences the onset, 
or is the result of 
other symptoms, 
perhaps becoming a 




P21 “Um so when I say they all 
revolve around pain, it's that you get 
different types 80 of pain, maybe the 
numbness will cause you a pain but 
it is probably not as high as scale of 
eight, it's probably more in a scale 
of one to three, just because of the 
sensation not feeling so go [I: Yeah] 
and any sensation that you are not 
supposed to get in your body just 
makes you feel pain, I think [I: Mm], 
maybe it's all in the mind, but  I feel 
like a weird sensation and it causes 
like interruptions 85 to my day [I: 
Yeah], so I mean, can you call it 
pain.” 
 
P15 “Pain is part of the symptom, if 
that makes sense, that’s probably 
why the symptom is becoming more 
of an issue rather than, because of 
the pain within, I think all of my MS 
symptoms, yeah, every single MS 
symptom I have ever had was 
attached to pain 48.” 
 
P23 “Everything comes together 
212. They all happen at around the 
same time, and that normally starts 
to occur the more tired I get, the 
more stress, the more strain I feel on 
my muscles, my activity, so the less 
activity you participate in the less 
you feel anything.” 
2. VIVID AND 
PARADOXICAL 
DESCRIPTIONS 
Describing pain can 





experience of pain 
difficult to put into 
words or describe, 
perhaps highlighting 
that the experience is 
P12 “Yeah, like a tightness of, you 
know, yeah, oh man it's so hard to 
describe these things [I: Yeah], it’s 
like a tightness and again a 
discomfort.  I guess, I guess in my 
arm and legs I do have that as well, 
I guess where the comparison 150 
could be is that there’s discomfort 
an there’s discomfort in using a 
hand or arm or whatever and then 
there’s just the general crampy 
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particularly unusual.  feelings that I have [I: Mm] which is 
pain, that’s more like a pain, 
whereas, yeah it is so hard to 
describe, honestly!” 
 
P13 “I don’t know how to describe 
it, I haven't got it, so 285 at the 
moment so it's really hard to 
actually describe it unless I’m in it 
or have got it.” 
  
P14 “I really have no level of how 
to explain what level of pain I get, 
um I know compared to other people 
[I: Mm], and how you describe and 









or images to describe 
pain. 
P4 “In my feet, you know, I could 
say that um it feels as though 
somebody is um hammering my feet 
with a claw hammer, a metal 
hammer [I: Mm], but how do I know 
that because that has never 
happened to me 75?”  
 
P12 “In my 360 hands it’s more of 
a, like I said, like someone is 
actually stood on my hands, like 
they, it feels like my bones are 
crushed or something, it's weird.”  
 
P13 “The pain I experience is um 
mainly headaches and nerve pain, 
shooting pain and pins and needles, 
um, it 5 does feel like somebody is 
throwing darts at me sometimes.”  
 
P14 “I have what I call the ‘pick axe 
syndrome’ which goes through the 
top of the head but would generally 
only last 15 thirty seconds, 
maximum one minute and then goes 
away but it’s strong enough to stop 
you in your tracks.”  
 
P17 “The sort of, most pain with 
regards to the MS Hug which is 
around 15 the chest, mid rift, it's as 
though um you are wearing a really 
tight corset and someone is pulling 
the strings you know [I: Mm], that’s 
the sort of, that’s the most painful 
side of it.” 
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3. PAIN BELIEFS Pain is 
unpredictable 
 
This reflects pwMS 





P13 “It's unexplained, there is no 
rhyme or reason for it, to be honest 
sometimes I can be 75 sitting there 
watching the telly and I’ll suddenly 
get these shooting pains up my arm, 
so yeah it is such a, oh god 
unpredictable to be honest.”  
 
P20 “I suppose I don’t think about 
that as much, unless I am really 
thinking, oh that’s really sharp 
today or and again there is no 
rhyme or reason as to why it would 
be worse one day than the next 
274.”  
 
P6 “I couldn’t tell you, there is no 
way I could point to a diary and say 
it is going to happen then [I: Mm] 
it's just decides um “OK, we are 
going to do this today” and you just, 
as I have already mentioned, you do 
not know until you get up in the 
morning and you just try and 
manage your day, from what 115 
symptoms you have got [I: Mm] at 
that particular time.”  
 
P24 “I know everything can change 
55 within an hour of each other but 
the beginning of the day it normally 
– is normally a good representation 
of how the day will go with me… Or 
I can be in the middle of a day and I 
have been fine, all of a sudden the 
pain will hit, bam, and it’s like being 
– walking straight into a wall.”  
 Pain will get worse 
 
This reflects pwMS 
beliefs or ideas about 
pain getting worse in 
the future. 
P17 “Well, I am expecting, I am 
expecting it because it does, it has 
got worse, as I say over the past say 
five or six years, walking distances 
is more and more difficult so I am 
imagining that it will get worse and 
you know, hopefully not too quickly 
110 [coughs] because my progress 
has been quite steady, you know 
quite slow over the years.”  
 
P3 “I think it will get worse. (I: 
That’s your view is it?) Yes because 





P19 “I hope I won't get the chronic 
pain thing that other people get, that 
does 255 worry me [I: Mm] because 
I know, I have been around others 
who have, you know, who actually 
do go through a lot of pain and I 
don’t want to, you know, I don’t 
want to, I think what I go through is 
more than enough [laughing] I am 
trying not to, hopefully just praying I 
just don’t go that way basically.”  
 
P13 “I’m not like that, I’m sort of 
quite a positivity sort of person, so I 
tend not-, all these people you know 
they can't get me, 235 they make 
plans for the future, oh you never 
make any plans, well I don’t because 
I don’t know what's gonna happen, 
you know so I get on with today [I: 
Mm] and that’s, that’s my plans for 
the future really.”  
 Personal causal 
beliefs 
 
This reflects pwMS 
idiosyncratic beliefs 
about the causes or 
triggers of their pain. 
P18 “Yeah, I definitely think that the 
pain is from the MS because before I 
was unwell 70, I don’t think I really, 
I didn’t really suffer from that much 
pain and I was able to be quite 
active and I used to work but um, 
um, I do definitely think that the 
pain is due to the MS and it does 
affect me every day.” 
 
P22 “I can't be sitting down [I: Mm] 
on my own and then stuck with the 
pain and then, for me, the pain just 
gets worse and worse when I am on 
my own 223.” 
 
P13 “I’m also taking Ibuprofen and 
Simvastatin because I’ve got high 
cholesterol 550 (P: and that’s not 
related to pain though…) well No… 
having said that, I say no now I 
since I’ve been on them I have felt 
like a 90-year-old lady, and 
strangely enough I’ve been on them 
just over a year when I started to 
feel worse. Now I’m thinking, and I 
had forgotten all about this, that it 
could be related in some way. When 
I spoke to my next door neighbour 
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who’s actually married to a doctor, 
err he said that he was on them and 
he’s had to come off them because 
they were making him feel like a 90-
year-old man, and he was taking 
Q10 I think it is, some kind of 
vitamin because apparently this 
takes away. So the Jury is out on 
that one. (I: so are you suggesting 
that it may be related to your pain in 
some way?) I’m suggesting it is 
yeah, maybe related and I have 
suggested this to my doctor and I 
had forgotten about it… So I’m 
taking it, not for pain but for high 
cholesterol, and it and it may have 
affected my pain.” 
 
P15 “In my hands, pins and needles, 
it's kind of quite painful [I: Mm] 
particularly if it is cold, because 
even though I have got the pins and 
needles you would think it would get 
mottled because it was cold [I: Mm], 
my hand, they get, it's like a burning 
pain sensation that I, I do notice 
that, you know like in your palm [I: 
Mm], where the fingers are splits 
into three 24.” 
 
P2 “Fluorescent lights in particular 
disturb my eye, if I get pains after 
I’ve been in a room like that I know 





Pains is frustrating 
and annoying in 
itself 
 
This reflects pwMS’ 




P4 “So let’s have a think, it's all 
frustration, um it's why me, um, so I 
get a bit doomy 425 about it.”  
 
P25 “If I can't go for a walk with my 
friend, say my friend is walking her 
dog, and they come, after half an 
hour, I know I can feel pain 
increasing, I can feel it travelling up 
my leg, I can feel the hugging 
starting, I can feel myself getting 
upset and cross and then I have to 
sit down and wait for them [I: Mm], 
that makes me angry, really angry 
that I can't and if I dwell on that, if I 
415 go home and dwell on that, for 
an hour, while I am waiting for it to 
recede and if it doesn’t recede, then 
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I get more angry and then more 
upset [I: Yeah, yeah], I try not to 
because I think, “you are being 
ridiculous” but I can't stop it.”  
 
P12 “The discomfort causes 
frustration, so it's just, because it 
just such weird pain, it's not normal 
pain a lot of the time [I: Mm], it's 
just discomfort, like I said before, 
discomfort leads to frustration, you 
know when just like the 350 hands, 
‘oh god they are so annoying’. You 
know when, you know the best way 
to describe it, you know when 
something, oh, something is just, it's 
kind of like a dripping tap or 
something, it's just like, oh god why 
is this, just go away kind of thing [I: 
Mm] that sense of frustration.”  
I can't always do 
the things I want to 
do! 
 
One of the major 
elements in this code 
was the frustration 
and anger expressed 
from pain preventing 
the person doing 
everyday tasks or 
meaningful 
activities. 
P13 “It just interferes with your life 
so much, like if somebody says to 
me, oh do you fancy going to the pub 
tonight or do you fancy meeting up 
and go to the restaurant, you have to 
sort of load yourself up with loads of 
painkillers and then you don’t quite, 
you know you are not always quite 
with it [I: Mm] and um yeah I find it 
really annoying, yeah it is annoying 
and I do find it very 220 frustrating 
that I’m not able to be like everyone 
else just to go out and take things 
for granted, I think is the word [I: 
Mm] because we all take, I mean 
everybody, I used to take things for 
granted, you know, but and now it's 
just like um, I really have to plan 
every and I can't adlib and if I do, 
you know, generally it goes 
disastrously wrong [laughing] [I: 
Mm] so yeah, I think that’s the 
frustrating bit.”  
 
P25 “Because I can't do 400 what I 
want to be able to do and it's 
ridiculous to say to people, um, I 
have to go one flight of stairs [I: 
Mm] make a cup of tea, so I can get 
the lift and I used to, now I try to 
walk that one flight of stairs and to 
many people, it would be nothing 
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but sometimes, it feels like an effort 
that I can't do [I: Mm] and that 
makes me really cross or really 
upset [I: Yeah].”  
Pain is annoying 






some types of pain 
relative to others,  
and how over time 
this can cause 
frustration and anger 
P13 “Okay I got up in the morning, 
and sometimes I would think, oh I 
feel fantastic okay I have a woolly 
leg or a woolly arm or a woolly 
head even but you know no pain, 
lovely, and then sort of later on in 
the evening or in the afternoon, you 
know you 175 start to get these odd 
shooters or the pins and needles and 
things which is annoying, 
aggravating, and they are always 
there.”  
 
P15 “I wouldn’t wish this on 
anyone, because the days when, it's 
just every day the symptoms are 
becoming annoyance, becoming and 
then you are doing 175 something 
like getting off a train and you think, 
oh for god sake when is it going to 
stop and it isn't going to stop.”  
 
P20 “Um, it's just there and it 
bothers me 25 because its pain and 
it's there every day and it's just one 
of those little things that niggles and 
it's just, hi, hi I am there, I am still 
here, you know, just reminding me 
that I have got MS, I suppose.”  






highlight how some 
pwMS respond to 
others angrily when 
experiencing severe 
pain, or pain which 
has lasted for long 
time.  
P15 “It affects my mood, if I am in a 
lot of pain, I can get really grumpy 
[I: Mm, can you tell me why you get 
grumpy?] If I knew that, I would 
have a million pounds, I have no 
idea why I get grumpy when I am in 
pain, I get really grumpy [I: Mm] 
115 irritable and to the point where 
nobody can talk to me because I am 
so ahhhhhhh leave me alone [I: 
Mm] and then let them know 
everything is painful, I feel guilty 
about it afterward but at the time I 
am in pain, leave  me alone, I have 
to deal with it, I can go and chill out 
and you know.”  
 
P5 “It’s not very nice for people 192 
around you when you know, like my 
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kids or my wife, like one day I’ve got 
my grumps on and it’s like, ‘What 
have you got the hump for?’, ‘I’ve 
not got the hump I’m just in pain 
and it won’t go away.”  
 
P14 “Going out in this weather, I 
want to do something, I want to take 
my mother for lunch say but that 
involved going out in the heat, 
getting in a car, driving, helping her 
and stuff and I know if I did that I’d 
be exhausted [I: Mm] by the time I 
got there and then I’d start to feel 
uncomfortable and then pain would 
generally, or discomfort, would 
generally start in my right foot 180 
and travel up and then you tend to 
get a little short tempered because 
it's very unfair for other people so if 
I didn’t go out into the heat and I 
didn’t do that, then I wouldn’t have 
to suffer that and nor would 
anybody else, so that’s what I mean 
about behaving badly, you have just 
got to control your life and do what 
the things you can do and not make 
it worse.”  




I’ve tried most 
things and it’s a 
case of hit and miss 
 
This subtheme 
attempts to capture 
the seemingly vast 
list of strategies used 
by pwMS to their 
manage pain. Whilst 
pwMS suggested 
some strategies were 
effective, they also 
indicated that other 
times they were not. 
This also includes 
comments about 
using strategies even 
when the person 
knows they are 
ineffective.     
P18 “Um, I don’t think that they are 
great but it just 180, I think that it's 
mostly for comfort [I: Okay] 
because it doesn’t really take away 
the pain, it just makes me feel a bit 
better, like even with paracetamol or 
Nurofen, I don’t think it helps at 
all.” 
 
P24 “I have also used cold packs. 
You can put them – you put them in 
the freezer and you can use them 
again and again and again and you 
can strap them 455 to an area of 
your body that’s the painful area 
and that tends to work as well. I 
think it’s like different stimulations 
will affect different kinds of pain or 
different areas… 
 
… The least effective thing 466 … 
would be – the least effective thing – 
oh, the least effective thing for me 




…Um, I have tried some herbal 
remedies. Doesn’t help. I have had 
acupuncture. [Laughter] That 
doesn’t help either 228.” 
 
P9 “Um, mindfulness doesn’t 
eliminate it 310, but it does make it 
more bearable, so yeah from that 
point of view it is helping.” 
 
P18 “If it's like pains that feel like 
they are in my muscle or deep in my 
bones, I use um like hot water 
bottles or um paracetamol or the 
heat, you know the heat rub [I: Yes] 
I don’t usually use, I never usually 
use ice [I: Do you mean Deep 
Heat?] yeah.” 
 
P10 “I did try reflexology for a 
while 405, I know some people love 
it but I didn’t find I got any benefit 
from it at all.  It's nice to have and it 
makes you relax for a while [I: Mm] 
but it didn’t actually help any pain 
that I was having.”  
 
P6 “I have tried all these things that 
I have already mentioned, and I 
tried, tried and tried and nothing 





This reflects pwMS 
frequently expressed 
a tendency to either 





comments about the 
ills of doing either. It 
also includes taking 
pain medications. 
 
P17 “I think the thing that makes 
pain worse is certainly over doing it, 
it is you know, over doing, whatever 
you are doing, today we came home 
yesterday, and the reason I didn’t go 
to bed last night and I am not going 
to work today but I did 150 cut the 
grass, I went out and cut the grass 
[I: Mm] I have got a petrol driven 
mower which has got, which has got 
gears so it's um, I don’t have to 
actually physically push it [I: Mm], I 
just walk behind it and keep it in 
line, you know [I: Yeah] but I cut the 
grass and then I will be absolutely 
exhausted after that.” 
 
P9 “So instantly being able go and 
garden all day like I used to be able 
to do, um, I know I can do it for, I 
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can do 110 it okay for ten minutes 
without problems, if I do it for half 
an hour, um, I am on my hands and 
knees coming back into the house 
and then I have to lay down for a 
couple of hours.” 
 
P12 “Well if it is really bad, I just 
stay in bed and I rest, you know and 
if I, and 185 also if I haven't had a 
good night’s sleep, because if you, if 
the pain is going through the sleep, 
then obviously in the morning I’m 
like, well you know I think it is best 
if I just stay home and rest.” 
 
P14 “I’m a long-termer with this 
295 so, it, it's just is, if that makes 
any sense, it's there [I: Mm], I know 
it's going to be there, if it's a good 
day it's not going to be there, good 
day I do a lot more, a bad day I do a 
lot less.” 
 
P2 “I had to rest my right-eye [optic 
neuritis] 147 and rest in general 
really because the neurologist said I 
needed to get the inflammation 
down.” 
 
P12 “I’m going to maybe take some 
ibuprofen or something or whatever 
and just try 170 and deal with it.” 
 
P25 “I do take different drugs for it, 
135 um so I take quite a high dose of 
Pregabalin [I: Mm] with 
Amitriptyline.” 
 
P23 “Yeah, I think it is working 
[pain medications], it’s working. I’m 
not feeling too much pain. It must be 






fighting or battling 
with pain, engaging 
in fighting talk, and 
their efforts to 
P5 “Find me wonder drug… I, I 
don’t care what it is, how it works 
but find 555 me a wonder drug that 
will take the pain away enough that 
I can function without taking a 
handful of tablets all the time.” 
 
P15 “Just relief from the pain I 
have, so I don’t have it anymore, or 
281 
 
reduce or control 
pain. Some pwMS 
recited long lists of 
strategies they 
continue to use with 
little effect (see 
subtheme: I’ve tried 
most things and it’s 
a case of hit and 
miss). 
   
if I do, that it's 570 less than what I 
have been experiencing [I: Mm] that 
has to be the ultimate goal, I can't 
think of anything else, if I was, if I 
was going to do something for pain, 
I would want the pain to be less or 
non-existent [I: Mm] it has to be.”  
 
P25 “I don’t really have that toolkit 
of like pain 680 relieving 
mechanisms in my brain to do that 
[I: Yeah], that would be really 
good.”   
 
P1 “If I can find a drug 135 that 
nobody else has had I’ll get it.”  
 
P8 “Um what I think I try and do is I 
try and take proper painkillers and 
if that doesn’t work then I try 
something, rather than just giving 
up, so I would have something to eat 
to see it that might help, I might 
have something to drink to see 355 if 





described pain as 
incurable, and 
described a different 
approach to 
managing pain that 
did not involve 
trying to reduce or 
control it. Rather 
greater emphasis was 
placed on being open 
to the idea that pain 
will come and go, 
and make room for it 
in one’s life. 
P6 “Unfortunately the pain I am 
getting now, um is not, incurable [I: 
Mm] um, it will not go away 
completely” 145. 
 
P14 “Specifically, it limits me doing 
things I want to do at times, but I 
will do, there’s a way of doing 
everything I want to do, I just have 
to organise my life and think about 
it, so if I want to go out to dinner 
with my husband and it's a company 
do or something like that, then I’m 
not going to be able to go out the 
night before or the night after, and 
probably not for the next two day, so 
I will 205 rest for two days, just to 
do that one event, so if I can control 
my life, then, then things work out 
well.”  
 
P13 “Because we all take, I mean 
everybody 220, I used to take things 
for granted, you know, but and now 
it's just like um, I really have to plan 
every day, and I can't ad-lib and if I 
do, you know, generally it goes 
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disastrously wrong ((laughing)) [I: 
Mm] so yeah, I think that’s the 
frustrating bit.”  
 
P24 “What is – my view on pain is, 
it’s 180– some of it you can work 
through [I: Hmm]. And there is 
certain pains you can work through, 
which – I have three – two classes of 
pain: a secondary pain and a 
predominant pain. My secondary 
pain I can work through on day-to-
day things. Even though I am in pain 
today [I: Mm mm]. I will still do 
various bits and pieces that I need to 
do. [I: Yeah]. Because it has to be 
done. In the house, I must 185stress 
this, in the house or when it’s nicer 
and warmer I will go in the garden 
and do my flowers and do the roses 
blah, blah, blah and I will just work 
through it. And it helps sometimes to 
do that. [I: Yeah]. But on the other 
side of it, when I have predominant 
pain it is excruciating and I know I 
cannot push myself through that. [I: 
Hm]. I just – there are some days 
it’s like with the MS, you just 190 go 
with it, you have to. You can’t fight 
it; you just go with it. [I: Hm]. And 
that is my – um, when I talk to a 
friend of mine about her problems, I 
say to her well, you know, today is 
one of the days you can’t work 
through it, you have just got to go 
with it. So – because we – we’re not 
these kind of defeatist people, we 
like to you know, just hold our own, 
you know but you 195 can’t… I am 
very determined but I am a realist 
and I know when to fight it and 
when not to fight it.” 
 
P7 “I have got the referral to the 
pain 295management clinic and I 
suppose until I have heard what 
there is out there and, you know, if 
there is anything that will promote 
me in managing my pain, you know, 
my – my belief at the moment is – is 
that I don’t – I think it is just there. 
And I will have to adapt to leading 
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my life with it there.”  
 
P12 “Um, right okay, what would I 
expect the outcome to be? [I: Yeah, 
what would you expect, sorry] being 
able to cope, but the thing is you 
can't cure it can you, that’s the 
thing, so it is all about 
management… And managing 
yourself [I: Right] and knowing 
what medications to take at 565 
what time and these, it is, a lot of it 
is management [I: Mm] pain 





comments about the 
cycle or 'roundabout' 
of pain’s interaction 
with other symptoms 
(usually pain and 
fatigue) and its 
impact on behaviour. 
Usually there is a 
focus on trying to 




experience their own 
unique catch-22 




P12 “I think it does, I think it does, I 
think stress, all these things, there 
another thing I could of added with 
diet, you know, diet, exercise, sleep 
and stress is a major one [I: Mm] 
you know and le- you know, because 
it's a brain related illness, I think 
that you 605 have to not let your, not 
let yourself get wound about things 
in your head because, you know it's 
like, it's like a, what's the word I’m, 
what do they call it, a circle, you 
know it's like you are getting pain, 
and then you get stressed about the 
pain and then the stress causes the 
pain to get worse [I: Mm] and again 
that goes back to management as 
well, a vicious circle, that’s what 
I’m thinking of, you know the 610 
saying, a vicious circle you know 
you get the pain, you get the stress 
and then you get more pain, you 
know you’ve got to break the circle, 
you’ve got to say to yourself, right I 
have got some pain, I’ve got to cope 
with this and I have to not let it 
stress me out, I have to go and sit in 
a cool bath or something, take 
myself away from everything, you 
know.”  
 
P13 “Um yeah, well the sitting down 
thing for too long 533 obviously it 
just hurts my back too much, so um I 
have to move around, but in moving 
around I tire myself out, or then the 
MS kicks-in, so it is a little bit of a 
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catch-22 there. Um, but yeah I have 
to say it is one of these things that 
um unfortunately because I put on a 
lot of weight recently I think my MS 
has got worse, I’ve actually put on 
loads of weight because I can’t do 
much to get rid of it. And even 
though I don’t eat too much I’m 
obviously not burning up the 
calories, so that is a problem at the 
moment. And as I was told by the 
neurologist when I was first 
diagnosed carrying the weight 
doesn’t help the legs. So again I’m 
in like a little circle here, it’s really 
hard. I mean I have cut down on my 
eating, I’ve actually lost half a 
stone, but it took months, months it’s 
taken me to lose it. Um, and it’s an 
ongoing thing that I keep off the 
chocolate and the puddings and the 
sweets and everything else. Um but I 
have to do it (I: it’s all part of this 
isn’t it?) Well yeah this is it, so it is 
a catch-22 and that’s the way as 
well.”  
 
P17 “There are other things they 
prescribe for, um, for MS Hug which 
is like, like the Gabapentin or 
Amitriptyline, those drugs [I: Mm] 
which do help but unfortunately they 
also have side effects [I: Mm] and 
the side effects are, ((chuckles)) they 
keep you more tired and when, and 
when that 100 is a major factor in 
suffering with MS, you tend to think, 
well I don’t really want to take that 
because I know how it's going to 
make me feel so, you sort of suffer in 






tendency for some 
pwMS to vocalise 
their frustration with 
pain and MS, and 
describe going into 
battle or fighting 
P21 “Um, with that, it is definitely, 
just because I am a fighter in terms 
of like, I don’t dwell on the fact that 
I have MS, I try and get on with it [I: 
Mm] so when I do get pain, it is 
really awkward for me because I 
want to continue my day, I feel 25 
like I have been slowed down, I feel 
like I have been defeated so I tend to 
just try and get on with it, so it's 
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with it, or and feeling 
defeated.  
awkward for me.”  
 
P6 “I don’t like that idea at all, that 
is to me the worse consequence and 
unfortunately I mustn’t think about it 
because that is what really, I’m a 
fighter and I will fight as much as I 
can, now 270 once I can't and that 
doesn’t bear thinking about.” 
 
P25 “Because, I am not good at 
resting, I hate it, I hate the fact that I 
have to rest, I find it depressing [I: 
Mm], that makes me want to cry, 
just the, just talking to you thinking 
about it, I hate, um so probably I 
battle it and actually I was just 
saying to a friend, “I just feel I am 
in a fight all the time, with myself” 
[I: Mm] “and my work!” [I: Yeah], 
470 sorry I seem to be talking about 
work quite a lot but [I: No, it makes 
sense], that’s where it impacts in my 
life the most [I: Yeah], I have to 
pretend [I: Mm] and if I could just 
like allow myself, I don’t know, I 
don’t know if it is a good thing that I 
fight it or a bad thing.”  
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Pain and MS is 
Invisible to Others 
 
Comments where 
pwMS highlight that 
others fail to see, or 
are blind, to the 
invisible nature of 
pain and MS.  
P2 “Because it’s something people 
can’t see... You know, somebody’s 
walking around with an arm in a 
sling or plaster 305 on their arm or 
leg people go oh you’ve broken your 
leg.” 
 
P10 “I think it is quite difficult for 
people 331, unless you are actually 
in a wheelchair or permanently on 
walking sticks, they say “oh you are 
looking really well today!”  
 
P12 “Can I give you an example of, 
well like I said it is just people not 
understanding and people looking at 
me funny because I’ve got a glove 
on, you know, when I’m like walking  
425 slowly or something, people are 
like, why are you walking so slowly, 
people just not being very 
understanding but I think they, I 
think they’ve become more 
understanding [I: Mm] over the 
years um but when I first had it, 
people were a bit like, what is there 
really anything-, what on earth is 
wrong with you?  I think that’s the 
big thing with MS, it's not a very 
visible disease.”  
 
P17 “Because it isn't visible, you 
know, I find that most people will 
look at me and see, and don’t really 
think there is anything wrong with 
me, because there’s you 245 know, 
there’s nothing, there is nothing 
visible as far as MS is concerned 
and because um it's such a, what's 
the word, it's, the disease is so 
diverse that symptoms change 












intentioned, but often 
disempowering, 
actions and stigma 
from others by 
concealing the 
experience of pain 
from others. This can 




P3 “You can’t keep on moaning to 
people [pain], because, well, they 
wouldn’t come and see you anymore 
would they 102?” 
 
P18 “Um, I am not too sure because 
um when I do experience pain and I 
have been 295 unwell, I don’t really 
go out and I don’t think I am open 
with my MS or my pain in this, I am 
quite close to the person, it's not 
something that I really, that I would 
tell anybody else, unless I have a 
good relationship with, like I don’t 
really open up about it? (Crying) [I: 
May I ask why that might be, from 
your perspective?] P:  Um, I am not 
sure, I didn’t think it was deliberate, 
um I don’t know why [I: 310 Mm] I 
haven't really thought about it.” 
  
P8 “Um, I don’t actually let on very 
much actually, it's only my kids that 
know I 370 am in pain, um and my 
husband, other than that I don’t let 
it on.”  
 
P1 “If you’re just standing there 
talking to them [I: Mm] they don’t 
recognise that you’re ill [I: Yeah]. 
Err, and thank God for it! I do, I-I-I 
think it’s a good thing for your self-
esteem. Um, and the fact that you’re 
able to 255 carry off, particularly 
doing what I’m doing, you’re able to 
at least be taken as somebody who is 
still in their right mind.”  
 
P25 “I kind of pretend and that 
makes me feel sad, I feel quite 
angry, I fluctuate between feeling 
really pissed off and angry [I: Mm] 
feeling really upset and kind of 
teary, I 400 used to feel really teary 
at work a lot [I: What's the nature... 
sorry] but I could, sorry, but I would 
quite easily feel teary tomorrow.” 
Feeling alone with 
the embodied 
experience of pain 
and MS 
 
 P3 “That’s right, ‘cause I mean 
pain is very, um, what can I say it’s 
sort of like to you alone, you know 





other people (family 
and friends) never 
fully understanding 
the nature and extent 
of pain and MS, 
which can feel 
isolating. In addition, 
describing it to 
others is felt by some 
to be a rather limited 
way to convey their 
pain experience.  
P13 “I don’t think you can ever, 
ever, ever describe a pain that you 
are feeling to anyone else and I 
don’t think, unless other people are 
in the same position as you 110 and 
experiencing the pain, nobody can 
understand it, nobody. There is 
nobody out there that, I mean I can 
whinge to my sons or my friends and 
say, oh god you know I’ve had such 
an awful-, now funnily enough my 
friend who has had a stroke can 
actually empathise, yeah, just you 
know he understands where I‘m 
coming from now, because he 
actually gets very, very similar 
things.”  
 
P15 “I now see, pain and people 
differently, because I am a civil 
servant and if somebody was to say 
to me, I am in chronic pain but I 
want to work, I would more look at 
it and think, I can kind of 
understand what you mean [I: Mm] 
because I have experienced it [I: 
Mm] rather thinking, I will just take 
a tablet, you know what I mean [I: 
Yeah] and you know 170 they say, 
you have a walk a mile in 
somebody’s shoes before you can 
understand, I wouldn’t want anyone 
to walk in my shoes [I: Mm] because 
((chuckles)) I don’t think I could 
walk a mile but two, it's not nice [I: 
Yeah], it's not, I wouldn’t wish this 
on anyone. 
 
P18 “Even if I describe my pain [I: 
Mm] it's, it's, I know that, it would 
take a while for those people to 
understand how I am describing it 
[I: Yeah] because it's not something 
that they get [I: Right] do you 
understand how I 145 mean?”  
 
P21 “I am just thinking, um, I might 
watch a DVD, there is not much that 
I would do really because I just 
think sometimes that just the day for 
me to rest [I: Yeah] it's 335 just my 




think I have done my part and I just 
rest for a bit and then we can get 
back to doing it how you want to”, 
that’s how I just speak to myself like 
that [I: Mm], but um [I: So some 
self-talk going on?] Yeah! [I: Yeah] 
It helps me because, I mean, yeah it 
helps because I am the only one who 
understands me [I: Mm] so, or even 
understands what I am going 340 
through in terms of how I feel 
today” 
 
P7 “It feels like there is something – 
what I 80 said to a friend of mine 
last week, touch my hand, just feel 
how odd they feel, and of course you 
can’t. You know, because only I can 





Appendix F. Chapter 5 Cross-sectional Study: Hierarchical Regression Sensitivity Analyses Examining Psychosocial 
Predictors of Pain Severity (n=567) and Pain Interference (n=568) (BPI) after Removing Anxiety and Depression (HADS) 
 Pain Severity Pain Interference 
 Beta p ∆R2 Beta p ∆R2 
Step 1: Demographic and disease variables   .19 
(F=14.638, p<.001) 
95% CIs 
  .27 
( F = 22.297, p<0.001) 
95% CIs 
Age -.125 .004 -.042 to -.008 -.224 <.001 -.071 to -.033 
Gender .049 .213 -.139 to .619 .069 .065 -.025 to .825 
Employment status .089 .049 .002 to .813 .163 <.001 .427 to 1.337 
RRMS (Ref) vs SPMS subtype .028 .521 -.286 to .564 .063 .136 -.114 to .841 
RRMS (Ref) vs PPMS subtype -.008 .876 -.518 to .442 -.010 .834 -.597 to .482  
No current relapse (Ref) vs Current relapse .089 .025 .065 to .982 .126 .001 .360 to 1.390 
No current relapse (Ref) vs Not applicable .048 .299 -.220 to .716 .032 .468 -.331 to .720 
Mobility (EDSS-S) .269 <.001 .307 to .620 .329 <.001 .493 to .844 
Pain type (S-LANSS) .262 <.001 .811 to 1.492 .211 <.001 .709 to 1.473 
BPI: Brief Pain Inventory; Ref: Reference group; Beta: Standardized Coefficients; ∆R2: R-squared change; Overall R2: Total effect in regression model; p:  95% 
significance value; NS: Non-significant parameters; 95% CIs: 95% Confidence Intervals for standardised Beta.  
Demographic and disease variables: Employment status: Employed vs unemployed; EDSS-S: Self-report Expanded Disability Status Scale; HADS: Hospital Anxiety 
and Depression Scale; PPMS: primary progressive multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis. 
Psychosocial predictors: AEQ: Avoidance-Endurance Questionnaire; CFQ: Cognitive Fusion Questionnaire; CPAQ: Chronic Pain Acceptance Questionnaire; IPQ-R: 
Illness Perceptions Questionnaire; PCS: Pain Catastrophizing Scale  








 Pain Severity Pain Interference  
 Beta p ∆R2 Beta p ∆R2 
Step 2: Psychosocial factors   .23  
(F=20.35, p< 0.001) 
95% CIs 
  .28 
(F=31.77, p< 0.001) 
95% CIs 
Cognitive fusion (CFQ) -.105 .013 -.038 to -.005 -.003 .928 -.018 to .017 
Pain acceptance (CPAQ) .053 .331 -.014 to .040 -.012 .808 -.032 to .025 
Avoidance of social activities (AEQ) .073 .132 -.035 to .263 .161 <.001 .142 to .453 
Avoidance of physical activities (AEQ) -.038 .389 -.215 to .084 -.034 .389 -.225 to .088 
Behavioural endurance (AEQ) .134 <.001 .150 to .517 .076 .022 .033 to .415 
Pain catastrophizing (PCS) .225 <.001 .024 to .060 .166 <.001 .018 to .055 
Timeline (IPQ-R) .260 <.001 .079 to .147 .095 .007 .014 to .084 
Timeline-cyclical (IPQ-R) -.074 .042 -.084 to -.002 .012 .714 -.035 to .051 
Consequences (IPQ-R) .209 <.001 .051 to .131 .354 <.001 .139 to .223 
Personal control  (IPQ-R) -.053 .146 -.056 to .008 -.056 .081 -.063 to .004 




( F=20.30, p< 0.001) 
     Overall R2 =.55 
           (F=33.59, p<.001) 
BPI: Brief Pain Inventory; Ref: Reference group; Beta: Standardized Coefficients; ∆R2: R-squared change; Overall R2: Total effect in regression model; p:  95% 
significance value; NS: Non-significant parameters; 95% CIs: 95% Confidence Intervals for standardised Beta.  
Demographic and disease variables: Employment status: Employed vs unemployed; EDSS-S: Self-report Expanded Disability Status Scale; HADS: Hospital Anxiety 
and Depression Scale; PPMS: primary progressive multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis. 
Psychosocial predictors: AEQ: Avoidance-Endurance Questionnaire; CFQ: Cognitive Fusion Questionnaire; CPAQ: Chronic Pain Acceptance Questionnaire; IPQ-R: 
Illness Perceptions Questionnaire; PCS: Pain Catastrophizing Scale  





Appendix G. Chapter 5 Cross-sectional Study: Third Step of the Hierarchical Regressions Including Pain Subtype 
and Psychosocial Predictor Interaction Terms of Pain Severity (n=567) and Pain Interference (n=568) (BPI) 
 Pain Severity Pain Interference 
Step 3: All psychosocial factors and pain type (S-
LANSS) interaction terms 
Beta p ∆R2 Beta p ∆R2 
   .008  
(F=.655, p= .794) 
  .004  
(F=.436, p= .949) 
   95% CIs   95% CIs 
Anxiety and depression (HADS) x S-LANSS -.049 .562 -.84 to 0.46 .004 .957 -.065 to .069 
Cognitive fusion (CFQ) x S-LANSS .069 .365 -.021 to 0.56 -.025 .711 -.047 to .032 
Pain acceptance (CPAQ) x S-LANSS -.056 .516 -.075 to .038 .050 .506 -.038 to 0.078 
Avoidance of social activities (AEQ) x S-LANSS -.098 .209 -518 to .114 -.034 .614 -.408 to .241 
Avoidance of physical activities (AEQ) x S-LANSS -.005 .942 -314 to .291 -.018 .750 -361 to .260 
Behavioural endurance (AEQ) x S-LANSS .035 .536 -.254 to .487 .035 .477 -.243 to .518 
Pain catastrophizing (PCS) x S-LANSS .015 .865 -.036 to .043 .056 .449 -.025 to .056 
Timeline (IPQ-R) x S-LANSS -.079 .183 -.116 to .022 .036 .485 -.088 to .055 
Timeline-cyclical (IPQ-R) x S-LANSS .017 .772 -.073 to 0.098 -.023 .648 -.056 to .119 
Consequences (IPQ-R) x S-LANSS .051 .454 -.051 to .114 .029 .633 -.064 to .105 
Personal control  (IPQ-R) x S-LANSS -.078 .175 -.112 to .020 -.007 .892 -.072 to .063 
Coherence (IPQ-R) x S-LANSS -.047 .437 -.084 to 0.36 -.043 .416 -.087 to .036 
BPI: Brief Pain Inventory; Ref: Reference group; Beta: Standardized Coefficients; ∆R2: R-squared change; Overall R2: Total effect in regression model; p:  95% 
significance value; NS: Non-significant parameters; 95% CIs: 95% Confidence Intervals for standardised Beta.  
Demographic and disease variables: Employment status: Employed vs unemployed; EDSS-S: Self-report Expanded Disability Status Scale; HADS: Hospital  
Anxiety and Depression Scale; PPMS: primary progressive multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive 
 multiple sclerosis. 
Psychosocial predictors: AEQ: Avoidance-Endurance Questionnaire; CFQ: Cognitive Fusion Questionnaire; CPAQ: Chronic Pain Acceptance Questionnaire;  
IPQ-R: Illness Perceptions Questionnaire; PCS: Pain Catastrophizing Scale  




Appendix H. Chapter 5 Cross-sectional Study: Hierarchical Regression Subgroup Analyses Examining Psychosocial 
Predictors of Pain Severity and Pain Interference (BPI) in PwMS with Neuropathic Pain (n=342)   
 Pain Severity Pain Interference 
 Beta p ∆R2 Beta p ∆R2 
Step 1: Demographic and disease variables   .16 
(F=7.72, p<.001) 
95% CIs 
  .27 
( F=15.22, p<0.001) 
95% CIs 
Age -.220 <.001 -.066 to -.022 -.290 <.001 -.090 to -.043  
Gender .041 .429 -.321 to .753 .103 .033 .051 to 1.199 
Employment status .085 .145 -.132 to .896 .148 .007 .211 to 1.310 
RRMS (Ref) vs SPMS subtype .062 .282 -.235 to .806 .081 .129 -.126 to .986 
RRMS (Ref) vs PPMS subtype .028 .671 -.519 to .805 -.008 .897 -.754 to .661 
No current relapse (Ref) vs Current relapse .118 .024 .083 to 1.203 .162 .001 .410 to 1.607 
No current relapse (Ref) vs Not applicable .113 .060 -.025 to 1.258 .059 .295 -.320 to 1.051 
Mobility (EDSS-S) .306 <.001 .328 to .740 .399 <.001 .578 to 1.018 
BPI: Brief Pain Inventory; Ref: Reference group; Beta: Standardized Coefficients; ∆R2: R-squared change; Overall R2: Total effect in regression model; p:  95% 
significance value; NS: Non-significant parameters; 95% CIs: 95% Confidence Intervals for standardised Beta.  
Demographic and disease variables: Employment status: Employed vs unemployed; EDSS-S: Self-report Expanded Disability Status Scale; HADS: Hospital Anxiety 
and Depression Scale; PPMS: primary progressive multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis. 
Psychosocial predictors: AEQ: Avoidance-Endurance Questionnaire; CFQ: Cognitive Fusion Questionnaire; CPAQ: Chronic Pain Acceptance Questionnaire; IPQ-R: 
Illness Perceptions Questionnaire; PCS: Pain Catastrophizing Scale  










 Pain Severity Pain Interference  
 Beta p ∆R2 Beta p ∆R2 
Step 2: Psychosocial factors   .20  
(F=8.32, p <0.001) 
95% CIs 
  .25 
(F=14.21, p< 0.001) 
95% CIs 
Anxiety and depression (HADS) .067 .343 -.021 to .061 .209 .001 .031 to .113 
Cognitive fusion (CFQ) -.122 .067 -.050 to .002 -.116 .044 -.052 to -.001 
Pain acceptance (CPAQ) .046 .535 -.025 to .049 .037 .563 -.026 to .047 
Avoidance of social activities (AEQ) -.008 .906 -.244 to .198 .095 .104 -.036 to .382 
Avoidance of physical activities (AEQ) -.017 .783 -.250 to .189 -.019 .728 -.256 to .179 
Behavioural endurance (AEQ) .137 .012 .079 to .618  .073 .117 -.053 to .480 
Pain catastrophizing (PCS) .224 .001 .017 to .064  .161 .005 .010 to .057 
Timeline (IPQ-R) .186 .001 .035 to .136  .059 .221 -.019 to .080 
Timeline-cyclical (IPQ-R) -.064 .226 -.093 to .022  .024 .603 -.042 to .072 
Consequences (IPQ-R) .213 .001 .041 to .160 .354 <.001 .134 to .251 
Personal control  (IPQ-R) -.092 .078 -.086 to .005  -.073 .103 -.082 to .008 





     Overall R2 =.52 
           (F=17.51, p<.001) 
BPI: Brief Pain Inventory; Ref: Reference group; Beta: Standardized Coefficients; ∆R2: R-squared change; Overall R2: Total effect in regression model; p:  95% 
significance value; NS: Non-significant parameters; 95% CIs: 95% Confidence Intervals for standardised Beta.  
Demographic and disease variables: Employment status: Employed vs unemployed; EDSS-S: Self-report Expanded Disability Status Scale; HADS: Hospital Anxiety 
and Depression Scale; PPMS: primary progressive multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis. 
Psychosocial predictors: AEQ: Avoidance-Endurance Questionnaire; CFQ: Cognitive Fusion Questionnaire; CPAQ: Chronic Pain Acceptance Questionnaire; IPQ-R: 
Illness Perceptions Questionnaire; PCS: Pain Catastrophizing Scale  





Appendix I. Chapter 5 Cross-sectional Study: Hierarchical Regression Subgroup Analyses Examining Psychosocial 
Predictors of Pain Severity and Pain Interference  (BPI) in PwMS with Non-Neuropathic Pain (n=225) 
 Pain Severity Pain Interference 
 Beta p ∆R2 Beta p ∆R2 
Step 1: Demographic and disease variables   .09 
(F=2.75 p=0.006) 
95% CIs 
  .15 
(F=4.61, p< 0.001) 
95% CIs 
Age .029 .705 -.021 to .031 -.149 .047 -.064 to <.001 
Gender .046 .498 -.361 to .740 .023 .720 -.550 to .794 
Employment status .102 .200 -.230 to 1.092 .204 .008 .281 to 1.888 
RRMS (Ref) vs SPMS subtype -.049 .527 -.980 to .504 .023 .764 -.767 to 1.043 
RRMS (Ref) vs PPMS subtype -.103 .245 1.130 to .290  -.034 .688 -.1042 to .689 
No current relapse (Ref) vs Current relapse .055 .412 -.470 to 1.144 .072 .268 -.430 to 1.538 
No current relapse (Ref) vs Not applicable -.034 .680 -.855 to .558 -.010 .898 -918 to .806 
Mobility (EDSS-S) .254 .002 .142 to .625 <.001 .001 .210 to .799 
BPI: Brief Pain Inventory; Ref: Reference group; Beta: Standardized Coefficients; ∆R2: R-squared change; Overall R2: Total effect in regression model; p:  95% 
significance value; NS: Non-significant parameters; 95% CIs: 95% Confidence Intervals for standardised Beta.  
Demographic and disease variables: Employment status: Employed vs unemployed; EDSS-S: Self-report Expanded Disability Status Scale; HADS: Hospital Anxiety 
and Depression Scale; PPMS: primary progressive multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis. 
Psychosocial predictors: AEQ: Avoidance-Endurance Questionnaire; CFQ: Cognitive Fusion Questionnaire; CPAQ: Chronic Pain Acceptance Questionnaire; IPQ-R: 
Illness Perceptions Questionnaire; PCS: Pain Catastrophizing Scale  









 Pain Severity Pain Interference  
 Beta p ∆R2 Beta p ∆R2 
Step 2: Psychosocial factors   .36  
(F=11.37, p< 0.001) 
95% CIs 
  .44 
(F=18.16, p< 0.001) 
95% CIs 
Anxiety and depression (HADS) .162 .063 -.063 to -.003 .169 .025 .117 to .357 
Cognitive fusion (CFQ) -.229 .003 .003 to -.073 -.053 .424 .019 to .458 
Pain acceptance (CPAQ) .134 .148 .148 to -.011 -.015 .489 .041 to .313 
Avoidance of social activities (AEQ) .173 .039 .039 to .013 .190 .009 .583 to .384 
Avoidance of physical activities (AEQ) -.007 .921 -.921 to .219 -.001 .987 .226 to .493 
Behavioural endurance (AEQ) .133 .027 .027 to .033 .054 .300 .426 to .744 
Pain catastrophizing (PCS) .179 .030 .030 to .003 .081 .259 .052 to .395 
Timeline (IPQ-R) .355 <.001 <.001 to .084 .086 .128 .091 to .640 
Timeline-cyclical (IPQ-R) -.099 .086 .086 to -.116 -.015 .770 .057 to .818 
Consequences (IPQ-R) .218 .006 .006 to .023 .389 <.001 .241 to .443 
Personal control  (IPQ-R) .001 .990 .990 to -.046 -.058 .249 .021 to .802 





     Overall R2 =.59 
           (F=14.502, p<.001) 
BPI: Brief Pain Inventory; Ref: Reference group; Beta: Standardized Coefficients; ∆R2: R-squared change; Overall R2: Total effect in regression model; p:  95% 
significance value; NS: Non-significant parameters; 95% CIs: 95% Confidence Intervals for standardised Beta.  
Demographic and disease variables: Employment status: Employed vs unemployed; EDSS-S: Self-report Expanded Disability Status Scale; HADS: Hospital Anxiety 
and Depression Scale; PPMS: primary progressive multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis. 
Psychosocial predictors: AEQ: Avoidance-Endurance Questionnaire; CFQ: Cognitive Fusion Questionnaire; CPAQ: Chronic Pain Acceptance Questionnaire; IPQ-R: 
Illness Perceptions Questionnaire; PCS: Pain Catastrophizing Scale  







INFORMATION SHEET FOR PARTICIPANTS 
 
REC Reference Number: 13/LO/1429        
 
YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET 
Pain Experience in MS (PEMS) Study 
 
You are being invited to take part in a research study. Before you decide whether you want to take 
part, it is important for you to understand why the research is being done and what your participation 
will involve.  Please take time to read the following information carefully and discuss it with family 
members or friends if you wish. Please contact me if anything is unclear or if you would like more 
information. Take time to decide whether or not you wish to take part. Thank you for reading this. 
 
Who is conducting the study?  
This study is part of a larger research project that is being conducted by researchers at The Section 
of Health Psychology, Institute of Psychiatry at King’s College in collaboration with the MS Society 
UK. The study is being conducted as part of the Principal Investigator (Anthony Harrison’s) doctoral 
studies in conjunction with Lead Investigators Professor Rona Moss-Morris and Professor Lance 
McCracken. Anthony is being supervised by the Lead Investigators with all aspects of the project.  
 
What is the purpose of the study?  
Research has shown that people with MS experience different kinds of pain, but there is little 
research into how this symptom is experienced by people with MS. We are interested in how people 
with MS experience their pain, how much it affects them, and how they deal with it from the day-to-
day. Understanding how people with MS live from the day-to-day with different kinds of pain will help 
researchers develop new treatments aiming to improve how people with MS deal with their pain. 
 
Why have I been chosen?  
You have been approached about this study because you have Multiple Sclerosis and have reported 
to us that you experience some form of pain. We have invited those people with a variety of MS pain 
symptoms to take part in the project.  
 
Do I have to take part?  
No. It is up to you to decide whether to take part or not. If you decide to take part you will be asked to 
sign the consent form provided. Whether or not you take part will not affect the standard of care you 
receive. If you agree to take part you may be asked whether you are happy to be contacted about 
participation in future studies. However, your participation in this study will not be affected should you 
request not to be re-contacted. 
 
What will happen to me if I take part?  
If you agree to take part you can either access the online questionnaire directly: 
https://www.survey.bris.ac.uk/kcl.pemsstudy. Alternatively, a member of the research team will 
contact you using the contact details you provide. They will arrange to send you either a paper-
version of the questionnaire survey or web-link to access the online version. The questionnaires 
should take around 20-30 minutes to complete. The research team is in no way connected with the 
team involved in your treatment. The survey will ask you some standard questions about how you 
view your pain, how it affects your life, how you deal with pain alongside other more general 
difficulties.  
 





Will You Compensate Me for My Time? 
We would very much appreciate your help and to express our thanks for your time completing the 
survey we will offer you a £5 Marks & Spencer’s gift voucher, which we can give to you at your 
appointment or post to your home address if you prefer. At the conclusion of the study, we will also 
provide you with a newsletter summarising the main findings.  
 
Are there any costs? 
There are no costs to participants associated with the project. 
 
What are the possible disadvantages and risks of taking part?  
The risks involved in participating are minimal. It is possible that some people might find it distressing 
to reflecting on the questions in relation to their own lived experiences of pain and MS in general. If 
you get upset you can skip questions, take a break or decide not to continue with the survey. If you 
are very distressed we will offer you some sources of support.  
 
What are the possible benefits of taking part?  
There may not be any immediate or direct benefits to you by taking part. However, some people may 
find it helpful or interesting to talk about their illness and how it affects them. Your participation will 
help us to develop a better idea of how we can help people who experience MS pain. At the 
conclusion of the project, we will send you a newsletter describing the major findings and alerting you 
to any research publications we have generated from the project. 
 
If this study has harmed you in any way…  
In the unlikely event that you are unhappy with the way that the research is conducted complaint 
mechanisms are available to you. In the first instance please contact Professor Rona Moss-Morris 
rona.moss-morris@kcl.ac.uk. If you are not satisfied with this process, we advise you contact the 
Patient Advice and Liaison Service (PALS), at Guy’s and St. Thomas’ Hospital’s PALS KIC Ground 
floor, North Wing, St Thomas' Hospital, Westminster Bridge Road London SE1 7EH (tel. 0207 
1888801 or 0207 1888803 or email pals@gstt.nhs.uk). Kings College Hospital PALS, King's 
College Hospital, Denmark Hill, London SE5 9RS (tel. 020 3299 3601 or email kch-
tr.PALS@nhs.net). University College London Hospitals NHS Foundation Trust PALS, 250 
Euston Road, London, NW1 2PG (tel: 0203 4567890 email: pals@uclh.nhs.uk). Queen Mary’s 
PALS, Frognal Pl, Sidcup, Kent DA14 6LT (Tel: 0208 3085449 email: slh-tr.qm-pals@nhs.net) 
Bromley Hospitals PALS, Princess Royal University Site, Farnborough Common, Orpington, Kent 
BR6 8ND (Tel: 0168 9863252 email: slh-tr.br-pals@nhs.net) Queen Elizabeth PALS, Stadium Road, 
Woolwich, London SE18 4QH (tel: 0208 8364592 email: pals.qeht@nhs.net). St George's 
Healthcare PALS, St George's Healthcare NHS Trust, Blackshaw Road, Tooting, London, SW17 
0QT (tel: 0208 7252453). Cumbria Partnership NHS Foundation Trust Patient Experience Team, 
Carleton Clinic, Cumwhinton Drive, Carlisle, Cumbria CA1 3SX (tel: 0800 633 5547 email: 
PET@cumbria.nhs.uk. Plymouth Hospitals PALS, Patient Advice & Liaison Service, Patient 
Services Office, Level 7 Derriford Hospital, Plymouth PL6 8DH (tel: 08451558123 email: plh-
tr.PALS@nhs.net). Adelaide Health Centre (Patient Experience Service), Western Community 
Hospital, William Macleod Way, Southampton, Hampshire, SO16 4XE (tel: 0800 013 2319 email: soc-
pct.schpatientexperience@nhs.uk). 
 
Will my taking part in the study be kept confidential?  
Yes. All information about your participation in this study will be kept confidential in accordance with 
the Data Protection Act 1998. Once the survey is complete, your name on the consent form will be 
kept separately from the survey data, and a linking participant ID number will be used, making it 
anonymised. Your information will be stored on secure computers, locked within offices and in locked 
file cabinets, and will only be available to members of the research team. This information will only be 
used for the purposes of the current study. Your study data will be retained for a minimum of 5-years 
and subsequently disposed of securely. Your responses to our questions will remain completely 
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confidential unless you tell us something to indicate that your own health and safety are currently in 
danger. Your anonymised data will be shared with other researchers and may be used for other 
research purposes. Please note, the deadline to request withdrawal of your data from the study will 
be October 2014. 
 
What will happen if I don’t want to carry on with the study?  
You are free to withdraw from the study at any time without having to give a reason even if you 
decide to take part initially. 
 
What will happen to the results of the research study?  
The results will be used to help the researchers better understand MS pain with a view to developing 
future treatments. The study will be presented at scientific conferences and be written up for 
publication in scientific journals. We will provide you with a summary sheet of the results.  
 
Who is organizing and funding the research?  
The study is funded by the Multiple Sclerosis Society. It is being organized and conducted by 
researchers from The Health Psychology Department, Institute of Psychiatry, King’s College London.  
 
Who has reviewed the study?  
The study has been reviewed by the (Queen’s Square) NHS Research Ethics Committee (REC) 
(13/LO/1429), and by the research development team and patient and public involvement members 
at the UK Multiple Sclerosis Society.  
 
What if I have questions about the project? Contact details for further information  




Name: Mr Anthony Harrison  
Job title: Principal Investigator (Doctoral Student) 
Telephone number: 07936 448 926 Email address: anthony.harrison@kcl.ac.uk  
Address: Department of Health Psychology, Institute of Psychiatry, Kings College 
London, 5th Floor Bermondsey Wing, Guys Campus, London SE1 9RT 
ALTERNATIVELY: Fill in the attached contact details form, return it in a stamped 
addressed envelope and one of the researchers will contact you  
Please retain this information sheet.  
If, after discussing the research with us, you decide that you wish to participate we will 
















Pain Experience in MS (PEMS) Study (Study ethics Ref: 13/LO/1429) 
 
Please complete this form if you think you might be interested in taking part in this 
study.  
 
Please initial at the end of each statement to confirm     
1. I confirm that I have read and understand the information sheet (dated 14th August 
2013, version 1) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily             
                                             …… 
2. I understand that my participation is voluntary and that I am free to withdraw  
at any time, without giving any reason, without my medical care or legal rights  
being affected                                            .…...
                              
3. I consent to the processing of my data in accordance with the Data Protection Act 
(1998)                   
                                                                                                    …… 
4. I agree to take part in the above study          
                                                                                        …… 
5. I give permission for my unidentifiable data to be used for future research       
                             …… 
6. I agree to a researcher from the Health Psychology Department, King’s College 
London contacting me to discuss my potential involvement in this research project 
                       …… 
7. I understand that by giving my name and contact details I am not obliged to take part.         
                       
            ……  
8. I agree to be contacted by the researcher to be informed about future studies       
              ……                                      
                    
Please select either: ‘Yes’ to opt-in    Or ‘No’ to opt-out                                                      
                                                                                                                           
 
Name of Participant__________________ Date_____Signature_______________ 
            
Telephone number/s: ………………………………………………………………….. 
 
Best days/times to contact me ………………………………………………………… 
 
Email address (if checked regularly):…………………………………………………. 
 
When completed: 1 copy for the patient; 1 for researcher’s file.  




Questions about you 
 
1. Throughout our lives, most of us have had pain from time to time (such as minor 
headaches, sprains, and toothaches). Have you had pain other than these everyday kinds 
of pain today? 
  Yes     No 
2. Your date of birth (DD/MM/YY): ...../......./........    
3. What is your gender:  Male    Female 
4. What is your ethnicity? 
 White - English / 
Welsh / Scottish / 
Northern Irish / 
British 
 Mixed / Multiple 
ethnic group  - White and 
Black Caribbean 
 Asian / Asian 
British – Indian 
 Black / African / 
Caribbean / Black British – 
African 
White - Irish  Mixed / Multiple 
ethnic group  - White and 
Black African 
 Asian / Asian 
British – Pakistani
  
 Black / African / 
Caribbean / Black British – 
Caribbean 
White - Gypsy or 
Irish Traveller  
 Mixed / Multiple 
ethnic group - White and 
Asian 
 Asian / Asian 
British – 
Bangladeshi 
 Black / African / 
Caribbean / Black British – 
Any other Black / African / 
Caribbean background 
White - Any Other 
White background 
 Mixed / Multiple 
ethnic group - Any Other 
Mixed / multiple ethnic 
background 
 Asian / Asian 
British – Chinese 
 Asian / Asian 
British - Any other 
Asian background 
 Other ethnic group – 
Arab 
 
 Other ethnic group – 
Any other ethnic group 
 Not known/not 
provided 
 
5. Present relationship status:  Single  Married   Widowed  Separated/divorced  
Co-habiting 
6. How many years of education have you completed? …… Years 
7. Which of the following best describes your current job status? 
 Employed outside the home, full-time   Employed outside the home, part-time 
 Homemaker                                           Retired            Unemployed     Other 
If unemployed, are you not working due to your MS?              Yes                   No 




Questions about your MS & Other Conditions 
 
Are you currently experiencing a relapse?                Yes          No       Not applicable 
8. When was your MS diagnosed? (DD/MM/YY): .........../............./............. 
9. The next question asks you about whether you experience certain MS symptoms, and 
then  
asks how much this symptom interferes with your life?  
 (Tick ‘Yes’ or ‘No’ if you experience this symptom and then rate how much it interferes.) 



























































































10. Have you ever been diagnosed with any other physical or psychiatric condition  
(e.g. depression, anxiety, schizophrenia) other than MS?        Yes                No          
 
If ‘yes’, what 
condition/s?_____________________________________________________________ 
 
I heard about this study through the  
NHS neurology / MS specialist service:   Yes      No 
If 'no’, I heard about this study through the (please tick): 
MS Society UK                               
Local MS Therapy Centre           
SHIFT Website                           
MS Register UK                          
NHS                                            
 











If through the NHS, can you tell us which Trust /hospital: 
King’s College Hospital   
Guy’s & St. Thomas’   
Cumbria  
South London Healthcare   
Queen Elizabeth Hospital, Woolwich   
University College London Institute of Neurology, NMR Research Unit   
Wolfson Research Unit, University College London   
University College London Outpatient Clinic   
St. George's Hospital, Tooting   
Cumbria Hospitals NHS Foundation Trust   
Turner Centre, St James Hospital, Portsmouth   
Plymouth Hospitals NHS Trust   
Royal Devon & Exeter Hospitals NHS Trust   
Sussex Community NHS Trust 
Derby Hospitals   
Ashford & St Peter's Hospitals NHS Trust   
Harrogate and District NHS Foundation Trust  





Self-administered  Multiple sclerosis Disease Course Questionnaire  
(Bamer et al., 2007) 




Attacks (exacerbations, relapses) come on over a 
few hours or days, last from one day to several 
weeks, but once they are over, you feel the same as 





Attacks (exacerbations, relapses) come on over a 
few hours or days, last from one day to several 
weeks. After some attacks, your symptoms are 
worse than before. The symptoms that remain after 





At the start of the disease, attacks (exacerbations, 
relapses) occur. You may feel your symptoms get 
worse because of these attacks. Then even between 
the attacks, you feel you are getting worse.  In 
some cases, attacks cease, yet your symptoms 





Symptoms worsen from the beginning. Your 
symptoms may be stable for a time, gradually 
worsen, or deteriorate rapidly, but attacks 





Symptoms gradually worsen from the beginning. 
Your symptoms may be stable for a time at the 
beginning, or may deteriorate rapidly. Attacks 
(exacerbations, relapses) did not occur at the start, 
but may occur later in the course of the disease. 






















    Time 
Worse
No
Symptoms     Time
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Self-report EDSS (EDSS-S) Mobility Scale (Bowen et al., 2001)  
WALKING DISTANCES 
We would like to know how well your body functions on an average day, not your 
worst days and not your best days. Please tick the box that most closely matches your 
abilities.** 
 
On an average day I can: 
 
  Walk more than 500 metres (about 530 yards) without stopping to rest. 
 (This is approximately 5 football field lengths.) 
    I would need    no help    a cane     two canes     a walker 
 
  Walk 300 metres (about 350 yards) without stopping to rest.  
          (This is approximately 3 football field lengths.)  
    I would need     no help     a cane     two canes     a walker 
 
  Walk 200 metres (about 200 yards) without stopping to rest.  
   (This is approximately 2 football field lengths.)  
    I would need     No help    A cane    Two canes    A walker 
 
 Walk 100 metres (about 100 yards) without stopping to rest.  
     (This is approximately 1 football field length.) 
    I would need     No help     A cane    Two canes    A walker 
 
  Walk 20 metres (about 60 feet) without stopping to rest. 
    I would need     No help      A cane    Two canes   A walker 
 
  Walk 5 metres (about 15 feet) without stopping to rest 
    I would need     No help     A cane     Two canes   A walker 
 
  Walk a few steps. 
    I would need     No help     A cane     Two canes     A walker 
 
                               Use a wheelchair 
 
If you use a wheelchair please tick one of the following 4 statements: 
 
1.   On an average day, I can bear my weight with my legs (stand up and 
move) and get myself from one chair to another. 
2.  On an average day, I can bear my weight (with the strength in my arms) 
and lift myself from one chair to another. 
3.  On an average day, I cannot bear any weight or get myself from one 
chair to another. 





Brief Pain Inventory (BPI) (Cleeland & Ryan, 1994)  
 
About the Pain You Experience  
 
1. Please rate your pain by circling the one number that best describes your pain at its 










2. Please rate your pain by circling the one number that best describes your pain at its 

































6. In the last 24 hours, how much relief have pain treatments or medications provided? 













7. Circle the one number that describes how, during the past 24 hours, pain has interfered 
with your: 
 




























































8. Where is your pain located? Please indicate if more than one location. 
 
Head               
 
 
Face             
 
 
Eyes               
 
 
Ears       
 
 
Mouth       
 
 
Nose     
 
Chest/ 
upper torso     
       
Stomach/ 





   
Shoulders        
 
Arms            
 
Forearms       
 
Hands    
 
Fingers     
 
 
Upper-back      
 
Mid-back      
 




Hips          
 
Groin     
 
Thighs             
 
Knees          
 
Calves           
 
Shins      
 




9.  When did you begin experiencing pain related to your MS? ……Years 
…… Months ago 
 
10. Does your pain come and go?    Yes  No 
       … Or is it always present?  Yes  No  
 
If you pain comes and goes, can you estimate how many days per month 
do you have pain _______________________________________________ 
11. What treatments or medications are you receiving for your pain? 
 
   Numb
er per 
day?  
 Used regularly …or as required 
Paracetamol             
 
  Yes      No  Yes      No  
Ibuprofen                 
 
Diclofenac       
 
  Yes      No  Yes      No  
Codeine                    
 
Co-codamol     
 
Tramadol        
  
 Yes      No  Yes      No  




Oxycontin    
  
 Yes      No  Yes      No  
Amitriptyline            
 
Duloxetine       
 
  Yes      No  Yes      No  
Gabapentin               
 
Pregabilin          
 
Carbamazep
ine    
 Yes      No  Yes      No  
Lignocaine 
patch     
 
   Yes      No  Yes      No  
Smoked 
cannabis    
 
Sativex spray     
 
 








Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983) 
 
Researchers and clinicians are aware that emotions play an important role in 
most illness. This questionnaire is designed to help the researcher to know how 
you feel. Read each item and place a firm tick in the box opposite the reply 
which comes to how you have been feeling in the past week. Don’t take too 
long over your replies: your immediate reaction to each item will probably be 
more accurate than a long thought-out response. 
 
Tick only one grey box for each section: 
 
1. I feel tense or wound up: 6. I feel cheerful: 
Most of the time…………….  Not at all……………………………  
A lot of the time…………….  Not often……………………………  
Time to time, occasionally.  Sometimes…………………………  
Not at all……………………  Most of the time……………………  
 
2. I still enjoy the things I used to: 7. I can sit at ease and feel relaxed: 
Definitely as much………..   Definitely……………………………  
Not quite so much…………  Usually………………………………  
Only a little…………………..  Not often……………………………  
Hardly at all………………..  Not at all…………………………….  
 
3. I get a sort of frightened feeling 
as if something awful is about to 
happen: 
8. I feel as if I am slowed down: 
Very definitely & quite badly  Nearly all the time…………………  
Yes, but not too badly  Very often…………………………  
A little, but it doesn’t worry me  Sometimes…………………………  
Not at all…………………  Not at all……………………………  
 
4. I can laugh and see the funny 
side of things: 
9. I get a sort of frightened feeling 
like 'butterflies' in the stomach: 
As much as I always could……….  Not at all……………………..........  
Not quite as much now……………  Occasionally…………………………  
Definitely not so much now……….  Quite often………………………….  
Not at all…………………………….  Very often…………………………..  
 
5. Worrying thoughts go through 
my mind: 
10. I have lost interest in my 
appearance; 
A great deal of the time…………..  Definitely……………………………  
 
A lot of the time……………………  I don’t take as much care as I 
should……………………………….  
 
From time to time but not too often.  I may not take quite as much care as 
ever……………………………………. 
 







11. I feel restless as if I have to 
be on the move: 
13. I get sudden feelings of 
panic: 
Very much indeed………………..  Very often indeed………………  
Quite a lot………………………  Quite often………………………  
Not very much…………………..  Not very often……………………  
Not at all……………………………  Not at all…………………………  
 
12. I look forward with enjoyment 
to things: 
14. I can enjoy a good book or 
radio or TV programme: 
As much as ever did……………….  Often………………………………..  
Rather less than I used to………..  Sometimes…………………………  
Definitely less than I used to………  Not often………………………….  




Kiel Pain Inventory Avoidance-Endurance Measure 
Pain-related Behavioural Responses (KPI-AEM-PBR) (Hasenbring et al., 2009) 
 
A number of actions are set out below which we may observe in ourselves 
when we are in pain. How we behave is often dependent on the severity of this 
pain at any given moment. Please go through each of the following 
statements and check both scales to indicate if and how often you have acted 
in such a way in the past 14 days when you experienced mild and/or severe 
pain. 
 










Pain Catastrophizing Scale (PCS) (Sullivan et al., 1995)  
 
We are interested in the types of thoughts and feelings that you have when you are in 
pain. Listed below are thirteen statements describing different thoughts and feelings that 
may be associated with pain. Using the following scale, please indicate the degree to 
which you have these thoughts and feelings when you are experiencing pain. 
 
When I’m in pain… (Please tick one grey box for each statement.) 
 
1. I worry all the time about whether the pain will end. 
 
Not at all To a slight  
degree 
To a moderate  
degree 
To a great  
degree 
All the time 
     
 
2. I feel I can’t go on. 
 
Not at all To a slight  
degree 
To a moderate  
degree 
To a great  
degree 
All the time 
     
 
3. It’s terrible and I think it’s never going to get any better. 
 
Not at all To a slight  
degree 
To a moderate  
degree 
To a great  
degree 
All the time 
     
 
4. It’s awful and I feel that it overwhelms me. 
 
Not at all To a slight  
degree 
To a moderate  
degree 
To a great  
degree 
All the time 
     
 
5. I feel I can’t stand it anymore. 
 
Not at all To a slight  
degree 
To a moderate  
degree 
To a great  
degree 
All the time 
     
 
6. I become afraid that the pain will get worse. 
 
Not at all To a slight  
degree 
To a moderate  
degree 
To a great  
degree 
All the time 
     
 
7. I keep thinking of other painful events. 
 
Not at all To a slight  
degree 
To a moderate  
degree 
To a great  
degree 
All the time 




8. I anxiously want the pain to go away. 
 
Not at all To a slight  
degree 
To a moderate  
degree 
To a great  
degree 
All the time 
     
 
9. I can’t seem to keep it out of my mind. 
 
Not at all To a slight  
degree 
To a moderate  
degree 
To a great  
degree 
All the time 
     
 
10. I keep thinking about how much it hurts. 
 
Not at all To a slight  
degree 
To a moderate  
degree 
To a great  
degree 
All the time 
     
 
11.  I keep thinking about how badly I want the pain to stop.  
Not at all To a slight  
degree 
To a moderate  
degree 
To a great  
degree 
All the time 
     
 
12. There’s nothing I can do to reduce the intensity of the pain. 
 
Not at all To a slight  
degree 
To a moderate  
degree 
To a great  
degree 
All the time 
     
 
13. I wonder whether something serious may happen. 
 
Not at all To a slight  
degree 
To a moderate  
degree 
To a great  
degree 
All the time 




Chronic Pain Acceptance Questionnaire-8 items (CPAQ-8)  
(Fish et al., 2010) 
 
 
Below you will find a list of statements. Please rate the truth of each statement as it 
applies to you by circling a number. 
 
Use the following rating scale to make your choices (Please tick one grey box for 
each statement.) 
 

















       
 

















       
 

















       
 

















       
 









































       
 

















       
 






















Illness Perceptions Questionnaire Revised (IPQ-R) (Moss-Morris et al., 2002) 
 
 























My MSP will last a short 
time 
 
     
IP2 My MSP is likely to be 
permanent rather than 
temporary 
 
     
IP3 My MSP will last for a long 
time 
 
     
IP4* This MSP will pass quickly 
 
     
IP5* I expect to have this MSP 
for the rest of my life 
 
     
IP6 My MSP is a serious 
condition 
 
     
IP7 My MSP has major 




    
IP8* MY MSP does not have 
much of an effect on my 
life 
 
     
IP9 My MSP strongly affects 
the way others see me 
 
     
IP10 My MSP has serious 
financial consequences 
 
     
IP11 My MSP causes difficulties 
for those who are close to 
me 
 
     
IP12 There is a lot which I can 
do to control my MSP 
 
     
IP13 What I do can determine 
whether my MSP gets 
better or worse 
 
     
IP14 The course of my MSP 
































Nothing I do will affect my 
MSP 
 
     
IP16 I have the power to 
influence my MSP 
 
     
IP17
* 
My actions will have no 
effect on the outcome of 
my MSP 
     
IP18
* 
My MSP will improve in 
time 
 
     
IP24 The MSP of my condition 
are puzzling to me 
 
     
IP25 My MSP is a mystery to 
me 
 
     
IP26 I don’t understand my 
MSP 
 
     
IP27 My MSP doesn’t make any 
sense to me 
 
     
IP28
* 
I have a clear picture or 
understanding of my MSP 
 
     
IP29 The symptoms of my MSP 
change a great deal from 
day to day 
 
     
IP30 My MSP come and go in 
cycles 
 
     
IP31 My MSP is very 
unpredictable 
 
     
IP32 I go through cycles in 
which my MSP gets better 
and worse. 
 
     
IP33 I get depressed when I 
think about my MSP 
 
     
IP34 When I think about my 
MSP I get upset 
 
     

































IP36 My MSP does not worry 
me 
 
     
IP37 Having this MSP makes 
me feel anxious 
     
IP38 My MSP makes me feel 
afraid 
 
     
321 
 
Cognitive Fusion Questionnaire (CFQ) (Gillanders et al., 2014) 
Below you will find a list of statements. Please rate how true each statement is for 
you by ticking one grey box for each statement. 

















       
 


















       
 

















       
 

















       
 

















       
 






















7. It is such a struggle to let go of upsetting thoughts even when I know that letting go 

















       
 
Thank you for completing this questionnaire 
 
In order to send you a debriefing statement, summary of findings and a £5 Marks & 
Spencer gift voucher for completing the questionnaire, please tell us your name and 











Appendix N. Chapter 7 Case Series: Post-treatment telephone interview schedule 
 
Questions Prompts 
1. First of all can you start by 
telling me what you were 
expecting from the eight 
sessions? 
-What did you think the programme would be 
like? 
-In what ways (if any) did you think it might 
help you? 
 
2. How did you find the 
programme overall? 
-Tell me how you found your first session 
-Tell me about the other sessions 
-Tell me how you found using the treatment 
booklet and task sheets 
-Tell me how you found the homework tasks  
- What about the telephone/skype support 
sessions? How did you find them?  
- Do you have any other thoughts about different 
or additional support alongside the programme?  
3. Can you tell me what you liked 
about the programme? 
-What was helpful? Why? How? 
-Were there some sessions/ some aspects that 
were more helpful than others? 
4. Can you tell me what you 
disliked about the programme? 
-What was unhelpful? Why? How? 
-Were there some sessions/ some aspects that 
were less helpful than others? 
5. Tell me about anything that you 
feel has changed from having 
done the programme? 
-Can you tell me what changed? (Anything 
different in your day-to-day life, the way you are 
dealing with MS pain?) 
-Can you tell me how you came to notice things 
changing? 
-Why/how do you think things changed? 
6. What do you think of the 
questionnaires used and the 
overall set up of the study? 
-Any further comments regarding the 
questionnaires used? 
7. Do you have anything else you 
would like to tell me about your 
experiences of this programme 
that haven’t already covered? 
-What would you feed back to the people who 
put together the programme? 
-What advice would you give to people thinking 
about taking part in CBT-based programmes?  
- If I were to take one key message away with 
me today as a researcher about your experience 











Appendix O. Case Series: Participant’s pain medication use at pre-treatment and 
pain relief 
 
ID Reported Pain Medications Pre-treatment Pain Relief from 
Medications % (BPI)2 
1 Paracetamol (as required) 
Ibuprofen (as required) 
Codiene (as required) 
Co-codamol (as required)  
Duloxetine (60mgs daily) 
Pregabilin (600mg daily) 
Tegretol (200mg x 2 daily) 
Lamotrigine (100mg daily) 
Smoked cannabis (very infrequently) 
 
10 
2 Ibuprofen once or twice a week (800mg 
to 2400mg daily)  
Sativex (single bottle weekly)  
 
75 
3 Amitriptyline (20mg Daily) 
 Pregabilin (300mg Daily) 
60 
4 Co-codamol (500mg as required) 
Baclofen (20mg to 30mg daily) 
Gabapentin (900mg daily) 
 
50 
5 Ibuprofen (200mg daily) 
Co- codamol (from 30mg to 500mg daily)  
 
90 
6 Gabapentin (2100mg daily). 
Clonazepam (750mg daily). 
Paracetamol (500mg to 1000mg daily as 
required). 
30 
7 Sativex (6 sprays daily) 
Gabapentin (1200mg daily) 
Amitriptyline (50mg daily) 
Baclofen (40mg daily).   
90 





P.1 Treatment and maintenance effects for Pain Severity 4 day ratings (BPI) tested using SMA 
 Baseline (Phase A) versus Treatment (Phase B) Baseline (Phase A) versus Follow-up (Phase C) 
ID Phase  
M 
 
AR Level  











 A B    A C    
1 
 
6.63 4.50 0.36 1.42 (.029*)+ 0.50 (.078) 6.63 3.88 0.01 1.64 (.007**)+ -0.60 (.020*) 
2 
 
3.75 3.25 0.24 0.65 (.240) -0.15 (.580) 3.75 3.0 0.37 0.90 (.292) -0.52 (.151) 
3 
 
6.63 6.56 0.44 0.04 (.952) 0.26 (.436) 6.63 6.88 0.28 0.22 (.767) .19 (.579) 
4 
 
6.00 3.68 0.16 0.93 (.083) -0.54 (.017**) 6.00 3.5 -0.03 0.93 (.100) -.13 (.619) 
5 3.50 4.19 0.19 0.30 (.555) 0.21 (.414) 
 
3.50 5.62 0.39 1.01 (.228) 0.61 (.076) 
6 3.75 6.25 0.70 
 
1.67 (.087) 0.81 (.018**) 3.75 7.25 0.81 3.40 (.023*) 0.866 (.031*) 
7 7.12 5.75 0.51 1.15 (.128) -0.66 (.030*) 7.12 5.25 0.47 1.66 (.080) -0.74 ( .023*) 
SMA: Simulation Modelling Analysis; BPI = Brief Pain Inventory short-form; ID: Participant identification number; M: Phase mean values; AR: Pooled phases autocorrelation estimate 
(r Lag (1)); P: p-value accounting for autocorrelation; r: Pearson’s r correlation. 
110000 null distribution simulations generated; Error of mean = 0; Standard deviation = 1; Valid phase n-size of sample (for each individual) = 24: Phase A (baseline) = 8; Phase B 
(treatment) = 16. Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and 
gradual change during treatment (0, 0, 0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16). 
210000 null simulations generated; Error of mean =0; standard deviation = 1; Valid phase n-size of sample (for each individual) = 16: Phase B (baseline) = 8; Phase C (follow-up) = 8. 
Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and gradual change during follow-up (0, 0, 
0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8). 
** = Effect size significant at the 0.01 level 
* = Effect size significant at the 0.05 level 
+ = Significant at the 0.05 level after manually imputing AR=.40. 
































SMA: Simulation Modelling Analysis; BPI = Brief Pain Inventory short-form; ID: Participant identification number; M: Phase mean values; AR: Pooled phases autocorrelation estimate 
(r Lag (1)); P: p-value accounting for autocorrelation; r: Pearson’s r correlation. 
110000 null distribution simulations generated; Error of mean = 0; Standard deviation = 1; Valid phase n-size of sample (for each individual) = 24: Phase A (baseline) = 8; Phase B 
(treatment) = 16. Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and 
gradual change during treatment (0, 0, 0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16). 
210000 null simulations generated; Error of mean =0; standard deviation = 1; Valid phase n-size of sample (for each individual) = 16: Phase B (baseline) = 8; Phase C (follow-up) = 8. 
Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and gradual change during follow-up (0, 0, 
0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8). 
** = Effect size significant at the 0.01 level 
* = Effect size significant at the 0.05 level 
+ = Significant at the 0.05 level after manually imputing AR=.40. 




P.2 Treatment and maintenance effects for Pain Interference 4 day ratings (BPI) tested using SMA 
 Baseline (Phase A) versus Treatment (Phase B) Baseline (Phase A) versus Follow-up (Phase C) 
ID Phase  
M 
 
AR Level  











 A B    A C    
1 
 






4.00 3.25 0.28 1.04 (.076) -0.26 (.356) 4.00 2.88 0.56 1.35 (.193) -0.70 (.076) 
3 
 
6.75 6.44 0.36 0.22 (.722) 0.19 (.542) 6.75 6.75 0.31 0.00 (1.000) 0.15 (.6765) 
4 
 




5 2.50 3.94 0.24 0.61 (.275) 0.34 (.191) 2.50 5.34 0.47 1.28 (.164) 0.65 (.066) 
6 7.75 8.50 0.45 
 
0.58 (.383) .59 (.052*) 7.75 9.25 0.42 1.25 (.1643) 0.622 (.083) 





























SMA: Simulation Modelling Analysis; PCS: Pain Catastrophizing Scale; ID: Participant identification number; M: Phase mean values; AR: Pooled phases autocorrelation estimate (r Lag 
(1)); P: p-value accounting for autocorrelation; r: Pearson’s r correlation. 
110000 null distribution simulations generated; Error of mean = 0; Standard deviation = 1; Valid phase n-size of sample (for each individual) = 24: Phase A (baseline) = 8; Phase B 
(treatment) = 16. Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and 
gradual change during treatment (0, 0, 0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16). 
210000 null simulations generated; Error of mean =0; standard deviation = 1; Valid phase n-size of sample (for each individual) = 16: Phase B (baseline) = 8; Phase C (follow-up) = 8. 
Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and gradual change during follow-up (0, 0, 
0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8). ** = Effect size significant at the 0.01 level 
* = Effect size significant at the 0.05 level  
d = 0.2 = small, 0.5 = medium = 0.8 = large effect size; r= 0.1 = small, 0.3 = medium and 0 .5 = large effect size. 
 
 
Appendix Q. Chapter 7 case series: Simulation Modelling Analysis (SMA) output secondary process variables 
Q.1 Treatment and maintenance effects for Pain Catastrophizing 4 day ratings (PCS) tested using SMA 
 Baseline (Phase A) versus Treatment (Phase B) Baseline (Phase A) versus Follow-up (Phase C) 
ID Phase  
M 
 
AR Level  











 A B    A C    
1 
 
30.38 16.28 0.58 1.76 (.036*) -0.63 (.074) 30.38 9.00 0.56 2.58 (.015**) -0.68 (.078) 
2 
 
30.25 13.81 0.77 3.90 (.001**) -0.69 (.121) 30.25 12.00 0.75 4.39 (.002**) -0.80 (.064) 
3 
 
30.63 27.17 -0.30 
 





34.38 19.13 0.84 1.96 (.098) 
 
-0.92 (.001**) 34.37 5.00 0.85 9.85 (<.001**) -0.86 (.042*) 
5 40.75 39.25 0.19 0.37 (.483) -0.09 (.701) 40.75 43.65 0.58 0.77 (.465) 0.51 (.270) 
6 42.37 42.50 0.45 
 
0.04 (.953) 0.36 (.287) 42.37 43.65 0.45 0.45 (.609) 0.43 (.281) 



























SMA: Simulation Modelling Analysis; CPAQ-8: Chronic Pain Acceptance Questionnaire 8 items; ID: Participant identification number; M: Phase mean values; AR: Pooled phases 
autocorrelation estimate (r Lag (1)); P: p-value accounting for autocorrelation; r: Pearson’s r correlation. 
110000 null distribution simulations generated; Error of mean = 0; Standard deviation = 1; Valid phase n-size of sample (for each individual) = 24: Phase A (baseline) = 8; Phase B 
(treatment) = 16. Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and 
gradual change during treatment (0, 0, 0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16). 
210000 null simulations generated; Error of mean =0; standard deviation = 1; Valid phase n-size of sample (for each individual) = 16: Phase B (baseline) = 8; Phase C (follow-up) = 8. 
Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and gradual change during follow-up (0, 0, 
0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8). 
** = Effect size significant at the 0.01 level 
* = Effect size significant at the 0.05 level;  




Q.2 Treatment and maintenance effects for Pain Acceptance 4 day ratings (CPAQ) tested using SMA 
 Baseline (Phase A) versus Treatment (Phase B) Baseline (Phase A) versus Follow-up (Phase C) 
ID Phase  
M 
 
AR Level  











 A B    A C    
1 
 
30.88 32.56 0.37 0.30 (.618) -0.11 (.725) 30.88 32.67 0.28 0.28 (.680) 0.14 (.670) 
2 
 
23.13 24.27 0.36 1.67 (.016**) 0.51 (.070) 23.13 22.00 -0.04 0.22 (.670) 0.45 (.059*) 
3 
 








31.38 42.75 0.77 6.86 (<.001**) 0.84 (.045*) 
5 17.00 14.18 0.43 1.01 (.140) -0.44 (.151) 
 
17.0 15.75 0.56 0.47 (.641) 0.03 (.936) 
6 11.62 8.81 0.50 0.85 (.242) -0.44 (.208) 11.62 8.62 0.62 1.19 (.283) -0.526 (.270) 




























SMA: Simulation Modelling Analysis; ASAS: Avoidance of social activities due to pain subscale from the Avoidance-Endurance Questionnaire (AEQ); ID: Participant identification 
number; M: Phase mean values; AR: Pooled phases autocorrelation estimate (r Lag (1)); P: p-value accounting for autocorrelation; r: Pearson’s r correlation. 
110000 null distribution simulations generated; Error of mean = 0; Standard deviation = 1; Valid phase n-size of sample (for each individual) = 24: Phase A (baseline) = 8; Phase B 
(treatment) = 16. Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and 
gradual change during treatment (0, 0, 0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16). 
210000 null simulations generated; Error of mean =0; standard deviation = 1; Valid phase n-size of sample (for each individual) = 16: Phase B (baseline) = 8; Phase C (follow-up) = 8. 
Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and gradual change during follow-up (0, 0, 0, 
0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8). 
** = Effect size significant at the 0.01 level 




Q.3 Treatment and maintenance effects for Avoidance of Social Activities 4 day ratings (ASAS) tested using SMA 
 Baseline (Phase A) versus Treatment (Phase B) Baseline (Phase A) versus Follow-up (Phase C) 
ID Phase  
M 
 
AR Level  











 A B    A C    
1 
 
1.46 0.90 0.15 0.49 (0.319) -0.07 (.778) 1.46 0.46 0.06 0.82 (.151) -0.33 (.212) 
2 
 
3.00 3.00 - - - 3.00 3.00 - - - 
3 
 
2.48 2.62 -0.04 0.32 (0.464) 
 




4.93 3.41 0.86 1.91 (0.127) -0.92 (.004**) 
 
4.93 1.06 0.89 6.86 (<.001**) -0.92 (.016**) 




5.50 5.77 0.54 0.98 (.325) 0.55 (.187) 
6 5.81 6.0 0.27 
 
0.77 (0.166) 0.26 (.329) 5.81 6.0 0.27 0.68 (.360) 0.263 (.453) 



























SMA: Simulation Modelling Analysis; BIPQ: Brief Illness Perceptions Questionnaire single item adapted for MS pain; ID: Participant identification number; M: Phase mean values; AR: 
Pooled phases autocorrelation estimate (r Lag (1)); P: p-value accounting for autocorrelation; r: Pearson’s r correlation. 
110000 null distribution simulations generated; Error of mean = 0; Standard deviation = 1; Valid phase n-size of sample (for each individual) = 24: Phase A (baseline) = 8; Phase B 
(treatment) = 16. Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and 
gradual change during treatment (0, 0, 0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16). 
210000 null simulations generated; Error of mean =0; standard deviation = 1; Valid phase n-size of sample (for each individual) = 16: Phase B (baseline) = 8; Phase C (follow-up) = 8. 
Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and gradual change during follow-up (0, 0, 
0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8). 
** = Effect size significant at the 0.01 level 
* = Effect size significant at the 0.05 level;  




Q.4 Treatment and maintenance effects for Emotional Representations 4 day ratings (BIPQ) tested using SMA 
 Baseline (Phase A) versus Treatment (Phase B) Baseline (Phase A) versus Follow-up (Phase C) 
ID Phase  
M 
 
AR Level  











 A B    A C    
1 
 
4.25 1.38 0.25 1.19 (.038*) 
 
-0.38  (.147) 
 
4.25 0.91 0.18 1.54 (.025*) -0.54 (.055*) 
2 
 
4.75 3.25 0.56 2.76 (.001**) 
 




7.88 7.56 -0.13 0.43 (.268) -0.12 (.525) 7.87 7.5 0.10 0.97 (.154) -0.231 (.431) 
4 
 
6.88 4.56 0.35 1.09 (.082) -0.61 (.022*) 6.87 1.62 0.62 3.90 (.001**) -0.83  (.017*) 
 
5 5.38 4.19 -0.16 0.63 (.099) -0.12 (.506) 5.37 4.0 0.13 0.85 (.019) 0.02  (.919) 
6 8.5 8.5 0.01 
 
0.00  (1.000) 0.26 (.209) 8.5 9.0 -0.12 0.82 (.108) 0.204 (.407) 


























SMA: Simulation Modelling Analysis; BIPQ: Brief Illness Perceptions Questionnaire single item adapted for MS pain; ID: Participant identification number; M: Phase mean values; AR: 
Pooled phases autocorrelation estimate (r Lag (1)); P: p-value accounting for autocorrelation; r: Pearson’s r correlation. 
110000 null distribution simulations generated; Error of mean = 0; Standard deviation = 1; Valid phase n-size of sample (for each individual) = 24: Phase A (baseline) = 8; Phase B 
(treatment) = 16. Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and 
gradual change during treatment (0, 0, 0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16). 
210000 null simulations generated; Error of mean =0; standard deviation = 1; Valid phase n-size of sample (for each individual) = 16: Phase B (baseline) = 8; Phase C (follow-up) = 8. 
Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and gradual change during follow-up (0, 0, 
0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8). 
** = Effect size significant at the 0.01 level 
* = Effect size significant at the 0.05 level;  





Q.5 Treatment and maintenance effects for Perceived Consequences 4 day ratings (BIPQ) tested using SMA 
 Baseline (Phase A) versus Treatment (Phase B) Baseline (Phase A) versus Follow-up (Phase C) 
ID Phase  
M 
 
AR Level  











 A B    A C    
1 
 
6.88 4.38 0.19 1.22 (.024*) 
 
-0.37 (.134) 6.88 4.63 0.05 1.28 (.806) -0.52 (.051*) 
2 
 
5.25 3.44 0.60 2.27 (.012**) 
 
.33 (.426) 5.25 2.75 0.73 2.76 (.042*) -0.80 (.058) 
3 
 




2.25 4.13 0.39 1.09 (.094) 0.06 (.847) 2.25 1.37 -0.09 0.61 (.230) -0.33 (.171) 
5 4.75 4.19 -0.28 0.30 (.362) -0.03 (.849) 4.75 4.25 -0.16 0.28  (.544) 0.15 (.510) 
6 9.12 9.37 0.09 
 
0.32 (.489) 0.38 (.079) 9.12 9.75 0.02 .98 (0.093) 0.48 (0.058) 



























SMA: Simulation Modelling Analysis; BIPQ: Brief Illness Perceptions Questionnaire single item adapted for MS pain; ID: Participant identification number; M: Phase mean values; AR: 
Pooled phases autocorrelation estimate (r Lag (1)); P: p-value accounting for autocorrelation; r: Pearson’s r correlation. 
110000 null distribution simulations generated; Error of mean = 0; Standard deviation = 1; Valid phase n-size of sample (for each individual) = 24: Phase A (baseline) = 8; Phase B 
(treatment) = 16. Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and 
gradual change during treatment (0, 0, 0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16). 
210000 null simulations generated; Error of mean =0; standard deviation = 1; Valid phase n-size of sample (for each individual) = 16: Phase B (baseline) = 8; Phase C (follow-up) = 8. 
Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and gradual change during follow-up (0, 0, 
0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8). 
** = Effect size significant at the 0.01 level 
* = Effect size significant at the 0.05 level  




 Q.6 Treatment and maintenance effects for Timeline 4 day ratings (BIPQ) tested using SMA 
 Baseline (Phase A) versus Treatment (Phase B) Baseline (Phase A) versus Follow-up (Phase C) 
ID Phase  
M 
 
AR Level  











 A B    A C    
1 
 




8.63 5.88 0.31 1.81 (.025*) -0.57 (.077) 
2 
 




6.00 3.00 0.80 2.87 (.046*) -0.76 (.123) 
3 
 
8.38 7.75 0.22 1.09 (.050*) 
 
-0.39 (.124) 8.37 7.0 0.01 0.93 (.102) -0.30 (.269) 
4 
 
7.88 3.94 0.92 1.35 (.336) 
 
0.90 (.017**) 7.87 0.37 0.83 9.85 (<.001**) 0.83 (.065) 
5 4.50 4.56 -0.13 0.06 (.874) -0.02 (.914) 4.5 4.87 -0.36 0.41 (.304) 0.20 (298) 
6 10.0 10.0 - 
 
- - 10.0 10.0 - - - 
7 8.0 6.87 0.80 
 



























SMA: Simulation Modelling Analysis; BIPQ: Brief Illness Perceptions Questionnaire single item adapted for MS pain; ID: Participant identification number; M: Phase mean values; AR: 
Pooled phases autocorrelation estimate (r Lag (1)); P: p-value accounting for autocorrelation; r: Pearson’s r correlation. 
110000 null distribution simulations generated; Error of mean = 0; Standard deviation = 1; Valid phase n-size of sample (for each individual) = 24: Phase A (baseline) = 8; Phase B 
(treatment) = 16. Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and 
gradual change during treatment (0, 0, 0, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16). 
210000 null simulations generated; Error of mean =0; standard deviation = 1; Valid phase n-size of sample (for each individual) = 16: Phase B (baseline) = 8; Phase C (follow-up) = 8. 
Level change vector (0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1) converted to Cohen’s d; SMA’s predefined ‘Slope vector 2’ with a stable baseline and gradual change during follow-up (0, 0, 0, 
0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8). 
** = Effect size significant at the 0.01 level 
* = Effect size significant at the 0.05 level 
d = 0.2 = small, 0.5 = medium = 0.8 = large effect size; r= 0.1 = small, 0.3 = medium and 0 .5 = large effect size
  Q.7 Treatment and maintenance effects for Perceived Control 4 day ratings (BIPQ) tested using SMA 
 Baseline (Phase A) versus Treatment (Phase B) Baseline (Phase A) versus Follow-up (Phase C) 
ID Phase  
M 
 
AR Level  











 A B    A C    
1 
 
6.38 6.75 0.03 0.22  (.616) 0.08 (.709) 6.38 6.88 0.09 0.26 (.655) 0.06 (.839) 
2 
 
4.63 3.88 0.19 1.01 (.062) -0.35 (.155) 4.63 4.38 0.29 0.28 (.694) -0.13 (.714) 
3 
 
5.75 7.06 -0.24 0.58 (.101) 0.29 (.089) 5.75 5.37 -0.30 0.14 (.690) -.10 (.590) 
4 
 




6.37 6.5 -0.14 0.06 (.863) 0.07 (.770) 
5 3.00 3.81 -0.10 0.68 (.092) 0.10 (.602) 3.0 3.87 0.19 1.15 (.088) 0.35 (.252) 
6 2.87 2.75 -0.14 0.17 (.675) -0.05  (.784) 2.87 2.62 -0.15 0.31 (0.524) 0.02 (0.901) 












INFORMATION SHEET FOR PARTICIPANTS 
 
REC Reference Number: 14/LO/1909 
 
YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET 
Study title: Guided cognitive behavioural selF-help Treatment for multiple 
sclerosis pain (GIFT Study) 
 
We would like to invite you to participate in this original research project.  You should only participate 
if you want to. Choosing not to take part will not disadvantage you in any way. Before you decide 
whether you want to take part, it is important for you to understand why the research is being done 
and what your participation will involve.  Please take time to read the following information carefully 
and discuss it with others if you wish.  Ask us if there is anything that is not clear or if you would like 
more information (contact details on page 5). 
 
 Part 1 tells you the purpose of this study and what will happen to you if you take part. 
 
 Part 2 gives you more detailed information about the conduct of the study. 
 
Who is conducting the study? 
This study is part of a larger research project that is being conducted by researchers at The Section 
of Health Psychology, Institute of Psychiatry at King’s College in collaboration with the MS Society 
UK. The study is being conducted as part of the Principal Investigator (Anthony Harrison’s) doctoral 
studies in conjunction with Lead Investigators Professor Rona Moss-Morris and Professor Lance 
McCracken, and Katherine Jones, an undergraduate student completing her science degree. Anthony 
and Katherine are being supervised by the Lead Investigators with all aspects of the project. 
 
What is the purpose of the study? 
Research has shown that people with MS experience different kinds of pain, and that coping with the 
emotions, lifestyle changes and other problems associated with pain can be challenging. Many 
people with MS pain experience periods of feeling frustrated or angry, down, distressed and/or 
anxious. In this small pilot study we would like to find out whether a guided self-help programme 
based on both Cognitive behavioural Therapy (CBT) and Acceptance and Commitment Therapy 
(ACT) could help people with MS-related pain and how to make this programme more relevant to your 
needs in the future. 
 
What is the therapy that is being tested? 
The guided self-help programme will test a combination of techniques from both traditional Cognitive 
Behavioural Therapy (CBT) and Acceptance and Commitment Therapy (ACT). With Anthony’s 
support, participants will be encouraged to look at the ways that their thoughts, feelings, behaviours 
and physiology all interact and influence how MS pain affects their lives. The treatment is quite 
structured and different topics will be covered in different sessions (e.g. relationships with others or 





related symptoms). Participants will also be expected to set goals to achieve. Participants will have 
small tasks or “homework” to do in between the sessions. 
 
Why was I invited to take part? 
Four to six people with MS-related pain will take part in this project. You have been approached 
because you took part in our previous pain experience in Multiple Sclerosis (PEMS) survey study 
(REC No: 13/LO/1429). In your completed PEMS survey you indicated that you experience some 
form of MS-related pain for longer than six months and expressed an interest in us contacting you 
about future MS pain studies. This invitation to take part does not mean that your doctors think you 
are having particular difficulties or are having problems coping. We are inviting people to take part 
regardless of whether they feel distressed, down or anxious at the moment. 
 
Can I take part in this study? 
You will take part in a screening session over the telephone where Anthony will confirm your eligibility 
to take part. 
 
Our criteria request you are: 
 18 years-of-age or over 
 Have a definite diagnosis of any subtype of MS and any level of disability 
 Have any form of pain starting either at the time of MS diagnosis or suspected diagnosis, or 
after the diagnosis of MS. 
 On a 10-point scale of 1 (‘No pain’) to 10 (‘Pain as bad as you can imagine’), rate your pain 
severity as ‘4’ or greater. 
 On a 10-point scale of 1 (‘Does not interfere) to 10 (‘Completely interferes’), rate your pain 
severity as ‘4’ or greater. 
 If you are taking pain medications you must have been on the medication for at least three 
months and intend to continue for the duration of the study. 
 Have not received any formal training in CBT or ACT. This is because we would like to see 
whether our programme is helpful and we won’t be able to do so if you have completed similar 
programmes before or if you are receiving additional psychological help. 
 Not currently receiving any other psychological treatment. 
 Are willing not to try any new psychological treatments during the duration of the study. 
However, if new treatments are required, they will be allowed and we ask that you inform 
Anthony 
 You have a telephone or Skype internet access 
 
Unfortunately, you won’t be able to take part in this study if you have severe mental problems or 
substance misuse. Also, if you are highly distressed, this type of intervention might not be the most 
appropriate for you. We will discuss these issues with you over the phone before the start of the 
programme and we may suggest an alternative approach for you. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part after reading this information sheet. If you 
agree to take part, you will be given this information sheet to keep and be asked to sign a consent 
form at the end of this document. You are still free to leave the study at any stage without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect the standard 
of care you receive. 
 
What will happen to me if I take part? What do I have to do? 
The research project will involve an 8-week guided self-help programme for MS pain. The sessions of 
the guided self-help MS pain programme will take place once a week for eight weeks, with each 
session lasting about an hour. Anthony will facilitate the programme and distribute the booklets and 
assistive media you will need. Around three sessions will be scheduled during the 8 weeks to help 
guide you through the programme and answer any questions you have. Your Skype and/or telephone 
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sessions with Anthony will need to be undertaken in a private location where you can talk 
undisturbed. We ask that you complete the remaining five sessions independently. However, Anthony 
will be contactable throughout the programme if you have any questions. As part of the programme 
we will ask you to practice new skills regularly using the booklet and CDs we will provide you with. 
 
We will ask you to fill in a short questionnaire ratings about your pain and how you are thinking and 
feeling every four days over the 16 week period: during the month before the programme begins, 
during the eight week programme and then one month after the programme has finished. The 
questionnaire ratings will take between 5 to 10 minutes to complete. A researcher, Ms Katherine 
Jones, independent of Mr Harrison, who will deliver the treatment, will send these to you every four 
weeks by post in a booklet format so you can complete them at home. Alternatively, you can 
complete the questionnaires online if you prefer. Ms Jones will also send you regular reminder text 
messages or emails to remind you to complete the questionnaire ratings every four days. You will be 
asked to refrain from taking part in any other CBT or ACT course during this period. 
 
We will record all telephone or Skype sessions so that we can check that Anthony is conducting the 
sessions in exactly the way that was planned. The recordings will be stored for supervision purposes 
until the end of the programme, at which point they will be safely destroyed. 
 
At the end of the treatment programme we will interview all participants about their experiences and 
views about the programme sessions. If you agree to take part Ms Katherine Jones will contact you 
and arrange a convenient time with you to conduct an informal interview over the telephone for about 
one hour. Ms Jones will not be involved in the delivery of the programme. Ms Jones will tape-record 
your interview and transcribe it omitting your name or any other identifiable information before giving 
the transcripts to the research team to study it at a later date. Katherine will transcribe your interview 
within two months, at which stage we will securely destroy the interview recordings. If you want to 
take part in the self-help programme but do not want to do this interview you do not have to. You can 
also change your mind if you agree to do the interview but decide you no longer want to at a later 
date. 
 
Expenses and benefits 
You will be given a £80 if you complete the 8-week programme and all the associated questionnaire 
ratings. If you complete only one session for instance we will pay you £10. Unfortunately, we cannot 
compensate you if you withdraw prior to attending any sessions. There will be no cost to you for the 
self-help materials or initial session. The researchers will make and pay for the telephone calls for 
your treatment sessions. We will either contact you via telephone or use Skype (a free online 
application), depending on your preferences. The questionnaires and any telephone headset 
equipment you need will be mailed to you Ms Jones and delivery will be arranged and will contain 
pre-paid envelopes for their return to us. 
 
What are the alternatives for treatment? 
This treatment is in addition to any current NHS treatments you are receiving for your pain including 
pain medication and physiotherapy. You will not be required to stop these treatments, although we 
request that you do not start other new treatment whilst taking part in this study. Currently there is no 
other readily available NHS pain management programme specifically for people with MS. However, 
there are pain self-help guides for more general pain problems which are available for purchase. 
Some hospital trusts also run a specialised pain service where people can be referred to learn pain 
management strategies. However, these are not specific to MS and often focus on people with a 
primary pain problem (i.e. pain that is not secondary to a disease) 
 
Do I need any special equipment to take part? 
You will need to have a working telephone or a computer with an Internet connection that has Skype 





What are the possible disadvantages and risks of taking part? 
The main disadvantage of taking part is simply the time and effort it will take. It is also possible that 
exploring issues to do with your pain may be difficult for you. However, CBT and ACT approaches are 
designed to help people to feel better and we don’t expect that people will feel any worse as a result 
of taking part. If, through taking part in the research, it becomes clear that you are having any major 
difficulties (e.g. with depression) we will refer you to further sources of support. 
 
What are the side effects of any treatment received when taking part? 
You are being offered a self-management programme with elements of talking therapy. It is very 
unlikely that there will be any side-effects. 
 
What are the possible benefits of taking part? 
We cannot promise the study will help you. However, the evidence so far shows that both CBT and 
ACT programmes are helpful for people with chronic pain conditions. Further the information we get 
will help us make the programme more relevant to the needs of people with MS-related pain. At the 
conclusion of the project, we will send you a newsletter describing the major findings and alerting you 
to any research publications we have generated from the project. 
 
What happens when the research study stops? 
The information we will gain from this project will help us to decide whether the intervention is helpful 
for people with MS-related pain and will help us find out ways to make the programme more helpful. 
However, the programme will not be available after the eight-week treatment period has finished. 
Even if the results of this study show that the programme was very effective it will not necessarily be 
available in the foreseeable future at your local NHS hospital. However, you can keep the assisted 
self-help guide and media at the end of the study. 
 
What if there is a problem? 
It is up to you to decide whether to take part or not.  If you decide to take part you are still free to 
withdraw at any time and without giving a reason.  If you have a concern about any aspect of this 
study, you should ask to speak to the researchers who will do their best to answer your questions. 
Please contact: Anthony Harrison (Principle Investigator) (anthony.harrison@kcl.ac.uk or tel. 
02071889324) or Rona Moss-Morris (Chief Investigator) (rona.moss-morris@kcl.ac.uk or tel. 020 
7188 0180). If you have a complaint, you should talk to your research doctor who will do their best to 
answer your questions. If you remain unhappy, you may be able to make a formal complaint through 
the NHS complaints procedure.  Details can be obtained through the Guy’s and St Thomas’ Patient 
Advisory Liaison Service (PALS) on 0207 1887188 or email pals@gstt.nhs.uk, address: PALS, KIC, 
Ground floor, north wing, St Thomas’ Hospital, Westminster Bridge Road, London, SE1 7EH . 
 
This trial is sponsored by King’s College London. The sponsor will at all times maintain adequate 
insurance in relation to the study independently. Kings College London, through its own professional 
indemnity (Clinical Trials) and no fault compensation and the Trust having a duty of care to patients 
via NHS indemnity cover, in respect of any claims arising as a result of clinical negligence by its 
employees, brought by or on behalf of a study patient. 
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering 





Part 2  
Information you need to know if you still want to take part 
 
What will happen if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time without having to give a reason even if you 
decide to take part initially. However, we will need to use the data you have provided so far so that we 
can analyse the results from the study accurately. We will remove any information that can reveal 
your identity. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researcher who 
will do his best to answer your questions (Anthony Harrison on 07936 448 926 or 
anthony.harrison@kcl.ac.uk).  
  
Will my part in this study be kept confidential? 
Yes. The procedures for handling, processing, storing and destroying data are compliant with the 
Data Protection Act 1998.  Data about you will be linked to a number rather than your name in order 
to maintain anonymity. Information about you will be stored securely and will be available only to 
members of the research team. It will be used only for the purposes of the current study. Data from 
this study will be retained until the study has been written up for publication (not more than 5 years) 
and subsequently disposed of securely. 
 
What will happen to the results of the research study? 
The results will be used to help the researchers to decide whether the guided self-help programme is 
useful for people with MS-related pain and identify possible ways to make it more relevant to their 
needs. The study will also be written up for publication in scientific journals and may be presented at 
scientific conferences. If you would like to know the results you can be provided with a summary 
sheet. 
 
Who is organising and funding the research?  
The research is being organised and conducted by researchers from King’s College London, UK and 
it is funded by the MS Society, UK.  
 
Who has reviewed the study? 
This study has been reviewed and given favourable opinion by the Camden & Islington NHS Ethics 
Committee (Ref: 14/LO/1909) and by a patient and public involvement members at the UK Multiple 
Sclerosis Society. 
 
What if I have questions about the project?  
If you would like to discuss your potential involvement in this research further please contact: 
 
Name: Mr Anthony Harrison Job title: Principal Investigator (Doctoral Student) 
Telephone number: 07936 448 926 Email address: anthony.harrison@kcl.ac.uk 
 Address: Department of Health Psychology, Institute of Psychiatry, Kings College London, 5th Floor 
Bermondsey Wing, Guys Campus, London SE1 9RT 
Please retain this information sheet.  
If, after discussing the research with us, you decide that you wish to participate we will ask you to 
complete and return a consent form. You will get a copy of the consent form to keep. 
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Title of Project: Guided cognitive behavioural selF-help Treatment for multiple 
sclerosis pain (GIFT Study) (REC REF: 14/LO/1909)      
 
Name of Researchers: Mr Anthony Harrison, Ms Katherine Jones, Professor Rona Moss-Morris, 
Professor Lance McCracken  
Please initial the box at the end of each statement to confirm 
1. I confirm that I have read and understand the information sheet dated 
10.11.2014 (version 1) for the above study.  I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily.  
   
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care or 
legal rights being affected. 
 
3. I understand that data collected during the study, may be looked at by 
individuals from King’s College London, from regulatory authorities or from 
the NHS Trust, where it is relevant to my taking part in this research.  I give 
permission for these individuals to have access to my records. 
 
4. I give permission for the sessions I take part to be audiotaped. 
 
5. I agree to my GP being informed of my participation in the study.    
 








Appendix S. Chapter 6 Case Series: Consent Form 











OPTIONAL EXTRA INTERVIEW 
(You can do the rest of the project without doing this) 
 
1.  I agree to take part in an interview about my experiences of therapy at the 
end of my treatment.  
2. I give permission for the interview I take part to be audiotaped.  
3. I understand that when the research is published it may include direct 
quotations from my interview but that I will not be identified as an 
individual. 
 
___________________________                     ___________              _______________________ 







_____________________________________________________________________________    
 
 






























PARTICIPANT ID: _____________________ (To be stored separately to ICF) 
 



















Brief Pain Inventory (BPI) (adapted single-item pain severity and interference 
numerical rating scales) (Cleeland & Ryan, 1994) 
 




1 2 3 4 5 6 7 8 9  10  
Pain as bad 
as you can 
imagine 





















 Score ‘1’ for each correct 
answer and ‘0’ if incorrect 
Orientation   
1. (i) What day of the week is it?  Day  
   (ii) What is today’s date? 
 





  (iii) What season are we in? Season  
2. What is your age? Age  
3. What is your telephone number? (Code+number)   
Registration/Free Recall   
4. I’m going to read you a list of 10 words. 
Please listen carefully and try to remember Cabin & 
them. When I am done, tell me as many as you can in any order. Ready? 
 












Attention/Calculation   
5. Please take 7 away from 100 







6. Please count backwards from 20 to 1 No mistakes  
Comprehension, Semantic and Recent Memory   
7. What do people usually use to cut paper? Scissors  
8. What is the prickly green plant found in the desert? Cactus  
9. Who is the reigning monarch now? E, QE, QE2  
10. Who is the Prime Minister now? Correct 
surname 
 
11. What is the opposite of east? West  
Language/Repetition   
12. Please say this ‘Methodist Episcopal’  Exactly right  
Delayed Recall   















Self-report EDSS (EDSS-S) (Bowen et al., 2001) 
WALKING DISTANCES 
We would like to know how well your body functions on an average day, not your 
worst days and not your best days. Please tick the box that most closely matches your 
abilities.** 
 
On an average day I can: 
 
  Walk more than 500 metres (about 530 yards) without stopping to rest. 
 (This is approximately 5 football field lengths.) 
    I would need    no help    a cane     two canes     a walker 
 
  Walk 300 metres (about 350 yards) without stopping to rest.  
          (This is approximately 3 football field lengths.)  
    I would need     no help     a cane     two canes     a walker 
 
  Walk 200 metres (about 200 yards) without stopping to rest.  
   (This is approximately 2 football field lengths.)  
    I would need     No help    A cane    Two canes    A walker 
 
 Walk 100 metres (about 100 yards) without stopping to rest.  
     (This is approximately 1 football field length.) 
    I would need     No help     A cane    Two canes    A walker 
 
  Walk 20 metres (about 60 feet) without stopping to rest. 
    I would need     No help      A cane    Two canes   A walker 
 
  Walk 5 metres (about 15 feet) without stopping to rest 
    I would need     No help     A cane     Two canes   A walker 
 
  Walk a few steps. 
    I would need     No help     A cane     Two canes     A walker 
 










If you use a wheelchair please tick one of the following 4 statements: 
 
1.   On an average day, I can bear my weight with my legs (stand up and 
move) and get myself from one chair to another. 
2.  On an average day, I can bear my weight (with the strength in my arms) 
and lift myself from one chair to another. 
3.  On an average day, I cannot bear any weight or get myself from one 
chair to another. 
4.   On an average day, I cannot sit up in a chair. 
 
STRENGTH  
When answering the following questions, please think about an average day for 
you (not a particularly good, or bad day) then think of the “best” part of that day. 
(Maybe the best part of your day is in the morning, or maybe later, after you 
have moved around a bit.)  
On an average day, at my best, my strength is: 
 The same as 








in the air 
Can move 
limb, but 
not raise it 





Right arm      
Left arm      
Right leg      































I must get 













Right arm      
Left arm      
Right leg      




For touch, pain, cold, or heat, please mark the appropriate box in the table 
below. Use the worst – the one that has lost the most sensitivity – of the 
four sensations (touch, pain, cold, or heat) to answer each question. Please 
think of an average day.  
(For example: your left hand has very little sensitivity to pain, mild sensitivity to 
touch, and normal for heat and cold, then you would mark “can feel very little” 
on the line for left hand.) 
 
 Same as 
before I had 
MS 






Right hand     
Right arm     
Left hand     
Left arm     
Right foot     
Left foot     




On an average day, I have: 
Yes No  
  A normal bladder 
  Urgency (once I need to go I have a hard time holding it) 
  Hesitancy (I feel I need to go but nothing happens) 
  Accidents (incontinence) occasionally but once a week or less 
  Accidents (incontinence) twice a week or more, but less than 
daily 
  Accidents (incontinence) daily 
  Use self-catheterization 
  Use continuous catheter (indwelling or condom catheter) 
 
VISION 








   
 
9 3 7 8 2 6 
 
 
   4 2 8 3 6 5 














Cannot read any 





2.  I see double (two things, where there is really only one) 
 
     Never        About once a week       Almost daily         
     Constantly 
 
3.  On an average day, my eye movements are unsteady 




On an average day, my speech is: 
  The same as before I had MS   
  Slightly Slurred  
  Moderately Slurred  




On an average day, my swallowing is: 
   Normal      
   Occasional choking        




Although some people may wish to consider thinking and memory separately, 
we need you to combine them and tick one box below. 
 
On an average day, my thinking and memory is: 
   Is the same as before I had MS 
   Is almost the same as before I had MS 
   Occasionally causes a problem in my daily life 
   Frequently causes a problem in my daily life 




















Brief Pain Inventory (BPI) (adapted single-item pain severity and interference 
numerical rating scales) (Cleeland & Ryan, 1994) 
 




1 2 3 4 5 6 7 8 9  10  
Pain as bad 
as you can 
imagine 

















Brief Illness/Pain Perceptions Questionnaire (BIPQ)  
(Broadbent et al., 2006) 
 
For the following questions, please select the number that best corresponds to your views: 
 

















 1 2 3 4 5 6 7 8 9 10 
Forever 
 




























Validated Chronic Pain Acceptance Questionnaire-8 items (CPAQ-8) 
 (Fish et al., 2010) 
 
 
Below you will find a list of statements. Please rate the truth of each statement as it 
applies to you by circling a number. 
 
Use the following rating scale to make your choices (Please tick one grey box for 
each statement.) 
 
















       
 
















       
 
















       
 
















       
 
















       
 








































       
 





















Avoidance-Endurance Questionnaire (AEQ) Avoidance of Social Activities Scale 
(ASAS) (adapted for pain overall rather than for mild or moderate) (Hasenbring 
et al., 2009) 
 
























1. I avoid visiting friends 0  1  2  3  4  5  6 
 
2. I cancel private appointments   0  1  2  3  4  5  6 
 
3. I cancel a visit to an event              0  1  2  3  4  5  6 
 
4. I break-off a meeting with friends                   0  1  2  3  4  5  6 
 
5. I call my guests to cancel an invitation 0  1  2  3  4  5  6 
 






Pain Catastrophizing Scale (PCS) (Sullivan et al., 1995) 
We are interested in the types of thoughts and feelings that you have when you are in 
pain. Listed below are thirteen statements describing different thoughts and feelings that 
may be associated with pain. Using the following scale, please indicate the degree to 
which you have these thoughts and feelings when you are experiencing pain. 
 
When I’m in pain… (Please tick one grey box for each statement.) 
 
1.  I worry all the time about whether the pain will end. 
 
Not at all To a slight degree  To a moderate degree To a great degree All the time 
     
 
2. I feel I can’t go on. 
Not at all To a slight degree  To a moderate degree To a great degree All the time 
     
 
3. It’s terrible and I think it’s never going to get any better. 
Not at all To a slight degree  To a moderate degree To a great degree All the time 
     
 
4. It’s awful and I feel that it overwhelms me. 
 
Not at all To a slight degree  To a moderate degree To a great degree All the time 
     
 
5. I feel I can’t stand it anymore. 
 
Not at all To a slight degree  To a moderate degree To a great degree All the time 
     
 
6. I become afraid that the pain will get worse. 
 
Not at all To a slight degree  To a moderate degree To a great degree All the time 
     
 
7. I keep thinking of other painful events. 
 
Not at all To a slight degree  To a moderate degree To a great degree All the time 
     
 
8. I anxiously want the pain to go away. 
 
Not at all To a slight degree  To a moderate degree To a great degree All the time 




9. I can’t seem to keep it out of my mind. 
 
Not at all To a slight degree  To a moderate degree To a great degree All the time 
     
 
10. I keep thinking about how much it hurts. 
 
Not at all To a slight degree  To a moderate degree To a great degree All the time 
     
 
11.  I keep thinking about how badly I want the pain to stop.  
 
Not at all To a slight degree  To a moderate degree To a great degree All the time 
     
 
12. There’s nothing I can do to reduce the intensity of the pain. 
 
Not at all To a slight degree  To a moderate degree To a great degree All the time 
     
 
13. I wonder whether something serious may happen. 
 
Not at all To a slight degree  To a moderate degree To a great degree All the time 
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